cancer.type	eQTL.type	tagSNP	LD	SNP.ID	SNP.position.hg19	Gene.symbol	Gene.position.hg19	Beta	t-stat	P-value	GWAS-Traits	
CESC	cis	1	rs1000113	chr5:150240076	LOC134466	chr5:150310000-150326146:-	0.5	5.44	1.17E-7	Crohn's disease	
CESC	cis	1	rs10008757	chr4:76903036	NAAA	chr4:76831809-76862166:-	-0.3	-3.97	9.32E-5	Longevity	
CESC	cis	1	rs1003719	chr21:38491095	PIGP	chr21:38437664-38445458:-	-0.43	-6.3	1.19E-9	Eye color traits	
CESC	cis	1	rs10041072	chr5:150259642	LOC134466	chr5:150310000-150326146:-	0.42	5.13	5.49E-7	Crohn's disease	
CESC	cis	1	rs10051747	chr5:56083289	C5orf35	chr5:56205103-56213010:+	0.83	11.9	1.26E-26	Type 2 diabetes	
CESC	cis	1	rs10051804	chr5:150226424	LOC134466	chr5:150310000-150326146:-	0.44	5.04	8.53E-7	Crohn's disease	
CESC	cis	1	rs10051924	chr5:150226639	LOC134466	chr5:150310000-150326146:-	0.44	5.04	8.53E-7	Crohn's disease	
CESC	cis	1	rs10052606	chr5:150272217	LOC134466	chr5:150310000-150326146:-	0.38	4.48	1.1E-5	Crohn's disease	
CESC	cis	1	rs10053750	chr5:150270051	LOC134466	chr5:150310000-150326146:-	0.4	4.73	3.64E-6	Crohn's disease	
CESC	cis	1	rs10057988	chr5:150272062	LOC134466	chr5:150310000-150326146:-	0.38	4.38	1.72E-5	Crohn's disease	
CESC	cis	1	rs10058821	chr5:150226385	LOC134466	chr5:150310000-150326146:-	0.44	5.04	8.53E-7	Crohn's disease	
CESC	cis	1	rs10058943	chr5:150226586	LOC134466	chr5:150310000-150326146:-	0.44	5.04	8.53E-7	Crohn's disease	
CESC	cis	1	rs10061105	chr5:150255185	LOC134466	chr5:150310000-150326146:-	0.4	4.92	1.48E-6	Crohn's disease	
CESC	cis	1	rs10065172	chr5:150227998	LOC134466	chr5:150310000-150326146:-	0.44	5.04	8.53E-7	Crohn's disease	
CESC	cis	1	rs10078968	chr5:150244273	LOC134466	chr5:150310000-150326146:-	0.4	4.93	1.39E-6	Crohn's disease	
CESC	cis	1	rs10078	chr5:438102	C5orf55	chr5:441645-443258:-	0.37	5.15	5.08E-7	Fat distribution (HIV)	
CESC	cis	1	rs1012376	chr14:65294790	CHURC1	chr14:65381140-65411309:+	0.69	4.32	2.16E-5	Daytime sleep phenotypes	
CESC	cis	1	rs10140433	chr14:74659989	LIN52	chr14:74551656-74667117:+	-0.41	-8.21	8.45E-15	Common traits (Other)	
CESC	cis	1	rs10144220	chr14:74647904	LIN52	chr14:74551656-74667117:+	-0.41	-8.23	7.39E-15	Common traits (Other)	
CESC	cis	1	rs10150201	chr14:74649157	LIN52	chr14:74551656-74667117:+	-0.41	-8.18	1.05E-14	Common traits (Other)	
CESC	cis	1	rs10157597	chr1:45990278	CCDC163P	chr1:45960581-45965646:-	-0.79	-13.92	1.02E-33	Homocysteine levels	
CESC	cis	1	rs1016669	chr3:41894440	ULK4	chr3:41288091-42003660:-	0.51	8.19	1.02E-14	Diastolic blood pressure	
CESC	cis	1	rs10169714	chr2:73808773	ALMS1P	chr2:73872046-73912692:+	0.4	5.52	7.95E-8	Metabolite levels	
CESC	cis	1	rs10175180	chr2:73673123	ALMS1P	chr2:73872046-73912692:+	0.38	5.56	6.25E-8	Metabolite levels	
CESC	cis	1	rs10178409	chr2:73855507	ALMS1P	chr2:73872046-73912692:+	0.39	5.04	8.27E-7	Urinary metabolites	
CESC	cis	1	rs10178982	chr2:202227640	ALS2CR12	chr2:202153148-202222101:-	-0.3	-4.08	5.96E-5	Basal cell carcinoma	
CESC	cis	1	rs10179134	chr2:73637519	ALMS1P	chr2:73872046-73912692:+	0.41	5.73	2.57E-8	Metabolite levels	
CESC	cis	1	rs1018184	chr6:86648475	SNHG5	chr6:86386726-86388451:-	0.57	9.28	5.4E-18	Response to antipsychotic treatment	
CESC	cis	1	rs10184268	chr2:73627044	ALMS1P	chr2:73872046-73912692:+	0.39	5.57	6.14E-8	Metabolite levels	
CESC	cis	1	rs10186501	chr2:73697844	ALMS1P	chr2:73872046-73912692:+	0.37	5.43	1.26E-7	Metabolite levels	
CESC	cis	1	rs10187192	chr2:73713500	ALMS1P	chr2:73872046-73912692:+	0.45	5.86	1.32E-8	Metabolite levels	
CESC	cis	1	rs10187416	chr2:73713741	ALMS1P	chr2:73872046-73912692:+	0.38	5.42	1.3E-7	Metabolite levels	
CESC	cis	1	rs10189574	chr2:73698518	ALMS1P	chr2:73872046-73912692:+	0.37	5.43	1.26E-7	Metabolite levels	
CESC	cis	1	rs10190219	chr2:73658331	ALMS1P	chr2:73872046-73912692:+	0.41	5.61	4.86E-8	Metabolite levels	
CESC	cis	1	rs10193373	chr2:281886	SH3YL1	chr2:218138-264810:-	-0.73	-12.18	1.34E-27	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs10193972	chr2:73717656	ALMS1P	chr2:73872046-73912692:+	0.38	5.52	7.97E-8	Metabolite levels	
CESC	cis	1	rs10206231	chr2:202229225	ALS2CR12	chr2:202153148-202222101:-	-0.32	-4.22	3.28E-5	Basal cell carcinoma	
CESC	cis	1	rs10207220	chr2:73785046	ALMS1P	chr2:73872046-73912692:+	0.42	5.88	1.2E-8	Metabolite levels	
CESC	cis	1	rs10212536	chr3:41827026	ULK4	chr3:41288091-42003660:-	0.5	7.44	1.31E-12	Diastolic blood pressure	
CESC	cis	1	rs10216533	chr8:143763690	LY6K	chr8:143781529-143785582:+	0.28	4.81	2.47E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs10216533	chr8:143763690	PSCA	chr8:143761875-143764142:+	0.43	7.21	5.58E-12	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs10218795	chr1:145416056	NOTCH2NL	chr1:145209111-145295525:+	0.7	7.4	1.69E-12	Coronary heart disease	
CESC	cis	1	rs10222496	chr3:114694757	ZBTB20	chr3:114057525-114866127:-	0.39	4.07	6.07E-5	Type 2 diabetes	
CESC	cis	1	rs10228845	chr7:21583617	DNAH11	chr7:21582833-21941455:+	-0.52	-7.57	5.68E-13	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
CESC	cis	1	rs10229224	chr7:21583921	DNAH11	chr7:21582833-21941455:+	-0.53	-7.74	1.85E-13	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
CESC	cis	1	rs10234309	chr7:135311167	PL-5283	chr7:135347221-135378160:+	0.58	7.72	2.1E-13	Paget's disease	
CESC	cis	1	rs10242455	chr7:99240179	CYP3A5	chr7:99245818-99332821:-	-0.28	-3.97	9.32E-5	Blood metabolite levels	
CESC	cis	1	rs10247526	chr7:65780696	CCT6P1	chr7:65216092-65228661:+	-0.55	-5.19	4.17E-7	Diabetic kidney disease	
CESC	cis	1	rs10247526	chr7:65780696	LOC493754	chr7:65993446-66057363:-	-0.54	-4.29	2.46E-5	Diabetic kidney disease	
CESC	cis	1	rs10256972	chr7:1039003	ZFAND2A	chr7:1192544-1199855:-	0.34	5.78	1.98E-8	Longevity;Endometriosis	
CESC	cis	1	rs10257427	chr7:65743208	NCRNA00174	chr7:65841032-65865395:-	0.25	4.01	7.95E-5	Aortic root size	
CESC	cis	1	rs1028449	chr14:35512995	PPP2R3C	chr14:35554679-35591679:-	0.47	5.29	2.56E-7	Atopic dermatitis	
CESC	cis	1	rs1030831	chr4:130025037	C4orf33	chr4:130014829-130033842:+	-0.46	-7.07	1.29E-11	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs1036554	chr2:86236099	LOC90784	chr2:86247339-86250991:-	-0.5	-4.82	2.33E-6	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
CESC	cis	1	rs1036554	chr2:86236099	POLR1A	chr2:86253453-86333278:-	0.34	4.45	1.27E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
CESC	cis	1	rs1037147	chr4:130025873	C4orf33	chr4:130014829-130033842:+	-0.43	-6.63	1.81E-10	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs1039664	chr7:65449716	CCT6P1	chr7:65216092-65228661:+	0.46	4.45	1.27E-5	Diabetic kidney disease	
CESC	cis	1	rs10410228	chr19:35979696	USF2	chr19:35759896-35770718:+	-0.35	-4.1	5.52E-5	Bipolar disorder	
CESC	cis	1	rs10419418	chr19:9994286	OR7D2	chr19:9296270-9299493:+	0.33	3.98	8.94E-5	Menarche (age at onset)	
CESC	cis	1	rs10421540	chr19:35971227	USF2	chr19:35759896-35770718:+	-0.4	-4.82	2.38E-6	Bipolar disorder	
CESC	cis	1	rs1042658	chr17:38173902	GSDMA	chr17:38119226-38134019:+	-0.32	-4.9	1.6E-6	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
CESC	cis	1	rs10431505	chr12:58178589	FAM119B	chr12:58166383-58176323:+	0.4	5.4	1.44E-7	Multiple sclerosis	
CESC	cis	1	rs10431505	chr12:58178589	TSFM	chr12:58176536-58191367:+	-0.32	-5.42	1.31E-7	Multiple sclerosis	
CESC	cis	1	rs10445300	chr17:2114587	SRR	chr17:2207248-2228553:+	-0.36	-4.8	2.6E-6	Esophageal cancer (squamous cell)	
CESC	cis	1	rs1044717	chr1:45976587	CCDC163P	chr1:45960581-45965646:-	-0.8	-14.25	7.21E-35	Homocysteine levels	
CESC	cis	1	rs10455158	chr6:86672825	SNHG5	chr6:86386726-86388451:-	-0.56	-8.91	6.99E-17	Response to antipsychotic treatment	
CESC	cis	1	rs1045531	chr8:143763547	LY6K	chr8:143781529-143785582:+	0.28	4.81	2.47E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs1045531	chr8:143763547	PSCA	chr8:143761875-143764142:+	0.43	7.21	5.58E-12	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs10455449	chr6:86592226	SNHG5	chr6:86386726-86388451:-	-0.58	-8.79	1.64E-16	Response to antipsychotic treatment	
CESC	cis	1	rs10455455	chr6:86670214	SNHG5	chr6:86386726-86388451:-	-0.57	-8.74	2.29E-16	Response to antipsychotic treatment	
CESC	cis	1	rs10455456	chr6:86670322	SNHG5	chr6:86386726-86388451:-	-0.56	-8.86	1.01E-16	Response to antipsychotic treatment	
CESC	cis	1	rs1045547	chr8:143763757	LY6K	chr8:143781529-143785582:+	0.28	4.81	2.47E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs1045547	chr8:143763757	PSCA	chr8:143761875-143764142:+	0.43	7.21	5.58E-12	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs1045574	chr8:143763958	LY6K	chr8:143781529-143785582:+	0.29	5.05	8.02E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs1045574	chr8:143763958	PSCA	chr8:143761875-143764142:+	0.44	7.32	2.79E-12	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs1045605	chr8:143764101	LY6K	chr8:143781529-143785582:+	0.28	4.81	2.5E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs1045605	chr8:143764101	PSCA	chr8:143761875-143764142:+	0.43	7.25	4.32E-12	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs10456362	chr6:28221816	ZNF323	chr6:28292517-28324048:-	-0.32	-3.99	8.62E-5	Depression	
CESC	cis	1	rs10456622	chr6:49396453	CENPQ	chr6:49431096-49460820:+	-0.24	-4.18	3.86E-5	Folate pathway vitamin levels	
CESC	cis	1	rs10456622	chr6:49396453	MUT	chr6:49398994-49431031:-	0.4	7	2.01E-11	Folate pathway vitamin levels	
CESC	cis	1	rs10461617	chr5:56104308	C5orf35	chr5:56205103-56213010:+	0.84	12.86	6.13E-30	Type 2 diabetes	
CESC	cis	1	rs10463240	chr5:150256853	LOC134466	chr5:150310000-150326146:-	0.4	4.92	1.48E-6	Crohn's disease	
CESC	cis	1	rs10463307	chr5:150254620	LOC134466	chr5:150310000-150326146:-	0.47	5.4	1.41E-7	Crohn's disease	
CESC	cis	1	rs10463310	chr5:150260905	LOC134466	chr5:150310000-150326146:-	0.4	4.73	3.64E-6	Crohn's disease	
CESC	cis	1	rs1046875	chr17:80685426	FN3KRP	chr17:80674582-80685889:+	0.32	4.42	1.4E-5	Glycated hemoglobin levels	
CESC	cis	1	rs1046917	chr17:80685655	FN3KRP	chr17:80674582-80685889:+	0.32	4.42	1.4E-5	Glycated hemoglobin levels	
CESC	cis	1	rs10470686	chr3:48449956	TREX1	chr3:48501186-48509043:+	-0.19	-4.4	1.53E-5	Longevity	
CESC	cis	1	rs1047418	chr14:75605792	EIF2B2	chr14:75469612-75476292:+	0.24	4.02	7.64E-5	Height	
CESC	cis	1	rs10483863	chr14:75322327	RPS6KL1	chr14:75372347-75389958:-	-0.27	-4.24	3.12E-5	Caffeine consumption	
CESC	cis	1	rs10496191	chr2:73673798	ALMS1P	chr2:73872046-73912692:+	0.38	5.56	6.25E-8	Metabolite levels	
CESC	cis	1	rs10496193	chr2:73773503	ALMS1P	chr2:73872046-73912692:+	0.39	5.66	3.75E-8	Metabolite levels	
CESC	cis	1	rs10498958	chr6:86649705	SNHG5	chr6:86386726-86388451:-	0.55	8.29	5.05E-15	Response to antipsychotic treatment	
CESC	cis	1	rs1056610	chr22:39080078	CBY1	chr22:39052658-39069853:+	-0.26	-4.65	5.16E-6	Resting heart rate	
CESC	cis	1	rs1056964	chr22:51017476	CPT1B	chr22:51007291-51017096:-	-0.51	-4.74	3.45E-6	Narcolepsy	
CESC	cis	1	rs1060431	chr17:4840868	SPAG7	chr17:4862523-4871132:-	0.45	4.43	1.35E-5	Platelet count	
CESC	cis	1	rs1062177	chr5:151184701	ATOX1	chr5:151122384-151138210:-	-0.22	-3.96	9.45E-5	Preschool internalizing problems	
CESC	cis	1	rs1062177	chr5:151184701	SLC36A1	chr5:150816553-150871939:+	-0.29	-4.01	7.96E-5	Preschool internalizing problems	
CESC	cis	1	rs1062687	chr22:39134715	CBY1	chr22:39052658-39069853:+	0.24	4.33	2.1E-5	Resting heart rate	
CESC	cis	1	rs1065201	chr22:39069510	CBY1	chr22:39052658-39069853:+	0.28	4.76	3.11E-6	Resting heart rate	
CESC	cis	1	rs10736426	chr1:45984353	CCDC163P	chr1:45960581-45965646:-	0.68	12.03	4.52E-27	Homocysteine levels	
CESC	cis	1	rs10739388	chr9:115977175	CDC26	chr9:116029290-116037869:-	-0.35	-5.09	6.58E-7	Hematology traits	
CESC	cis	1	rs1074286	chr8:130737601	GSDMC	chr8:130760443-130799134:-	0.3	5.36	1.73E-7	Infant length;Height	
CESC	cis	1	rs10747468	chr1:95686291	RWDD3	chr1:95583479-95712773:+	0.46	4.53	8.88E-6	Stearic acid (18:0) plasma levels	
CESC	cis	1	rs10747783	chr12:58176614	FAM119B	chr12:58166383-58176323:+	0.41	5.45	1.1E-7	Multiple sclerosis	
CESC	cis	1	rs10747783	chr12:58176614	TSFM	chr12:58176536-58191367:+	-0.33	-5.66	3.88E-8	Multiple sclerosis	
CESC	cis	1	rs10749860	chr1:46328210	CCDC163P	chr1:45960581-45965646:-	-0.33	-5.46	1.05E-7	Body mass index	
CESC	cis	1	rs10759636	chr9:116018777	CDC26	chr9:116029290-116037869:-	-0.36	-5.37	1.68E-7	Hematology traits	
CESC	cis	1	rs10783847	chr12:58196447	FAM119B	chr12:58166383-58176323:+	0.39	5.3	2.4E-7	Multiple sclerosis	
CESC	cis	1	rs10783847	chr12:58196447	TSFM	chr12:58176536-58191367:+	-0.31	-5.27	2.78E-7	Multiple sclerosis	
CESC	cis	1	rs10783848	chr12:58196528	FAM119B	chr12:58166383-58176323:+	0.39	5.29	2.47E-7	Multiple sclerosis	
CESC	cis	1	rs10783848	chr12:58196528	TSFM	chr12:58176536-58191367:+	-0.31	-5.26	2.84E-7	Multiple sclerosis	
CESC	cis	1	rs10788795	chr1:150758047	C1orf230	chr1:151682909-151702082:+	-0.3	-3.99	8.43E-5	Congenital left-sided heart lesions	
CESC	cis	1	rs10789475	chr1:46304177	CCDC163P	chr1:45960581-45965646:-	-0.34	-5.56	6.35E-8	Body mass index	
CESC	cis	1	rs10789481	chr1:46383583	CCDC163P	chr1:45960581-45965646:-	-0.34	-5.4	1.47E-7	Body mass index	
CESC	cis	1	rs10789487	chr1:46420221	CCDC163P	chr1:45960581-45965646:-	-0.35	-5.59	5.36E-8	Body mass index	
CESC	cis	1	rs1078968	chr3:53123486	RFT1	chr3:53122503-53164470:-	-0.36	-5.38	1.56E-7	Height	
CESC	cis	1	rs10804632	chr3:134294501	ANAPC13	chr3:134196547-134204865:-	0.3	4.08	5.84E-5	Height	
CESC	cis	1	rs10807701	chr7:65724686	CCT6P1	chr7:65216092-65228661:+	-0.54	-5.06	7.72E-7	Diabetic kidney disease	
CESC	cis	1	rs10807701	chr7:65724686	LOC493754	chr7:65993446-66057363:-	-0.53	-4.17	4.17E-5	Diabetic kidney disease	
CESC	cis	1	rs10824130	chr10:76008931	VCL	chr10:75754951-75879912:+	-0.3	-3.94	0.000102	Soluble interleukin-2 receptor subunit alpha	
CESC	cis	1	rs1085243	chr1:46544768	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.91	1.03E-8	Body mass index	
CESC	cis	1	rs1085244	chr1:46563680	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.82	1.63E-8	Body mass index	
CESC	cis	1	rs10853057	chr17:62998023	AMZ2P1	chr17:62962668-62971703:-	0.43	4.97	1.18E-6	White matter microstructure (global fractional anisotropy)	
CESC	cis	1	rs10857712	chr10:135225666	CYP2E1	chr10:135340867-135374724:+	-0.36	-4.51	9.43E-6	Systemic lupus erythematosus	
CESC	cis	1	rs10857712	chr10:135225666	MTG1	chr10:135207621-135234173:+	0.26	3.96	9.56E-5	Systemic lupus erythematosus	
CESC	cis	1	rs10865914	chr3:41919499	ULK4	chr3:41288091-42003660:-	-0.51	-8.2	9.04E-15	Diastolic blood pressure	
CESC	cis	1	rs10865956	chr3:49581559	KLHDC8B	chr3:49209068-49213918:+	-0.27	-4.28	2.6E-5	Menarche (age at onset)	
CESC	cis	1	rs10865956	chr3:49581559	WDR6	chr3:49044637-49053386:+	-0.27	-4.51	9.46E-6	Menarche (age at onset)	
CESC	cis	1	rs10877012	chr12:58162085	FAM119B	chr12:58166383-58176323:+	0.38	5	1.01E-6	Multiple sclerosis	
CESC	cis	1	rs10877012	chr12:58162085	TSFM	chr12:58176536-58191367:+	-0.36	-6.09	3.73E-9	Multiple sclerosis	
CESC	cis	1	rs10877013	chr12:58165085	FAM119B	chr12:58166383-58176323:+	0.37	4.98	1.13E-6	Multiple sclerosis	
CESC	cis	1	rs10877013	chr12:58165085	TSFM	chr12:58176536-58191367:+	-0.32	-5.45	1.15E-7	Multiple sclerosis	
CESC	cis	1	rs10877014	chr12:58167661	FAM119B	chr12:58166383-58176323:+	0.38	5.22	3.59E-7	Multiple sclerosis	
CESC	cis	1	rs10877014	chr12:58167661	TSFM	chr12:58176536-58191367:+	-0.32	-5.6	5.1E-8	Multiple sclerosis	
CESC	cis	1	rs10877015	chr12:58167788	FAM119B	chr12:58166383-58176323:+	0.38	5.05	8.06E-7	Multiple sclerosis	
CESC	cis	1	rs10877015	chr12:58167788	TSFM	chr12:58176536-58191367:+	-0.36	-6.12	3.2E-9	Multiple sclerosis	
CESC	cis	1	rs10877019	chr12:58172929	FAM119B	chr12:58166383-58176323:+	-0.37	-4.75	3.32E-6	Multiple sclerosis	
CESC	cis	1	rs10877019	chr12:58172929	TSFM	chr12:58176536-58191367:+	0.32	5.27	2.78E-7	Multiple sclerosis	
CESC	cis	1	rs10888396	chr1:150777514	C1orf230	chr1:151682909-151702082:+	-0.32	-4.3	2.36E-5	Congenital left-sided heart lesions	
CESC	cis	1	rs1088984	chr11:2377581	C11orf21	chr11:2317507-2323143:-	-0.27	-4.5	1.01E-5	Bacteremia	
CESC	cis	1	rs1088985	chr11:2377852	C11orf21	chr11:2317507-2323143:-	-0.25	-4.18	3.93E-5	Bacteremia	
CESC	cis	1	rs1088988	chr11:2380470	C11orf21	chr11:2317507-2323143:-	-0.26	-4.56	7.71E-6	Bacteremia	
CESC	cis	1	rs1088990	chr11:2381771	C11orf21	chr11:2317507-2323143:-	-0.27	-4.56	7.56E-6	Bacteremia	
CESC	cis	1	rs1088993	chr11:2382631	C11orf21	chr11:2317507-2323143:-	-0.25	-4.26	2.79E-5	Bacteremia	
CESC	cis	1	rs10890352	chr1:46283628	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.88	1.17E-8	Body mass index	
CESC	cis	1	rs10890354	chr1:46305347	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.77	2.1E-8	Body mass index	
CESC	cis	1	rs10890361	chr1:46346234	CCDC163P	chr1:45960581-45965646:-	-0.31	-5.34	1.98E-7	Body mass index	
CESC	cis	1	rs10890363	chr1:46356148	CCDC163P	chr1:45960581-45965646:-	0.35	5.66	3.75E-8	Body mass index	
CESC	cis	1	rs10893380	chr11:125311674	CHEK1	chr11:125495036-125546148:+	0.34	4.53	8.74E-6	Schizophrenia	
CESC	cis	1	rs10893380	chr11:125311674	DCPS	chr11:126173647-126215643:+	0.31	4.02	7.5E-5	Schizophrenia	
CESC	cis	1	rs10893380	chr11:125311674	EI24	chr11:125439298-125454574:+	0.41	5.35	1.81E-7	Schizophrenia	
CESC	cis	1	rs10893380	chr11:125311674	FOXRED1	chr11:126139055-126148026:+	0.36	4.3	2.34E-5	Schizophrenia	
CESC	cis	1	rs10893380	chr11:125311674	HYLS1	chr11:125753509-125770540:+	0.35	4.19	3.73E-5	Schizophrenia	
CESC	cis	1	rs10893380	chr11:125311674	RPUSD4	chr11:126071990-126081587:-	0.33	4.63	5.53E-6	Schizophrenia	
CESC	cis	1	rs10893380	chr11:125311674	SRPR	chr11:126132837-126138750:-	0.35	4.48	1.08E-5	Schizophrenia	
CESC	cis	1	rs10893380	chr11:125311674	STT3A	chr11:125462739-125491280:+	0.33	4.5	9.94E-6	Schizophrenia	
CESC	cis	1	rs10893380	chr11:125311674	TBRG1	chr11:124492742-124505821:+	0.31	4.35	1.96E-5	Schizophrenia	
CESC	cis	1	rs10893380	chr11:125311674	TMEM218	chr11:124966401-124981475:-	0.35	4.02	7.53E-5	Schizophrenia	
CESC	cis	1	rs10918605	chr1:166955638	MAEL	chr1:166958519-166991447:+	-0.34	-4.43	1.38E-5	Refractive astigmatism	
CESC	cis	1	rs10918606	chr1:166957249	MAEL	chr1:166958519-166991447:+	-0.34	-4.43	1.38E-5	Refractive astigmatism	
CESC	cis	1	rs10935120	chr3:134233092	ANAPC13	chr3:134196547-134204865:-	-0.31	-4.24	3.1E-5	Height	
CESC	cis	1	rs10944161	chr6:86630376	SNHG5	chr6:86386726-86388451:-	-0.57	-9.02	3.37E-17	Response to antipsychotic treatment	
CESC	cis	1	rs10944163	chr6:86658693	SNHG5	chr6:86386726-86388451:-	-0.57	-8.63	4.96E-16	Response to antipsychotic treatment	
CESC	cis	1	rs10944169	chr6:86683036	SNHG5	chr6:86386726-86388451:-	-0.57	-8.87	9.8E-17	Response to antipsychotic treatment	
CESC	cis	1	rs10944170	chr6:86685469	SNHG5	chr6:86386726-86388451:-	-0.56	-8.96	5.13E-17	Response to antipsychotic treatment	
CESC	cis	1	rs10950032	chr7:65738591	CCT6P1	chr7:65216092-65228661:+	-0.54	-5.06	7.72E-7	Diabetic kidney disease	
CESC	cis	1	rs10950032	chr7:65738591	LOC493754	chr7:65993446-66057363:-	-0.53	-4.17	4.17E-5	Diabetic kidney disease	
CESC	cis	1	rs11020847	chr11:94323912	ENDOD1	chr11:94823017-94865815:+	0.33	4.38	1.7E-5	Attention deficit hyperactivity disorder symptoms (interaction)	
CESC	cis	1	rs11020847	chr11:94323912	KIAA1731	chr11:93394816-93463522:+	0.29	3.98	8.72E-5	Attention deficit hyperactivity disorder symptoms (interaction)	
CESC	cis	1	rs11020847	chr11:94323912	MRE11A	chr11:94150469-94227040:-	0.3	4.5	9.91E-6	Attention deficit hyperactivity disorder symptoms (interaction)	
CESC	cis	1	rs11024101	chr11:17005544	KCNC1	chr11:17757495-17804602:+	0.31	4	7.99E-5	Glaucoma (primary angle closure)	
CESC	cis	1	rs11056837	chr12:16401495	MGST1	chr12:16500076-16523342:+	-0.28	-3.97	9.33E-5	Visceral fat	
CESC	cis	1	rs11079159	chr17:53373550	HLF	chr17:53342321-53402426:+	0.25	4.01	7.79E-5	QRS duration	
CESC	cis	1	rs11079706	chr17:65835470	LOC651250	chr17:66097696-66157623:+	-0.31	-3.99	8.36E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs11079707	chr17:65835617	LOC651250	chr17:66097696-66157623:+	0.3	4.14	4.66E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs1109227	chr3:48479207	TREX1	chr3:48501186-48509043:+	-0.2	-4.56	7.58E-6	Longevity	
CESC	cis	1	rs111226767	chr1:75853959	SLC44A5	chr1:75667816-76143610:-	-0.55	-4.27	2.68E-5	Whole-brain volume (Alzheimer's disease interaction)	
CESC	cis	1	rs11123170	chr2:113978940	LOC654433	chr2:113993107-114024579:+	-0.45	-6.32	1.02E-9	Renal function-related traits (BUN)	
CESC	cis	1	rs11123170	chr2:113978940	PAX8	chr2:113973575-114036498:-	-0.3	-4.31	2.26E-5	Renal function-related traits (BUN)	
CESC	cis	1	rs11130170	chr3:48449897	TREX1	chr3:48501186-48509043:+	-0.2	-4.63	5.59E-6	Longevity	
CESC	cis	1	rs11130171	chr3:48462461	TREX1	chr3:48501186-48509043:+	-0.19	-4.23	3.14E-5	Longevity	
CESC	cis	1	rs11130338	chr3:53120924	RFT1	chr3:53122503-53164470:-	-0.33	-4.93	1.4E-6	Height	
CESC	cis	1	rs111315781	chr2:201738724	PPIL3	chr2:201735680-201753999:-	-0.59	-5.85	1.4E-8	Triptolide cytotoxicity	
CESC	cis	1	rs11132254	chr4:185611592	MLF1IP	chr4:185615220-185655286:-	-0.47	-7.61	4.29E-13	Kawasaki disease	
CESC	cis	1	rs1114380	chr2:73804708	ALMS1P	chr2:73872046-73912692:+	0.41	5.68	3.42E-8	Metabolite levels	
CESC	cis	1	rs11156875	chr14:35619816	PPP2R3C	chr14:35554679-35591679:-	0.43	5	1.03E-6	Atopic dermatitis	
CESC	cis	1	rs11159067	chr14:74637444	LIN52	chr14:74551656-74667117:+	0.41	8.43	2.03E-15	Common traits (Other)	
CESC	cis	1	rs11167515	chr5:150239471	LOC134466	chr5:150310000-150326146:-	0.56	5.75	2.32E-8	Crohn's disease	
CESC	cis	1	rs11167518	chr5:150258920	LOC134466	chr5:150310000-150326146:-	0.42	5.16	4.85E-7	Crohn's disease	
CESC	cis	1	rs11167519	chr5:150265407	LOC134466	chr5:150310000-150326146:-	0.4	4.73	3.64E-6	Crohn's disease	
CESC	cis	1	rs11167520	chr5:150265639	LOC134466	chr5:150310000-150326146:-	0.4	4.73	3.64E-6	Crohn's disease	
CESC	cis	1	rs11167521	chr5:150271785	LOC134466	chr5:150310000-150326146:-	0.39	4.57	7.44E-6	Crohn's disease	
CESC	cis	1	rs11167526	chr5:150332481	LOC134466	chr5:150310000-150326146:-	0.56	4.64	5.37E-6	Crohn's disease	
CESC	cis	1	rs11168628	chr12:48949564	HDAC7	chr12:48176509-48213763:-	0.48	4.25	2.92E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs11168629	chr12:48949622	HDAC7	chr12:48176509-48213763:-	0.48	4.25	2.92E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs11168630	chr12:48950070	HDAC7	chr12:48176509-48213763:-	0.48	4.25	2.92E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs11168631	chr12:48950129	HDAC7	chr12:48176509-48213763:-	0.48	4.25	2.92E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs11168632	chr12:48950578	HDAC7	chr12:48176509-48213763:-	0.48	4.25	2.92E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs11168633	chr12:48951224	HDAC7	chr12:48176509-48213763:-	0.48	4.25	2.92E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs11168634	chr12:48951593	HDAC7	chr12:48176509-48213763:-	0.48	4.25	2.92E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs11168635	chr12:48951718	HDAC7	chr12:48176509-48213763:-	0.45	4.05	6.79E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs11168636	chr12:48951840	HDAC7	chr12:48176509-48213763:-	0.48	4.25	2.92E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs11168638	chr12:48953571	HDAC7	chr12:48176509-48213763:-	0.48	4.25	2.92E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs11168639	chr12:48953682	HDAC7	chr12:48176509-48213763:-	0.48	4.27	2.67E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs11168640	chr12:48955995	HDAC7	chr12:48176509-48213763:-	0.45	4	8.03E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs11172333	chr12:58170335	FAM119B	chr12:58166383-58176323:+	0.39	5.21	3.67E-7	Multiple sclerosis	
CESC	cis	1	rs11172333	chr12:58170335	TSFM	chr12:58176536-58191367:+	-0.36	-6.24	1.65E-9	Multiple sclerosis	
CESC	cis	1	rs11172335	chr12:58175201	FAM119B	chr12:58166383-58176323:+	0.39	5.19	4.03E-7	Multiple sclerosis	
CESC	cis	1	rs11172335	chr12:58175201	TSFM	chr12:58176536-58191367:+	-0.36	-6.04	5.11E-9	Multiple sclerosis	
CESC	cis	1	rs11172342	chr12:58187758	FAM119B	chr12:58166383-58176323:+	0.39	5.07	7.2E-7	Multiple sclerosis	
CESC	cis	1	rs11172342	chr12:58187758	TSFM	chr12:58176536-58191367:+	-0.35	-5.87	1.25E-8	Multiple sclerosis	
CESC	cis	1	rs11172343	chr12:58188157	FAM119B	chr12:58166383-58176323:+	0.39	5.07	7.2E-7	Multiple sclerosis	
CESC	cis	1	rs11172343	chr12:58188157	TSFM	chr12:58176536-58191367:+	-0.35	-5.87	1.25E-8	Multiple sclerosis	
CESC	cis	1	rs11172344	chr12:58193448	FAM119B	chr12:58166383-58176323:+	0.39	5.29	2.47E-7	Multiple sclerosis	
CESC	cis	1	rs11172344	chr12:58193448	TSFM	chr12:58176536-58191367:+	-0.31	-5.26	2.84E-7	Multiple sclerosis	
CESC	cis	1	rs11172349	chr12:58212528	FAM119B	chr12:58166383-58176323:+	0.38	5.02	9.23E-7	Multiple sclerosis	
CESC	cis	1	rs11172349	chr12:58212528	TSFM	chr12:58176536-58191367:+	-0.32	-5.47	9.87E-8	Multiple sclerosis	
CESC	cis	1	rs11172351	chr12:58213485	FAM119B	chr12:58166383-58176323:+	0.38	5.04	8.59E-7	Multiple sclerosis	
CESC	cis	1	rs11172351	chr12:58213485	TSFM	chr12:58176536-58191367:+	-0.32	-5.43	1.25E-7	Multiple sclerosis	
CESC	cis	1	rs11191419	chr10:104612335	C10orf32	chr10:104613967-104624718:+	-0.35	-5.22	3.5E-7	Schizophrenia	
CESC	cis	1	rs11201312	chr10:81795778	LOC219347	chr10:81805991-81838949:-	0.46	4.28	2.54E-5	Chronic obstructive pulmonary disease-related biomarkers	
CESC	cis	1	rs11201660	chr10:81854531	LOC219347	chr10:81805991-81838949:-	-0.49	-4.74	3.42E-6	Chronic obstructive pulmonary disease-related biomarkers	
CESC	cis	1	rs11211132	chr1:45990516	CCDC163P	chr1:45960581-45965646:-	-0.79	-13.94	8.65E-34	Homocysteine levels	
CESC	cis	1	rs11211199	chr1:46287869	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.9	1.06E-8	Body mass index	
CESC	cis	1	rs11211208	chr1:46334256	CCDC163P	chr1:45960581-45965646:-	-0.35	-5.69	3.17E-8	Body mass index	
CESC	cis	1	rs11211230	chr1:46406767	CCDC163P	chr1:45960581-45965646:-	-0.35	-5.6	5.26E-8	Body mass index	
CESC	cis	1	rs11211234	chr1:46438787	CCDC163P	chr1:45960581-45965646:-	-0.35	-5.71	2.96E-8	Body mass index	
CESC	cis	1	rs11211241	chr1:46452683	CCDC163P	chr1:45960581-45965646:-	-0.35	-5.71	2.96E-8	Body mass index	
CESC	cis	1	rs11223996	chr11:134626887	VPS26B	chr11:134094561-134117684:+	0.38	4.52	9.22E-6	Myopia (pathological)	
CESC	cis	1	rs11242	chr3:53125922	RFT1	chr3:53122503-53164470:-	0.31	4.73	3.57E-6	Height	
CESC	cis	1	rs112537273	chr8:38248306	WHSC1L1	chr8:38132563-38239790:-	-0.3	-4.14	4.66E-5	Schizophrenia	
CESC	cis	1	rs112572902	chr2:198175179	HSPD1	chr2:198351310-198364998:-	0.21	3.98	8.81E-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy)	
CESC	cis	1	rs113333037	chr17:2200106	SRR	chr17:2207248-2228553:+	-0.38	-4.9	1.62E-6	Esophageal cancer (squamous cell)	
CESC	cis	1	rs1133483	chr4:100023923	ADH4	chr4:100044835-100065449:-	-0.28	-4.53	8.84E-6	HDL cholesterol	
CESC	cis	1	rs1138273	chr3:134261437	ANAPC13	chr3:134196547-134204865:-	0.3	3.96	9.6E-5	Height	
CESC	cis	1	rs1141321	chr6:49412433	MUT	chr6:49398994-49431031:-	0.43	7.5	8.61E-13	Folate pathway vitamin levels	
CESC	cis	1	rs114200987	chr14:35586916	PPP2R3C	chr14:35554679-35591679:-	0.47	5.22	3.49E-7	Atopic dermatitis	
CESC	cis	1	rs114244137	chr5:150264753	LOC134466	chr5:150310000-150326146:-	0.4	4.73	3.64E-6	Crohn's disease	
CESC	cis	1	rs114407954	chr1:75871366	SLC44A5	chr1:75667816-76143610:-	-0.54	-4.19	3.75E-5	Whole-brain volume (Alzheimer's disease interaction)	
CESC	cis	1	rs114562844	chr3:52991584	RFT1	chr3:53122503-53164470:-	0.53	4.59	6.69E-6	Immune reponse to smallpox (secreted IL-2)	
CESC	cis	1	rs114865780	chr1:75871055	SLC44A5	chr1:75667816-76143610:-	-0.54	-4.19	3.75E-5	Whole-brain volume (Alzheimer's disease interaction)	
CESC	cis	1	rs114960066	chr3:41882323	ULK4	chr3:41288091-42003660:-	0.51	8.19	1.01E-14	Diastolic blood pressure	
CESC	cis	1	rs114976176	chr2:264621	SH3YL1	chr2:218138-264810:-	-0.7	-11.47	3.83E-25	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs11538349	chr7:65421871	CCT6P1	chr7:65216092-65228661:+	0.39	3.96	9.41E-5	Diabetic kidney disease	
CESC	cis	1	rs11553746	chr2:272203	SH3YL1	chr2:218138-264810:-	-0.72	-11.82	2.37E-26	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs11578336	chr1:166958710	MAEL	chr1:166958519-166991447:+	-0.32	-4.17	4.16E-5	Refractive astigmatism	
CESC	cis	1	rs11579634	chr1:46466391	CCDC163P	chr1:45960581-45965646:-	0.34	5.44	1.17E-7	Body mass index	
CESC	cis	1	rs11582427	chr1:59850368	OMA1	chr1:58939504-59012446:-	-0.36	-4.29	2.48E-5	Obesity-related traits	
CESC	cis	1	rs11582929	chr1:59851155	OMA1	chr1:58939504-59012446:-	-0.37	-4.44	1.32E-5	Obesity-related traits	
CESC	cis	1	rs11584915	chr1:59860256	OMA1	chr1:58939504-59012446:-	0.35	4.3	2.37E-5	Obesity-related traits	
CESC	cis	1	rs11589562	chr1:46466721	CCDC163P	chr1:45960581-45965646:-	0.25	4.03	7.29E-5	Body mass index	
CESC	cis	1	rs116139393	chr7:6771660	PMS2CL	chr7:6749757-6793492:+	-0.44	-4.77	2.94E-6	Alzheimer's disease (APOE e4 interaction)	
CESC	cis	1	rs11622962	chr14:65299145	CHURC1	chr14:65381140-65411309:+	0.66	4.13	4.83E-5	Daytime sleep phenotypes	
CESC	cis	1	rs11628710	chr14:74649280	LIN52	chr14:74551656-74667117:+	0.41	8.29	5.17E-15	Common traits (Other)	
CESC	cis	1	rs11641652	chr16:68588812	NIP7	chr16:69373546-69377007:+	0.3	4.22	3.25E-5	Response to antipsychotic treatment in schizophrenia (reasoning);HIV-1 viral setpoint	
CESC	cis	1	rs11651264	chr17:79576394	TSPAN10	chr17:79609349-79615778:+	-0.4	-6.31	1.1E-9	Eye color traits	
CESC	cis	1	rs11652797	chr17:79574124	TSPAN10	chr17:79609349-79615778:+	0.41	6.45	4.94E-10	Eye color traits	
CESC	cis	1	rs11665980	chr19:18749354	PGPEP1	chr19:18451408-18480763:+	-0.33	-4.31	2.31E-5	Orofacial clefts	
CESC	cis	1	rs11674602	chr2:73723185	ALMS1P	chr2:73872046-73912692:+	0.42	5.76	2.2E-8	Metabolite levels	
CESC	cis	1	rs1167613	chr7:65487439	CCT6P1	chr7:65216092-65228661:+	0.46	4.45	1.27E-5	Diabetic kidney disease	
CESC	cis	1	rs116774684	chr1:75873384	SLC44A5	chr1:75667816-76143610:-	-0.53	-4.06	6.31E-5	Whole-brain volume (Alzheimer's disease interaction)	
CESC	cis	1	rs1167827	chr7:75163169	PMS2L3	chr7:75137070-75157418:-	-0.5	-8.15	1.34E-14	Body mass index	
CESC	cis	1	rs11689392	chr2:73622026	ALMS1P	chr2:73872046-73912692:+	0.39	5.57	6.14E-8	Metabolite levels	
CESC	cis	1	rs116988415	chr14:65292145	CHURC1	chr14:65381140-65411309:+	0.68	4.17	4.07E-5	Daytime sleep phenotypes	
CESC	cis	1	rs11704021	chr22:39074716	CBY1	chr22:39052658-39069853:+	0.29	4.82	2.41E-6	Resting heart rate	
CESC	cis	1	rs11706117	chr3:134212526	ANAPC13	chr3:134196547-134204865:-	0.3	4.04	6.96E-5	Height	
CESC	cis	1	rs11707575	chr3:53113762	RFT1	chr3:53122503-53164470:-	0.37	4.01	7.77E-5	Immune reponse to smallpox (secreted IL-2)	
CESC	cis	1	rs11708531	chr3:134224902	ANAPC13	chr3:134196547-134204865:-	0.3	4.03	7.09E-5	Height	
CESC	cis	1	rs117094839	chr12:120922159	GCN1L1	chr12:120565016-120632513:-	-0.52	-4.22	3.34E-5	Insulin resistance/response	
CESC	cis	1	rs11712561	chr3:48435272	TREX1	chr3:48501186-48509043:+	-0.21	-4.67	4.73E-6	Longevity	
CESC	cis	1	rs11713290	chr3:52971579	RFT1	chr3:53122503-53164470:-	0.47	4.13	4.81E-5	Immune reponse to smallpox (secreted IL-2)	
CESC	cis	1	rs11718538	chr3:52975987	RFT1	chr3:53122503-53164470:-	0.47	4.13	4.81E-5	Immune reponse to smallpox (secreted IL-2)	
CESC	cis	1	rs11739344	chr5:56111087	C5orf35	chr5:56205103-56213010:+	0.81	11.73	4.97E-26	Type 2 diabetes	
CESC	cis	1	rs11739619	chr5:150264662	LOC134466	chr5:150310000-150326146:-	0.4	4.73	3.64E-6	Crohn's disease	
CESC	cis	1	rs11739677	chr5:150294883	LOC134466	chr5:150310000-150326146:-	0.7	6.84	4.98E-11	Crohn's disease	
CESC	cis	1	rs11740172	chr5:150300278	IRGM	chr5:150226085-150280295:+	0.42	4.12	4.95E-5	Crohn's disease	
CESC	cis	1	rs11740172	chr5:150300278	LOC134466	chr5:150310000-150326146:-	0.65	6.43	5.53E-10	Crohn's disease	
CESC	cis	1	rs11741861	chr5:150277909	IRGM	chr5:150226085-150280295:+	-0.46	-4.32	2.15E-5	Crohn's disease	
CESC	cis	1	rs11741861	chr5:150277909	LOC134466	chr5:150310000-150326146:-	-0.66	-6.16	2.52E-9	Crohn's disease	
CESC	cis	1	rs11743488	chr5:150279218	IRGM	chr5:150226085-150280295:+	0.47	4.27	2.65E-5	Crohn's disease	
CESC	cis	1	rs11743488	chr5:150279218	LOC134466	chr5:150310000-150326146:-	0.67	6.18	2.27E-9	Crohn's disease	
CESC	cis	1	rs11746108	chr5:150264622	LOC134466	chr5:150310000-150326146:-	0.4	4.73	3.64E-6	Crohn's disease	
CESC	cis	1	rs11746560	chr5:150185925	LOC134466	chr5:150310000-150326146:-	0.7	6.39	7.04E-10	Crohn's disease	
CESC	cis	1	rs11746807	chr5:150300419	IRGM	chr5:150226085-150280295:+	0.42	4.12	4.95E-5	Crohn's disease	
CESC	cis	1	rs11746807	chr5:150300419	LOC134466	chr5:150310000-150326146:-	0.65	6.43	5.53E-10	Crohn's disease	
CESC	cis	1	rs11747065	chr5:150295486	IRGM	chr5:150226085-150280295:+	0.42	4.12	4.95E-5	Crohn's disease	
CESC	cis	1	rs11747065	chr5:150295486	LOC134466	chr5:150310000-150326146:-	0.65	6.43	5.53E-10	Crohn's disease	
CESC	cis	1	rs11747270	chr5:150258867	LOC134466	chr5:150310000-150326146:-	-0.46	-5.63	4.43E-8	Crohn's disease	
CESC	cis	1	rs11748151	chr5:150226292	LOC134466	chr5:150310000-150326146:-	0.44	5.04	8.53E-7	Crohn's disease	
CESC	cis	1	rs11748158	chr5:150226345	LOC134466	chr5:150310000-150326146:-	0.44	5.04	8.53E-7	Crohn's disease	
CESC	cis	1	rs11748553	chr5:150184553	LOC134466	chr5:150310000-150326146:-	0.7	6.39	7.04E-10	Crohn's disease	
CESC	cis	1	rs11749391	chr5:150229066	LOC134466	chr5:150310000-150326146:-	0.4	4.66	4.86E-6	Crohn's disease	
CESC	cis	1	rs11758849	chr6:86708262	SNHG5	chr6:86386726-86388451:-	-0.6	-9.88	6.97E-20	Response to antipsychotic treatment	
CESC	cis	1	rs11759855	chr6:86610841	SNHG5	chr6:86386726-86388451:-	-0.59	-9.11	1.7E-17	Response to antipsychotic treatment	
CESC	cis	1	rs11769063	chr7:86918603	DBF4	chr7:87505544-87538856:+	0.56	4.4	1.53E-5	Bipolar disorder or major depressive disorder (combined)	
CESC	cis	1	rs11782652	chr8:82653644	CHMP4C	chr8:82644688-82671746:+	-0.78	-5.54	6.94E-8	Epithelial ovarian cancer;Ovarian cancer	
CESC	cis	1	rs117894641	chr12:120939099	GCN1L1	chr12:120565016-120632513:-	-0.52	-4.22	3.34E-5	Insulin resistance/response	
CESC	cis	1	rs117907570	chr6:86601283	SNHG5	chr6:86386726-86388451:-	-0.62	-11.88	1.46E-26	Response to antipsychotic treatment	
CESC	cis	1	rs11810993	chr1:46478793	CCDC163P	chr1:45960581-45965646:-	-0.33	-5.22	3.59E-7	Body mass index	
CESC	cis	1	rs118110670	chr10:81792242	LOC219347	chr10:81805991-81838949:-	0.45	4.14	4.64E-5	Chronic obstructive pulmonary disease-related biomarkers	
CESC	cis	1	rs11826771	chr11:58508972	FAM111B	chr11:58874658-58894886:+	0.53	4.42	1.44E-5	Body mass (lean)	
CESC	cis	1	rs11856184	chr15:43919162	CATSPER2	chr15:43922774-43959900:-	-0.44	-5.49	9.11E-8	Tumor biomarkers	
CESC	cis	1	rs11856184	chr15:43919162	CKMT1A	chr15:43985084-43991419:+	-0.44	-5.01	9.9E-7	Tumor biomarkers	
CESC	cis	1	rs11859322	chr16:68591386	NIP7	chr16:69373546-69377007:+	0.29	4.04	6.94E-5	Response to antipsychotic treatment in schizophrenia (reasoning);HIV-1 viral setpoint	
CESC	cis	1	rs11859375	chr16:68594846	NIP7	chr16:69373546-69377007:+	0.29	4.04	6.94E-5	Response to antipsychotic treatment in schizophrenia (reasoning);HIV-1 viral setpoint	
CESC	cis	1	rs11860220	chr16:68591715	NIP7	chr16:69373546-69377007:+	0.3	4.17	4.04E-5	Response to antipsychotic treatment in schizophrenia (reasoning);HIV-1 viral setpoint	
CESC	cis	1	rs11869819	chr17:65868669	LOC651250	chr17:66097696-66157623:+	-0.32	-4.13	4.82E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs11870068	chr17:65944515	LOC651250	chr17:66097696-66157623:+	-0.31	-4.13	4.9E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs11879853	chr19:23029434	ZNF492	chr19:22817126-22850472:+	0.35	4.24	3.12E-5	Bronchopulmonary dysplasia	
CESC	cis	1	rs11893832	chr2:88507537	THNSL2	chr2:88469835-88486145:+	-0.47	-4.51	9.68E-6	Plasma clusterin levels	
CESC	cis	1	rs11893881	chr2:73824373	ALMS1P	chr2:73872046-73912692:+	0.36	4.96	1.21E-6	Metabolite levels	
CESC	cis	1	rs11899576	chr2:86256193	LOC90784	chr2:86247339-86250991:-	-0.47	-4.53	8.89E-6	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
CESC	cis	1	rs11899576	chr2:86256193	POLR1A	chr2:86253453-86333278:-	0.31	4.02	7.53E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
CESC	cis	1	rs11899740	chr2:73631212	ALMS1P	chr2:73872046-73912692:+	0.39	5.24	3.2E-7	Metabolite levels	
CESC	cis	1	rs11899902	chr2:73631564	ALMS1P	chr2:73872046-73912692:+	0.41	5.8	1.86E-8	Metabolite levels	
CESC	cis	1	rs11901272	chr2:73720444	ALMS1P	chr2:73872046-73912692:+	0.38	5.5	8.66E-8	Metabolite levels	
CESC	cis	1	rs11903916	chr2:73815328	ALMS1P	chr2:73872046-73912692:+	0.37	5.35	1.9E-7	Metabolite levels	
CESC	cis	1	rs11919350	chr3:134235970	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.36	1.84E-5	Height	
CESC	cis	1	rs11927068	chr3:134266321	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.35	1.95E-5	Height	
CESC	cis	1	rs11928090	chr3:49604904	KLHDC8B	chr3:49209068-49213918:+	-0.26	-3.98	8.82E-5	Menarche (age at onset)	
CESC	cis	1	rs11928499	chr3:134232350	ANAPC13	chr3:134196547-134204865:-	-0.35	-4.63	5.68E-6	Height	
CESC	cis	1	rs11928580	chr3:41885722	ULK4	chr3:41288091-42003660:-	0.51	8.19	1.01E-14	Diastolic blood pressure	
CESC	cis	1	rs11950957	chr5:150253914	LOC134466	chr5:150310000-150326146:-	0.4	4.92	1.48E-6	Crohn's disease	
CESC	cis	1	rs11951694	chr5:150254338	LOC134466	chr5:150310000-150326146:-	0.4	4.92	1.48E-6	Crohn's disease	
CESC	cis	1	rs11955172	chr5:150254378	LOC134466	chr5:150310000-150326146:-	0.4	4.92	1.48E-6	Crohn's disease	
CESC	cis	1	rs11957134	chr5:150230950	LOC134466	chr5:150310000-150326146:-	-0.54	-5.6	5.14E-8	Crohn's disease	
CESC	cis	1	rs11974219	chr7:65647410	NCRNA00174	chr7:65841032-65865395:-	0.26	4.11	5.18E-5	Aortic root size	
CESC	cis	1	rs11976020	chr7:72247800	TYW1B	chr7:72023729-72298813:-	0.98	17.15	2.54E-45	Educational attainment (years of education)	
CESC	cis	1	rs11984666	chr8:130730280	GSDMC	chr8:130760443-130799134:-	0.31	5.56	6.51E-8	Infant length;Height	
CESC	cis	1	rs1199095	chr10:59950760	IPMK	chr10:59955618-60027694:-	0.22	4.72	3.72E-6	Inflammatory bowel disease	
CESC	cis	1	rs1199096	chr10:59950234	IPMK	chr10:59955618-60027694:-	0.23	5.13	5.54E-7	Inflammatory bowel disease	
CESC	cis	1	rs1199099	chr10:59948335	IPMK	chr10:59955618-60027694:-	0.23	4.93	1.39E-6	Inflammatory bowel disease	
CESC	cis	1	rs1199100	chr10:59948044	IPMK	chr10:59955618-60027694:-	0.23	4.93	1.39E-6	Inflammatory bowel disease	
CESC	cis	1	rs1199101	chr10:59947901	IPMK	chr10:59955618-60027694:-	0.23	5.08	6.96E-7	Inflammatory bowel disease	
CESC	cis	1	rs1199103	chr10:59947231	IPMK	chr10:59955618-60027694:-	-0.24	-5.24	3.15E-7	Inflammatory bowel disease	
CESC	cis	1	rs1199104	chr10:59946781	IPMK	chr10:59955618-60027694:-	0.22	4.87	1.85E-6	Inflammatory bowel disease	
CESC	cis	1	rs1199107	chr10:59943709	IPMK	chr10:59955618-60027694:-	0.21	4.54	8.59E-6	Inflammatory bowel disease	
CESC	cis	1	rs1199108	chr10:59942324	IPMK	chr10:59955618-60027694:-	0.21	4.56	7.55E-6	Inflammatory bowel disease	
CESC	cis	1	rs1199338	chr3:138087467	ARMC8	chr3:137906148-138016219:+	0.32	4.4	1.56E-5	Coronary artery disease;Coronary heart disease	
CESC	cis	1	rs12021587	chr1:46472759	CCDC163P	chr1:45960581-45965646:-	-0.33	-5.29	2.55E-7	Body mass index	
CESC	cis	1	rs12049588	chr1:46472422	CCDC163P	chr1:45960581-45965646:-	-0.33	-5.29	2.55E-7	Body mass index	
CESC	cis	1	rs12054923	chr5:150249059	LOC134466	chr5:150310000-150326146:-	0.45	5.32	2.18E-7	Crohn's disease	
CESC	cis	1	rs12091564	chr1:145395604	NOTCH2NL	chr1:145209111-145295525:+	-0.63	-6.92	3.13E-11	Coronary heart disease	
CESC	cis	1	rs12130629	chr1:166953284	MAEL	chr1:166958519-166991447:+	-0.33	-4.37	1.79E-5	Refractive astigmatism	
CESC	cis	1	rs12134698	chr1:209987801	C1orf133	chr1:210404804-210407466:-	0.28	4.08	5.85E-5	Orofacial clefts	
CESC	cis	1	rs12139630	chr1:46350935	CCDC163P	chr1:45960581-45965646:-	-0.34	-5.59	5.52E-8	Body mass index	
CESC	cis	1	rs12144263	chr1:46352446	CCDC163P	chr1:45960581-45965646:-	-0.34	-5.59	5.52E-8	Body mass index	
CESC	cis	1	rs12154056	chr6:86634094	SNHG5	chr6:86386726-86388451:-	-0.57	-9.02	3.37E-17	Response to antipsychotic treatment	
CESC	cis	1	rs12190598	chr6:86686074	SNHG5	chr6:86386726-86388451:-	-0.55	-8.66	4.12E-16	Response to antipsychotic treatment	
CESC	cis	1	rs12190604	chr6:86716215	SNHG5	chr6:86386726-86388451:-	-0.58	-9.16	1.22E-17	Response to antipsychotic treatment	
CESC	cis	1	rs12192992	chr6:86609915	SNHG5	chr6:86386726-86388451:-	-0.6	-9.14	1.37E-17	Response to antipsychotic treatment	
CESC	cis	1	rs12196037	chr6:86694631	SNHG5	chr6:86386726-86388451:-	-0.57	-8.65	4.51E-16	Response to antipsychotic treatment	
CESC	cis	1	rs12196411	chr6:86779762	SNHG5	chr6:86386726-86388451:-	-0.55	-8.44	1.86E-15	Response to antipsychotic treatment	
CESC	cis	1	rs12196937	chr6:49382808	CENPQ	chr6:49431096-49460820:+	-0.25	-4.5	1.02E-5	Folate pathway vitamin levels	
CESC	cis	1	rs12196937	chr6:49382808	MUT	chr6:49398994-49431031:-	0.38	6.68	1.3E-10	Folate pathway vitamin levels	
CESC	cis	1	rs12199516	chr6:86726221	SNHG5	chr6:86386726-86388451:-	-0.61	-9.61	4.88E-19	Response to antipsychotic treatment	
CESC	cis	1	rs12199784	chr6:86726808	SNHG5	chr6:86386726-86388451:-	-0.61	-9.62	4.46E-19	Response to antipsychotic treatment	
CESC	cis	1	rs12200330	chr6:86656653	SNHG5	chr6:86386726-86388451:-	-0.59	-8.96	5.15E-17	Response to antipsychotic treatment	
CESC	cis	1	rs12201571	chr6:86609750	SNHG5	chr6:86386726-86388451:-	-0.59	-9.11	1.7E-17	Response to antipsychotic treatment	
CESC	cis	1	rs12201735	chr6:86656939	SNHG5	chr6:86386726-86388451:-	-0.56	-8.76	2.02E-16	Response to antipsychotic treatment	
CESC	cis	1	rs12201741	chr6:86602619	SNHG5	chr6:86386726-86388451:-	-0.58	-9.17	1.17E-17	Response to antipsychotic treatment	
CESC	cis	1	rs12201880	chr6:86627007	SNHG5	chr6:86386726-86388451:-	-0.57	-9.02	3.37E-17	Response to antipsychotic treatment	
CESC	cis	1	rs12202075	chr6:49427655	CENPQ	chr6:49431096-49460820:+	-0.24	-4.32	2.14E-5	Folate pathway vitamin levels	
CESC	cis	1	rs12202075	chr6:49427655	MUT	chr6:49398994-49431031:-	0.39	6.87	4.19E-11	Folate pathway vitamin levels	
CESC	cis	1	rs12203493	chr6:86758642	SNHG5	chr6:86386726-86388451:-	-0.56	-8.73	2.46E-16	Response to antipsychotic treatment	
CESC	cis	1	rs12203924	chr6:86776412	SNHG5	chr6:86386726-86388451:-	-0.57	-8.78	1.77E-16	Response to antipsychotic treatment	
CESC	cis	1	rs12204015	chr6:86598334	SNHG5	chr6:86386726-86388451:-	-0.64	-11.98	6.66E-27	Response to antipsychotic treatment	
CESC	cis	1	rs12204365	chr6:86700532	SNHG5	chr6:86386726-86388451:-	-0.57	-8.99	4.01E-17	Response to antipsychotic treatment	
CESC	cis	1	rs12205336	chr6:86722367	SNHG5	chr6:86386726-86388451:-	-0.6	-9.22	8.29E-18	Response to antipsychotic treatment	
CESC	cis	1	rs12205548	chr6:86759770	SNHG5	chr6:86386726-86388451:-	-0.56	-8.55	8.6E-16	Response to antipsychotic treatment	
CESC	cis	1	rs12207305	chr6:86723502	SNHG5	chr6:86386726-86388451:-	-0.61	-9.67	3.23E-19	Response to antipsychotic treatment	
CESC	cis	1	rs12207610	chr6:86688016	SNHG5	chr6:86386726-86388451:-	-0.56	-8.87	9.48E-17	Response to antipsychotic treatment	
CESC	cis	1	rs12208493	chr6:86662267	SNHG5	chr6:86386726-86388451:-	-0.59	-9.06	2.46E-17	Response to antipsychotic treatment	
CESC	cis	1	rs12209127	chr6:86724427	SNHG5	chr6:86386726-86388451:-	-0.6	-9.22	8.29E-18	Response to antipsychotic treatment	
CESC	cis	1	rs12212733	chr6:86726013	SNHG5	chr6:86386726-86388451:-	-0.59	-9.21	8.45E-18	Response to antipsychotic treatment	
CESC	cis	1	rs12213149	chr6:86668644	SNHG5	chr6:86386726-86388451:-	-0.59	-9.06	2.46E-17	Response to antipsychotic treatment	
CESC	cis	1	rs12213740	chr6:86656733	SNHG5	chr6:86386726-86388451:-	-0.56	-8.8	1.54E-16	Response to antipsychotic treatment	
CESC	cis	1	rs12215037	chr6:86727631	SNHG5	chr6:86386726-86388451:-	-0.59	-8.85	1.09E-16	Response to antipsychotic treatment	
CESC	cis	1	rs12215903	chr6:86675028	SNHG5	chr6:86386726-86388451:-	-0.56	-8.91	6.99E-17	Response to antipsychotic treatment	
CESC	cis	1	rs12216203	chr6:86675301	SNHG5	chr6:86386726-86388451:-	-0.58	-9.12	1.67E-17	Response to antipsychotic treatment	
CESC	cis	1	rs12216328	chr6:86703418	SNHG5	chr6:86386726-86388451:-	-0.59	-9.2	9.17E-18	Response to antipsychotic treatment	
CESC	cis	1	rs12230448	chr12:48950938	HDAC7	chr12:48176509-48213763:-	0.48	4.25	2.92E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs12230471	chr12:48951189	HDAC7	chr12:48176509-48213763:-	0.48	4.25	2.92E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs12315013	chr12:120903598	GCN1L1	chr12:120565016-120632513:-	-0.55	-4.79	2.77E-6	Insulin resistance/response	
CESC	cis	1	rs12315013	chr12:120903598	RAB35	chr12:120532904-120554599:-	-0.56	-4.53	8.92E-6	Insulin resistance/response	
CESC	cis	1	rs12315013	chr12:120903598	RNF10	chr12:120972132-121015396:+	-0.66	-4.03	7.3E-5	Insulin resistance/response	
CESC	cis	1	rs12315013	chr12:120903598	RNF34	chr12:121837902-121868389:+	-0.63	-4.19	3.77E-5	Insulin resistance/response	
CESC	cis	1	rs12405357	chr1:75861616	SLC44A5	chr1:75667816-76143610:-	-0.54	-4.09	5.68E-5	Whole-brain volume (Alzheimer's disease interaction)	
CESC	cis	1	rs12405451	chr1:46384326	CCDC163P	chr1:45960581-45965646:-	-0.33	-5.37	1.69E-7	Body mass index	
CESC	cis	1	rs12407255	chr1:75876217	SLC44A5	chr1:75667816-76143610:-	-0.52	-3.97	9.22E-5	Whole-brain volume (Alzheimer's disease interaction)	
CESC	cis	1	rs12409773	chr1:46358831	CCDC163P	chr1:45960581-45965646:-	-0.34	-5.5	8.82E-8	Body mass index	
CESC	cis	1	rs12410071	chr1:46358886	CCDC163P	chr1:45960581-45965646:-	-0.34	-5.5	8.82E-8	Body mass index	
CESC	cis	1	rs12411269	chr1:46271052	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.88	1.17E-8	Body mass index	
CESC	cis	1	rs12414891	chr10:81690385	PLAC9	chr10:81892258-81904784:+	-0.45	-5.58	5.9E-8	Chronic obstructive pulmonary disease-related biomarkers	
CESC	cis	1	rs12416687	chr10:104629011	C10orf32	chr10:104613967-104624718:+	-0.44	-5.97	7.16E-9	Arsenic metabolism	
CESC	cis	1	rs12443102	chr15:43932103	CATSPER2	chr15:43922774-43959900:-	-0.39	-4.68	4.45E-6	Tumor biomarkers	
CESC	cis	1	rs12443102	chr15:43932103	CKMT1A	chr15:43985084-43991419:+	-0.43	-4.74	3.45E-6	Tumor biomarkers	
CESC	cis	1	rs12451511	chr17:65874861	LOC651250	chr17:66097696-66157623:+	-0.31	-4.05	6.54E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs12451707	chr17:65871598	LOC651250	chr17:66097696-66157623:+	-0.33	-4.25	2.96E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs12451721	chr17:65939075	LOC651250	chr17:66097696-66157623:+	-0.33	-4.25	2.98E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs12452511	chr17:65832576	LOC651250	chr17:66097696-66157623:+	-0.33	-4.31	2.23E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs12470450	chr2:232113888	ARMC9	chr2:232063342-232238606:+	0.21	4.03	7.16E-5	Food antigen IgG levels	
CESC	cis	1	rs12473740	chr2:88527647	THNSL2	chr2:88469835-88486145:+	-0.5	-4.92	1.5E-6	Plasma clusterin levels	
CESC	cis	1	rs12474201	chr2:46921285	ATP6V1E2	chr2:46738988-46769696:-	-0.32	-4.97	1.17E-6	Height	
CESC	cis	1	rs12487542	chr3:48426076	TREX1	chr3:48501186-48509043:+	-0.19	-4.4	1.56E-5	Longevity	
CESC	cis	1	rs12515762	chr5:151209922	ATOX1	chr5:151122384-151138210:-	-0.23	-4.2	3.57E-5	Preschool internalizing problems	
CESC	cis	1	rs12515762	chr5:151209922	SLC36A1	chr5:150816553-150871939:+	-0.3	-3.97	9.09E-5	Preschool internalizing problems	
CESC	cis	1	rs12518722	chr5:151231460	ATOX1	chr5:151122384-151138210:-	-0.22	-3.97	9.1E-5	Preschool internalizing problems	
CESC	cis	1	rs12561806	chr1:46396776	CCDC163P	chr1:45960581-45965646:-	-0.33	-5.38	1.58E-7	Body mass index	
CESC	cis	1	rs12564541	chr1:46380237	CCDC163P	chr1:45960581-45965646:-	-0.33	-5.36	1.74E-7	Body mass index	
CESC	cis	1	rs12569084	chr1:166943352	MAEL	chr1:166958519-166991447:+	-0.34	-4.52	9.4E-6	Refractive astigmatism	
CESC	cis	1	rs12577464	chr11:43662440	HSD17B12	chr11:43702143-43878160:+	-0.35	-5.27	2.71E-7	Forced vital capacity	
CESC	cis	1	rs12583	chr3:49571462	KLHDC8B	chr3:49209068-49213918:+	0.29	4.5	1.0E-5	Menarche (age at onset)	
CESC	cis	1	rs12583	chr3:49571462	WDR6	chr3:49044637-49053386:+	0.29	4.72	3.78E-6	Menarche (age at onset)	
CESC	cis	1	rs12600941	chr17:65918807	LOC651250	chr17:66097696-66157623:+	-0.33	-4.25	2.88E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs12602655	chr17:65909442	LOC651250	chr17:66097696-66157623:+	-0.33	-4.25	2.98E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs12602912	chr17:65870073	LOC651250	chr17:66097696-66157623:+	-0.32	-4.13	4.82E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs12622009	chr2:86248325	LOC90784	chr2:86247339-86250991:-	-0.5	-4.73	3.65E-6	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
CESC	cis	1	rs12622009	chr2:86248325	POLR1A	chr2:86253453-86333278:-	0.33	4.29	2.5E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
CESC	cis	1	rs12637751	chr3:134266124	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.35	1.95E-5	Height	
CESC	cis	1	rs12639255	chr3:41861738	ULK4	chr3:41288091-42003660:-	0.46	6.96	2.51E-11	Diastolic blood pressure	
CESC	cis	1	rs12652003	chr5:150231945	IRGM	chr5:150226085-150280295:+	0.42	4.23	3.14E-5	Crohn's disease	
CESC	cis	1	rs12652003	chr5:150231945	LOC134466	chr5:150310000-150326146:-	0.53	5.39	1.54E-7	Crohn's disease	
CESC	cis	1	rs12653926	chr5:151250248	SLC36A1	chr5:150816553-150871939:+	-0.3	-3.97	9.15E-5	Preschool internalizing problems	
CESC	cis	1	rs12656538	chr5:150251380	LOC134466	chr5:150310000-150326146:-	0.52	5.39	1.51E-7	Crohn's disease	
CESC	cis	1	rs12656600	chr5:150311872	IRGM	chr5:150226085-150280295:+	0.47	4.47	1.17E-5	Crohn's disease	
CESC	cis	1	rs12656600	chr5:150311872	LOC134466	chr5:150310000-150326146:-	0.64	6.19	2.17E-9	Crohn's disease	
CESC	cis	1	rs12659118	chr5:150324622	LOC134466	chr5:150310000-150326146:-	0.7	6.37	7.81E-10	Crohn's disease	
CESC	cis	1	rs12661204	chr6:86678586	SNHG5	chr6:86386726-86388451:-	-0.57	-8.7	3.2E-16	Response to antipsychotic treatment	
CESC	cis	1	rs12663651	chr6:86701655	SNHG5	chr6:86386726-86388451:-	-0.57	-8.99	4.01E-17	Response to antipsychotic treatment	
CESC	cis	1	rs12663690	chr6:86640162	SNHG5	chr6:86386726-86388451:-	0.56	8.7	3.04E-16	Response to antipsychotic treatment	
CESC	cis	1	rs12664335	chr6:86597774	SNHG5	chr6:86386726-86388451:-	0.6	9.54	7.94E-19	Response to antipsychotic treatment	
CESC	cis	1	rs12665321	chr6:86769289	SNHG5	chr6:86386726-86388451:-	-0.56	-8.55	8.6E-16	Response to antipsychotic treatment	
CESC	cis	1	rs1267817	chr7:66110040	CCT6P1	chr7:65216092-65228661:+	0.57	5.41	1.35E-7	Gout	
CESC	cis	1	rs1267817	chr7:66110040	LOC493754	chr7:65993446-66057363:-	0.55	4.4	1.58E-5	Gout	
CESC	cis	1	rs1267818	chr7:66107024	CCT6P1	chr7:65216092-65228661:+	0.57	5.41	1.35E-7	Gout	
CESC	cis	1	rs1267818	chr7:66107024	LOC493754	chr7:65993446-66057363:-	0.55	4.4	1.58E-5	Gout	
CESC	cis	1	rs1267820	chr7:66050295	CCT6P1	chr7:65216092-65228661:+	0.57	5.41	1.38E-7	Diabetic kidney disease	
CESC	cis	1	rs1267820	chr7:66050295	LOC493754	chr7:65993446-66057363:-	0.54	4.31	2.25E-5	Diabetic kidney disease	
CESC	cis	1	rs12698509	chr7:65418876	CCT6P1	chr7:65216092-65228661:+	0.46	4.59	6.76E-6	Diabetic kidney disease	
CESC	cis	1	rs12749053	chr1:95660556	RWDD3	chr1:95583479-95712773:+	0.59	5.29	2.5E-7	Stearic acid (18:0) plasma levels	
CESC	cis	1	rs12755552	chr1:95685026	RWDD3	chr1:95583479-95712773:+	0.62	5.03	8.95E-7	Stearic acid (18:0) plasma levels	
CESC	cis	1	rs12768613	chr10:81916566	PLAC9	chr10:81892258-81904784:+	-0.29	-4.17	4.1E-5	Chronic obstructive pulmonary disease-related biomarkers	
CESC	cis	1	rs12787909	chr11:117546482	ATP5L	chr11:118272104-118280561:+	0.44	3.95	9.95E-5	Lipoprotein (a) - cholesterol levels	
CESC	cis	1	rs12889309	chr14:75593902	EIF2B2	chr14:75469612-75476292:+	0.24	3.96	9.68E-5	Height	
CESC	cis	1	rs12948099	chr17:79600799	TSPAN10	chr17:79609349-79615778:+	0.38	5.85	1.39E-8	Eye color traits	
CESC	cis	1	rs12980225	chr19:23026745	ZNF492	chr19:22817126-22850472:+	-0.35	-4.1	5.45E-5	Bronchopulmonary dysplasia	
CESC	cis	1	rs12983770	chr19:23023614	ZNF492	chr19:22817126-22850472:+	-0.35	-4.1	5.45E-5	Bronchopulmonary dysplasia	
CESC	cis	1	rs12995491	chr2:88527414	THNSL2	chr2:88469835-88486145:+	-0.43	-6.2	2.01E-9	Response to metformin (IC50)	
CESC	cis	1	rs13014235	chr2:202215492	ALS2CR12	chr2:202153148-202222101:-	-0.32	-4.35	1.9E-5	Basal cell carcinoma	
CESC	cis	1	rs13016963	chr2:202162811	CASP8	chr2:202098166-202152434:+	0.28	4.1	5.34E-5	Melanoma;Esophageal squamous cell carcinoma	
CESC	cis	1	rs13059720	chr3:134242021	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.35	1.95E-5	Height	
CESC	cis	1	rs13062518	chr3:195038287	C3orf21	chr3:194789015-194991895:-	0.24	3.98	8.86E-5	Body mass index	
CESC	cis	1	rs13069724	chr3:48478039	TREX1	chr3:48501186-48509043:+	-0.21	-4.56	7.72E-6	Longevity	
CESC	cis	1	rs13071337	chr3:48438189	TREX1	chr3:48501186-48509043:+	-0.2	-4.44	1.28E-5	Longevity	
CESC	cis	1	rs13071551	chr3:134310867	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.39	1.64E-5	Height	
CESC	cis	1	rs13076076	chr3:48479039	TREX1	chr3:48501186-48509043:+	-0.19	-4.24	3.02E-5	Longevity	
CESC	cis	1	rs13081177	chr3:134289860	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.42	1.43E-5	Height	
CESC	cis	1	rs13081688	chr3:134259954	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.35	1.95E-5	Height	
CESC	cis	1	rs13083299	chr3:138117564	ARMC8	chr3:137906148-138016219:+	0.34	3.99	8.57E-5	Coronary artery disease;Coronary heart disease	
CESC	cis	1	rs13087875	chr3:134261123	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.35	1.95E-5	Height	
CESC	cis	1	rs13089966	chr3:134279197	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.35	1.95E-5	Height	
CESC	cis	1	rs13090969	chr3:134307257	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.39	1.64E-5	Height	
CESC	cis	1	rs13091785	chr3:48494098	TREX1	chr3:48501186-48509043:+	-0.2	-4.53	8.78E-6	Longevity	
CESC	cis	1	rs13092352	chr3:52969697	RFT1	chr3:53122503-53164470:-	0.47	4.13	4.81E-5	Immune reponse to smallpox (secreted IL-2)	
CESC	cis	1	rs13096604	chr3:134250099	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.35	1.95E-5	Height	
CESC	cis	1	rs13096934	chr3:138114291	ARMC8	chr3:137906148-138016219:+	0.34	4.02	7.65E-5	Coronary artery disease;Coronary heart disease	
CESC	cis	1	rs13104971	chr4:53820155	FIP1L1	chr4:54243820-54326102:+	-0.45	-5.14	5.27E-7	Lifetime average cigarettes per day in chronic obstructive pulmonary disease	
CESC	cis	1	rs13109003	chr4:129975969	C4orf33	chr4:130014829-130033842:+	-0.36	-5.37	1.7E-7	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs13130762	chr4:130022875	C4orf33	chr4:130014829-130033842:+	-0.44	-6.71	1.11E-10	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs13168670	chr5:140146899	WDR55	chr5:140044384-140050551:+	-0.24	-4.25	2.99E-5	Schizophrenia	
CESC	cis	1	rs13169221	chr5:2337193	NDUFS6	chr5:1801509-1816163:+	-0.22	-3.97	9.12E-5	Cognitive performance	
CESC	cis	1	rs131801	chr22:50966634	TYMP	chr22:50964184-50968514:-	0.17	4.06	6.42E-5	Mean corpuscular hemoglobin	
CESC	cis	1	rs13194429	chr6:86646705	SNHG5	chr6:86386726-86388451:-	-0.6	-9.35	3.14E-18	Response to antipsychotic treatment	
CESC	cis	1	rs13195401	chr6:26463574	BTN3A2	chr6:26365398-26378546:+	-0.67	-5.63	4.38E-8	Schizophrenia	
CESC	cis	1	rs13195402	chr6:26463575	BTN3A2	chr6:26365398-26378546:+	-0.67	-5.63	4.38E-8	Schizophrenia	
CESC	cis	1	rs13196930	chr6:86652245	SNHG5	chr6:86386726-86388451:-	-0.57	-8.55	8.79E-16	Response to antipsychotic treatment	
CESC	cis	1	rs13199006	chr6:86608708	SNHG5	chr6:86386726-86388451:-	-0.61	-11.49	3.21E-25	Response to antipsychotic treatment	
CESC	cis	1	rs1320893	chr7:143752112	ARHGEF35	chr7:143883677-143892736:-	-0.48	-6.28	1.34E-9	Obesity-related traits	
CESC	cis	1	rs1320894	chr7:143751802	ARHGEF35	chr7:143883677-143892736:-	-0.48	-6.15	2.66E-9	Obesity-related traits	
CESC	cis	1	rs13217384	chr6:86720000	SNHG5	chr6:86386726-86388451:-	-0.62	-9.98	3.28E-20	Response to antipsychotic treatment	
CESC	cis	1	rs13220979	chr7:65363204	CCT6P1	chr7:65216092-65228661:+	0.45	4.4	1.55E-5	Diabetic kidney disease	
CESC	cis	1	rs13226728	chr7:143746578	ARHGEF35	chr7:143883677-143892736:-	-0.5	-6.56	2.62E-10	Obesity-related traits	
CESC	cis	1	rs13235972	chr7:65883605	CCT6P1	chr7:65216092-65228661:+	0.56	5.23	3.42E-7	Diabetic kidney disease	
CESC	cis	1	rs13235972	chr7:65883605	LOC493754	chr7:65993446-66057363:-	0.53	4.19	3.8E-5	Diabetic kidney disease	
CESC	cis	1	rs13237037	chr7:65997882	CCT6P1	chr7:65216092-65228661:+	0.56	5.27	2.7E-7	Diabetic kidney disease	
CESC	cis	1	rs13237037	chr7:65997882	LOC493754	chr7:65993446-66057363:-	0.55	4.32	2.14E-5	Diabetic kidney disease	
CESC	cis	1	rs13243677	chr7:143746572	ARHGEF35	chr7:143883677-143892736:-	-0.49	-6.28	1.3E-9	Obesity-related traits	
CESC	cis	1	rs13247184	chr7:65358928	CCT6P1	chr7:65216092-65228661:+	0.55	5.34	1.91E-7	Diabetic kidney disease	
CESC	cis	1	rs13252719	chr8:71734569	XKR9	chr8:71581600-71648176:+	0.94	16.93	1.55E-44	Bone mineral density	
CESC	cis	1	rs13253842	chr8:71625503	XKR9	chr8:71581600-71648176:+	0.94	16.93	1.51E-44	Bone mineral density	
CESC	cis	1	rs1327866	chr1:166952910	MAEL	chr1:166958519-166991447:+	0.31	4.06	6.43E-5	Refractive astigmatism	
CESC	cis	1	rs13288059	chr9:117544299	TNFSF8	chr9:117665124-117692770:-	-0.25	-4.35	1.92E-5	Serum IgA levels	
CESC	cis	1	rs13310597	chr7:65598540	CCT6P1	chr7:65216092-65228661:+	0.56	5.25	2.99E-7	Diabetic kidney disease	
CESC	cis	1	rs13310597	chr7:65598540	LOC493754	chr7:65993446-66057363:-	0.53	4.23	3.16E-5	Diabetic kidney disease	
CESC	cis	1	rs13314659	chr3:48449149	TREX1	chr3:48501186-48509043:+	0.19	4.33	2.14E-5	Longevity	
CESC	cis	1	rs13322305	chr3:134310791	ANAPC13	chr3:134196547-134204865:-	0.3	4.08	5.9E-5	Height	
CESC	cis	1	rs13322887	chr3:49555583	KLHDC8B	chr3:49209068-49213918:+	0.28	4.45	1.26E-5	Menarche (age at onset)	
CESC	cis	1	rs13322887	chr3:49555583	WDR6	chr3:49044637-49053386:+	0.28	4.57	7.23E-6	Menarche (age at onset)	
CESC	cis	1	rs13325965	chr3:41914942	ULK4	chr3:41288091-42003660:-	0.38	4.86	1.95E-6	Diastolic blood pressure	
CESC	cis	1	rs13340416	chr6:5071438	RPP40	chr6:4995281-5004271:-	0.24	4.1	5.5E-5	Venous thromboembolism (SNP x SNP interaction)	
CESC	cis	1	rs13361189	chr5:150223387	LOC134466	chr5:150310000-150326146:-	0.46	5.25	3.03E-7	Crohn's disease	
CESC	cis	1	rs1337844	chr6:86677273	SNHG5	chr6:86386726-86388451:-	-0.56	-8.98	4.39E-17	Response to antipsychotic treatment	
CESC	cis	1	rs1337850	chr6:86729103	SNHG5	chr6:86386726-86388451:-	-0.6	-9.17	1.14E-17	Response to antipsychotic treatment	
CESC	cis	1	rs13383871	chr2:73631779	ALMS1P	chr2:73872046-73912692:+	0.4	5.53	7.54E-8	Metabolite levels	
CESC	cis	1	rs1339580	chr10:60027122	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs1339582	chr10:59937183	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs1339583	chr10:59937003	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs1339584	chr10:59936857	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs1339585	chr10:59936841	IPMK	chr10:59955618-60027694:-	0.23	4.89	1.74E-6	Inflammatory bowel disease	
CESC	cis	1	rs1339586	chr10:60017646	IPMK	chr10:59955618-60027694:-	0.23	5.06	7.55E-7	Inflammatory bowel disease	
CESC	cis	1	rs1339588	chr10:59998210	IPMK	chr10:59955618-60027694:-	0.23	5.09	6.79E-7	Inflammatory bowel disease	
CESC	cis	1	rs13398075	chr2:202376269	PPIL3	chr2:201735680-201753999:-	0.59	5.05	8.1E-7	Rheumatoid arthritis	
CESC	cis	1	rs13398956	chr2:73720258	ALMS1P	chr2:73872046-73912692:+	0.42	5.86	1.31E-8	Metabolite levels	
CESC	cis	1	rs13408294	chr2:202171573	PPIL3	chr2:201735680-201753999:-	-0.52	-5.45	1.14E-7	Rheumatoid arthritis	
CESC	cis	1	rs13421462	chr2:73719875	ALMS1P	chr2:73872046-73912692:+	0.42	5.72	2.76E-8	Metabolite levels	
CESC	cis	1	rs13428235	chr2:73633430	ALMS1P	chr2:73872046-73912692:+	0.41	5.8	1.83E-8	Metabolite levels	
CESC	cis	1	rs13431267	chr2:73782200	ALMS1P	chr2:73872046-73912692:+	0.42	5.77	2.09E-8	Metabolite levels	
CESC	cis	1	rs13432605	chr2:73810981	ALMS1P	chr2:73872046-73912692:+	0.39	5.39	1.54E-7	Metabolite levels	
CESC	cis	1	rs134869	chr22:42652074	CYP2D6	chr22:42522502-42526883:-	-0.43	-7.59	4.93E-13	Cognitive function	
CESC	cis	1	rs134873	chr22:42657566	CYP2D6	chr22:42522502-42526883:-	-0.42	-7.31	2.92E-12	Cognitive function	
CESC	cis	1	rs134882	chr22:42670965	CYP2D6	chr22:42522502-42526883:-	-0.41	-7.2	5.64E-12	Cognitive function	
CESC	cis	1	rs134900	chr22:42683343	CYP2D6	chr22:42522502-42526883:-	-0.44	-7.96	4.41E-14	Cognitive function	
CESC	cis	1	rs134902	chr22:42683997	CYP2D6	chr22:42522502-42526883:-	-0.44	-8.11	1.64E-14	Cognitive function	
CESC	cis	1	rs1352433	chr4:48393680	NIPAL1	chr4:48018791-48039078:+	-0.17	-3.96	9.7E-5	Crohn's disease;Inflammatory bowel disease	
CESC	cis	1	rs1358250	chr12:16402536	MGST1	chr12:16500076-16523342:+	-0.28	-3.97	9.23E-5	Visceral fat	
CESC	cis	1	rs1361353	chr10:59938091	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs1371135	chr15:90391270	AP3S2	chr15:90373832-90456222:-	-0.47	-5.83	1.51E-8	Type 2 diabetes	
CESC	cis	1	rs138704	chr22:39133410	CBY1	chr22:39052658-39069853:+	0.23	4.11	5.19E-5	Resting heart rate	
CESC	cis	1	rs138706	chr22:39137834	CBY1	chr22:39052658-39069853:+	0.27	4.71	3.88E-6	Resting heart rate	
CESC	cis	1	rs138709	chr22:39139216	CBY1	chr22:39052658-39069853:+	0.26	4.66	4.86E-6	Resting heart rate	
CESC	cis	1	rs138712	chr22:39141600	CBY1	chr22:39052658-39069853:+	0.25	4.16	4.23E-5	Resting heart rate	
CESC	cis	1	rs138713	chr22:39142615	CBY1	chr22:39052658-39069853:+	0.27	4.79	2.76E-6	Resting heart rate	
CESC	cis	1	rs1390006	chr17:56890663	RAD51C	chr17:56769963-56811690:+	-0.34	-5.82	1.61E-8	Cognitive test performance	
CESC	cis	1	rs1392104	chr7:65759107	CCT6P1	chr7:65216092-65228661:+	-0.54	-5.06	7.72E-7	Diabetic kidney disease	
CESC	cis	1	rs1392104	chr7:65759107	LOC493754	chr7:65993446-66057363:-	-0.53	-4.17	4.17E-5	Diabetic kidney disease	
CESC	cis	1	rs1401492	chr3:53680124	PBRM1	chr3:52579368-52719866:-	-0.36	-4.63	5.58E-6	Insulin resistance/response	
CESC	cis	1	rs1401492	chr3:53680124	RFT1	chr3:53122503-53164470:-	-0.48	-4.22	3.38E-5	Insulin resistance/response	
CESC	cis	1	rs14017	chr12:120941444	GCN1L1	chr12:120565016-120632513:-	-0.52	-4.22	3.34E-5	Insulin resistance/response	
CESC	cis	1	rs1403284	chr2:73726662	ALMS1P	chr2:73872046-73912692:+	-0.36	-4.53	8.71E-6	Metabolite levels	
CESC	cis	1	rs1404147	chr7:65264524	CCT6P1	chr7:65216092-65228661:+	0.5	5.11	5.97E-7	Diabetic kidney disease	
CESC	cis	1	rs1405507	chr12:16400932	MGST1	chr12:16500076-16523342:+	-0.29	-3.98	8.73E-5	Visceral fat	
CESC	cis	1	rs1415753	chr6:86753074	SNHG5	chr6:86386726-86388451:-	-0.56	-8.61	5.71E-16	Response to antipsychotic treatment	
CESC	cis	1	rs1416763	chr10:60029163	IPMK	chr10:59955618-60027694:-	0.21	4.47	1.13E-5	Inflammatory bowel disease	
CESC	cis	1	rs1416764	chr10:60040351	IPMK	chr10:59955618-60027694:-	0.21	4.4	1.57E-5	Inflammatory bowel disease	
CESC	cis	1	rs1416766	chr10:59978237	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.97E-7	Inflammatory bowel disease	
CESC	cis	1	rs1423620	chr5:56100996	C5orf35	chr5:56205103-56213010:+	0.78	12.15	1.7E-27	Type 2 diabetes	
CESC	cis	1	rs1423621	chr5:56101035	C5orf35	chr5:56205103-56213010:+	0.82	12.66	2.99E-29	Type 2 diabetes	
CESC	cis	1	rs1428551	chr5:150259832	LOC134466	chr5:150310000-150326146:-	0.47	5.46	1.04E-7	Crohn's disease	
CESC	cis	1	rs1428552	chr5:150259831	LOC134466	chr5:150310000-150326146:-	0.43	5.26	2.87E-7	Crohn's disease	
CESC	cis	1	rs1428554	chr5:150257616	LOC134466	chr5:150310000-150326146:-	0.41	5.12	5.62E-7	Crohn's disease	
CESC	cis	1	rs1428555	chr5:150257391	LOC134466	chr5:150310000-150326146:-	-0.45	-5.49	9.01E-8	Crohn's disease	
CESC	cis	1	rs1453560	chr17:38023441	ZPBP2	chr17:38024455-38034144:+	0.53	3.96	9.51E-5	Systemic lupus erythematosus	
CESC	cis	1	rs1459242	chr3:48413537	TREX1	chr3:48501186-48509043:+	0.21	4.68	4.42E-6	Longevity	
CESC	cis	1	rs1460561	chr6:56797574	BEND6	chr6:56819773-56892138:+	-0.39	-4.16	4.28E-5	Menarche (age at onset)	
CESC	cis	1	rs1466389	chr17:2096384	SRR	chr17:2207248-2228553:+	-0.35	-4.79	2.7E-6	Esophageal cancer (squamous cell)	
CESC	cis	1	rs1473580	chr3:114790058	ZBTB20	chr3:114057525-114866127:-	-0.39	-4.08	6.02E-5	Type 2 diabetes	
CESC	cis	1	rs148725943	chr3:41099747	CTNNB1	chr3:41236401-41281939:+	-0.24	-4.08	5.89E-5	Bone mineral density (hip)	
CESC	cis	1	rs1499613	chr7:65730860	CCT6P1	chr7:65216092-65228661:+	-0.54	-5.06	7.72E-7	Diabetic kidney disease	
CESC	cis	1	rs1499613	chr7:65730860	LOC493754	chr7:65993446-66057363:-	-0.53	-4.17	4.17E-5	Diabetic kidney disease	
CESC	cis	1	rs1499614	chr7:65730798	CCT6P1	chr7:65216092-65228661:+	0.51	4.88	1.81E-6	Diabetic kidney disease	
CESC	cis	1	rs1499614	chr7:65730798	LOC493754	chr7:65993446-66057363:-	0.52	4.21	3.48E-5	Diabetic kidney disease	
CESC	cis	1	rs151964	chr5:96123666	ERAP1	chr5:96096515-96149837:-	-0.41	-7.97	4.25E-14	Ankylosing spondylitis	
CESC	cis	1	rs151964	chr5:96123666	ERAP2	chr5:96211644-96255398:+	0.4	6.12	3.17E-9	Ankylosing spondylitis	
CESC	cis	1	rs1533266	chr7:143766714	ARHGEF35	chr7:143883677-143892736:-	-0.46	-5.71	2.88E-8	Obesity-related traits	
CESC	cis	1	rs1533267	chr7:143766440	ARHGEF35	chr7:143883677-143892736:-	-0.47	-5.84	1.44E-8	Obesity-related traits	
CESC	cis	1	rs1533268	chr7:143766358	ARHGEF35	chr7:143883677-143892736:-	-0.47	-5.83	1.56E-8	Obesity-related traits	
CESC	cis	1	rs1534025	chr3:134313304	ANAPC13	chr3:134196547-134204865:-	-0.31	-4.14	4.65E-5	Height	
CESC	cis	1	rs1534026	chr3:134284767	ANAPC13	chr3:134196547-134204865:-	0.31	4.12	5.0E-5	Height	
CESC	cis	1	rs1534471	chr2:73647508	ALMS1P	chr2:73872046-73912692:+	0.37	5.32	2.13E-7	Metabolite levels	
CESC	cis	1	rs1540894	chr7:143767676	ARHGEF35	chr7:143883677-143892736:-	-0.48	-5.83	1.53E-8	Obesity-related traits	
CESC	cis	1	rs1546059	chr7:65654709	CCT6P1	chr7:65216092-65228661:+	-0.51	-4.76	3.19E-6	Diabetic kidney disease	
CESC	cis	1	rs1550773	chr10:60044441	IPMK	chr10:59955618-60027694:-	0.22	4.71	4.02E-6	Inflammatory bowel disease	
CESC	cis	1	rs1553174	chr7:65731194	CCT6P1	chr7:65216092-65228661:+	-0.54	-5.06	7.72E-7	Diabetic kidney disease	
CESC	cis	1	rs1553174	chr7:65731194	LOC493754	chr7:65993446-66057363:-	-0.53	-4.17	4.17E-5	Diabetic kidney disease	
CESC	cis	1	rs1555569	chr17:2149425	SRR	chr17:2207248-2228553:+	-0.4	-5.28	2.59E-7	Esophageal cancer (squamous cell)	
CESC	cis	1	rs1559282	chr5:56099375	C5orf35	chr5:56205103-56213010:+	0.81	12.76	1.33E-29	Type 2 diabetes	
CESC	cis	1	rs1561288	chr2:25369002	POMC	chr2:25383722-25391559:-	0.28	4.02	7.44E-5	Body mass index	
CESC	cis	1	rs1561328	chr2:86272758	LOC90784	chr2:86247339-86250991:-	-0.48	-4.69	4.37E-6	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
CESC	cis	1	rs1563736	chr3:48436794	TREX1	chr3:48501186-48509043:+	-0.2	-4.44	1.28E-5	Longevity	
CESC	cis	1	rs1564716	chr3:41862613	ULK4	chr3:41288091-42003660:-	0.46	6.96	2.51E-11	Diastolic blood pressure	
CESC	cis	1	rs1565531	chr7:65663113	NCRNA00174	chr7:65841032-65865395:-	0.26	4.12	5.07E-5	Aortic root size	
CESC	cis	1	rs1577917	chr6:86691940	SNHG5	chr6:86386726-86388451:-	-0.57	-8.32	4.26E-15	Response to antipsychotic treatment	
CESC	cis	1	rs1577919	chr6:86757296	SNHG5	chr6:86386726-86388451:-	-0.56	-8.73	2.46E-16	Response to antipsychotic treatment	
CESC	cis	1	rs1599932	chr12:58177943	FAM119B	chr12:58166383-58176323:+	0.39	5.18	4.34E-7	Multiple sclerosis	
CESC	cis	1	rs1599932	chr12:58177943	TSFM	chr12:58176536-58191367:+	-0.35	-5.98	7.0E-9	Multiple sclerosis	
CESC	cis	1	rs160633	chr7:65528228	CCT6P1	chr7:65216092-65228661:+	0.52	5.12	5.83E-7	Diabetic kidney disease	
CESC	cis	1	rs160634	chr7:65528664	CCT6P1	chr7:65216092-65228661:+	-0.48	-5.12	5.67E-7	Diabetic kidney disease	
CESC	cis	1	rs160634	chr7:65528664	LOC493754	chr7:65993446-66057363:-	-0.46	-4.15	4.38E-5	Diabetic kidney disease	
CESC	cis	1	rs160637	chr7:65584318	CCT6P1	chr7:65216092-65228661:+	0.53	5.01	9.67E-7	Diabetic kidney disease	
CESC	cis	1	rs160637	chr7:65584318	LOC493754	chr7:65993446-66057363:-	0.54	4.28	2.62E-5	Diabetic kidney disease	
CESC	cis	1	rs160639	chr7:65579987	CCT6P1	chr7:65216092-65228661:+	0.45	4.23	3.24E-5	Diabetic kidney disease	
CESC	cis	1	rs160642	chr7:65558373	CCT6P1	chr7:65216092-65228661:+	0.53	4.98	1.14E-6	Diabetic kidney disease	
CESC	cis	1	rs160642	chr7:65558373	LOC493754	chr7:65993446-66057363:-	0.51	4.01	7.69E-5	Diabetic kidney disease	
CESC	cis	1	rs160643	chr7:65558222	CCT6P1	chr7:65216092-65228661:+	0.43	4.18	3.98E-5	Diabetic kidney disease	
CESC	cis	1	rs160644	chr7:65558186	CCT6P1	chr7:65216092-65228661:+	0.53	4.98	1.14E-6	Diabetic kidney disease	
CESC	cis	1	rs160644	chr7:65558186	LOC493754	chr7:65993446-66057363:-	0.51	4.01	7.69E-5	Diabetic kidney disease	
CESC	cis	1	rs160646	chr7:65556280	CCT6P1	chr7:65216092-65228661:+	0.53	4.96	1.21E-6	Diabetic kidney disease	
CESC	cis	1	rs160646	chr7:65556280	LOC493754	chr7:65993446-66057363:-	0.51	4.02	7.43E-5	Diabetic kidney disease	
CESC	cis	1	rs160648	chr7:65543384	CCT6P1	chr7:65216092-65228661:+	0.52	4.96	1.26E-6	Diabetic kidney disease	
CESC	cis	1	rs160648	chr7:65543384	LOC493754	chr7:65993446-66057363:-	0.5	4.01	7.77E-5	Diabetic kidney disease	
CESC	cis	1	rs160652	chr7:65538431	CCT6P1	chr7:65216092-65228661:+	0.55	5.09	6.5E-7	Diabetic kidney disease	
CESC	cis	1	rs160652	chr7:65538431	LOC493754	chr7:65993446-66057363:-	0.53	4.19	3.75E-5	Diabetic kidney disease	
CESC	cis	1	rs160655	chr7:65533214	CCT6P1	chr7:65216092-65228661:+	0.52	4.93	1.41E-6	Diabetic kidney disease	
CESC	cis	1	rs160655	chr7:65533214	LOC493754	chr7:65993446-66057363:-	0.49	3.99	8.38E-5	Diabetic kidney disease	
CESC	cis	1	rs1607908	chr3:41905196	ULK4	chr3:41288091-42003660:-	0.5	8.19	9.59E-15	Diastolic blood pressure	
CESC	cis	1	rs1612124	chr3:41967893	ULK4	chr3:41288091-42003660:-	-0.47	-7.46	1.14E-12	Diastolic blood pressure	
CESC	cis	1	rs1613759	chr3:41906183	ULK4	chr3:41288091-42003660:-	0.5	8.19	9.59E-15	Diastolic blood pressure	
CESC	cis	1	rs1615543	chr3:41906404	ULK4	chr3:41288091-42003660:-	0.5	8.19	9.59E-15	Diastolic blood pressure	
CESC	cis	1	rs1616063	chr9:33219898	SPINK4	chr9:33240196-33248564:+	0.31	4.22	3.33E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs1618814	chr10:59963477	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs1623294	chr10:59939025	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs1630731	chr10:59959530	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs1638731	chr7:66144679	CCT6P1	chr7:65216092-65228661:+	0.58	5.4	1.41E-7	Gout	
CESC	cis	1	rs1638731	chr7:66144679	LOC493754	chr7:65993446-66057363:-	0.58	4.58	7.01E-6	Gout	
CESC	cis	1	rs1638734	chr7:66097539	CCT6P1	chr7:65216092-65228661:+	0.57	5.41	1.35E-7	Diabetic kidney disease	
CESC	cis	1	rs1638734	chr7:66097539	LOC493754	chr7:65993446-66057363:-	0.55	4.4	1.58E-5	Diabetic kidney disease	
CESC	cis	1	rs16823443	chr3:114711353	ZBTB20	chr3:114057525-114866127:-	0.4	4.15	4.49E-5	Type 2 diabetes	
CESC	cis	1	rs16837131	chr2:202173812	PPIL3	chr2:201735680-201753999:-	0.49	4.63	5.77E-6	Rheumatoid arthritis	
CESC	cis	1	rs16876529	chr6:86591202	SNHG5	chr6:86386726-86388451:-	-0.64	-12.42	2.1E-28	Response to antipsychotic treatment	
CESC	cis	1	rs16942155	chr15:60418758	GTF2A2	chr15:59930263-59949737:-	0.47	4.43	1.35E-5	Type 2 diabetes	
CESC	cis	1	rs16952009	chr17:2102437	SRR	chr17:2207248-2228553:+	-0.33	-4.56	7.67E-6	Esophageal cancer (squamous cell)	
CESC	cis	1	rs16958445	chr15:74176557	CSK	chr15:75074425-75095539:+	0.64	4.4	1.55E-5	Exfoliation glaucoma or exfoliation syndrome	
CESC	cis	1	rs16958445	chr15:74176557	ULK3	chr15:75128459-75135552:-	0.56	4.2	3.58E-5	Exfoliation glaucoma or exfoliation syndrome	
CESC	cis	1	rs16967141	chr19:32971223	ZNF507	chr19:32836514-32878571:+	0.31	4.02	7.45E-5	Bipolar disorder	
CESC	cis	1	rs16973500	chr16:71965196	TXNL4B	chr16:72072001-72128215:-	-0.46	-4.73	3.55E-6	Attention deficit hyperactivity disorder and conduct disorder;Response to anti-TNF therapy in rheumatoid arthritis	
CESC	cis	1	rs1698392	chr10:59967089	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs1698395	chr10:59938724	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs1698396	chr10:59937308	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs1698402	chr10:59936444	IPMK	chr10:59955618-60027694:-	0.2	4.34	2.02E-5	Inflammatory bowel disease	
CESC	cis	1	rs1698468	chr10:59961590	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs1699379	chr4:129992337	C4orf33	chr4:130014829-130033842:+	-0.36	-5.48	9.52E-8	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs1699389	chr4:130004079	C4orf33	chr4:130014829-130033842:+	-0.38	-5.69	3.18E-8	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs1699391	chr4:130005096	C4orf33	chr4:130014829-130033842:+	-0.38	-5.69	3.18E-8	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs1699392	chr4:130022347	C4orf33	chr4:130014829-130033842:+	-0.44	-6.71	1.11E-10	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs1699393	chr4:130019352	C4orf33	chr4:130014829-130033842:+	-0.42	-6.2	2.02E-9	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs1699394	chr4:130019312	C4orf33	chr4:130014829-130033842:+	-0.43	-6.57	2.55E-10	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs16995986	chr4:86693317	WDFY3	chr4:85590697-85887544:-	-0.45	-4.45	1.25E-5	Diisocyanate-induced asthma	
CESC	cis	1	rs1701750	chr7:65467145	CCT6P1	chr7:65216092-65228661:+	0.46	4.45	1.27E-5	Diabetic kidney disease	
CESC	cis	1	rs1701758	chr7:65470201	CCT6P1	chr7:65216092-65228661:+	0.46	4.45	1.27E-5	Diabetic kidney disease	
CESC	cis	1	rs1702980	chr9:33217406	SPINK4	chr9:33240196-33248564:+	0.31	4.25	2.97E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs1702981	chr9:33219903	SPINK4	chr9:33240196-33248564:+	0.31	4.22	3.33E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs17061431	chr3:41792655	ULK4	chr3:41288091-42003660:-	0.52	8.25	6.68E-15	Diastolic blood pressure	
CESC	cis	1	rs17062109	chr3:41810364	ULK4	chr3:41288091-42003660:-	0.5	7.5	8.88E-13	Diastolic blood pressure	
CESC	cis	1	rs17063584	chr3:41861463	ULK4	chr3:41288091-42003660:-	0.47	6.96	2.48E-11	Diastolic blood pressure	
CESC	cis	1	rs17063599	chr3:41861676	ULK4	chr3:41288091-42003660:-	0.46	6.96	2.51E-11	Diastolic blood pressure	
CESC	cis	1	rs17063649	chr3:41863406	ULK4	chr3:41288091-42003660:-	0.45	6.92	3.14E-11	Diastolic blood pressure	
CESC	cis	1	rs17064124	chr3:41890803	ULK4	chr3:41288091-42003660:-	0.51	8.24	6.95E-15	Diastolic blood pressure	
CESC	cis	1	rs1707304	chr1:46598269	CCDC163P	chr1:45960581-45965646:-	-0.37	-6	6.26E-9	Body mass index	
CESC	cis	1	rs1707321	chr1:46505309	CCDC163P	chr1:45960581-45965646:-	-0.35	-5.79	1.9E-8	Body mass index	
CESC	cis	1	rs1707335	chr1:46571921	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.82	1.63E-8	Body mass index	
CESC	cis	1	rs1707336	chr1:46493460	CCDC163P	chr1:45960581-45965646:-	-0.33	-5.41	1.38E-7	Body mass index	
CESC	cis	1	rs1707340	chr1:46514942	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.97	7.35E-9	Body mass index	
CESC	cis	1	rs17096228	chr14:74558669	LIN52	chr14:74551656-74667117:+	0.41	8.22	8.08E-15	Common traits (Other)	
CESC	cis	1	rs17111376	chr5:150226899	LOC134466	chr5:150310000-150326146:-	0.44	5.04	8.53E-7	Crohn's disease	
CESC	cis	1	rs17116334	chr11:113961762	C11orf71	chr11:114262170-114271255:-	-0.33	-4.26	2.78E-5	Conduct disorder (interaction)	
CESC	cis	1	rs17116334	chr11:113961762	RBM7	chr11:114271384-114279632:+	-0.35	-4.57	7.33E-6	Conduct disorder (interaction)	
CESC	cis	1	rs17116334	chr11:113961762	REXO2	chr11:114310108-114320998:+	-0.42	-5.18	4.34E-7	Conduct disorder (interaction)	
CESC	cis	1	rs17116334	chr11:113961762	USP28	chr11:113668598-113746256:-	-0.37	-4.47	1.16E-5	Conduct disorder (interaction)	
CESC	cis	1	rs17116334	chr11:113961762	ZW10	chr11:113603911-113644425:-	-0.42	-4.94	1.34E-6	Conduct disorder (interaction)	
CESC	cis	1	rs1715235	chr7:65488394	CCT6P1	chr7:65216092-65228661:+	0.53	5.13	5.56E-7	Diabetic kidney disease	
CESC	cis	1	rs17164851	chr7:130003487	CPA5	chr7:129984630-130008571:+	0.56	6.23	1.71E-9	Age-related hearing impairment (interaction)	
CESC	cis	1	rs1716644	chr3:41968028	ULK4	chr3:41288091-42003660:-	-0.47	-7.46	1.14E-12	Diastolic blood pressure	
CESC	cis	1	rs1716657	chr3:41918456	ULK4	chr3:41288091-42003660:-	-0.51	-8.2	9.04E-15	Diastolic blood pressure	
CESC	cis	1	rs1716661	chr3:41962818	ULK4	chr3:41288091-42003660:-	-0.48	-7.84	1.0E-13	Diastolic blood pressure	
CESC	cis	1	rs1716668	chr3:41907850	ULK4	chr3:41288091-42003660:-	0.5	8.19	9.59E-15	Diastolic blood pressure	
CESC	cis	1	rs1716669	chr3:41908681	ULK4	chr3:41288091-42003660:-	0.5	8.19	9.59E-15	Diastolic blood pressure	
CESC	cis	1	rs1716676	chr3:41903208	ULK4	chr3:41288091-42003660:-	0.51	8.21	8.95E-15	Diastolic blood pressure	
CESC	cis	1	rs1716987	chr3:41970516	ULK4	chr3:41288091-42003660:-	-0.46	-7.38	1.83E-12	Diastolic blood pressure	
CESC	cis	1	rs1716993	chr3:41974556	ULK4	chr3:41288091-42003660:-	-0.47	-7.49	9.15E-13	Diastolic blood pressure	
CESC	cis	1	rs1716997	chr3:41924333	ULK4	chr3:41288091-42003660:-	-0.51	-8.1	1.85E-14	Diastolic blood pressure	
CESC	cis	1	rs1717006	chr3:41940448	ULK4	chr3:41288091-42003660:-	0.49	7.96	4.53E-14	Diastolic blood pressure	
CESC	cis	1	rs1717014	chr3:41917395	ULK4	chr3:41288091-42003660:-	0.51	8.2	9.04E-15	Diastolic blood pressure	
CESC	cis	1	rs1717017	chr3:41915616	ULK4	chr3:41288091-42003660:-	0.5	8.19	9.59E-15	Diastolic blood pressure	
CESC	cis	1	rs1717020	chr3:41981490	ULK4	chr3:41288091-42003660:-	0.49	7.72	2.15E-13	Diastolic blood pressure	
CESC	cis	1	rs1717031	chr3:41905791	ULK4	chr3:41288091-42003660:-	0.5	8.19	9.59E-15	Diastolic blood pressure	
CESC	cis	1	rs1717033	chr3:41910216	ULK4	chr3:41288091-42003660:-	0.51	8.25	6.54E-15	Diastolic blood pressure	
CESC	cis	1	rs1723267	chr7:65473314	CCT6P1	chr7:65216092-65228661:+	0.53	5.13	5.56E-7	Diabetic kidney disease	
CESC	cis	1	rs1723269	chr7:65472786	CCT6P1	chr7:65216092-65228661:+	0.59	5.7	3.1E-8	Diabetic kidney disease	
CESC	cis	1	rs1723270	chr7:65469830	CCT6P1	chr7:65216092-65228661:+	0.56	5.46	1.05E-7	Diabetic kidney disease	
CESC	cis	1	rs17237094	chr12:48952456	HDAC7	chr12:48176509-48213763:-	0.45	4.01	7.76E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs17237198	chr12:48953932	HDAC7	chr12:48176509-48213763:-	-0.45	-4.13	4.74E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs173334	chr6:88080223	C6orf162	chr6:88032306-88052043:+	-0.26	-4.25	2.92E-5	Depressive episodes in bipolar disorder	
CESC	cis	1	rs17431357	chr12:120880434	GCN1L1	chr12:120565016-120632513:-	-0.55	-4.5	9.89E-6	Insulin resistance/response	
CESC	cis	1	rs17431357	chr12:120880434	RAB35	chr12:120532904-120554599:-	-0.53	-4.07	6.24E-5	Insulin resistance/response	
CESC	cis	1	rs17431446	chr12:120884291	GCN1L1	chr12:120565016-120632513:-	-0.56	-4.59	6.7E-6	Insulin resistance/response	
CESC	cis	1	rs17431446	chr12:120884291	RAB35	chr12:120532904-120554599:-	-0.6	-4.65	5.27E-6	Insulin resistance/response	
CESC	cis	1	rs17431446	chr12:120884291	RNF10	chr12:120972132-121015396:+	-0.73	-4.23	3.24E-5	Insulin resistance/response	
CESC	cis	1	rs17431446	chr12:120884291	RNF34	chr12:121837902-121868389:+	-0.66	-4.13	4.87E-5	Insulin resistance/response	
CESC	cis	1	rs17433780	chr1:89474818	GBP3	chr1:89472367-89488549:-	0.83	16.47	6.96E-43	Carotid intima media thickness	
CESC	cis	1	rs174551	chr11:61573684	FADS1	chr11:61567103-61584529:-	-0.3	-4.51	9.57E-6	LDL cholesterol	
CESC	cis	1	rs17471869	chr10:70749869	KIAA1279	chr10:70748493-70776734:+	-0.31	-4.25	2.9E-5	Schizophrenia	
CESC	cis	1	rs17496332	chr1:107546375	PRMT6	chr1:107599267-107601907:+	0.29	4.11	5.24E-5	Sex hormone-binding globulin levels	
CESC	cis	1	rs175449	chr14:75590846	EIF2B2	chr14:75469612-75476292:+	-0.23	-4	8.05E-5	Height	
CESC	cis	1	rs17551703	chr1:166957879	MAEL	chr1:166958519-166991447:+	-0.34	-4.43	1.38E-5	Refractive astigmatism	
CESC	cis	1	rs1757924	chr4:130019599	C4orf33	chr4:130014829-130033842:+	-0.43	-6.54	3.02E-10	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs1757925	chr4:130020791	C4orf33	chr4:130014829-130033842:+	0.41	6.33	9.88E-10	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs1757927	chr4:130022069	C4orf33	chr4:130014829-130033842:+	-0.44	-6.71	1.11E-10	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs1757928	chr4:130022161	C4orf33	chr4:130014829-130033842:+	-0.44	-6.71	1.11E-10	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs1757930	chr4:130022356	C4orf33	chr4:130014829-130033842:+	-0.43	-6.57	2.55E-10	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs1757935	chr4:130023759	C4orf33	chr4:130014829-130033842:+	-0.44	-6.71	1.11E-10	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs17584320	chr1:75879593	SLC44A5	chr1:75667816-76143610:-	-0.49	-4.17	4.07E-5	Whole-brain volume (Alzheimer's disease interaction)	
CESC	cis	1	rs17584461	chr12:121004236	GCN1L1	chr12:120565016-120632513:-	-0.52	-4.2	3.65E-5	Insulin resistance/response	
CESC	cis	1	rs17596617	chr11:43690717	HSD17B12	chr11:43702143-43878160:+	-0.35	-5.34	1.99E-7	Forced vital capacity	
CESC	cis	1	rs17608059	chr17:13910549	CDRT15P	chr17:13927815-13928915:+	-0.41	-6.65	1.55E-10	Temperament	
CESC	cis	1	rs17608677	chr2:219936871	AAMP	chr2:219128853-219134893:-	0.36	4.13	4.78E-5	Height	
CESC	cis	1	rs17608677	chr2:219936871	FAM134A	chr2:220042939-220050190:+	0.41	4.85	2.05E-6	Height	
CESC	cis	1	rs17638216	chr19:35978458	USF2	chr19:35759896-35770718:+	-0.36	-4.24	3.01E-5	Bipolar disorder	
CESC	cis	1	rs17665028	chr6:50261699	MUT	chr6:49398994-49431031:-	0.53	4.24	3.11E-5	Body mass index	
CESC	cis	1	rs17665087	chr6:50264922	MUT	chr6:49398994-49431031:-	0.5	4.03	7.32E-5	Body mass index	
CESC	cis	1	rs17665162	chr6:50275258	MUT	chr6:49398994-49431031:-	-0.46	-4.09	5.65E-5	Body mass index	
CESC	cis	1	rs1768803	chr1:46546208	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.91	1.03E-8	Body mass index	
CESC	cis	1	rs1768816	chr1:46528599	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.94	8.75E-9	Body mass index	
CESC	cis	1	rs1769003	chr10:59937590	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs1769005	chr10:59935940	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs1769006	chr10:59935547	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs1769040	chr10:59954081	IPMK	chr10:59955618-60027694:-	0.22	4.72	3.72E-6	Inflammatory bowel disease	
CESC	cis	1	rs1769042	chr10:59956734	IPMK	chr10:59955618-60027694:-	0.22	4.73	3.66E-6	Inflammatory bowel disease	
CESC	cis	1	rs1769044	chr10:59958956	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs1769045	chr10:59960522	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs1769046	chr10:59960630	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs1769047	chr10:59963046	IPMK	chr10:59955618-60027694:-	0.24	5.21	3.66E-7	Inflammatory bowel disease	
CESC	cis	1	rs17713396	chr2:227201	SH3YL1	chr2:218138-264810:-	-0.69	-10.88	3.69E-23	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs17713729	chr2:249092	SH3YL1	chr2:218138-264810:-	-0.68	-11.09	7.13E-24	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs17714252	chr2:285471	SH3YL1	chr2:218138-264810:-	-0.7	-11.72	5.33E-26	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs17727568	chr5:150244688	LOC134466	chr5:150310000-150326146:-	0.64	6.24	1.64E-9	Crohn's disease	
CESC	cis	1	rs17737795	chr6:50268664	MUT	chr6:49398994-49431031:-	0.47	3.97	9.23E-5	Body mass index	
CESC	cis	1	rs17761723	chr17:2107090	SRR	chr17:2207248-2228553:+	0.37	5	1.0E-6	Esophageal cancer (squamous cell)	
CESC	cis	1	rs17761864	chr17:2171637	SRR	chr17:2207248-2228553:+	-0.42	-5.62	4.72E-8	Esophageal cancer (squamous cell)	
CESC	cis	1	rs17800886	chr5:150309539	IRGM	chr5:150226085-150280295:+	0.45	4.31	2.23E-5	Crohn's disease	
CESC	cis	1	rs17800886	chr5:150309539	LOC134466	chr5:150310000-150326146:-	0.66	6.47	4.59E-10	Crohn's disease	
CESC	cis	1	rs17800987	chr5:150323428	LOC134466	chr5:150310000-150326146:-	0.6	5.73	2.66E-8	Crohn's disease	
CESC	cis	1	rs17804178	chr5:151197729	ATOX1	chr5:151122384-151138210:-	-0.23	-4.06	6.38E-5	Preschool internalizing problems	
CESC	cis	1	rs17818399	chr2:46826026	ATP6V1E2	chr2:46738988-46769696:-	-0.35	-5.14	5.27E-7	Height	
CESC	cis	1	rs17834627	chr17:2198892	SRR	chr17:2207248-2228553:+	-0.39	-4.94	1.33E-6	Esophageal cancer (squamous cell)	
CESC	cis	1	rs1796220	chr7:66062100	CCT6P1	chr7:65216092-65228661:+	0.57	5.43	1.25E-7	Diabetic kidney disease	
CESC	cis	1	rs1796220	chr7:66062100	LOC493754	chr7:65993446-66057363:-	0.55	4.44	1.31E-5	Diabetic kidney disease	
CESC	cis	1	rs1796228	chr7:66033084	CCT6P1	chr7:65216092-65228661:+	0.57	5.41	1.38E-7	Diabetic kidney disease	
CESC	cis	1	rs1796228	chr7:66033084	LOC493754	chr7:65993446-66057363:-	0.54	4.31	2.25E-5	Diabetic kidney disease	
CESC	cis	1	rs1798682	chr12:16414476	MGST1	chr12:16500076-16523342:+	-0.29	-4	8.26E-5	Visceral fat	
CESC	cis	1	rs1799457	chr12:16419756	MGST1	chr12:16500076-16523342:+	-0.29	-3.98	8.98E-5	Visceral fat	
CESC	cis	1	rs1799466	chr12:16417735	MGST1	chr12:16500076-16523342:+	-0.28	-3.95	9.76E-5	Visceral fat	
CESC	cis	1	rs1799487	chr12:16414737	MGST1	chr12:16500076-16523342:+	-0.29	-4	8.26E-5	Visceral fat	
CESC	cis	1	rs1800615	chr1:15832281	CASP9	chr1:15817324-15851384:-	0.34	4.28	2.55E-5	Glomerular filtration rate (creatinine)	
CESC	cis	1	rs1800777	chr16:57017319	FAM192A	chr16:57186382-57219976:-	0.69	4.54	8.38E-6	HDL cholesterol	
CESC	cis	1	rs1814336	chr3:134200823	ANAPC13	chr3:134196547-134204865:-	0.31	4.08	5.79E-5	Height	
CESC	cis	1	rs1814337	chr3:134200682	ANAPC13	chr3:134196547-134204865:-	0.31	4.2	3.68E-5	Height	
CESC	cis	1	rs1816256	chr5:150272853	LOC134466	chr5:150310000-150326146:-	0.43	4.89	1.68E-6	Crohn's disease	
CESC	cis	1	rs1820682	chr5:150262142	LOC134466	chr5:150310000-150326146:-	0.4	4.73	3.64E-6	Crohn's disease	
CESC	cis	1	rs1832556	chr10:60028248	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs1833896	chr5:56097669	C5orf35	chr5:56205103-56213010:+	0.81	12.76	1.33E-29	Type 2 diabetes	
CESC	cis	1	rs1854774	chr4:129988405	C4orf33	chr4:130014829-130033842:+	-0.37	-5.48	9.45E-8	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs1856564	chr10:60017452	IPMK	chr10:59955618-60027694:-	0.23	5.06	7.55E-7	Inflammatory bowel disease	
CESC	cis	1	rs1857354	chr1:75902948	SLC44A5	chr1:75667816-76143610:-	-0.5	-3.95	0.000101	Whole-brain volume (Alzheimer's disease interaction)	
CESC	cis	1	rs1857964	chr6:86635994	SNHG5	chr6:86386726-86388451:-	-0.59	-9.22	8.22E-18	Response to antipsychotic treatment	
CESC	cis	1	rs1857965	chr6:86630776	SNHG5	chr6:86386726-86388451:-	-0.57	-9.02	3.37E-17	Response to antipsychotic treatment	
CESC	cis	1	rs1862619	chr5:56098256	C5orf35	chr5:56205103-56213010:+	0.81	12.76	1.33E-29	Type 2 diabetes	
CESC	cis	1	rs186378	chr7:65582058	CCT6P1	chr7:65216092-65228661:+	0.53	5.01	9.67E-7	Diabetic kidney disease	
CESC	cis	1	rs186378	chr7:65582058	LOC493754	chr7:65993446-66057363:-	0.54	4.28	2.62E-5	Diabetic kidney disease	
CESC	cis	1	rs1863998	chr5:150271753	LOC134466	chr5:150310000-150326146:-	0.39	4.55	8.16E-6	Crohn's disease	
CESC	cis	1	rs1864367	chr3:53111704	RFT1	chr3:53122503-53164470:-	-0.35	-5.24	3.25E-7	Height	
CESC	cis	1	rs1867571	chr10:60038850	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs1867572	chr10:60038940	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs1867573	chr10:60042972	IPMK	chr10:59955618-60027694:-	-0.21	-4.48	1.08E-5	Inflammatory bowel disease	
CESC	cis	1	rs1873494	chr7:65649899	CCT6P1	chr7:65216092-65228661:+	-0.51	-4.76	3.19E-6	Diabetic kidney disease	
CESC	cis	1	rs1874883	chr3:134205071	ANAPC13	chr3:134196547-134204865:-	0.3	3.98	8.93E-5	Height	
CESC	cis	1	rs1875124	chr12:58196802	FAM119B	chr12:58166383-58176323:+	0.39	5.07	7.2E-7	Multiple sclerosis	
CESC	cis	1	rs1875124	chr12:58196802	TSFM	chr12:58176536-58191367:+	-0.35	-5.87	1.25E-8	Multiple sclerosis	
CESC	cis	1	rs1880376	chr3:134270347	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.35	1.95E-5	Height	
CESC	cis	1	rs1880377	chr3:134270468	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.35	1.95E-5	Height	
CESC	cis	1	rs1881245	chr2:73649928	ALMS1P	chr2:73872046-73912692:+	0.37	5.26	2.91E-7	Metabolite levels	
CESC	cis	1	rs1882655	chr7:66147057	CCT6P1	chr7:65216092-65228661:+	-0.57	-5.35	1.9E-7	Gout	
CESC	cis	1	rs1882655	chr7:66147057	LOC493754	chr7:65993446-66057363:-	-0.58	-4.59	6.88E-6	Gout	
CESC	cis	1	rs1885986	chr17:2203175	SRR	chr17:2207248-2228553:+	-0.39	-5.01	9.77E-7	Esophageal cancer (squamous cell)	
CESC	cis	1	rs1896707	chr5:150245129	LOC134466	chr5:150310000-150326146:-	0.4	4.93	1.4E-6	Crohn's disease	
CESC	cis	1	rs1896708	chr5:150245076	LOC134466	chr5:150310000-150326146:-	0.45	5.32	2.16E-7	Crohn's disease	
CESC	cis	1	rs1896709	chr5:150245032	LOC134466	chr5:150310000-150326146:-	0.4	4.93	1.39E-6	Crohn's disease	
CESC	cis	1	rs190414	chr5:56116772	C5orf35	chr5:56205103-56213010:+	0.82	11.98	7.03E-27	Type 2 diabetes	
CESC	cis	1	rs1911552	chr6:86638024	SNHG5	chr6:86386726-86388451:-	-0.61	-11.52	2.47E-25	Response to antipsychotic treatment	
CESC	cis	1	rs1911553	chr6:86630892	SNHG5	chr6:86386726-86388451:-	-0.57	-9.05	2.7E-17	Response to antipsychotic treatment	
CESC	cis	1	rs1919948	chr7:143762843	ARHGEF35	chr7:143883677-143892736:-	-0.49	-6.11	3.47E-9	Obesity-related traits	
CESC	cis	1	rs1919949	chr7:143767723	ARHGEF35	chr7:143883677-143892736:-	-0.49	-6.11	3.44E-9	Obesity-related traits	
CESC	cis	1	rs1919950	chr7:143767898	ARHGEF35	chr7:143883677-143892736:-	-0.49	-5.9	1.06E-8	Obesity-related traits	
CESC	cis	1	rs1919951	chr7:143768891	ARHGEF35	chr7:143883677-143892736:-	-0.5	-6.05	4.71E-9	Obesity-related traits	
CESC	cis	1	rs1930961	chr22:25875265	CRYBB2	chr22:25615612-25627836:+	0.8	9.06	2.43E-17	Bipolar disorder with mood-incongruent psychosis	
CESC	cis	1	rs1962716	chr6:86648436	SNHG5	chr6:86386726-86388451:-	-0.58	-9.14	1.39E-17	Response to antipsychotic treatment	
CESC	cis	1	rs1964692	chr7:65454183	CCT6P1	chr7:65216092-65228661:+	0.53	5.13	5.56E-7	Diabetic kidney disease	
CESC	cis	1	rs1976053	chr17:65833002	LOC651250	chr17:66097696-66157623:+	-0.3	-4.42	1.45E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs1976054	chr17:65833224	LOC651250	chr17:66097696-66157623:+	-0.28	-3.98	8.79E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs1979823	chr7:65704613	CCT6P1	chr7:65216092-65228661:+	-0.54	-5.06	7.72E-7	Diabetic kidney disease	
CESC	cis	1	rs1979823	chr7:65704613	LOC493754	chr7:65993446-66057363:-	-0.53	-4.17	4.17E-5	Diabetic kidney disease	
CESC	cis	1	rs1979	chr6:26377591	BTN3A2	chr6:26365398-26378546:+	-0.71	-7.6	4.53E-13	Schizophrenia	
CESC	cis	1	rs1982861	chr3:49577665	KLHDC8B	chr3:49209068-49213918:+	-0.28	-4.44	1.32E-5	Menarche (age at onset)	
CESC	cis	1	rs1982861	chr3:49577665	WDR6	chr3:49044637-49053386:+	-0.28	-4.58	6.96E-6	Menarche (age at onset)	
CESC	cis	1	rs1994157	chr3:41897482	ULK4	chr3:41288091-42003660:-	0.4	5.25	3.03E-7	Diastolic blood pressure	
CESC	cis	1	rs1995688	chr6:86632319	SNHG5	chr6:86386726-86388451:-	-0.57	-9.05	2.7E-17	Response to antipsychotic treatment	
CESC	cis	1	rs1999852	chr6:86705738	SNHG5	chr6:86386726-86388451:-	-0.61	-9.94	4.48E-20	Response to antipsychotic treatment	
CESC	cis	1	rs1999997	chr10:59996969	IPMK	chr10:59955618-60027694:-	0.23	5.09	6.79E-7	Inflammatory bowel disease	
CESC	cis	1	rs2004711	chr5:150225068	LOC134466	chr5:150310000-150326146:-	0.44	5.04	8.53E-7	Crohn's disease	
CESC	cis	1	rs2006751	chr11:43670501	HSD17B12	chr11:43702143-43878160:+	-0.35	-5.33	2.01E-7	Forced vital capacity	
CESC	cis	1	rs2010648	chr14:35604892	PPP2R3C	chr14:35554679-35591679:-	0.43	4.95	1.28E-6	Atopic dermatitis	
CESC	cis	1	rs2016409	chr5:151126324	SLC36A1	chr5:150816553-150871939:+	0.32	4.14	4.54E-5	Preschool internalizing problems	
CESC	cis	1	rs2019022	chr10:60024052	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs2028299	chr15:90374257	AP3S2	chr15:90373832-90456222:-	-0.45	-5.38	1.63E-7	Type 2 diabetes	
CESC	cis	1	rs2046323	chr17:65849927	LOC651250	chr17:66097696-66157623:+	-0.31	-4.05	6.75E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs2048672	chr7:130653851	CPA4	chr7:129932974-129964019:+	0.23	3.99	8.53E-5	Breast cancer	
CESC	cis	1	rs2052187	chr17:65834737	LOC651250	chr17:66097696-66157623:+	-0.28	-3.95	9.99E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs2056486	chr2:73717567	ALMS1P	chr2:73872046-73912692:+	0.38	5.52	7.97E-8	Metabolite levels	
CESC	cis	1	rs2056604	chr3:134312648	ANAPC13	chr3:134196547-134204865:-	0.3	4.08	5.9E-5	Height	
CESC	cis	1	rs2058059	chr7:72311817	TYW1B	chr7:72023729-72298813:-	-0.44	-5.7	3.03E-8	Subcutaneous adipose tissue	
CESC	cis	1	rs2062078	chr8:130734461	GSDMC	chr8:130760443-130799134:-	-0.29	-5.29	2.5E-7	Infant length;Height	
CESC	cis	1	rs2068737	chr10:59999575	IPMK	chr10:59955618-60027694:-	0.23	5.09	6.79E-7	Inflammatory bowel disease	
CESC	cis	1	rs2069502	chr12:58144665	FAM119B	chr12:58166383-58176323:+	-0.33	-4.27	2.7E-5	Multiple sclerosis	
CESC	cis	1	rs2069502	chr12:58144665	TSFM	chr12:58176536-58191367:+	0.35	5.95	8.33E-9	Multiple sclerosis	
CESC	cis	1	rs2072052	chr12:58146719	FAM119B	chr12:58166383-58176323:+	0.33	4.38	1.67E-5	Multiple sclerosis	
CESC	cis	1	rs2072052	chr12:58146719	TSFM	chr12:58176536-58191367:+	-0.35	-5.99	6.57E-9	Multiple sclerosis	
CESC	cis	1	rs2072293	chr14:74537885	LIN52	chr14:74551656-74667117:+	0.41	8.35	3.49E-15	Common traits (Other)	
CESC	cis	1	rs2072794	chr22:39150543	CBY1	chr22:39052658-39069853:+	0.27	4.45	1.24E-5	Resting heart rate	
CESC	cis	1	rs2072796	chr22:39064230	CBY1	chr22:39052658-39069853:+	0.25	4.12	5.0E-5	Resting heart rate	
CESC	cis	1	rs2072798	chr22:39148483	CBY1	chr22:39052658-39069853:+	0.26	4.35	1.94E-5	Resting heart rate	
CESC	cis	1	rs2074038	chr11:44087989	ACCS	chr11:44087475-44105569:+	1.03	9.9	5.97E-20	IgA nephropathy	
CESC	cis	1	rs2076028	chr22:39150450	CBY1	chr22:39052658-39069853:+	0.26	4.39	1.62E-5	Resting heart rate	
CESC	cis	1	rs2077808	chr1:45988115	CCDC163P	chr1:45960581-45965646:-	-0.79	-13.94	8.65E-34	Homocysteine levels	
CESC	cis	1	rs2083634	chr4:129976478	C4orf33	chr4:130014829-130033842:+	-0.36	-5.49	9.16E-8	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs2087647	chr7:65593188	NCRNA00174	chr7:65841032-65865395:-	0.26	3.99	8.33E-5	Aortic root size	
CESC	cis	1	rs2095892	chr10:60023719	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs2095893	chr10:59969551	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs2095894	chr10:59968671	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs2105220	chr10:59969064	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs2113078	chr5:56087190	C5orf35	chr5:56205103-56213010:+	0.82	11.31	1.27E-24	Type 2 diabetes	
CESC	cis	1	rs2113079	chr5:56157951	C5orf35	chr5:56205103-56213010:+	0.84	12.39	2.53E-28	Type 2 diabetes	
CESC	cis	1	rs2115069	chr5:150252365	LOC134466	chr5:150310000-150326146:-	0.44	5.07	7.17E-7	Crohn's disease	
CESC	cis	1	rs2126129	chr2:212548	SH3YL1	chr2:218138-264810:-	-0.67	-10.77	8.22E-23	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs2128792	chr17:65857177	LOC651250	chr17:66097696-66157623:+	-0.31	-4.08	5.99E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs2128834	chr3:41862645	ULK4	chr3:41288091-42003660:-	0.46	6.88	4.0E-11	Diastolic blood pressure	
CESC	cis	1	rs2128835	chr3:41862873	ULK4	chr3:41288091-42003660:-	0.46	6.96	2.57E-11	Diastolic blood pressure	
CESC	cis	1	rs2130392	chr4:185639169	MLF1IP	chr4:185615220-185655286:-	-0.42	-7.3	3.17E-12	Kawasaki disease	
CESC	cis	1	rs2140195	chr2:73702344	ALMS1P	chr2:73872046-73912692:+	0.38	5.35	1.87E-7	Metabolite levels	
CESC	cis	1	rs2141924	chr7:66186246	CCT6P1	chr7:65216092-65228661:+	0.56	5.28	2.57E-7	Gout	
CESC	cis	1	rs2141924	chr7:66186246	LOC493754	chr7:65993446-66057363:-	0.57	4.57	7.5E-6	Gout	
CESC	cis	1	rs2143950	chr14:35572357	PPP2R3C	chr14:35554679-35591679:-	0.47	5.17	4.46E-7	Atopic dermatitis	
CESC	cis	1	rs2153281	chr10:59972453	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs2153282	chr10:59972416	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs2153283	chr10:59972299	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs2154536	chr21:38492147	PIGP	chr21:38437664-38445458:-	-0.42	-6.1	3.52E-9	Eye color traits	
CESC	cis	1	rs2160908	chr22:37586792	C1QTNF6	chr22:37576206-37594341:-	-0.25	-4.1	5.34E-5	Parasitemia in Tripanosoma cruzi seropositivity	
CESC	cis	1	rs2163167	chr3:53131772	RFT1	chr3:53122503-53164470:-	-0.37	-5.55	6.85E-8	Height	
CESC	cis	1	rs216345	chr9:33799370	NUDT2	chr9:34329504-34343695:+	-0.34	-5.92	9.35E-9	Bipolar disorder	
CESC	cis	1	rs2166663	chr6:86593896	SNHG5	chr6:86386726-86388451:-	-0.63	-11.94	9.18E-27	Response to antipsychotic treatment	
CESC	cis	1	rs2173033	chr1:59850907	OMA1	chr1:58939504-59012446:-	-0.36	-4.34	1.98E-5	Obesity-related traits	
CESC	cis	1	rs2177601	chr3:134245434	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.35	1.95E-5	Height	
CESC	cis	1	rs2177703	chr7:65391717	CCT6P1	chr7:65216092-65228661:+	0.45	4.32	2.14E-5	Diabetic kidney disease	
CESC	cis	1	rs2179142	chr22:39037954	CBY1	chr22:39052658-39069853:+	0.26	4.3	2.36E-5	Resting heart rate	
CESC	cis	1	rs2205802	chr22:39046327	CBY1	chr22:39052658-39069853:+	0.25	4.11	5.23E-5	Resting heart rate	
CESC	cis	1	rs2210913	chr1:157668993	FCRL3	chr1:157646278-157670775:-	0.35	8.35	3.34E-15	Type 1 diabetes autoantibodies	
CESC	cis	1	rs2217266	chr5:150272621	LOC134466	chr5:150310000-150326146:-	0.38	4.48	1.1E-5	Crohn's disease	
CESC	cis	1	rs2227336	chr17:38174855	GSDMA	chr17:38119226-38134019:+	-0.32	-4.9	1.6E-6	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
CESC	cis	1	rs2229384	chr6:49425521	CENPQ	chr6:49431096-49460820:+	0.47	8.56	8.09E-16	Homocysteine levels	
CESC	cis	1	rs2235230	chr22:39124467	CBY1	chr22:39052658-39069853:+	-0.28	-4.45	1.27E-5	Resting heart rate	
CESC	cis	1	rs2236352	chr14:24610733	FAM158A	chr14:24608175-24610797:-	-0.38	-6.59	2.25E-10	IgG glycosylation	
CESC	cis	1	rs2239557	chr14:74551970	LIN52	chr14:74551656-74667117:+	0.41	8.09	1.96E-14	Common traits (Other)	
CESC	cis	1	rs2242150	chr3:48505964	TREX1	chr3:48501186-48509043:+	0.19	4.12	5.0E-5	Longevity	
CESC	cis	1	rs2243103	chr17:4839400	SPAG7	chr17:4862523-4871132:-	0.42	4.31	2.25E-5	Platelet count	
CESC	cis	1	rs224446	chr12:51381718	TFCP2	chr12:51488608-51566917:-	0.34	4.02	7.56E-5	Type 2 diabetes	
CESC	cis	1	rs224568	chr12:51386548	TFCP2	chr12:51488608-51566917:-	-0.35	-4.03	7.09E-5	Type 2 diabetes	
CESC	cis	1	rs2245715	chr15:43818052	CATSPER2	chr15:43922774-43959900:-	-0.38	-4.99	1.05E-6	Tumor biomarkers	
CESC	cis	1	rs2251039	chr10:60028894	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs2251115	chr6:49446509	CENPQ	chr6:49431096-49460820:+	-0.4	-7.24	4.62E-12	Homocysteine levels	
CESC	cis	1	rs2251115	chr6:49446509	MUT	chr6:49398994-49431031:-	0.28	4.6	6.37E-6	Homocysteine levels	
CESC	cis	1	rs2251844	chr15:43836478	CATSPER2	chr15:43922774-43959900:-	-0.4	-5.18	4.22E-7	Tumor biomarkers	
CESC	cis	1	rs2251844	chr15:43836478	CKMT1B	chr15:43885252-43891603:+	-0.31	-4	8.09E-5	Tumor biomarkers	
CESC	cis	1	rs2253192	chr10:59999323	IPMK	chr10:59955618-60027694:-	-0.22	-4.7	4.03E-6	Inflammatory bowel disease	
CESC	cis	1	rs2253209	chr3:53115160	RFT1	chr3:53122503-53164470:-	-0.34	-5.14	5.26E-7	Height	
CESC	cis	1	rs2253656	chr3:53119099	RFT1	chr3:53122503-53164470:-	-0.35	-5.26	2.96E-7	Height	
CESC	cis	1	rs2253685	chr3:53119703	RFT1	chr3:53122503-53164470:-	-0.33	-4.98	1.14E-6	Height	
CESC	cis	1	rs2253796	chr3:53120098	RFT1	chr3:53122503-53164470:-	-0.33	-4.97	1.19E-6	Height	
CESC	cis	1	rs2254545	chr10:60034981	IPMK	chr10:59955618-60027694:-	0.2	4.21	3.46E-5	Inflammatory bowel disease	
CESC	cis	1	rs2254775	chr10:60036815	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs2255042	chr15:43834318	CATSPER2	chr15:43922774-43959900:-	0.44	5.83	1.59E-8	Tumor biomarkers	
CESC	cis	1	rs2255042	chr15:43834318	CKMT1B	chr15:43885252-43891603:+	0.34	4.5	1.0E-5	Tumor biomarkers	
CESC	cis	1	rs2255051	chr15:43846161	CATSPER2	chr15:43922774-43959900:-	-0.4	-5.19	4.03E-7	Tumor biomarkers	
CESC	cis	1	rs2255051	chr15:43846161	CKMT1B	chr15:43885252-43891603:+	-0.3	-3.99	8.57E-5	Tumor biomarkers	
CESC	cis	1	rs2255440	chr15:43830467	CATSPER2	chr15:43922774-43959900:-	-0.39	-5.12	5.76E-7	Tumor biomarkers	
CESC	cis	1	rs2257790	chr7:65600450	CCT6P1	chr7:65216092-65228661:+	0.48	4.54	8.34E-6	Diabetic kidney disease	
CESC	cis	1	rs2260160	chr15:43895643	CATSPER2	chr15:43922774-43959900:-	-0.37	-4.72	3.69E-6	Tumor biomarkers	
CESC	cis	1	rs2260160	chr15:43895643	CKMT1A	chr15:43985084-43991419:+	-0.39	-4.65	5.14E-6	Tumor biomarkers	
CESC	cis	1	rs2260160	chr15:43895643	CKMT1B	chr15:43885252-43891603:+	-0.31	-4.17	4.13E-5	Tumor biomarkers	
CESC	cis	1	rs2267393	chr22:39101619	CBY1	chr22:39052658-39069853:+	0.23	3.99	8.6E-5	Resting heart rate	
CESC	cis	1	rs2267394	chr22:39101633	CBY1	chr22:39052658-39069853:+	0.23	3.99	8.6E-5	Resting heart rate	
CESC	cis	1	rs2269381	chr22:51020069	CPT1B	chr22:51007291-51017096:-	-0.5	-4.1	5.5E-5	Narcolepsy	
CESC	cis	1	rs2269382	chr22:51018911	CPT1B	chr22:51007291-51017096:-	-0.5	-4.08	6.0E-5	Narcolepsy	
CESC	cis	1	rs2269558	chr16:682250	WFIKKN1	chr16:679239-684116:+	0.33	5.18	4.29E-7	Height	
CESC	cis	1	rs2272007	chr3:41996136	ULK4	chr3:41288091-42003660:-	-0.52	-8.28	5.59E-15	Diastolic blood pressure	
CESC	cis	1	rs2273	chr4:76889388	NAAA	chr4:76831809-76862166:-	0.31	4.24	3.11E-5	Longevity	
CESC	cis	1	rs2275426	chr1:46487552	CCDC163P	chr1:45960581-45965646:-	-0.34	-5.49	9.13E-8	Body mass index	
CESC	cis	1	rs2277862	chr20:34152782	CPNE1	chr20:34213968-34262539:-	-0.53	-5.62	4.74E-8	Cholesterol, total	
CESC	cis	1	rs2279077	chr3:48474249	TREX1	chr3:48501186-48509043:+	-0.2	-4.5	1.03E-5	Longevity	
CESC	cis	1	rs2279241	chr3:138121198	ARMC8	chr3:137906148-138016219:+	0.34	4.06	6.46E-5	Coronary artery disease;Coronary heart disease	
CESC	cis	1	rs2281019	chr22:39064378	CBY1	chr22:39052658-39069853:+	0.25	4.12	5.0E-5	Resting heart rate	
CESC	cis	1	rs2281020	chr22:39064406	CBY1	chr22:39052658-39069853:+	0.25	4.12	5.0E-5	Resting heart rate	
CESC	cis	1	rs2281021	chr22:39064667	CBY1	chr22:39052658-39069853:+	0.25	4.12	5.0E-5	Resting heart rate	
CESC	cis	1	rs2284073	chr22:39105948	CBY1	chr22:39052658-39069853:+	0.23	4.06	6.49E-5	Resting heart rate	
CESC	cis	1	rs2285087	chr4:3088211	GRK4	chr4:2965343-3042474:+	-0.3	-4.1	5.42E-5	Parental longevity (mother's age at death)	
CESC	cis	1	rs2285946	chr7:21583329	DNAH11	chr7:21582833-21941455:+	-0.52	-7.58	5.24E-13	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
CESC	cis	1	rs2285947	chr7:21584088	DNAH11	chr7:21582833-21941455:+	0.51	7.49	9.69E-13	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
CESC	cis	1	rs2285949	chr7:21584243	DNAH11	chr7:21582833-21941455:+	-0.53	-7.64	3.69E-13	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
CESC	cis	1	rs2285950	chr7:21584432	DNAH11	chr7:21582833-21941455:+	0.52	7.48	1.0E-12	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
CESC	cis	1	rs2290143	chr13:21280363	IFT88	chr13:21141208-21265574:+	-0.31	-4.3	2.38E-5	Dental caries	
CESC	cis	1	rs2290822	chr3:48473204	TREX1	chr3:48501186-48509043:+	-0.19	-4.24	3.07E-5	Longevity	
CESC	cis	1	rs2290911	chr2:224919	SH3YL1	chr2:218138-264810:-	-0.71	-11.66	8.37E-26	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs2291127	chr3:138122477	ARMC8	chr3:137906148-138016219:+	0.38	4.34	1.97E-5	Coronary artery disease;Coronary heart disease	
CESC	cis	1	rs2291127	chr3:138122477	DBR1	chr3:137879853-137893773:-	0.37	4.04	7.01E-5	Coronary artery disease;Coronary heart disease	
CESC	cis	1	rs2292239	chr12:56482180	RPS26	chr12:56435686-56438005:+	0.59	9.7	2.58E-19	Cognitive function	
CESC	cis	1	rs2294008	chr8:143761931	LY6K	chr8:143781529-143785582:+	0.28	4.84	2.14E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2294008	chr8:143761931	PSCA	chr8:143761875-143764142:+	0.43	7.05	1.41E-11	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2294010	chr8:143762430	LY6K	chr8:143781529-143785582:+	0.28	4.81	2.47E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2294010	chr8:143762430	PSCA	chr8:143761875-143764142:+	0.43	7.21	5.58E-12	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2294296	chr22:39053049	CBY1	chr22:39052658-39069853:+	0.24	3.97	9.29E-5	Resting heart rate	
CESC	cis	1	rs2296837	chr1:166958601	MAEL	chr1:166958519-166991447:+	-0.35	-4.58	7.01E-6	Refractive astigmatism	
CESC	cis	1	rs2302138	chr14:74363305	PTGR2	chr14:74318534-74352166:+	0.37	4.01	7.71E-5	Morning vs. evening chronotype	
CESC	cis	1	rs2302139	chr14:74362935	PTGR2	chr14:74318534-74352166:+	0.36	4.14	4.7E-5	Morning vs. evening chronotype	
CESC	cis	1	rs2303759	chr19:49869051	DKKL1	chr19:49867042-49878371:+	-0.33	-4.19	3.83E-5	Multiple sclerosis	
CESC	cis	1	rs2306374	chr3:138119952	ARMC8	chr3:137906148-138016219:+	0.36	4.51	9.69E-6	Coronary artery disease;Coronary heart disease	
CESC	cis	1	rs2312462	chr3:49601255	KLHDC8B	chr3:49209068-49213918:+	-0.25	-3.98	8.91E-5	Menarche (age at onset)	
CESC	cis	1	rs2324843	chr6:86617501	SNHG5	chr6:86386726-86388451:-	-0.58	-8.74	2.35E-16	Response to antipsychotic treatment	
CESC	cis	1	rs2336540	chr3:52974589	RFT1	chr3:53122503-53164470:-	0.47	4.13	4.81E-5	Immune reponse to smallpox (secreted IL-2)	
CESC	cis	1	rs2336541	chr3:52974630	RFT1	chr3:53122503-53164470:-	0.47	4.13	4.81E-5	Immune reponse to smallpox (secreted IL-2)	
CESC	cis	1	rs2336723	chr3:53106047	RFT1	chr3:53122503-53164470:-	-0.32	-4.64	5.43E-6	Height	
CESC	cis	1	rs2344180	chr5:150267357	LOC134466	chr5:150310000-150326146:-	0.4	4.71	4.0E-6	Crohn's disease	
CESC	cis	1	rs2344181	chr5:150262574	LOC134466	chr5:150310000-150326146:-	0.4	4.71	4.0E-6	Crohn's disease	
CESC	cis	1	rs2345001	chr5:150266518	LOC134466	chr5:150310000-150326146:-	0.4	4.73	3.64E-6	Crohn's disease	
CESC	cis	1	rs2347596	chr5:151179199	ATOX1	chr5:151122384-151138210:-	-0.22	-4.01	7.94E-5	Preschool internalizing problems	
CESC	cis	1	rs2349075	chr2:202223566	ALS2CR12	chr2:202153148-202222101:-	-0.3	-4.08	5.84E-5	Basal cell carcinoma	
CESC	cis	1	rs2351706	chr15:90384115	AP3S2	chr15:90373832-90456222:-	-0.45	-5.38	1.57E-7	Type 2 diabetes	
CESC	cis	1	rs2351707	chr15:90384045	AP3S2	chr15:90373832-90456222:-	-0.46	-5.56	6.26E-8	Type 2 diabetes	
CESC	cis	1	rs2356559	chr1:45981512	CCDC163P	chr1:45960581-45965646:-	-0.72	-12.93	3.41E-30	Homocysteine levels	
CESC	cis	1	rs2356561	chr1:45980862	CCDC163P	chr1:45960581-45965646:-	-0.66	-11.62	1.18E-25	Homocysteine levels	
CESC	cis	1	rs2358628	chr14:74631757	LIN52	chr14:74551656-74667117:+	-0.4	-8.11	1.68E-14	Common traits (Other)	
CESC	cis	1	rs2358633	chr14:74647418	LIN52	chr14:74551656-74667117:+	-0.41	-8.36	3.25E-15	Common traits (Other)	
CESC	cis	1	rs236121	chr20:5972594	MCM8	chr20:5931298-5975829:+	-0.26	-4.14	4.67E-5	HIV-1 viral setpoint	
CESC	cis	1	rs2363731	chr2:88521793	THNSL2	chr2:88469835-88486145:+	-0.52	-5.03	8.92E-7	Plasma clusterin levels	
CESC	cis	1	rs2365764	chr17:65857714	LOC651250	chr17:66097696-66157623:+	-0.31	-4.06	6.3E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs2370578	chr3:134199612	ANAPC13	chr3:134196547-134204865:-	0.33	4.4	1.57E-5	Height	
CESC	cis	1	rs2371244	chr7:143757611	ARHGEF35	chr7:143883677-143892736:-	-0.49	-6.11	3.47E-9	Obesity-related traits	
CESC	cis	1	rs2371247	chr7:143764179	ARHGEF35	chr7:143883677-143892736:-	-0.49	-6.16	2.58E-9	Obesity-related traits	
CESC	cis	1	rs2371248	chr7:143764189	ARHGEF35	chr7:143883677-143892736:-	-0.49	-6.11	3.47E-9	Obesity-related traits	
CESC	cis	1	rs2373865	chr3:134291556	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.42	1.43E-5	Height	
CESC	cis	1	rs2413546	chr22:39107001	CBY1	chr22:39052658-39069853:+	0.29	4.85	2.07E-6	Resting heart rate	
CESC	cis	1	rs2413547	chr22:39107338	CBY1	chr22:39052658-39069853:+	0.29	4.85	2.07E-6	Resting heart rate	
CESC	cis	1	rs2420168	chr7:65630631	NCRNA00174	chr7:65841032-65865395:-	0.26	4.13	4.74E-5	Aortic root size	
CESC	cis	1	rs2420170	chr7:65656053	CCT6P1	chr7:65216092-65228661:+	-0.51	-4.76	3.19E-6	Diabetic kidney disease	
CESC	cis	1	rs2420171	chr7:65637760	CCT6P1	chr7:65216092-65228661:+	-0.51	-4.78	2.88E-6	Diabetic kidney disease	
CESC	cis	1	rs2421555	chr2:73816955	ALMS1P	chr2:73872046-73912692:+	0.36	5.28	2.57E-7	Metabolite levels	
CESC	cis	1	rs242271	chr6:88082029	C6orf162	chr6:88032306-88052043:+	-0.27	-3.99	8.4E-5	Depressive episodes in bipolar disorder	
CESC	cis	1	rs2429030	chr10:70751673	KIAA1279	chr10:70748493-70776734:+	-0.31	-4.28	2.58E-5	Schizophrenia	
CESC	cis	1	rs2429031	chr10:70755877	KIAA1279	chr10:70748493-70776734:+	-0.29	-4	8.17E-5	Schizophrenia	
CESC	cis	1	rs2432195	chr5:56120413	C5orf35	chr5:56205103-56213010:+	0.84	12.62	3.99E-29	Type 2 diabetes	
CESC	cis	1	rs2440845	chr10:59971884	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs2440846	chr10:59974293	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs2440847	chr10:59996176	IPMK	chr10:59955618-60027694:-	0.23	5.09	6.79E-7	Inflammatory bowel disease	
CESC	cis	1	rs2440848	chr10:59996403	IPMK	chr10:59955618-60027694:-	0.23	5.09	6.79E-7	Inflammatory bowel disease	
CESC	cis	1	rs2440849	chr10:60002164	IPMK	chr10:59955618-60027694:-	0.23	5.06	7.55E-7	Inflammatory bowel disease	
CESC	cis	1	rs2440850	chr10:60011731	IPMK	chr10:59955618-60027694:-	0.23	5.06	7.55E-7	Inflammatory bowel disease	
CESC	cis	1	rs2440855	chr10:59964744	IPMK	chr10:59955618-60027694:-	0.24	5.27	2.72E-7	Inflammatory bowel disease	
CESC	cis	1	rs2440856	chr10:60030789	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs2447196	chr15:43893818	CATSPER2	chr15:43922774-43959900:-	0.41	5.01	9.97E-7	Tumor biomarkers	
CESC	cis	1	rs2447196	chr15:43893818	CKMT1A	chr15:43985084-43991419:+	0.42	4.69	4.27E-6	Tumor biomarkers	
CESC	cis	1	rs2447208	chr15:43933895	CATSPER2	chr15:43922774-43959900:-	-0.45	-5.82	1.66E-8	Tumor biomarkers	
CESC	cis	1	rs2447208	chr15:43933895	CKMT1A	chr15:43985084-43991419:+	-0.45	-5.22	3.5E-7	Tumor biomarkers	
CESC	cis	1	rs2447208	chr15:43933895	CKMT1B	chr15:43885252-43891603:+	-0.32	-4.21	3.44E-5	Tumor biomarkers	
CESC	cis	1	rs2447211	chr15:43936351	CATSPER2	chr15:43922774-43959900:-	-0.43	-5.33	2.07E-7	Tumor biomarkers	
CESC	cis	1	rs2447211	chr15:43936351	CKMT1A	chr15:43985084-43991419:+	-0.46	-5.18	4.32E-7	Tumor biomarkers	
CESC	cis	1	rs2448704	chr6:49453672	CENPQ	chr6:49431096-49460820:+	0.43	7.89	7.04E-14	Homocysteine levels	
CESC	cis	1	rs2448704	chr6:49453672	MUT	chr6:49398994-49431031:-	-0.26	-4.15	4.41E-5	Homocysteine levels	
CESC	cis	1	rs2448707	chr6:49446951	CENPQ	chr6:49431096-49460820:+	0.26	4.57	7.4E-6	Folate pathway vitamin levels	
CESC	cis	1	rs2448707	chr6:49446951	MUT	chr6:49398994-49431031:-	-0.38	-6.64	1.69E-10	Folate pathway vitamin levels	
CESC	cis	1	rs2460422	chr7:65601505	CCT6P1	chr7:65216092-65228661:+	0.57	5.35	1.88E-7	Diabetic kidney disease	
CESC	cis	1	rs2460422	chr7:65601505	LOC493754	chr7:65993446-66057363:-	0.53	4.23	3.19E-5	Diabetic kidney disease	
CESC	cis	1	rs2462569	chr7:65474846	CCT6P1	chr7:65216092-65228661:+	-0.43	-4.27	2.66E-5	Diabetic kidney disease	
CESC	cis	1	rs246454	chr5:96123264	ERAP1	chr5:96096515-96149837:-	-0.41	-7.99	3.82E-14	Ankylosing spondylitis	
CESC	cis	1	rs246454	chr5:96123264	ERAP2	chr5:96211644-96255398:+	0.4	6.1	3.66E-9	Ankylosing spondylitis	
CESC	cis	1	rs2465120	chr7:65620974	CCT6P1	chr7:65216092-65228661:+	0.51	4.78	2.88E-6	Diabetic kidney disease	
CESC	cis	1	rs2470134	chr15:43849886	CATSPER2	chr15:43922774-43959900:-	0.34	4.14	4.59E-5	Tumor biomarkers	
CESC	cis	1	rs2486447	chr1:46545724	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.83	1.59E-8	Body mass index	
CESC	cis	1	rs2486483	chr10:60003000	IPMK	chr10:59955618-60027694:-	0.23	5.06	7.55E-7	Inflammatory bowel disease	
CESC	cis	1	rs2486486	chr10:60046654	IPMK	chr10:59955618-60027694:-	0.22	4.67	4.74E-6	Inflammatory bowel disease	
CESC	cis	1	rs2487702	chr10:70750148	KIAA1279	chr10:70748493-70776734:+	-0.3	-4.14	4.61E-5	Schizophrenia	
CESC	cis	1	rs2487706	chr10:70764444	KIAA1279	chr10:70748493-70776734:+	-0.3	-4.12	5.06E-5	Schizophrenia	
CESC	cis	1	rs2487707	chr10:70765092	KIAA1279	chr10:70748493-70776734:+	-0.3	-4.12	5.06E-5	Schizophrenia	
CESC	cis	1	rs2487708	chr10:70767402	C10orf35	chr10:71390003-71393347:+	-0.28	-4.26	2.82E-5	Schizophrenia	
CESC	cis	1	rs2487708	chr10:70767402	KIAA1279	chr10:70748493-70776734:+	-0.3	-4.2	3.65E-5	Schizophrenia	
CESC	cis	1	rs2501962	chr6:49453636	CENPQ	chr6:49431096-49460820:+	0.25	4.51	9.46E-6	Folate pathway vitamin levels	
CESC	cis	1	rs2501962	chr6:49453636	MUT	chr6:49398994-49431031:-	-0.39	-6.84	5.17E-11	Folate pathway vitamin levels	
CESC	cis	1	rs2501963	chr6:49454281	CENPQ	chr6:49431096-49460820:+	0.25	4.5	1.0E-5	Folate pathway vitamin levels	
CESC	cis	1	rs2501963	chr6:49454281	MUT	chr6:49398994-49431031:-	-0.39	-6.8	6.41E-11	Folate pathway vitamin levels	
CESC	cis	1	rs2526932	chr14:73081068	ACOT1	chr14:74003928-74042357:+	0.25	4.46	1.19E-5	C-reactive protein and white blood cell count	
CESC	cis	1	rs2526933	chr14:73080440	ACOT1	chr14:74003928-74042357:+	0.25	4.46	1.19E-5	C-reactive protein and white blood cell count	
CESC	cis	1	rs252887	chr5:56166188	C5orf35	chr5:56205103-56213010:+	0.83	12.05	3.88E-27	Type 2 diabetes	
CESC	cis	1	rs252898	chr5:56188931	C5orf35	chr5:56205103-56213010:+	0.85	12.55	6.98E-29	Type 2 diabetes	
CESC	cis	1	rs252902	chr5:56116085	C5orf35	chr5:56205103-56213010:+	0.83	12.36	3.33E-28	Type 2 diabetes	
CESC	cis	1	rs252904	chr5:56118733	C5orf35	chr5:56205103-56213010:+	0.82	11.94	9.05E-27	Type 2 diabetes	
CESC	cis	1	rs252909	chr5:56121131	C5orf35	chr5:56205103-56213010:+	0.83	12.03	4.64E-27	Type 2 diabetes	
CESC	cis	1	rs252910	chr5:56192983	C5orf35	chr5:56205103-56213010:+	0.83	11.38	7.91E-25	Type 2 diabetes	
CESC	cis	1	rs252915	chr5:56121754	C5orf35	chr5:56205103-56213010:+	-0.82	-11.84	2.03E-26	Type 2 diabetes	
CESC	cis	1	rs252916	chr5:56121788	C5orf35	chr5:56205103-56213010:+	0.84	12.62	3.99E-29	Type 2 diabetes	
CESC	cis	1	rs252919	chr5:56124111	C5orf35	chr5:56205103-56213010:+	0.83	12.03	4.64E-27	Type 2 diabetes	
CESC	cis	1	rs252921	chr5:56137787	C5orf35	chr5:56205103-56213010:+	0.85	12.71	1.97E-29	Type 2 diabetes	
CESC	cis	1	rs252922	chr5:56136343	C5orf35	chr5:56205103-56213010:+	0.85	12.82	8.14E-30	Type 2 diabetes	
CESC	cis	1	rs2533288	chr7:66056711	CCT6P1	chr7:65216092-65228661:+	0.57	5.41	1.38E-7	Diabetic kidney disease	
CESC	cis	1	rs2533288	chr7:66056711	LOC493754	chr7:65993446-66057363:-	0.54	4.31	2.25E-5	Diabetic kidney disease	
CESC	cis	1	rs2548664	chr5:56133555	C5orf35	chr5:56205103-56213010:+	0.84	12.21	1.07E-27	Type 2 diabetes	
CESC	cis	1	rs2548665	chr5:56131805	C5orf35	chr5:56205103-56213010:+	0.84	12.21	1.07E-27	Type 2 diabetes	
CESC	cis	1	rs2562784	chr15:84286492	WDR73	chr15:85186012-85197524:-	0.3	4.06	6.46E-5	Height	
CESC	cis	1	rs2562784	chr15:84286492	WHAMM	chr15:83477973-83503611:+	0.3	4.17	4.02E-5	Height	
CESC	cis	1	rs2564921	chr3:53125585	RFT1	chr3:53122503-53164470:-	0.36	5.31	2.27E-7	Height	
CESC	cis	1	rs2564940	chr3:53107569	RFT1	chr3:53122503-53164470:-	-0.36	-5.31	2.31E-7	Height	
CESC	cis	1	rs2572910	chr8:143770135	LY6K	chr8:143781529-143785582:+	0.27	4.73	3.61E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2572910	chr8:143770135	PSCA	chr8:143761875-143764142:+	0.43	7.32	2.76E-12	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2581782	chr3:53122257	RFT1	chr3:53122503-53164470:-	-0.36	-5.36	1.79E-7	Height	
CESC	cis	1	rs2581783	chr3:53122258	RFT1	chr3:53122503-53164470:-	-0.36	-5.36	1.79E-7	Height	
CESC	cis	1	rs2581786	chr3:53126143	RFT1	chr3:53122503-53164470:-	-0.36	-5.54	7.11E-8	Height	
CESC	cis	1	rs2581787	chr3:53127677	RFT1	chr3:53122503-53164470:-	-0.38	-5.74	2.47E-8	Height	
CESC	cis	1	rs2581800	chr3:53109352	RFT1	chr3:53122503-53164470:-	-0.32	-4.68	4.42E-6	Height	
CESC	cis	1	rs2585179	chr8:143774193	LY6K	chr8:143781529-143785582:+	0.27	4.73	3.59E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2585179	chr8:143774193	PSCA	chr8:143761875-143764142:+	0.43	7.32	2.75E-12	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2590299	chr10:59969000	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs2590305	chr10:59973844	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs2590306	chr10:59976966	IPMK	chr10:59955618-60027694:-	0.24	5.23	3.4E-7	Inflammatory bowel disease	
CESC	cis	1	rs2590307	chr10:59977161	IPMK	chr10:59955618-60027694:-	0.23	5.25	3.08E-7	Inflammatory bowel disease	
CESC	cis	1	rs2590308	chr10:59977569	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.97E-7	Inflammatory bowel disease	
CESC	cis	1	rs2590311	chr10:59983565	IPMK	chr10:59955618-60027694:-	0.23	5.09	6.79E-7	Inflammatory bowel disease	
CESC	cis	1	rs2590313	chr10:59986383	IPMK	chr10:59955618-60027694:-	0.23	5.09	6.79E-7	Inflammatory bowel disease	
CESC	cis	1	rs2590315	chr10:59986492	IPMK	chr10:59955618-60027694:-	0.23	5.09	6.79E-7	Inflammatory bowel disease	
CESC	cis	1	rs2590317	chr10:59987658	IPMK	chr10:59955618-60027694:-	0.23	5.09	6.79E-7	Inflammatory bowel disease	
CESC	cis	1	rs2590321	chr10:59996693	IPMK	chr10:59955618-60027694:-	0.23	5.09	6.79E-7	Inflammatory bowel disease	
CESC	cis	1	rs2590323	chr10:60000781	IPMK	chr10:59955618-60027694:-	0.23	5.06	7.55E-7	Inflammatory bowel disease	
CESC	cis	1	rs2590330	chr10:60008219	IPMK	chr10:59955618-60027694:-	0.23	5.06	7.55E-7	Inflammatory bowel disease	
CESC	cis	1	rs2590335	chr10:60009389	IPMK	chr10:59955618-60027694:-	0.23	5.06	7.55E-7	Inflammatory bowel disease	
CESC	cis	1	rs2590336	chr10:60010497	IPMK	chr10:59955618-60027694:-	0.23	5.06	7.55E-7	Inflammatory bowel disease	
CESC	cis	1	rs2590339	chr10:60012231	IPMK	chr10:59955618-60027694:-	0.23	5.12	5.76E-7	Inflammatory bowel disease	
CESC	cis	1	rs2590340	chr10:60012271	IPMK	chr10:59955618-60027694:-	0.23	5.06	7.55E-7	Inflammatory bowel disease	
CESC	cis	1	rs2590344	chr10:60013067	IPMK	chr10:59955618-60027694:-	0.23	5.06	7.55E-7	Inflammatory bowel disease	
CESC	cis	1	rs2590348	chr10:60014595	IPMK	chr10:59955618-60027694:-	0.23	5.06	7.55E-7	Inflammatory bowel disease	
CESC	cis	1	rs2590349	chr10:60014646	IPMK	chr10:59955618-60027694:-	0.23	5.06	7.55E-7	Inflammatory bowel disease	
CESC	cis	1	rs2590356	chr10:60019047	IPMK	chr10:59955618-60027694:-	0.23	5.06	7.55E-7	Inflammatory bowel disease	
CESC	cis	1	rs2590357	chr10:60019964	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs2590358	chr10:60020982	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs2590359	chr10:60021247	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs2590364	chr10:60038406	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs2590367	chr10:60041574	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs2590368	chr10:60043482	IPMK	chr10:59955618-60027694:-	0.22	4.67	4.74E-6	Inflammatory bowel disease	
CESC	cis	1	rs2590370	chr10:60049020	IPMK	chr10:59955618-60027694:-	0.22	4.67	4.74E-6	Inflammatory bowel disease	
CESC	cis	1	rs2590371	chr10:60054487	IPMK	chr10:59955618-60027694:-	0.22	4.78	2.9E-6	Inflammatory bowel disease	
CESC	cis	1	rs259346	chr1:95728746	RWDD3	chr1:95583479-95712773:+	0.5	4.6	6.4E-6	Stearic acid (18:0) plasma levels	
CESC	cis	1	rs259354	chr1:95718205	RWDD3	chr1:95583479-95712773:+	-0.53	-4.65	5.16E-6	Stearic acid (18:0) plasma levels	
CESC	cis	1	rs259359	chr1:95709039	RWDD3	chr1:95583479-95712773:+	-0.53	-4.65	5.16E-6	Stearic acid (18:0) plasma levels	
CESC	cis	1	rs2602836	chr4:100014805	ADH4	chr4:100044835-100065449:-	0.31	4.85	2.03E-6	HDL cholesterol	
CESC	cis	1	rs2605583	chr11:93164957	CCDC67	chr11:93063156-93171634:+	-0.32	-4.03	7.1E-5	Pulmonary function decline	
CESC	cis	1	rs2614811	chr15:43913487	CATSPER2	chr15:43922774-43959900:-	-0.42	-5.29	2.44E-7	Tumor biomarkers	
CESC	cis	1	rs2614811	chr15:43913487	CKMT1A	chr15:43985084-43991419:+	-0.44	-5.05	8.12E-7	Tumor biomarkers	
CESC	cis	1	rs2614811	chr15:43913487	CKMT1B	chr15:43885252-43891603:+	-0.31	-3.96	9.66E-5	Tumor biomarkers	
CESC	cis	1	rs2625667	chr3:41900951	ULK4	chr3:41288091-42003660:-	0.51	8.19	1.02E-14	Diastolic blood pressure	
CESC	cis	1	rs2625668	chr3:41905930	ULK4	chr3:41288091-42003660:-	0.5	8.19	9.59E-15	Diastolic blood pressure	
CESC	cis	1	rs2637678	chr6:116787378	FAM26F	chr6:116782556-116784933:+	0.21	4.31	2.3E-5	Ulcerative colitis	
CESC	cis	1	rs26510	chr5:96125910	ERAP1	chr5:96096515-96149837:-	-0.39	-7.61	4.31E-13	Ankylosing spondylitis	
CESC	cis	1	rs26510	chr5:96125910	ERAP2	chr5:96211644-96255398:+	0.41	6.14	2.86E-9	Ankylosing spondylitis	
CESC	cis	1	rs2651829	chr11:2308304	C11orf21	chr11:2317507-2323143:-	0.25	4.01	7.83E-5	Obesity-related traits	
CESC	cis	1	rs2653503	chr10:59964034	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs2653504	chr10:59964042	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs2653505	chr10:59964142	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs2655310	chr4:130017919	C4orf33	chr4:130014829-130033842:+	-0.43	-6.49	4.09E-10	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs2657888	chr12:56938383	STAT2	chr12:56735384-56753909:-	0.23	4.07	6.21E-5	Adiponectin levels	
CESC	cis	1	rs2658779	chr11:93163137	CCDC67	chr11:93063156-93171634:+	0.34	4.27	2.72E-5	Pulmonary function decline	
CESC	cis	1	rs2659903	chr7:66180931	CCT6P1	chr7:65216092-65228661:+	0.56	5.28	2.57E-7	Gout	
CESC	cis	1	rs2659903	chr7:66180931	LOC493754	chr7:65993446-66057363:-	0.57	4.57	7.5E-6	Gout	
CESC	cis	1	rs2659911	chr7:66158420	CCT6P1	chr7:65216092-65228661:+	0.56	5.28	2.57E-7	Gout	
CESC	cis	1	rs2659911	chr7:66158420	LOC493754	chr7:65993446-66057363:-	0.57	4.57	7.5E-6	Gout	
CESC	cis	1	rs2659913	chr7:66157336	CCT6P1	chr7:65216092-65228661:+	0.56	5.28	2.57E-7	Gout	
CESC	cis	1	rs2659913	chr7:66157336	LOC493754	chr7:65993446-66057363:-	0.57	4.57	7.5E-6	Gout	
CESC	cis	1	rs2683695	chr3:41914928	ULK4	chr3:41288091-42003660:-	0.51	8.25	6.54E-15	Diastolic blood pressure	
CESC	cis	1	rs2707828	chr7:66171377	CCT6P1	chr7:65216092-65228661:+	0.56	5.28	2.57E-7	Gout	
CESC	cis	1	rs2707828	chr7:66171377	LOC493754	chr7:65993446-66057363:-	0.57	4.57	7.5E-6	Gout	
CESC	cis	1	rs2707830	chr7:66167645	CCT6P1	chr7:65216092-65228661:+	0.56	5.28	2.57E-7	Gout	
CESC	cis	1	rs2707830	chr7:66167645	LOC493754	chr7:65993446-66057363:-	0.57	4.57	7.5E-6	Gout	
CESC	cis	1	rs2707831	chr7:66062511	CCT6P1	chr7:65216092-65228661:+	0.57	5.43	1.25E-7	Diabetic kidney disease	
CESC	cis	1	rs2707831	chr7:66062511	LOC493754	chr7:65993446-66057363:-	0.55	4.44	1.31E-5	Diabetic kidney disease	
CESC	cis	1	rs2707832	chr7:66136549	CCT6P1	chr7:65216092-65228661:+	0.59	5.49	9.28E-8	Gout	
CESC	cis	1	rs2707832	chr7:66136549	LOC493754	chr7:65993446-66057363:-	0.57	4.49	1.04E-5	Gout	
CESC	cis	1	rs2707838	chr7:66159201	CCT6P1	chr7:65216092-65228661:+	0.56	5.28	2.57E-7	Gout	
CESC	cis	1	rs2707838	chr7:66159201	LOC493754	chr7:65993446-66057363:-	0.57	4.57	7.5E-6	Gout	
CESC	cis	1	rs2707840	chr7:66158015	CCT6P1	chr7:65216092-65228661:+	0.56	5.21	3.68E-7	Gout	
CESC	cis	1	rs2707840	chr7:66158015	LOC493754	chr7:65993446-66057363:-	0.55	4.36	1.81E-5	Gout	
CESC	cis	1	rs2707844	chr7:66059509	CCT6P1	chr7:65216092-65228661:+	0.57	5.43	1.25E-7	Diabetic kidney disease	
CESC	cis	1	rs2707844	chr7:66059509	LOC493754	chr7:65993446-66057363:-	0.55	4.44	1.31E-5	Diabetic kidney disease	
CESC	cis	1	rs2717562	chr8:143776668	LY6K	chr8:143781529-143785582:+	0.27	4.73	3.59E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2717562	chr8:143776668	PSCA	chr8:143761875-143764142:+	0.43	7.32	2.75E-12	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2724648	chr12:11858191	TAS2R20	chr12:11148561-11150474:-	-0.29	-4.07	6.08E-5	Height	
CESC	cis	1	rs27529	chr5:96126308	ERAP1	chr5:96096515-96149837:-	-0.42	-7.95	4.77E-14	Ankylosing spondylitis	
CESC	cis	1	rs27529	chr5:96126308	ERAP2	chr5:96211644-96255398:+	0.41	5.98	7.1E-9	Ankylosing spondylitis	
CESC	cis	1	rs27710	chr5:96126197	ERAP1	chr5:96096515-96149837:-	0.39	7.7	2.54E-13	Ankylosing spondylitis	
CESC	cis	1	rs27710	chr5:96126197	ERAP2	chr5:96211644-96255398:+	-0.4	-6.04	5.0E-9	Ankylosing spondylitis	
CESC	cis	1	rs2790145	chr10:59976277	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.97E-7	Inflammatory bowel disease	
CESC	cis	1	rs2790146	chr10:59975743	IPMK	chr10:59955618-60027694:-	0.24	5.22	3.61E-7	Inflammatory bowel disease	
CESC	cis	1	rs2790157	chr10:59973396	IPMK	chr10:59955618-60027694:-	0.24	5.37	1.68E-7	Inflammatory bowel disease	
CESC	cis	1	rs2790159	chr10:60018794	IPMK	chr10:59955618-60027694:-	0.23	5.06	7.55E-7	Inflammatory bowel disease	
CESC	cis	1	rs2790161	chr10:59968090	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs2790167	chr10:60024470	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs2790168	chr10:60025448	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs2790169	chr10:60025654	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs2790170	chr10:60028507	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs2790172	chr10:60008464	IPMK	chr10:59955618-60027694:-	0.23	5.06	7.55E-7	Inflammatory bowel disease	
CESC	cis	1	rs2790173	chr10:60031575	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs2790174	chr10:60031931	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs2790178	chr10:60034083	IPMK	chr10:59955618-60027694:-	0.21	4.41	1.48E-5	Inflammatory bowel disease	
CESC	cis	1	rs2790179	chr10:60035372	IPMK	chr10:59955618-60027694:-	-0.23	-4.83	2.23E-6	Inflammatory bowel disease	
CESC	cis	1	rs2790185	chr10:60041840	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs2790188	chr10:60042186	IPMK	chr10:59955618-60027694:-	0.21	4.45	1.26E-5	Inflammatory bowel disease	
CESC	cis	1	rs2790189	chr10:60042576	IPMK	chr10:59955618-60027694:-	0.23	5.01	9.56E-7	Inflammatory bowel disease	
CESC	cis	1	rs2790191	chr10:60045091	IPMK	chr10:59955618-60027694:-	0.22	4.67	4.74E-6	Inflammatory bowel disease	
CESC	cis	1	rs2790193	chr10:60046226	IPMK	chr10:59955618-60027694:-	0.22	4.67	4.74E-6	Inflammatory bowel disease	
CESC	cis	1	rs2790212	chr10:60013138	IPMK	chr10:59955618-60027694:-	0.23	5.06	7.55E-7	Inflammatory bowel disease	
CESC	cis	1	rs2790214	chr10:60013404	IPMK	chr10:59955618-60027694:-	0.23	5.06	7.55E-7	Inflammatory bowel disease	
CESC	cis	1	rs2790216	chr10:59997926	IPMK	chr10:59955618-60027694:-	0.23	5.09	6.79E-7	Inflammatory bowel disease	
CESC	cis	1	rs2790217	chr10:59997644	IPMK	chr10:59955618-60027694:-	0.23	5.09	6.79E-7	Inflammatory bowel disease	
CESC	cis	1	rs2790218	chr10:59997301	IPMK	chr10:59955618-60027694:-	0.23	5.09	6.79E-7	Inflammatory bowel disease	
CESC	cis	1	rs2790219	chr10:60013849	IPMK	chr10:59955618-60027694:-	0.23	5.06	7.55E-7	Inflammatory bowel disease	
CESC	cis	1	rs2790222	chr10:59995438	IPMK	chr10:59955618-60027694:-	0.23	5.09	6.79E-7	Inflammatory bowel disease	
CESC	cis	1	rs2790228	chr10:60014325	IPMK	chr10:59955618-60027694:-	0.23	5.06	7.55E-7	Inflammatory bowel disease	
CESC	cis	1	rs2790230	chr10:59989772	IPMK	chr10:59955618-60027694:-	0.23	5.09	6.79E-7	Inflammatory bowel disease	
CESC	cis	1	rs2790231	chr10:59989010	IPMK	chr10:59955618-60027694:-	0.23	5.09	6.79E-7	Inflammatory bowel disease	
CESC	cis	1	rs2790235	chr10:59985274	IPMK	chr10:59955618-60027694:-	0.23	5.09	6.79E-7	Inflammatory bowel disease	
CESC	cis	1	rs2790238	chr10:59983573	IPMK	chr10:59955618-60027694:-	0.23	5.09	6.79E-7	Inflammatory bowel disease	
CESC	cis	1	rs2790240	chr10:59982139	IPMK	chr10:59955618-60027694:-	0.23	5.09	6.79E-7	Inflammatory bowel disease	
CESC	cis	1	rs2790241	chr10:60015313	IPMK	chr10:59955618-60027694:-	0.23	4.98	1.15E-6	Inflammatory bowel disease	
CESC	cis	1	rs2790242	chr10:59980652	IPMK	chr10:59955618-60027694:-	-0.23	-5.03	8.91E-7	Inflammatory bowel disease	
CESC	cis	1	rs2797983	chr10:95899646	HELLS	chr10:96305543-96361855:+	0.22	3.95	0.0001	Blood pressure	
CESC	cis	1	rs2803961	chr14:73082826	ACOT1	chr14:74003928-74042357:+	0.25	4.53	8.99E-6	C-reactive protein and white blood cell count	
CESC	cis	1	rs2803962	chr14:73083240	ACOT1	chr14:74003928-74042357:+	-0.23	-4.09	5.58E-5	C-reactive protein and white blood cell count	
CESC	cis	1	rs280603	chr4:129915063	C4orf33	chr4:130014829-130033842:+	-0.38	-5.73	2.67E-8	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs280604	chr4:129921170	C4orf33	chr4:130014829-130033842:+	-0.38	-5.72	2.72E-8	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs2812972	chr6:86669880	SNHG5	chr6:86386726-86388451:-	-0.61	-11.47	3.87E-25	Response to antipsychotic treatment	
CESC	cis	1	rs2816815	chr6:86691656	SNHG5	chr6:86386726-86388451:-	-0.61	-11.1	6.56E-24	Response to antipsychotic treatment	
CESC	cis	1	rs2816821	chr6:86657084	SNHG5	chr6:86386726-86388451:-	-0.61	-11.38	7.34E-25	Response to antipsychotic treatment	
CESC	cis	1	rs2835607	chr21:38491973	PIGP	chr21:38437664-38445458:-	-0.42	-6.02	5.6E-9	Eye color traits	
CESC	cis	1	rs2835608	chr21:38493455	PIGP	chr21:38437664-38445458:-	-0.42	-6.05	4.69E-9	Eye color traits	
CESC	cis	1	rs28365850	chr14:35591316	PPP2R3C	chr14:35554679-35591679:-	0.49	5.36	1.72E-7	Atopic dermatitis	
CESC	cis	1	rs2839181	chr21:47685939	C21orf57	chr21:47706267-47717664:+	-0.37	-6.07	4.33E-9	Testicular germ cell tumor	
CESC	cis	1	rs2839186	chr21:47690068	C21orf57	chr21:47706267-47717664:+	-0.39	-6.47	4.48E-10	Testicular germ cell tumor	
CESC	cis	1	rs28399702	chr14:35625217	PPP2R3C	chr14:35554679-35591679:-	0.4	4.73	3.54E-6	Atopic dermatitis	
CESC	cis	1	rs28409322	chr3:134252385	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.35	1.95E-5	Height	
CESC	cis	1	rs28447319	chr9:33218922	SPINK4	chr9:33240196-33248564:+	0.36	4.31	2.24E-5	Influenza A (H1N1) infection;Severe influenza A (H1N1) infection;Mild influenza (H1N1) infection	
CESC	cis	1	rs28514764	chr9:33218762	SPINK4	chr9:33240196-33248564:+	0.31	4.24	3.01E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs2862961	chr11:43656535	HSD17B12	chr11:43702143-43878160:+	0.34	5.19	4.14E-7	Forced vital capacity	
CESC	cis	1	rs2862963	chr11:43640115	HSD17B12	chr11:43702143-43878160:+	0.34	5.1	6.36E-7	Forced vital capacity	
CESC	cis	1	rs2862996	chr11:43653833	HSD17B12	chr11:43702143-43878160:+	-0.36	-5.27	2.8E-7	Forced vital capacity	
CESC	cis	1	rs28648645	chr9:33218766	SPINK4	chr9:33240196-33248564:+	0.31	4.24	3.01E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs28702390	chr3:41889920	ULK4	chr3:41288091-42003660:-	0.4	5.25	3.03E-7	Diastolic blood pressure	
CESC	cis	1	rs28733681	chr3:41863444	ULK4	chr3:41288091-42003660:-	0.45	6.92	3.14E-11	Diastolic blood pressure	
CESC	cis	1	rs28755797	chr3:41774446	ULK4	chr3:41288091-42003660:-	0.4	5.12	5.63E-7	Diastolic blood pressure	
CESC	cis	1	rs2880791	chr5:150267376	LOC134466	chr5:150310000-150326146:-	0.4	4.73	3.64E-6	Crohn's disease	
CESC	cis	1	rs28824259	chr3:48425675	TREX1	chr3:48501186-48509043:+	-0.19	-4.4	1.56E-5	Longevity	
CESC	cis	1	rs2885510	chr3:48418226	TREX1	chr3:48501186-48509043:+	0.19	4.4	1.54E-5	Longevity	
CESC	cis	1	rs2887797	chr3:134202506	ANAPC13	chr3:134196547-134204865:-	0.3	4.02	7.51E-5	Height	
CESC	cis	1	rs2901286	chr10:122900623	WDR11	chr10:122610695-122669035:+	-0.55	-4.29	2.48E-5	Response to treatment for acute lymphoblastic leukemia	
CESC	cis	1	rs2901354	chr10:124733038	PSTK	chr10:124739556-124749906:+	0.26	4.15	4.39E-5	Migraine without aura	
CESC	cis	1	rs2901438	chr2:73665656	ALMS1P	chr2:73872046-73912692:+	0.38	5.51	8.11E-8	Metabolite levels	
CESC	cis	1	rs2915869	chr5:151171509	ATOX1	chr5:151122384-151138210:-	-0.22	-4.01	7.94E-5	Preschool internalizing problems	
CESC	cis	1	rs2915878	chr5:151149662	SLC36A1	chr5:150816553-150871939:+	-0.3	-4.01	7.81E-5	Preschool internalizing problems	
CESC	cis	1	rs2915880	chr5:151147334	SLC36A1	chr5:150816553-150871939:+	-0.31	-4.14	4.54E-5	Preschool internalizing problems	
CESC	cis	1	rs2915882	chr5:151145436	SLC36A1	chr5:150816553-150871939:+	-0.31	-4.14	4.54E-5	Preschool internalizing problems	
CESC	cis	1	rs2915887	chr5:151205504	ATOX1	chr5:151122384-151138210:-	-0.23	-4.1	5.45E-5	Preschool internalizing problems	
CESC	cis	1	rs2920280	chr8:143761144	LY6K	chr8:143781529-143785582:+	0.32	5.46	1.08E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2920280	chr8:143761144	PSCA	chr8:143761875-143764142:+	0.41	6.71	1.13E-10	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2920282	chr8:143757763	LY6K	chr8:143781529-143785582:+	0.28	4.82	2.39E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2920282	chr8:143757763	PSCA	chr8:143761875-143764142:+	0.43	7.02	1.73E-11	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2920283	chr8:143757037	LY6K	chr8:143781529-143785582:+	0.28	4.78	2.85E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2920283	chr8:143757037	PSCA	chr8:143761875-143764142:+	0.42	6.9	3.54E-11	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2920292	chr8:143765699	LY6K	chr8:143781529-143785582:+	0.28	4.8	2.6E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2920292	chr8:143765699	PSCA	chr8:143761875-143764142:+	0.43	7.25	4.14E-12	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2920293	chr8:143765414	LY6K	chr8:143781529-143785582:+	0.28	4.8	2.64E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2920293	chr8:143765414	PSCA	chr8:143761875-143764142:+	0.43	7.2	5.59E-12	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2920294	chr8:143765326	LY6K	chr8:143781529-143785582:+	0.28	4.8	2.6E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2920294	chr8:143765326	PSCA	chr8:143761875-143764142:+	0.43	7.25	4.14E-12	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2920295	chr8:143764937	LY6K	chr8:143781529-143785582:+	0.27	4.74	3.44E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2920295	chr8:143764937	PSCA	chr8:143761875-143764142:+	0.41	6.89	3.91E-11	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2920296	chr8:143763109	LY6K	chr8:143781529-143785582:+	0.28	4.81	2.47E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2920296	chr8:143763109	PSCA	chr8:143761875-143764142:+	0.43	7.21	5.58E-12	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2920297	chr8:143763083	LY6K	chr8:143781529-143785582:+	0.28	4.81	2.47E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2920297	chr8:143763083	PSCA	chr8:143761875-143764142:+	0.43	7.21	5.58E-12	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2920298	chr8:143763043	LY6K	chr8:143781529-143785582:+	0.28	4.81	2.47E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2920298	chr8:143763043	PSCA	chr8:143761875-143764142:+	0.43	7.21	5.58E-12	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2920781	chr15:43924682	CATSPER2	chr15:43922774-43959900:-	-0.42	-5.27	2.76E-7	Tumor biomarkers	
CESC	cis	1	rs2920781	chr15:43924682	CKMT1A	chr15:43985084-43991419:+	-0.44	-4.94	1.37E-6	Tumor biomarkers	
CESC	cis	1	rs2924584	chr4:99988208	ADH4	chr4:100044835-100065449:-	-0.27	-4.27	2.65E-5	HDL cholesterol	
CESC	cis	1	rs2927072	chr15:43922398	CATSPER2	chr15:43922774-43959900:-	-0.44	-5.49	9.11E-8	Tumor biomarkers	
CESC	cis	1	rs2927072	chr15:43922398	CKMT1A	chr15:43985084-43991419:+	-0.44	-5.01	9.9E-7	Tumor biomarkers	
CESC	cis	1	rs2951308	chr7:143767149	ARHGEF35	chr7:143883677-143892736:-	0.45	5.56	6.39E-8	Obesity-related traits	
CESC	cis	1	rs2951353	chr7:143761116	ARHGEF35	chr7:143883677-143892736:-	-0.49	-6.16	2.58E-9	Obesity-related traits	
CESC	cis	1	rs2951354	chr7:143761001	ARHGEF35	chr7:143883677-143892736:-	-0.49	-6.11	3.47E-9	Obesity-related traits	
CESC	cis	1	rs2951360	chr7:143757349	ARHGEF35	chr7:143883677-143892736:-	-0.49	-6.08	4.1E-9	Obesity-related traits	
CESC	cis	1	rs2951363	chr7:143754724	ARHGEF35	chr7:143883677-143892736:-	-0.47	-6.02	5.7E-9	Obesity-related traits	
CESC	cis	1	rs2951364	chr7:143754483	ARHGEF35	chr7:143883677-143892736:-	-0.47	-6.02	5.7E-9	Obesity-related traits	
CESC	cis	1	rs2951368	chr7:143752821	ARHGEF35	chr7:143883677-143892736:-	-0.48	-6.15	2.66E-9	Obesity-related traits	
CESC	cis	1	rs2951369	chr7:143752638	ARHGEF35	chr7:143883677-143892736:-	-0.48	-6.15	2.66E-9	Obesity-related traits	
CESC	cis	1	rs2951372	chr7:143749503	ARHGEF35	chr7:143883677-143892736:-	-0.48	-6.15	2.66E-9	Obesity-related traits	
CESC	cis	1	rs2961102	chr7:65424658	CCT6P1	chr7:65216092-65228661:+	0.58	5.65	4.06E-8	Diabetic kidney disease	
CESC	cis	1	rs2961115	chr7:143753371	ARHGEF35	chr7:143883677-143892736:-	-0.48	-6.15	2.66E-9	Obesity-related traits	
CESC	cis	1	rs2961117	chr7:143755253	ARHGEF35	chr7:143883677-143892736:-	-0.47	-5.75	2.31E-8	Obesity-related traits	
CESC	cis	1	rs2961118	chr7:143755443	ARHGEF35	chr7:143883677-143892736:-	-0.48	-6.04	4.98E-9	Obesity-related traits	
CESC	cis	1	rs2961119	chr7:143755852	ARHGEF35	chr7:143883677-143892736:-	-0.48	-6.04	4.98E-9	Obesity-related traits	
CESC	cis	1	rs2961120	chr7:143756585	ARHGEF35	chr7:143883677-143892736:-	-0.49	-6.08	4.1E-9	Obesity-related traits	
CESC	cis	1	rs2961125	chr7:143761770	ARHGEF35	chr7:143883677-143892736:-	-0.49	-6.11	3.47E-9	Obesity-related traits	
CESC	cis	1	rs2961126	chr7:143762736	ARHGEF35	chr7:143883677-143892736:-	-0.49	-6.11	3.47E-9	Obesity-related traits	
CESC	cis	1	rs2961128	chr7:143763483	ARHGEF35	chr7:143883677-143892736:-	-0.49	-6.11	3.47E-9	Obesity-related traits	
CESC	cis	1	rs2961132	chr7:143768128	ARHGEF35	chr7:143883677-143892736:-	-0.5	-6.14	2.94E-9	Obesity-related traits	
CESC	cis	1	rs2961134	chr7:143771062	ARHGEF35	chr7:143883677-143892736:-	-0.51	-6.5	3.83E-10	Obesity-related traits	
CESC	cis	1	rs2961144	chr7:143747870	ARHGEF35	chr7:143883677-143892736:-	0.48	6.18	2.34E-9	Obesity-related traits	
CESC	cis	1	rs2964571	chr5:151171256	ATOX1	chr5:151122384-151138210:-	-0.22	-4.01	7.94E-5	Preschool internalizing problems	
CESC	cis	1	rs2964578	chr5:151147198	SLC36A1	chr5:150816553-150871939:+	-0.32	-4.25	2.91E-5	Preschool internalizing problems	
CESC	cis	1	rs2964584	chr5:151142878	SLC36A1	chr5:150816553-150871939:+	-0.3	-4.08	5.9E-5	Preschool internalizing problems	
CESC	cis	1	rs2964585	chr5:151141895	SLC36A1	chr5:150816553-150871939:+	-0.32	-4.25	2.91E-5	Preschool internalizing problems	
CESC	cis	1	rs2964612	chr5:151198750	ATOX1	chr5:151122384-151138210:-	-0.23	-4.11	5.29E-5	Preschool internalizing problems	
CESC	cis	1	rs2976388	chr8:143760256	LY6K	chr8:143781529-143785582:+	0.31	5.32	2.15E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2976388	chr8:143760256	PSCA	chr8:143761875-143764142:+	0.42	6.71	1.09E-10	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2976392	chr8:143762932	LY6K	chr8:143781529-143785582:+	0.28	4.81	2.47E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2976392	chr8:143762932	PSCA	chr8:143761875-143764142:+	0.43	7.21	5.58E-12	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2976394	chr8:143763622	LY6K	chr8:143781529-143785582:+	0.28	4.8	2.61E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2976394	chr8:143763622	PSCA	chr8:143761875-143764142:+	0.43	7.19	5.97E-12	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2976396	chr8:143764001	LY6K	chr8:143781529-143785582:+	-0.3	-5.28	2.57E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2976396	chr8:143764001	PSCA	chr8:143761875-143764142:+	-0.41	-6.72	1.05E-10	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2976398	chr8:143764879	LY6K	chr8:143781529-143785582:+	0.27	4.71	3.96E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2976398	chr8:143764879	PSCA	chr8:143761875-143764142:+	0.43	7.25	4.23E-12	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2978982	chr8:143763490	LY6K	chr8:143781529-143785582:+	0.28	4.81	2.47E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2978982	chr8:143763490	PSCA	chr8:143761875-143764142:+	0.43	7.21	5.58E-12	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
CESC	cis	1	rs2993259	chr1:46001550	CCDC163P	chr1:45960581-45965646:-	-0.78	-13.88	1.45E-33	Homocysteine levels	
CESC	cis	1	rs2993834	chr10:59971616	IPMK	chr10:59955618-60027694:-	0.24	5.34	1.92E-7	Inflammatory bowel disease	
CESC	cis	1	rs30187	chr5:96124330	ERAP1	chr5:96096515-96149837:-	-0.39	-7.62	4.05E-13	Ankylosing spondylitis	
CESC	cis	1	rs30187	chr5:96124330	ERAP2	chr5:96211644-96255398:+	0.4	6.08	3.95E-9	Ankylosing spondylitis	
CESC	cis	1	rs30378	chr5:96121994	ERAP1	chr5:96096515-96149837:-	-0.4	-7.76	1.72E-13	Ankylosing spondylitis	
CESC	cis	1	rs30378	chr5:96121994	ERAP2	chr5:96211644-96255398:+	0.4	5.99	6.54E-9	Ankylosing spondylitis	
CESC	cis	1	rs30379	chr5:96122260	ERAP1	chr5:96096515-96149837:-	-0.41	-7.98	3.95E-14	Ankylosing spondylitis	
CESC	cis	1	rs30379	chr5:96122260	ERAP2	chr5:96211644-96255398:+	0.4	6.09	3.77E-9	Ankylosing spondylitis	
CESC	cis	1	rs30380	chr5:96122281	ERAP1	chr5:96096515-96149837:-	-0.41	-7.98	3.95E-14	Ankylosing spondylitis	
CESC	cis	1	rs30380	chr5:96122281	ERAP2	chr5:96211644-96255398:+	0.4	6.09	3.77E-9	Ankylosing spondylitis	
CESC	cis	1	rs3091242	chr1:25674785	RHD	chr1:25598981-25656935:+	-0.4	-5.7	3.12E-8	Erythrocyte sedimentation rate	
CESC	cis	1	rs3097417	chr3:53088601	TMEM110	chr3:52867139-52931547:-	-0.37	-3.97	9.1E-5	Immune reponse to smallpox (secreted IL-2)	
CESC	cis	1	rs3099459	chr5:56137170	C5orf35	chr5:56205103-56213010:+	0.84	12.21	1.07E-27	Type 2 diabetes	
CESC	cis	1	rs3099899	chr4:129917368	C4orf33	chr4:130014829-130033842:+	-0.38	-5.72	2.72E-8	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs3101443	chr15:43912372	CATSPER2	chr15:43922774-43959900:-	-0.42	-5.23	3.33E-7	Tumor biomarkers	
CESC	cis	1	rs3101443	chr15:43912372	CKMT1A	chr15:43985084-43991419:+	-0.44	-5.04	8.44E-7	Tumor biomarkers	
CESC	cis	1	rs3101443	chr15:43912372	CKMT1B	chr15:43885252-43891603:+	-0.32	-4.13	4.87E-5	Tumor biomarkers	
CESC	cis	1	rs3105369	chr4:130022448	C4orf33	chr4:130014829-130033842:+	-0.44	-6.71	1.11E-10	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs3113489	chr4:129961179	C4orf33	chr4:130014829-130033842:+	-0.39	-5.7	3.03E-8	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs313798	chr7:65493031	CCT6P1	chr7:65216092-65228661:+	0.59	5.72	2.71E-8	Diabetic kidney disease	
CESC	cis	1	rs313799	chr7:65494330	CCT6P1	chr7:65216092-65228661:+	0.46	4.45	1.27E-5	Diabetic kidney disease	
CESC	cis	1	rs313802	chr7:65516373	CCT6P1	chr7:65216092-65228661:+	0.51	4.92	1.52E-6	Diabetic kidney disease	
CESC	cis	1	rs313803	chr7:65514731	CCT6P1	chr7:65216092-65228661:+	0.51	4.92	1.52E-6	Diabetic kidney disease	
CESC	cis	1	rs313807	chr7:65499481	CCT6P1	chr7:65216092-65228661:+	0.46	4.45	1.27E-5	Diabetic kidney disease	
CESC	cis	1	rs313809	chr7:65499983	CCT6P1	chr7:65216092-65228661:+	0.59	5.72	2.71E-8	Diabetic kidney disease	
CESC	cis	1	rs313813	chr7:65503500	CCT6P1	chr7:65216092-65228661:+	0.46	4.39	1.59E-5	Diabetic kidney disease	
CESC	cis	1	rs313814	chr7:65503293	CCT6P1	chr7:65216092-65228661:+	0.52	4.93	1.4E-6	Diabetic kidney disease	
CESC	cis	1	rs313820	chr7:65574466	CCT6P1	chr7:65216092-65228661:+	0.53	5.01	9.67E-7	Diabetic kidney disease	
CESC	cis	1	rs313820	chr7:65574466	LOC493754	chr7:65993446-66057363:-	0.54	4.28	2.62E-5	Diabetic kidney disease	
CESC	cis	1	rs313824	chr7:65581207	CCT6P1	chr7:65216092-65228661:+	0.53	5.01	9.67E-7	Diabetic kidney disease	
CESC	cis	1	rs313824	chr7:65581207	LOC493754	chr7:65993446-66057363:-	0.54	4.28	2.62E-5	Diabetic kidney disease	
CESC	cis	1	rs313831	chr7:65551226	CCT6P1	chr7:65216092-65228661:+	0.53	4.99	1.05E-6	Diabetic kidney disease	
CESC	cis	1	rs313831	chr7:65551226	LOC493754	chr7:65993446-66057363:-	0.53	4.23	3.2E-5	Diabetic kidney disease	
CESC	cis	1	rs313832	chr7:65550891	CCT6P1	chr7:65216092-65228661:+	0.53	4.99	1.09E-6	Diabetic kidney disease	
CESC	cis	1	rs313832	chr7:65550891	LOC493754	chr7:65993446-66057363:-	0.53	4.21	3.46E-5	Diabetic kidney disease	
CESC	cis	1	rs316304	chr7:65616894	CCT6P1	chr7:65216092-65228661:+	0.55	5.19	4.01E-7	Diabetic kidney disease	
CESC	cis	1	rs316304	chr7:65616894	LOC493754	chr7:65993446-66057363:-	0.54	4.25	2.97E-5	Diabetic kidney disease	
CESC	cis	1	rs316307	chr7:65570171	CCT6P1	chr7:65216092-65228661:+	0.52	4.87	1.91E-6	Diabetic kidney disease	
CESC	cis	1	rs316307	chr7:65570171	LOC493754	chr7:65993446-66057363:-	0.51	4.05	6.59E-5	Diabetic kidney disease	
CESC	cis	1	rs316312	chr7:65596491	CCT6P1	chr7:65216092-65228661:+	0.56	5.25	2.99E-7	Diabetic kidney disease	
CESC	cis	1	rs316312	chr7:65596491	LOC493754	chr7:65993446-66057363:-	0.53	4.23	3.16E-5	Diabetic kidney disease	
CESC	cis	1	rs316313	chr7:65593548	CCT6P1	chr7:65216092-65228661:+	0.56	5.25	2.99E-7	Diabetic kidney disease	
CESC	cis	1	rs316313	chr7:65593548	LOC493754	chr7:65993446-66057363:-	0.53	4.23	3.16E-5	Diabetic kidney disease	
CESC	cis	1	rs316315	chr7:65591205	CCT6P1	chr7:65216092-65228661:+	-0.43	-4.66	4.94E-6	Diabetic kidney disease	
CESC	cis	1	rs316317	chr7:65613637	CCT6P1	chr7:65216092-65228661:+	0.57	5.35	1.89E-7	Diabetic kidney disease	
CESC	cis	1	rs316317	chr7:65613637	LOC493754	chr7:65993446-66057363:-	0.53	4.21	3.53E-5	Diabetic kidney disease	
CESC	cis	1	rs316318	chr7:65612904	CCT6P1	chr7:65216092-65228661:+	0.57	5.35	1.89E-7	Diabetic kidney disease	
CESC	cis	1	rs316318	chr7:65612904	LOC493754	chr7:65993446-66057363:-	0.53	4.21	3.53E-5	Diabetic kidney disease	
CESC	cis	1	rs316321	chr7:65611613	CCT6P1	chr7:65216092-65228661:+	0.57	5.35	1.89E-7	Diabetic kidney disease	
CESC	cis	1	rs316321	chr7:65611613	LOC493754	chr7:65993446-66057363:-	0.53	4.21	3.53E-5	Diabetic kidney disease	
CESC	cis	1	rs316322	chr7:65611233	CCT6P1	chr7:65216092-65228661:+	0.57	5.36	1.74E-7	Diabetic kidney disease	
CESC	cis	1	rs316322	chr7:65611233	LOC493754	chr7:65993446-66057363:-	0.53	4.22	3.38E-5	Diabetic kidney disease	
CESC	cis	1	rs316325	chr7:65609518	CCT6P1	chr7:65216092-65228661:+	0.57	5.35	1.89E-7	Diabetic kidney disease	
CESC	cis	1	rs316325	chr7:65609518	LOC493754	chr7:65993446-66057363:-	0.53	4.21	3.53E-5	Diabetic kidney disease	
CESC	cis	1	rs316326	chr7:65609453	CCT6P1	chr7:65216092-65228661:+	0.57	5.35	1.89E-7	Diabetic kidney disease	
CESC	cis	1	rs316326	chr7:65609453	LOC493754	chr7:65993446-66057363:-	0.53	4.21	3.53E-5	Diabetic kidney disease	
CESC	cis	1	rs316327	chr7:65609201	CCT6P1	chr7:65216092-65228661:+	-0.44	-4.15	4.45E-5	Diabetic kidney disease	
CESC	cis	1	rs316329	chr7:65608416	CCT6P1	chr7:65216092-65228661:+	0.59	5.46	1.04E-7	Diabetic kidney disease	
CESC	cis	1	rs316329	chr7:65608416	LOC493754	chr7:65993446-66057363:-	0.56	4.37	1.76E-5	Diabetic kidney disease	
CESC	cis	1	rs316330	chr7:65605372	CCT6P1	chr7:65216092-65228661:+	0.57	5.35	1.89E-7	Diabetic kidney disease	
CESC	cis	1	rs316330	chr7:65605372	LOC493754	chr7:65993446-66057363:-	0.53	4.21	3.53E-5	Diabetic kidney disease	
CESC	cis	1	rs316331	chr7:65604622	CCT6P1	chr7:65216092-65228661:+	-0.45	-4.22	3.34E-5	Diabetic kidney disease	
CESC	cis	1	rs316332	chr7:65604299	CCT6P1	chr7:65216092-65228661:+	0.48	4.54	8.31E-6	Diabetic kidney disease	
CESC	cis	1	rs316334	chr7:65602126	CCT6P1	chr7:65216092-65228661:+	0.57	5.35	1.88E-7	Diabetic kidney disease	
CESC	cis	1	rs316334	chr7:65602126	LOC493754	chr7:65993446-66057363:-	0.53	4.23	3.19E-5	Diabetic kidney disease	
CESC	cis	1	rs3180872	chr22:51017394	CPT1B	chr22:51007291-51017096:-	-0.51	-4.76	3.08E-6	Narcolepsy	
CESC	cis	1	rs3204270	chr17:79682051	ARL16	chr17:79648234-79650954:-	-0.62	-5.27	2.7E-7	Dental caries	
CESC	cis	1	rs3213445	chr22:51015838	CPT1B	chr22:51007291-51017096:-	-0.52	-4.29	2.46E-5	Narcolepsy	
CESC	cis	1	rs3213446	chr22:51015674	CPT1B	chr22:51007291-51017096:-	-0.47	-4.12	4.96E-5	Narcolepsy	
CESC	cis	1	rs3213762	chr17:38178627	GSDMA	chr17:38119226-38134019:+	-0.31	-4.76	3.17E-6	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
CESC	cis	1	rs3214041	chr3:48454468	TREX1	chr3:48501186-48509043:+	-0.19	-4.39	1.61E-5	Longevity	
CESC	cis	1	rs33322	chr5:56175226	C5orf35	chr5:56205103-56213010:+	0.83	12.07	3.27E-27	Type 2 diabetes	
CESC	cis	1	rs33325	chr5:56142547	C5orf35	chr5:56205103-56213010:+	0.85	12.71	1.97E-29	Type 2 diabetes	
CESC	cis	1	rs33326	chr5:56142601	C5orf35	chr5:56205103-56213010:+	0.84	12.11	2.38E-27	Type 2 diabetes	
CESC	cis	1	rs34037437	chr1:95660921	RWDD3	chr1:95583479-95712773:+	0.59	5.27	2.7E-7	Stearic acid (18:0) plasma levels	
CESC	cis	1	rs34102169	chr1:46424864	CCDC163P	chr1:45960581-45965646:-	-0.35	-5.59	5.36E-8	Body mass index	
CESC	cis	1	rs34106666	chr6:86676258	SNHG5	chr6:86386726-86388451:-	-0.56	-8.95	5.55E-17	Response to antipsychotic treatment	
CESC	cis	1	rs34136756	chr7:65381256	CCT6P1	chr7:65216092-65228661:+	0.51	5	1.04E-6	Diabetic kidney disease	
CESC	cis	1	rs34156253	chr5:150226230	LOC134466	chr5:150310000-150326146:-	0.42	4.71	4.0E-6	Crohn's disease	
CESC	cis	1	rs34192067	chr7:65887657	CCT6P1	chr7:65216092-65228661:+	0.56	5.23	3.42E-7	Diabetic kidney disease	
CESC	cis	1	rs34192067	chr7:65887657	LOC493754	chr7:65993446-66057363:-	0.53	4.19	3.8E-5	Diabetic kidney disease	
CESC	cis	1	rs34193460	chr7:65393110	CCT6P1	chr7:65216092-65228661:+	0.6	5.64	4.13E-8	Diabetic kidney disease	
CESC	cis	1	rs34281561	chr6:86701872	SNHG5	chr6:86386726-86388451:-	-0.59	-9.2	9.17E-18	Response to antipsychotic treatment	
CESC	cis	1	rs34313969	chr3:52995166	RFT1	chr3:53122503-53164470:-	0.53	4.53	8.93E-6	Immune reponse to smallpox (secreted IL-2)	
CESC	cis	1	rs34396223	chr1:95697828	RWDD3	chr1:95583479-95712773:+	0.58	4.71	4.01E-6	Stearic acid (18:0) plasma levels	
CESC	cis	1	rs344081	chr3:156555984	LEKR1	chr3:156544076-156763918:+	-0.37	-4.15	4.45E-5	Bone mineral density	
CESC	cis	1	rs344088	chr3:156561361	LEKR1	chr3:156544076-156763918:+	-0.37	-4.15	4.45E-5	Bone mineral density	
CESC	cis	1	rs344090	chr3:156563140	LEKR1	chr3:156544076-156763918:+	-0.37	-4.15	4.45E-5	Bone mineral density	
CESC	cis	1	rs34529418	chr7:65403209	CCT6P1	chr7:65216092-65228661:+	0.45	4.32	2.14E-5	Diabetic kidney disease	
CESC	cis	1	rs34560516	chr7:65404092	CCT6P1	chr7:65216092-65228661:+	0.57	5.39	1.54E-7	Diabetic kidney disease	
CESC	cis	1	rs34577383	chr7:65385726	CCT6P1	chr7:65216092-65228661:+	0.45	4.32	2.14E-5	Diabetic kidney disease	
CESC	cis	1	rs34581302	chr6:86705948	SNHG5	chr6:86386726-86388451:-	-0.59	-9.54	7.92E-19	Response to antipsychotic treatment	
CESC	cis	1	rs34622557	chr6:86630852	SNHG5	chr6:86386726-86388451:-	-0.57	-9.05	2.7E-17	Response to antipsychotic treatment	
CESC	cis	1	rs34629498	chr19:23060720	ZNF492	chr19:22817126-22850472:+	-0.35	-3.97	9.24E-5	Bronchopulmonary dysplasia	
CESC	cis	1	rs34637256	chr7:65360131	CCT6P1	chr7:65216092-65228661:+	0.52	5.07	7.2E-7	Diabetic kidney disease	
CESC	cis	1	rs34663797	chr9:117543204	TNFSF8	chr9:117665124-117692770:-	-0.25	-4.38	1.7E-5	Serum IgA levels	
CESC	cis	1	rs34702770	chr7:65344823	CCT6P1	chr7:65216092-65228661:+	0.5	4.96	1.23E-6	Diabetic kidney disease	
CESC	cis	1	rs34703416	chr7:65300642	CCT6P1	chr7:65216092-65228661:+	0.5	5.05	8.18E-7	Diabetic kidney disease	
CESC	cis	1	rs34815098	chr7:65292254	CCT6P1	chr7:65216092-65228661:+	0.44	4.42	1.44E-5	Diabetic kidney disease	
CESC	cis	1	rs34852683	chr6:86702330	SNHG5	chr6:86386726-86388451:-	-0.57	-9.06	2.48E-17	Response to antipsychotic treatment	
CESC	cis	1	rs34872586	chr17:65863466	LOC651250	chr17:66097696-66157623:+	-0.32	-4.13	4.82E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs34933390	chr3:53006265	RFT1	chr3:53122503-53164470:-	0.45	3.97	9.29E-5	Immune reponse to smallpox (secreted IL-2)	
CESC	cis	1	rs34933526	chr7:65383199	CCT6P1	chr7:65216092-65228661:+	0.51	5	1.04E-6	Diabetic kidney disease	
CESC	cis	1	rs34970380	chr7:65431493	CCT6P1	chr7:65216092-65228661:+	0.56	5.42	1.33E-7	Diabetic kidney disease	
CESC	cis	1	rs34974928	chr7:65364006	CCT6P1	chr7:65216092-65228661:+	0.45	4.4	1.55E-5	Diabetic kidney disease	
CESC	cis	1	rs35006492	chr4:129878342	C4orf33	chr4:130014829-130033842:+	0.38	5.43	1.22E-7	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs35046236	chr7:65408613	CCT6P1	chr7:65216092-65228661:+	0.51	5	1.04E-6	Diabetic kidney disease	
CESC	cis	1	rs35056702	chr6:109736326	SMPD2	chr6:109761931-109765121:+	0.25	3.96	9.73E-5	Height	
CESC	cis	1	rs35058610	chr7:65390925	CCT6P1	chr7:65216092-65228661:+	0.51	5	1.04E-6	Diabetic kidney disease	
CESC	cis	1	rs35060985	chr11:43693110	HSD17B12	chr11:43702143-43878160:+	-0.36	-5.37	1.64E-7	Forced vital capacity	
CESC	cis	1	rs35068485	chr11:466032	RNH1	chr11:494512-507273:-	-0.37	-4.04	6.84E-5	Body mass index	
CESC	cis	1	rs35141484	chr4:39088341	UBE2K	chr4:39699664-39784408:+	-0.63	-4.07	6.09E-5	Asthma (childhood onset)	
CESC	cis	1	rs35143903	chr1:95622527	RWDD3	chr1:95583479-95712773:+	0.66	5.41	1.39E-7	Stearic acid (18:0) plasma levels	
CESC	cis	1	rs35179427	chr1:95670888	RWDD3	chr1:95583479-95712773:+	0.62	5.02	9.21E-7	Stearic acid (18:0) plasma levels	
CESC	cis	1	rs35243555	chr17:65876477	LOC651250	chr17:66097696-66157623:+	-0.31	-4.05	6.54E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs35283677	chr7:65359233	CCT6P1	chr7:65216092-65228661:+	0.55	5.34	1.91E-7	Diabetic kidney disease	
CESC	cis	1	rs35385043	chr6:86648546	SNHG5	chr6:86386726-86388451:-	-0.62	-11.66	8.24E-26	Response to antipsychotic treatment	
CESC	cis	1	rs35391607	chr7:65360829	CCT6P1	chr7:65216092-65228661:+	0.45	4.4	1.55E-5	Diabetic kidney disease	
CESC	cis	1	rs35396113	chr7:65495461	CCT6P1	chr7:65216092-65228661:+	0.56	5.46	1.05E-7	Diabetic kidney disease	
CESC	cis	1	rs35419329	chr6:86702291	SNHG5	chr6:86386726-86388451:-	-0.59	-9.2	9.17E-18	Response to antipsychotic treatment	
CESC	cis	1	rs35421653	chr7:65363429	CCT6P1	chr7:65216092-65228661:+	0.57	5.47	1.02E-7	Diabetic kidney disease	
CESC	cis	1	rs35432774	chr7:65393019	CCT6P1	chr7:65216092-65228661:+	0.45	4.32	2.14E-5	Diabetic kidney disease	
CESC	cis	1	rs35435780	chr17:79579602	TSPAN10	chr17:79609349-79615778:+	0.4	6.31	1.1E-9	Eye color traits	
CESC	cis	1	rs35522482	chr22:39063015	CBY1	chr22:39052658-39069853:+	0.25	4.12	5.0E-5	Resting heart rate	
CESC	cis	1	rs35542501	chr7:65431215	CCT6P1	chr7:65216092-65228661:+	0.46	4.62	5.84E-6	Diabetic kidney disease	
CESC	cis	1	rs35565791	chr22:39063011	CBY1	chr22:39052658-39069853:+	0.25	4.12	5.0E-5	Resting heart rate	
CESC	cis	1	rs35718987	chr3:134272783	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.35	1.95E-5	Height	
CESC	cis	1	rs35735127	chr7:65300423	CCT6P1	chr7:65216092-65228661:+	0.44	4.42	1.44E-5	Diabetic kidney disease	
CESC	cis	1	rs35737577	chr3:53002557	RFT1	chr3:53122503-53164470:-	0.47	4.16	4.23E-5	Immune reponse to smallpox (secreted IL-2)	
CESC	cis	1	rs35760725	chr6:86648985	SNHG5	chr6:86386726-86388451:-	-0.61	-11.29	1.59E-24	Response to antipsychotic treatment	
CESC	cis	1	rs35761942	chr6:86629504	SNHG5	chr6:86386726-86388451:-	-0.58	-8.73	2.46E-16	Response to antipsychotic treatment	
CESC	cis	1	rs35797755	chr6:86706554	SNHG5	chr6:86386726-86388451:-	-0.61	-9.94	4.48E-20	Response to antipsychotic treatment	
CESC	cis	1	rs35820085	chr7:65442758	CCT6P1	chr7:65216092-65228661:+	0.59	5.67	3.52E-8	Diabetic kidney disease	
CESC	cis	1	rs35825738	chr7:65318027	CCT6P1	chr7:65216092-65228661:+	0.43	4.31	2.28E-5	Diabetic kidney disease	
CESC	cis	1	rs35849389	chr3:53005235	RFT1	chr3:53122503-53164470:-	0.47	4.16	4.22E-5	Immune reponse to smallpox (secreted IL-2)	
CESC	cis	1	rs36033484	chr7:65390558	CCT6P1	chr7:65216092-65228661:+	0.57	5.39	1.54E-7	Diabetic kidney disease	
CESC	cis	1	rs36068983	chr7:65408991	CCT6P1	chr7:65216092-65228661:+	0.51	5	1.04E-6	Diabetic kidney disease	
CESC	cis	1	rs36096931	chr6:86693134	SNHG5	chr6:86386726-86388451:-	-0.56	-8.88	8.86E-17	Response to antipsychotic treatment	
CESC	cis	1	rs36216559	chr2:262335	SH3YL1	chr2:218138-264810:-	-0.71	-11.74	4.37E-26	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs371454	chr9:6078614	UHRF2	chr9:6413151-6507049:+	0.37	4.15	4.41E-5	Asthma and hay fever	
CESC	cis	1	rs3732837	chr3:138121920	ARMC8	chr3:137906148-138016219:+	-0.34	-4.2	3.66E-5	Coronary artery disease;Coronary heart disease	
CESC	cis	1	rs3734266	chr6:34823187	UHRF1BP1	chr6:34759794-34853117:+	0.38	4.13	4.8E-5	Systemic lupus erythematosus	
CESC	cis	1	rs3738848	chr2:73761881	ALMS1P	chr2:73872046-73912692:+	0.38	5.56	6.32E-8	Metabolite levels	
CESC	cis	1	rs3742500	chr14:24611978	FAM158A	chr14:24608175-24610797:-	-0.38	-6.67	1.37E-10	IgG glycosylation	
CESC	cis	1	rs374283	chr6:5073845	RPP40	chr6:4995281-5004271:-	-0.25	-4.09	5.77E-5	Venous thromboembolism (SNP x SNP interaction)	
CESC	cis	1	rs3747170	chr22:39067331	CBY1	chr22:39052658-39069853:+	0.26	4.35	1.9E-5	Resting heart rate	
CESC	cis	1	rs3747172	chr22:39067524	CBY1	chr22:39052658-39069853:+	0.28	4.76	3.11E-6	Resting heart rate	
CESC	cis	1	rs3747174	chr22:39069181	CBY1	chr22:39052658-39069853:+	0.28	4.76	3.11E-6	Resting heart rate	
CESC	cis	1	rs3761454	chr22:39066820	CBY1	chr22:39052658-39069853:+	0.26	4.35	1.9E-5	Resting heart rate	
CESC	cis	1	rs3761959	chr1:157669278	FCRL3	chr1:157646278-157670775:-	0.37	8.96	5.01E-17	Type 1 diabetes autoantibodies	
CESC	cis	1	rs376362	chr3:41111939	CTNNB1	chr3:41236401-41281939:+	-0.22	-3.95	0.0001	Bone mineral density (hip)	
CESC	cis	1	rs3764628	chr19:18747605	PGPEP1	chr19:18451408-18480763:+	0.33	3.96	9.72E-5	Orofacial clefts	
CESC	cis	1	rs3770087	chr2:86267068	LOC90784	chr2:86247339-86250991:-	-0.5	-4.79	2.75E-6	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
CESC	cis	1	rs3770087	chr2:86267068	POLR1A	chr2:86253453-86333278:-	0.32	4.19	3.82E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
CESC	cis	1	rs3770090	chr2:86263288	LOC90784	chr2:86247339-86250991:-	-0.5	-4.79	2.75E-6	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
CESC	cis	1	rs3770090	chr2:86263288	POLR1A	chr2:86253453-86333278:-	0.32	4.19	3.82E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
CESC	cis	1	rs3770752	chr2:37576136	CEBPZ	chr2:37428778-37458740:-	0.3	4.32	2.2E-5	Schizophrenia	
CESC	cis	1	rs3774372	chr3:41877414	ULK4	chr3:41288091-42003660:-	0.4	5.23	3.38E-7	Diastolic blood pressure	
CESC	cis	1	rs3774808	chr3:48481647	TREX1	chr3:48501186-48509043:+	-0.2	-4.56	7.58E-6	Longevity	
CESC	cis	1	rs3778483	chr6:46627100	SLC25A27	chr6:46620679-46645925:+	-0.26	-4.11	5.24E-5	QRS complex (Sokolow-Lyon)	
CESC	cis	1	rs3782130	chr12:58161898	FAM119B	chr12:58166383-58176323:+	0.39	5.14	5.28E-7	Multiple sclerosis	
CESC	cis	1	rs3782130	chr12:58161898	TSFM	chr12:58176536-58191367:+	-0.35	-6.02	5.68E-9	Multiple sclerosis	
CESC	cis	1	rs378259	chr6:5073836	RPP40	chr6:4995281-5004271:-	-0.25	-4.09	5.77E-5	Venous thromboembolism (SNP x SNP interaction)	
CESC	cis	1	rs3788545	chr22:39065172	CBY1	chr22:39052658-39069853:+	0.25	4.17	4.04E-5	Resting heart rate	
CESC	cis	1	rs378952	chr9:6078146	UHRF2	chr9:6413151-6507049:+	0.37	4.13	4.78E-5	Asthma and hay fever	
CESC	cis	1	rs3791220	chr2:227066	SH3YL1	chr2:218138-264810:-	-0.68	-11.04	1.04E-23	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs3791221	chr2:226933	SH3YL1	chr2:218138-264810:-	-0.69	-11.39	6.87E-25	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs3791223	chr2:222336	SH3YL1	chr2:218138-264810:-	-0.71	-11.53	2.42E-25	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs3791224	chr2:221981	SH3YL1	chr2:218138-264810:-	-0.72	-11.6	1.38E-25	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs3796392	chr3:129137127	SNORA7B	chr3:129115060-129116797:-	-0.79	-4.54	8.29E-6	Diisocyanate-induced asthma	
CESC	cis	1	rs3806692	chr3:53080987	TMEM110	chr3:52867139-52931547:-	0.37	3.94	0.000101	Immune reponse to smallpox (secreted IL-2)	
CESC	cis	1	rs3806988	chr6:49431569	CENPQ	chr6:49431096-49460820:+	-0.23	-4.05	6.68E-5	Folate pathway vitamin levels	
CESC	cis	1	rs3806988	chr6:49431569	MUT	chr6:49398994-49431031:-	0.41	7.37	2.05E-12	Folate pathway vitamin levels	
CESC	cis	1	rs3813227	chr2:73651967	ALMS1P	chr2:73872046-73912692:+	-0.36	-5.27	2.79E-7	Metabolite levels	
CESC	cis	1	rs3823114	chr6:49431720	CENPQ	chr6:49431096-49460820:+	-0.24	-4.29	2.5E-5	Folate pathway vitamin levels	
CESC	cis	1	rs3823114	chr6:49431720	MUT	chr6:49398994-49431031:-	0.38	6.9	3.65E-11	Folate pathway vitamin levels	
CESC	cis	1	rs3825079	chr12:58203354	FAM119B	chr12:58166383-58176323:+	0.39	5.14	5.18E-7	Multiple sclerosis	
CESC	cis	1	rs3825079	chr12:58203354	TSFM	chr12:58176536-58191367:+	-0.35	-5.91	1.01E-8	Multiple sclerosis	
CESC	cis	1	rs3826331	chr17:38150492	GSDMA	chr17:38119226-38134019:+	0.3	4.55	8.21E-6	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
CESC	cis	1	rs3827066	chr20:44586023	WFDC3	chr20:44402847-44420547:-	-0.42	-3.96	9.57E-5	Abdominal aortic aneurysm	
CESC	cis	1	rs3827357	chr22:39079413	CBY1	chr22:39052658-39069853:+	0.3	5.01	9.94E-7	Resting heart rate	
CESC	cis	1	rs3828165	chr2:220889	SH3YL1	chr2:218138-264810:-	-0.7	-11.43	5.07E-25	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs3828496	chr4:48388292	NIPAL1	chr4:48018791-48039078:+	-0.18	-3.97	9.11E-5	Crohn's disease;Inflammatory bowel disease	
CESC	cis	1	rs383402	chr7:65586653	CCT6P1	chr7:65216092-65228661:+	-0.42	-4.2	3.58E-5	Diabetic kidney disease	
CESC	cis	1	rs3843667	chr12:16403364	MGST1	chr12:16500076-16523342:+	-0.28	-3.97	9.11E-5	Visceral fat	
CESC	cis	1	rs3846055	chr3:134203973	ANAPC13	chr3:134196547-134204865:-	0.32	4.2	3.63E-5	Height	
CESC	cis	1	rs3846056	chr3:134227292	ANAPC13	chr3:134196547-134204865:-	0.3	4.03	7.12E-5	Height	
CESC	cis	1	rs3856807	chr3:12527600	TSEN2	chr3:12525931-12581122:+	0.4	4.07	6.19E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs3857422	chr5:150268609	LOC134466	chr5:150310000-150326146:-	0.4	4.73	3.64E-6	Crohn's disease	
CESC	cis	1	rs3866330	chr3:49582994	KLHDC8B	chr3:49209068-49213918:+	-0.26	-4.18	3.98E-5	Menarche (age at onset)	
CESC	cis	1	rs3866330	chr3:49582994	WDR6	chr3:49044637-49053386:+	-0.26	-4.35	1.96E-5	Menarche (age at onset)	
CESC	cis	1	rs387676	chr7:65598220	CCT6P1	chr7:65216092-65228661:+	0.56	5.25	2.99E-7	Diabetic kidney disease	
CESC	cis	1	rs387676	chr7:65598220	LOC493754	chr7:65993446-66057363:-	0.53	4.23	3.16E-5	Diabetic kidney disease	
CESC	cis	1	rs3885839	chr7:65290403	CCT6P1	chr7:65216092-65228661:+	0.56	5.45	1.11E-7	Diabetic kidney disease	
CESC	cis	1	rs3886938	chr8:130737546	GSDMC	chr8:130760443-130799134:-	0.3	5.36	1.73E-7	Infant length;Height	
CESC	cis	1	rs3900064	chr5:150264414	LOC134466	chr5:150310000-150326146:-	-0.47	-5.45	1.14E-7	Crohn's disease	
CESC	cis	1	rs3905330	chr3:49550774	KLHDC8B	chr3:49209068-49213918:+	-0.26	-4.2	3.68E-5	Menarche (age at onset)	
CESC	cis	1	rs3905330	chr3:49550774	WDR6	chr3:49044637-49053386:+	-0.26	-4.29	2.51E-5	Menarche (age at onset)	
CESC	cis	1	rs3906527	chr5:150266392	LOC134466	chr5:150310000-150326146:-	0.4	4.73	3.64E-6	Crohn's disease	
CESC	cis	1	rs3906528	chr5:150266718	LOC134466	chr5:150310000-150326146:-	0.4	4.73	3.64E-6	Crohn's disease	
CESC	cis	1	rs391396	chr4:130037653	C4orf33	chr4:130014829-130033842:+	-0.42	-6.56	2.65E-10	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs3915247	chr12:16400613	MGST1	chr12:16500076-16523342:+	-0.29	-3.98	8.73E-5	Visceral fat	
CESC	cis	1	rs3915248	chr12:16400631	MGST1	chr12:16500076-16523342:+	-0.29	-3.98	8.73E-5	Visceral fat	
CESC	cis	1	rs3934103	chr3:41977214	ULK4	chr3:41288091-42003660:-	-0.46	-7.38	1.83E-12	Diastolic blood pressure	
CESC	cis	1	rs3935543	chr17:79579874	TSPAN10	chr17:79609349-79615778:+	0.4	6.31	1.1E-9	Eye color traits	
CESC	cis	1	rs3960018	chr15:90383307	AP3S2	chr15:90373832-90456222:-	-0.45	-5.38	1.57E-7	Type 2 diabetes	
CESC	cis	1	rs39841	chr5:96120170	ERAP1	chr5:96096515-96149837:-	-0.42	-7.6	4.62E-13	Inflammatory skin disease	
CESC	cis	1	rs39841	chr5:96120170	ERAP2	chr5:96211644-96255398:+	0.47	6.74	9.08E-11	Inflammatory skin disease	
CESC	cis	1	rs401834	chr9:6078991	UHRF2	chr9:6413151-6507049:+	0.37	4.15	4.41E-5	Asthma and hay fever	
CESC	cis	1	rs402418	chr7:65509469	CCT6P1	chr7:65216092-65228661:+	0.52	4.88	1.78E-6	Diabetic kidney disease	
CESC	cis	1	rs406900	chr6:88085447	C6orf162	chr6:88032306-88052043:+	-0.27	-4.27	2.74E-5	Depressive episodes in bipolar disorder	
CESC	cis	1	rs4073846	chr1:46462881	CCDC163P	chr1:45960581-45965646:-	0.33	5.47	1.02E-7	Body mass index	
CESC	cis	1	rs4074915	chr17:79579230	TSPAN10	chr17:79609349-79615778:+	-0.4	-6.2	2.04E-9	Eye color traits	
CESC	cis	1	rs4074916	chr17:79579248	TSPAN10	chr17:79609349-79615778:+	-0.4	-6.19	2.16E-9	Eye color traits	
CESC	cis	1	rs4076006	chr1:46438076	CCDC163P	chr1:45960581-45965646:-	-0.35	-5.71	2.96E-8	Body mass index	
CESC	cis	1	rs4096885	chr12:16400714	MGST1	chr12:16500076-16523342:+	-0.29	-3.98	8.73E-5	Visceral fat	
CESC	cis	1	rs410128	chr7:65603173	CCT6P1	chr7:65216092-65228661:+	0.56	5.19	4.0E-7	Diabetic kidney disease	
CESC	cis	1	rs410128	chr7:65603173	LOC493754	chr7:65993446-66057363:-	0.57	4.49	1.07E-5	Diabetic kidney disease	
CESC	cis	1	rs4134386	chr1:46395089	CCDC163P	chr1:45960581-45965646:-	-0.33	-5.38	1.58E-7	Body mass index	
CESC	cis	1	rs414013	chr6:88085866	C6orf162	chr6:88032306-88052043:+	-0.27	-4.27	2.74E-5	Depressive episodes in bipolar disorder	
CESC	cis	1	rs4144937	chr6:46628516	SLC25A27	chr6:46620679-46645925:+	-0.26	-4.19	3.81E-5	QRS complex (Sokolow-Lyon)	
CESC	cis	1	rs4145008	chr7:65647511	CCT6P1	chr7:65216092-65228661:+	-0.51	-4.76	3.19E-6	Diabetic kidney disease	
CESC	cis	1	rs41494545	chr5:151235094	ATOX1	chr5:151122384-151138210:-	0.22	4.06	6.36E-5	Preschool internalizing problems	
CESC	cis	1	rs41494545	chr5:151235094	SLC36A1	chr5:150816553-150871939:+	0.3	4.21	3.51E-5	Preschool internalizing problems	
CESC	cis	1	rs4149468	chr7:65825690	CCT6P1	chr7:65216092-65228661:+	0.55	5.12	5.68E-7	Diabetic kidney disease	
CESC	cis	1	rs4149468	chr7:65825690	LOC493754	chr7:65993446-66057363:-	0.52	4.08	5.79E-5	Diabetic kidney disease	
CESC	cis	1	rs419603	chr7:65597341	CCT6P1	chr7:65216092-65228661:+	0.56	5.25	2.99E-7	Diabetic kidney disease	
CESC	cis	1	rs419603	chr7:65597341	LOC493754	chr7:65993446-66057363:-	0.53	4.23	3.16E-5	Diabetic kidney disease	
CESC	cis	1	rs420259	chr16:23634026	DCTN5	chr16:23652807-23681182:+	-0.32	-4.4	1.55E-5	Bipolar disorder	
CESC	cis	1	rs421273	chr6:5073919	RPP40	chr6:4995281-5004271:-	-0.24	-4	8.15E-5	Venous thromboembolism (SNP x SNP interaction)	
CESC	cis	1	rs422164	chr7:65586605	CCT6P1	chr7:65216092-65228661:+	0.54	5.07	7.15E-7	Diabetic kidney disease	
CESC	cis	1	rs422164	chr7:65586605	LOC493754	chr7:65993446-66057363:-	0.54	4.3	2.33E-5	Diabetic kidney disease	
CESC	cis	1	rs4237643	chr11:43648368	HSD17B12	chr11:43702143-43878160:+	0.35	5.24	3.21E-7	Forced vital capacity	
CESC	cis	1	rs4241407	chr3:49600319	KLHDC8B	chr3:49209068-49213918:+	-0.27	-4.3	2.36E-5	Menarche (age at onset)	
CESC	cis	1	rs4241407	chr3:49600319	WDR6	chr3:49044637-49053386:+	-0.28	-4.64	5.34E-6	Menarche (age at onset)	
CESC	cis	1	rs4246215	chr11:61564299	FADS1	chr11:61567103-61584529:-	-0.28	-4.14	4.63E-5	Phospholipid levels (plasma);Platelet count;Red blood cell fatty acid levels;Trans fatty acid levels;Inflammatory bowel disease	
CESC	cis	1	rs4267943	chr6:49439805	CENPQ	chr6:49431096-49460820:+	0.29	4.9	1.65E-6	Folate pathway vitamin levels	
CESC	cis	1	rs4267943	chr6:49439805	MUT	chr6:49398994-49431031:-	-0.37	-6.14	2.95E-9	Folate pathway vitamin levels	
CESC	cis	1	rs427044	chr7:65508545	CCT6P1	chr7:65216092-65228661:+	0.51	4.81	2.45E-6	Diabetic kidney disease	
CESC	cis	1	rs4271626	chr17:65930133	LOC651250	chr17:66097696-66157623:+	-0.32	-4.22	3.28E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs4280164	chr14:24771285	DHRS1	chr14:24759806-24769039:-	-0.33	-4.42	1.39E-5	Parent of origin effect on language impairment (paternal)	
CESC	cis	1	rs4282209	chr4:76919536	NAAA	chr4:76831809-76862166:-	-0.32	-4.26	2.77E-5	Longevity	
CESC	cis	1	rs4294134	chr7:135293128	PL-5283	chr7:135347221-135378160:+	0.52	6.94	2.85E-11	Paget's disease	
CESC	cis	1	rs4309773	chr3:134277301	ANAPC13	chr3:134196547-134204865:-	0.3	4.05	6.69E-5	Height	
CESC	cis	1	rs431076	chr7:65600320	CCT6P1	chr7:65216092-65228661:+	0.57	5.35	1.88E-7	Diabetic kidney disease	
CESC	cis	1	rs431076	chr7:65600320	LOC493754	chr7:65993446-66057363:-	0.53	4.23	3.19E-5	Diabetic kidney disease	
CESC	cis	1	rs431318	chr7:65511597	CCT6P1	chr7:65216092-65228661:+	0.52	4.88	1.78E-6	Diabetic kidney disease	
CESC	cis	1	rs431328	chr19:22222236	ZNF208	chr19:22115760-22193745:-	0.26	4.18	3.98E-5	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
CESC	cis	1	rs4318247	chr17:65882172	LOC651250	chr17:66097696-66157623:+	-0.31	-4.05	6.54E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs43184	chr5:56141777	C5orf35	chr5:56205103-56213010:+	0.84	12.11	2.38E-27	Type 2 diabetes	
CESC	cis	1	rs4322591	chr14:75600697	EIF2B2	chr14:75469612-75476292:+	0.24	3.96	9.47E-5	Height	
CESC	cis	1	rs4334685	chr3:134304335	ANAPC13	chr3:134196547-134204865:-	0.3	4.02	7.56E-5	Height	
CESC	cis	1	rs433598	chr16:20680206	ACSM1	chr16:20634559-20709066:-	0.29	4.03	7.16E-5	Schizophrenia	
CESC	cis	1	rs4367113	chr3:134287975	ANAPC13	chr3:134196547-134204865:-	0.32	4.25	2.89E-5	Height	
CESC	cis	1	rs4368544	chr3:134300014	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.39	1.64E-5	Height	
CESC	cis	1	rs4376778	chr1:46288846	CCDC163P	chr1:45960581-45965646:-	-0.35	-5.76	2.22E-8	Body mass index	
CESC	cis	1	rs437889	chr7:65509234	CCT6P1	chr7:65216092-65228661:+	0.52	4.86	1.99E-6	Diabetic kidney disease	
CESC	cis	1	rs439295	chr3:156572455	LEKR1	chr3:156544076-156763918:+	-0.37	-4.13	4.79E-5	Bone mineral density	
CESC	cis	1	rs4394010	chr4:129894649	C4orf33	chr4:130014829-130033842:+	0.38	5.8	1.86E-8	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs4417907	chr3:134291363	ANAPC13	chr3:134196547-134204865:-	0.31	4.11	5.32E-5	Height	
CESC	cis	1	rs4466058	chr4:129923879	C4orf33	chr4:130014829-130033842:+	-0.37	-5.64	4.3E-8	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs4469291	chr6:49440614	CENPQ	chr6:49431096-49460820:+	-0.26	-4.57	7.4E-6	Folate pathway vitamin levels	
CESC	cis	1	rs4469291	chr6:49440614	MUT	chr6:49398994-49431031:-	0.38	6.64	1.69E-10	Folate pathway vitamin levels	
CESC	cis	1	rs4490383	chr3:48484683	TREX1	chr3:48501186-48509043:+	-0.19	-4.17	4.07E-5	Longevity	
CESC	cis	1	rs4497901	chr2:239969	SH3YL1	chr2:218138-264810:-	-0.7	-11.51	2.87E-25	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs4498009	chr3:134198008	ANAPC13	chr3:134196547-134204865:-	0.33	4.36	1.87E-5	Height	
CESC	cis	1	rs451396	chr7:65484074	CCT6P1	chr7:65216092-65228661:+	0.53	5.13	5.56E-7	Diabetic kidney disease	
CESC	cis	1	rs4535272	chr3:134299916	ANAPC13	chr3:134196547-134204865:-	-0.34	-4.52	9.2E-6	Height	
CESC	cis	1	rs4540592	chr1:75883281	SLC44A5	chr1:75667816-76143610:-	0.51	4.19	3.81E-5	Whole-brain volume (Alzheimer's disease interaction)	
CESC	cis	1	rs4545281	chr1:46360054	CCDC163P	chr1:45960581-45965646:-	-0.35	-5.69	3.22E-8	Body mass index	
CESC	cis	1	rs4548056	chr7:65298873	CCT6P1	chr7:65216092-65228661:+	0.44	4.38	1.67E-5	Diabetic kidney disease	
CESC	cis	1	rs4553560	chr14:75334199	RPS6KL1	chr14:75372347-75389958:-	-0.28	-4.2	3.64E-5	Caffeine consumption	
CESC	cis	1	rs4560537	chr5:150262586	LOC134466	chr5:150310000-150326146:-	0.4	4.73	3.64E-6	Crohn's disease	
CESC	cis	1	rs4560868	chr9:115985499	CDC26	chr9:116029290-116037869:-	0.36	5.25	3.04E-7	Hematology traits	
CESC	cis	1	rs4569324	chr17:65872750	LOC651250	chr17:66097696-66157623:+	-0.32	-4.16	4.33E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs4572812	chr3:134291177	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.42	1.43E-5	Height	
CESC	cis	1	rs4579248	chr5:150268151	IRGM	chr5:150226085-150280295:+	0.43	4	8.17E-5	Crohn's disease	
CESC	cis	1	rs4579248	chr5:150268151	LOC134466	chr5:150310000-150326146:-	0.57	5.31	2.23E-7	Crohn's disease	
CESC	cis	1	rs458291	chr7:65520479	CCT6P1	chr7:65216092-65228661:+	0.51	4.92	1.52E-6	Diabetic kidney disease	
CESC	cis	1	rs4594164	chr14:35509571	PPP2R3C	chr14:35554679-35591679:-	0.44	4.95	1.27E-6	Atopic dermatitis	
CESC	cis	1	rs462853	chr7:65558167	CCT6P1	chr7:65216092-65228661:+	0.53	4.98	1.14E-6	Diabetic kidney disease	
CESC	cis	1	rs462853	chr7:65558167	LOC493754	chr7:65993446-66057363:-	0.51	4.01	7.69E-5	Diabetic kidney disease	
CESC	cis	1	rs4646536	chr12:58157988	FAM119B	chr12:58166383-58176323:+	0.36	4.78	2.9E-6	Multiple sclerosis	
CESC	cis	1	rs4646536	chr12:58157988	TSFM	chr12:58176536-58191367:+	-0.34	-5.93	9.28E-9	Multiple sclerosis	
CESC	cis	1	rs464895	chr7:65527106	CCT6P1	chr7:65216092-65228661:+	0.52	5.12	5.83E-7	Diabetic kidney disease	
CESC	cis	1	rs465359	chr7:65558164	CCT6P1	chr7:65216092-65228661:+	0.53	4.98	1.14E-6	Diabetic kidney disease	
CESC	cis	1	rs465359	chr7:65558164	LOC493754	chr7:65993446-66057363:-	0.51	4.01	7.69E-5	Diabetic kidney disease	
CESC	cis	1	rs4660306	chr1:45978675	CCDC163P	chr1:45960581-45965646:-	0.77	13.8	2.75E-33	Homocysteine levels	
CESC	cis	1	rs4660317	chr1:46326226	CCDC163P	chr1:45960581-45965646:-	-0.34	-5.6	5.29E-8	Body mass index	
CESC	cis	1	rs4660319	chr1:46341623	CCDC163P	chr1:45960581-45965646:-	-0.33	-5.46	1.05E-7	Body mass index	
CESC	cis	1	rs4660321	chr1:46366760	CCDC163P	chr1:45960581-45965646:-	-0.33	-5.42	1.31E-7	Body mass index	
CESC	cis	1	rs4660870	chr1:45995231	CCDC163P	chr1:45960581-45965646:-	-0.67	-11.77	3.61E-26	Homocysteine levels	
CESC	cis	1	rs4660898	chr1:46402171	CCDC163P	chr1:45960581-45965646:-	-0.35	-5.54	7.1E-8	Body mass index	
CESC	cis	1	rs4660910	chr1:46548402	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.91	1.03E-8	Body mass index	
CESC	cis	1	rs466983	chr7:65520496	CCT6P1	chr7:65216092-65228661:+	0.54	5.17	4.46E-7	Diabetic kidney disease	
CESC	cis	1	rs4687701	chr3:53121276	RFT1	chr3:53122503-53164470:-	0.34	5.22	3.53E-7	Height	
CESC	cis	1	rs469758	chr5:96121715	ERAP1	chr5:96096515-96149837:-	-0.41	-8	3.53E-14	Ankylosing spondylitis	
CESC	cis	1	rs469758	chr5:96121715	ERAP2	chr5:96211644-96255398:+	0.4	6.09	3.69E-9	Ankylosing spondylitis	
CESC	cis	1	rs470119	chr22:50966914	TYMP	chr22:50964184-50968514:-	-0.17	-4.08	5.87E-5	Mean corpuscular hemoglobin	
CESC	cis	1	rs4706254	chr6:86602813	SNHG5	chr6:86386726-86388451:-	-0.63	-11.82	2.33E-26	Response to antipsychotic treatment	
CESC	cis	1	rs4707239	chr6:86610717	SNHG5	chr6:86386726-86388451:-	-0.61	-11.49	3.21E-25	Response to antipsychotic treatment	
CESC	cis	1	rs4715129	chr6:49415043	CENPQ	chr6:49431096-49460820:+	-0.25	-4.45	1.22E-5	Folate pathway vitamin levels	
CESC	cis	1	rs4715129	chr6:49415043	MUT	chr6:49398994-49431031:-	0.38	6.71	1.12E-10	Folate pathway vitamin levels	
CESC	cis	1	rs4715130	chr6:49416825	CENPQ	chr6:49431096-49460820:+	-0.23	-4.1	5.54E-5	Folate pathway vitamin levels	
CESC	cis	1	rs4715130	chr6:49416825	MUT	chr6:49398994-49431031:-	0.4	6.93	3.02E-11	Folate pathway vitamin levels	
CESC	cis	1	rs4718269	chr7:65200778	CCT6P1	chr7:65216092-65228661:+	-0.52	-4.96	1.23E-6	Diabetic kidney disease	
CESC	cis	1	rs4718270	chr7:65202407	CCT6P1	chr7:65216092-65228661:+	0.59	5.57	5.98E-8	Diabetic kidney disease	
CESC	cis	1	rs4718307	chr7:65610988	NCRNA00174	chr7:65841032-65865395:-	0.26	4.07	6.19E-5	Aortic root size	
CESC	cis	1	rs4718309	chr7:65627764	CCT6P1	chr7:65216092-65228661:+	-0.51	-4.78	2.88E-6	Diabetic kidney disease	
CESC	cis	1	rs4718315	chr7:65648541	CCT6P1	chr7:65216092-65228661:+	-0.51	-4.76	3.19E-6	Diabetic kidney disease	
CESC	cis	1	rs4718316	chr7:65648731	CCT6P1	chr7:65216092-65228661:+	-0.51	-4.76	3.19E-6	Diabetic kidney disease	
CESC	cis	1	rs4718333	chr7:65772758	CCT6P1	chr7:65216092-65228661:+	-0.54	-5.06	7.72E-7	Diabetic kidney disease	
CESC	cis	1	rs4718333	chr7:65772758	LOC493754	chr7:65993446-66057363:-	-0.53	-4.17	4.17E-5	Diabetic kidney disease	
CESC	cis	1	rs4718334	chr7:65789454	CCT6P1	chr7:65216092-65228661:+	-0.5	-4.81	2.45E-6	Diabetic kidney disease	
CESC	cis	1	rs4718334	chr7:65789454	LOC493754	chr7:65993446-66057363:-	-0.5	-4.15	4.51E-5	Diabetic kidney disease	
CESC	cis	1	rs4726669	chr7:143758191	ARHGEF35	chr7:143883677-143892736:-	-0.49	-6.11	3.47E-9	Obesity-related traits	
CESC	cis	1	rs4727443	chr7:99593346	TRIM4	chr7:99488037-99517154:-	-0.33	-4.78	2.87E-6	Interstitial lung disease	
CESC	cis	1	rs4728142	chr7:128573967	IRF5	chr7:128577769-128590086:+	0.26	4.57	7.42E-6	Systemic lupus erythematosus;Ulcerative colitis;Inflammatory bowel disease	
CESC	cis	1	rs473073	chr10:131429646	MGMT	chr10:131265454-131565783:+	0.32	5.61	5.01E-8	Response to temozolomide	
CESC	cis	1	rs4733724	chr8:130723728	GSDMC	chr8:130760443-130799134:-	0.28	5.06	7.56E-7	Infant length;Height	
CESC	cis	1	rs4733732	chr8:130738457	GSDMC	chr8:130760443-130799134:-	0.31	5.55	6.64E-8	Infant length;Height	
CESC	cis	1	rs473633	chr9:33216096	SPINK4	chr9:33240196-33248564:+	0.34	4.62	5.85E-6	Bipolar disorder and schizophrenia	
CESC	cis	1	rs473771	chr10:131408155	MGMT	chr10:131265454-131565783:+	0.35	6.39	7.13E-10	Response to temozolomide	
CESC	cis	1	rs4743805	chr9:107869834	LOC286367	chr9:107536633-107540044:+	0.26	4.44	1.29E-5	Behavioral disturbance or psychiatric symptoms in prion disease	
CESC	cis	1	rs4750759	chr10:131436603	MGMT	chr10:131265454-131565783:+	-0.33	-5.9	1.06E-8	Response to temozolomide	
CESC	cis	1	rs4755726	chr11:43642130	HSD17B12	chr11:43702143-43878160:+	-0.34	-5.21	3.64E-7	Forced vital capacity	
CESC	cis	1	rs4759229	chr12:56474480	RPS26	chr12:56435686-56438005:+	-0.59	-9.95	3.94E-20	Cognitive function	
CESC	cis	1	rs4763879	chr12:9910164	CLECL1	chr12:9868457-9885860:-	-0.26	-5.72	2.76E-8	Type 1 diabetes	
CESC	cis	1	rs4768942	chr12:51355701	TFCP2	chr12:51488608-51566917:-	-0.35	-4.06	6.44E-5	Type 2 diabetes	
CESC	cis	1	rs477422	chr9:33216528	SPINK4	chr9:33240196-33248564:+	0.31	4.25	2.97E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs477692	chr10:131426022	MGMT	chr10:131265454-131565783:+	0.32	5.73	2.65E-8	Response to temozolomide	
CESC	cis	1	rs4794202	chr17:45930539	SCRN2	chr17:45915049-45918699:-	-0.47	-5.42	1.32E-7	Alzheimer's disease (cognitive decline)	
CESC	cis	1	rs479478	chr10:131428959	MGMT	chr10:131265454-131565783:+	0.33	5.77	2.12E-8	Response to temozolomide	
CESC	cis	1	rs4794823	chr17:38166265	GSDMA	chr17:38119226-38134019:+	-0.32	-4.87	1.84E-6	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
CESC	cis	1	rs4794824	chr17:38179290	GSDMA	chr17:38119226-38134019:+	-0.33	-5.22	3.61E-7	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
CESC	cis	1	rs4795412	chr17:38150604	GSDMA	chr17:38119226-38134019:+	-0.31	-4.74	3.38E-6	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
CESC	cis	1	rs4795415	chr17:38157995	GSDMA	chr17:38119226-38134019:+	-0.32	-4.85	2.03E-6	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
CESC	cis	1	rs4795416	chr17:38158133	GSDMA	chr17:38119226-38134019:+	-0.32	-4.85	2.03E-6	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
CESC	cis	1	rs4795418	chr17:38164851	GSDMA	chr17:38119226-38134019:+	-0.32	-4.87	1.84E-6	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
CESC	cis	1	rs4803480	chr19:42066279	CEACAM21	chr19:42055886-42093196:+	0.51	8.1	1.83E-14	Schizophrenia	
CESC	cis	1	rs4803774	chr19:45450872	APOC2	chr19:45449243-45452817:+	-0.2	-4.22	3.3E-5	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
CESC	cis	1	rs4805754	chr19:32837166	ZNF507	chr19:32836514-32878571:+	0.31	3.98	8.67E-5	Bipolar disorder	
CESC	cis	1	rs4805834	chr19:33453659	SLC7A9	chr19:33321421-33360683:-	-0.4	-4.04	7.08E-5	Creatinine levels	
CESC	cis	1	rs4820345	chr22:39091151	CBY1	chr22:39052658-39069853:+	0.28	4.5	9.98E-6	Resting heart rate	
CESC	cis	1	rs4821810	chr22:39072098	CBY1	chr22:39052658-39069853:+	0.22	3.96	9.67E-5	Resting heart rate	
CESC	cis	1	rs4821811	chr22:39075145	CBY1	chr22:39052658-39069853:+	0.3	5.02	9.16E-7	Resting heart rate	
CESC	cis	1	rs4821812	chr22:39075235	CBY1	chr22:39052658-39069853:+	0.3	4.94	1.39E-6	Resting heart rate	
CESC	cis	1	rs482233	chr9:33217325	SPINK4	chr9:33240196-33248564:+	0.31	4.25	2.97E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs483254	chr9:33217448	SPINK4	chr9:33240196-33248564:+	0.31	4.25	2.97E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs485576	chr10:131425496	MGMT	chr10:131265454-131565783:+	0.32	5.73	2.65E-8	Response to temozolomide	
CESC	cis	1	rs4858817	chr3:48416756	TREX1	chr3:48501186-48509043:+	0.2	4.48	1.09E-5	Longevity	
CESC	cis	1	rs4862406	chr4:185629339	MLF1IP	chr4:185615220-185655286:-	0.44	7.45	1.18E-12	Kawasaki disease	
CESC	cis	1	rs486301	chr15:43836949	CATSPER2	chr15:43922774-43959900:-	-0.39	-5.1	6.42E-7	Tumor biomarkers	
CESC	cis	1	rs486301	chr15:43836949	CKMT1B	chr15:43885252-43891603:+	-0.3	-4	8.27E-5	Tumor biomarkers	
CESC	cis	1	rs4869313	chr5:96223880	ERAP2	chr5:96211644-96255398:+	-0.9	-20.37	7.53E-57	Pediatric autoimmune diseases	
CESC	cis	1	rs4888262	chr16:74670458	RFWD3	chr16:74655298-74700779:-	-0.29	-4.94	1.34E-6	Testicular germ cell tumor	
CESC	cis	1	rs4899148	chr14:65303778	CHURC1	chr14:65381140-65411309:+	0.66	4.11	5.25E-5	Daytime sleep phenotypes	
CESC	cis	1	rs4903201	chr14:74659690	LIN52	chr14:74551656-74667117:+	-0.42	-8.25	6.83E-15	Common traits (Other)	
CESC	cis	1	rs4903202	chr14:74660302	LIN52	chr14:74551656-74667117:+	-0.41	-8.21	8.45E-15	Common traits (Other)	
CESC	cis	1	rs4903203	chr14:74660508	LIN52	chr14:74551656-74667117:+	-0.41	-8.21	8.45E-15	Common traits (Other)	
CESC	cis	1	rs4903284	chr14:75592483	EIF2B2	chr14:75469612-75476292:+	0.24	4.02	7.61E-5	Height	
CESC	cis	1	rs4905138	chr14:94466357	DDX24	chr14:94517269-94547558:-	-0.29	-4.34	2.04E-5	Coronary artery aneurysm in Kawasaki disease	
CESC	cis	1	rs4919690	chr10:104616500	C10orf32	chr10:104613967-104624718:+	0.47	6.06	4.39E-9	Arsenic metabolism	
CESC	cis	1	rs4925166	chr17:18210810	FAM106A	chr17:18427880-18430160:-	-0.32	-4.23	3.21E-5	Multiple sclerosis	
CESC	cis	1	rs4925166	chr17:18210810	LOC220594	chr17:18414577-18445234:-	-0.45	-5.11	6.09E-7	Multiple sclerosis	
CESC	cis	1	rs4932143	chr15:90372067	AP3S2	chr15:90373832-90456222:-	-0.44	-5.22	3.61E-7	Type 2 diabetes	
CESC	cis	1	rs4932148	chr15:90394356	AP3S2	chr15:90373832-90456222:-	-0.47	-5.74	2.54E-8	Type 2 diabetes	
CESC	cis	1	rs4949851	chr1:75858519	SLC44A5	chr1:75667816-76143610:-	-0.53	-4.12	4.98E-5	Whole-brain volume (Alzheimer's disease interaction)	
CESC	cis	1	rs4955485	chr3:134295843	ANAPC13	chr3:134196547-134204865:-	0.3	4.05	6.7E-5	Height	
CESC	cis	1	rs4955555	chr3:134286427	ANAPC13	chr3:134196547-134204865:-	0.31	4.19	3.82E-5	Height	
CESC	cis	1	rs4958422	chr5:150186734	LOC134466	chr5:150310000-150326146:-	0.7	6.39	7.04E-10	Crohn's disease	
CESC	cis	1	rs4958424	chr5:150225036	LOC134466	chr5:150310000-150326146:-	0.44	5.04	8.53E-7	Crohn's disease	
CESC	cis	1	rs4958426	chr5:150278346	LOC134466	chr5:150310000-150326146:-	0.65	5.98	6.98E-9	Crohn's disease	
CESC	cis	1	rs4958842	chr5:150224877	IRGM	chr5:150226085-150280295:+	0.42	4.27	2.75E-5	Crohn's disease	
CESC	cis	1	rs4958842	chr5:150224877	LOC134466	chr5:150310000-150326146:-	0.55	5.54	6.93E-8	Crohn's disease	
CESC	cis	1	rs4958843	chr5:150224924	LOC134466	chr5:150310000-150326146:-	0.44	5.04	8.53E-7	Crohn's disease	
CESC	cis	1	rs4958848	chr5:150271122	LOC134466	chr5:150310000-150326146:-	0.39	4.57	7.44E-6	Crohn's disease	
CESC	cis	1	rs4958852	chr5:150330631	LOC134466	chr5:150310000-150326146:-	0.59	4.87	1.87E-6	Crohn's disease	
CESC	cis	1	rs496584	chr15:43831923	CATSPER2	chr15:43922774-43959900:-	-0.41	-4.88	1.77E-6	Tumor biomarkers	
CESC	cis	1	rs496584	chr15:43831923	CKMT1A	chr15:43985084-43991419:+	-0.37	-4.03	7.14E-5	Tumor biomarkers	
CESC	cis	1	rs496584	chr15:43831923	CKMT1B	chr15:43885252-43891603:+	-0.36	-4.5	1.0E-5	Tumor biomarkers	
CESC	cis	1	rs4969049	chr17:71000940	COG1	chr17:71189173-71204643:+	0.29	4.24	3.07E-5	Body mass index (interaction)	
CESC	cis	1	rs4974484	chr3:134219019	ANAPC13	chr3:134196547-134204865:-	0.3	3.97	9.04E-5	Height	
CESC	cis	1	rs4975193	chr4:129980630	C4orf33	chr4:130014829-130033842:+	-0.37	-5.57	6.09E-8	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs4975194	chr4:129982377	C4orf33	chr4:130014829-130033842:+	-0.37	-5.57	6.09E-8	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs4985124	chr16:15125441	RRN3	chr16:15153881-15188158:-	-0.29	-3.97	9.11E-5	Metabolic traits;Glycerophospholipid levels	
CESC	cis	1	rs503660	chr10:131418999	MGMT	chr10:131265454-131565783:+	0.32	5.87	1.26E-8	Response to temozolomide	
CESC	cis	1	rs506274	chr10:131409392	MGMT	chr10:131265454-131565783:+	0.35	6.32	1.06E-9	Response to temozolomide	
CESC	cis	1	rs508303	chr10:131424996	MGMT	chr10:131265454-131565783:+	-0.34	-6.04	5.07E-9	Response to temozolomide	
CESC	cis	1	rs513736	chr10:131406489	MGMT	chr10:131265454-131565783:+	0.33	6.01	5.72E-9	Response to temozolomide	
CESC	cis	1	rs515387	chr9:33218659	SPINK4	chr9:33240196-33248564:+	0.31	4.24	3.01E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs516704	chr10:131419879	MGMT	chr10:131265454-131565783:+	0.33	6.02	5.61E-9	Response to temozolomide	
CESC	cis	1	rs522891	chr10:131430916	MGMT	chr10:131265454-131565783:+	-0.31	-5.5	8.67E-8	Response to temozolomide	
CESC	cis	1	rs530466	chr10:131427717	MGMT	chr10:131265454-131565783:+	0.33	5.96	7.57E-9	Response to temozolomide	
CESC	cis	1	rs531572	chr10:131427569	MGMT	chr10:131265454-131565783:+	-0.33	-5.94	8.45E-9	Response to temozolomide	
CESC	cis	1	rs538011	chr9:33218468	SPINK4	chr9:33240196-33248564:+	0.31	4.19	3.77E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs538969	chr10:131410608	MGMT	chr10:131265454-131565783:+	0.34	6.14	2.83E-9	Response to temozolomide	
CESC	cis	1	rs539826	chr9:33218668	SPINK4	chr9:33240196-33248564:+	0.31	4.24	3.01E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs539911	chr9:33218692	SPINK4	chr9:33240196-33248564:+	0.31	4.24	3.01E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs548390	chr10:131417427	MGMT	chr10:131265454-131565783:+	0.33	5.86	1.33E-8	Response to temozolomide	
CESC	cis	1	rs553371	chr10:131413676	MGMT	chr10:131265454-131565783:+	0.33	5.93	8.86E-9	Response to temozolomide	
CESC	cis	1	rs554792	chr10:131423181	MGMT	chr10:131265454-131565783:+	0.33	5.91	1.03E-8	Response to temozolomide	
CESC	cis	1	rs55753056	chr2:243929	SH3YL1	chr2:218138-264810:-	-0.7	-11.61	1.23E-25	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs558764	chr10:131426957	MGMT	chr10:131265454-131565783:+	-0.32	-5.72	2.81E-8	Response to temozolomide	
CESC	cis	1	rs55895244	chr7:65387678	CCT6P1	chr7:65216092-65228661:+	0.45	4.32	2.14E-5	Diabetic kidney disease	
CESC	cis	1	rs55896768	chr17:65913358	LOC651250	chr17:66097696-66157623:+	-0.28	-4.04	6.96E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs55913793	chr3:134285968	ANAPC13	chr3:134196547-134204865:-	0.31	4.19	3.82E-5	Height	
CESC	cis	1	rs55936726	chr2:258210	SH3YL1	chr2:218138-264810:-	-0.72	-11.97	7.13E-27	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs55939964	chr17:65869297	LOC651250	chr17:66097696-66157623:+	-0.32	-4.13	4.82E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs55946380	chr2:268293	SH3YL1	chr2:218138-264810:-	-0.72	-11.93	9.89E-27	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs55962025	chr4:3112109	GRK4	chr4:2965343-3042474:+	-0.31	-4.13	4.76E-5	Parental longevity (mother's age at death)	
CESC	cis	1	rs55962648	chr7:65625751	NCRNA00174	chr7:65841032-65865395:-	0.26	4.13	4.74E-5	Aortic root size	
CESC	cis	1	rs56016656	chr7:65383481	CCT6P1	chr7:65216092-65228661:+	0.57	5.39	1.54E-7	Diabetic kidney disease	
CESC	cis	1	rs56040780	chr16:28861881	EIF3CL	chr16:28699879-28747052:+;chr16	0.35	5.04	8.53E-7	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
CESC	cis	1	rs56043407	chr17:2166078	SRR	chr17:2207248-2228553:+	-0.41	-5.35	1.88E-7	Esophageal cancer (squamous cell)	
CESC	cis	1	rs56121764	chr3:41883975	ULK4	chr3:41288091-42003660:-	0.4	5.23	3.4E-7	Diastolic blood pressure	
CESC	cis	1	rs56154726	chr2:73721767	ALMS1P	chr2:73872046-73912692:+	0.42	5.86	1.31E-8	Metabolite levels	
CESC	cis	1	rs56158380	chr3:41885588	ULK4	chr3:41288091-42003660:-	0.4	5.23	3.4E-7	Diastolic blood pressure	
CESC	cis	1	rs56167434	chr2:282137	SH3YL1	chr2:218138-264810:-	-0.73	-12.14	1.95E-27	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs56207540	chr3:41976627	ULK4	chr3:41288091-42003660:-	0.4	4.42	1.44E-5	Diastolic blood pressure	
CESC	cis	1	rs56291018	chr7:65390339	CCT6P1	chr7:65216092-65228661:+	0.57	5.39	1.54E-7	Diabetic kidney disease	
CESC	cis	1	rs56317427	chr10:81861934	PLAC9	chr10:81892258-81904784:+	-0.43	-5.56	6.24E-8	Chronic obstructive pulmonary disease-related biomarkers	
CESC	cis	1	rs56321614	chr2:268191	SH3YL1	chr2:218138-264810:-	-0.68	-11.3	1.47E-24	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs563512	chr9:33216484	SPINK4	chr9:33240196-33248564:+	0.31	4.25	2.97E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs563538	chr13:37433721	ALG5	chr13:37523910-37573504:-	0.55	5	1.01E-6	Spontaneous preterm birth (preterm birth)	
CESC	cis	1	rs563538	chr13:37433721	EXOSC8	chr13:37574678-37583749:+	0.57	5.84	1.5E-8	Spontaneous preterm birth (preterm birth)	
CESC	cis	1	rs563538	chr13:37433721	FAM48A	chr13:37583453-37633850:-	0.5	4.42	1.45E-5	Spontaneous preterm birth (preterm birth)	
CESC	cis	1	rs563538	chr13:37433721	RFXAP	chr13:37393339-37403740:+	0.55	5.13	5.5E-7	Spontaneous preterm birth (preterm birth)	
CESC	cis	1	rs56393562	chr17:65933918	LOC651250	chr17:66097696-66157623:+	-0.31	-4.15	4.5E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs56404791	chr17:65893019	LOC651250	chr17:66097696-66157623:+	-0.28	-4.06	6.3E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs565974	chr10:131423274	MGMT	chr10:131265454-131565783:+	0.33	5.91	1.03E-8	Response to temozolomide	
CESC	cis	1	rs56672945	chr2:73622663	ALMS1P	chr2:73872046-73912692:+	0.4	5.61	4.9E-8	Metabolite levels	
CESC	cis	1	rs567700	chr10:131423126	MGMT	chr10:131265454-131565783:+	0.33	5.91	1.03E-8	Response to temozolomide	
CESC	cis	1	rs56776628	chr3:41866856	ULK4	chr3:41288091-42003660:-	0.46	7.07	1.26E-11	Diastolic blood pressure	
CESC	cis	1	rs568617	chr11:65653242	CTSW	chr11:65647284-65651212:+	-0.51	-10.54	4.92E-22	Crohn's disease	
CESC	cis	1	rs56922390	chr17:38157021	GSDMA	chr17:38119226-38134019:+	-0.32	-4.85	2.03E-6	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
CESC	cis	1	rs569235	chr10:131411620	MGMT	chr10:131265454-131565783:+	0.34	6.16	2.53E-9	Response to temozolomide	
CESC	cis	1	rs56985706	chr7:65394562	CCT6P1	chr7:65216092-65228661:+	0.45	4.32	2.14E-5	Diabetic kidney disease	
CESC	cis	1	rs57001853	chr5:150272452	LOC134466	chr5:150310000-150326146:-	0.38	4.45	1.27E-5	Crohn's disease	
CESC	cis	1	rs57057549	chr7:65405738	CCT6P1	chr7:65216092-65228661:+	0.6	5.64	4.13E-8	Diabetic kidney disease	
CESC	cis	1	rs57075379	chr14:35577801	PPP2R3C	chr14:35554679-35591679:-	0.47	5.22	3.49E-7	Atopic dermatitis	
CESC	cis	1	rs57406211	chr5:150170966	LOC134466	chr5:150310000-150326146:-	0.69	6.84	5.16E-11	Crohn's disease	
CESC	cis	1	rs57479675	chr3:41798038	ULK4	chr3:41288091-42003660:-	0.52	8.19	1.0E-14	Diastolic blood pressure	
CESC	cis	1	rs5750626	chr22:38977890	CBY1	chr22:39052658-39069853:+	0.26	4.13	4.79E-5	Resting heart rate	
CESC	cis	1	rs5750630	chr22:38985818	CBY1	chr22:39052658-39069853:+	0.28	4.44	1.32E-5	Resting heart rate	
CESC	cis	1	rs5750659	chr22:39068789	CBY1	chr22:39052658-39069853:+	0.28	4.76	3.11E-6	Resting heart rate	
CESC	cis	1	rs5750662	chr22:39072472	CBY1	chr22:39052658-39069853:+	0.28	4.76	3.11E-6	Resting heart rate	
CESC	cis	1	rs5750664	chr22:39072769	CBY1	chr22:39052658-39069853:+	0.28	4.76	3.11E-6	Resting heart rate	
CESC	cis	1	rs5750668	chr22:39079964	CBY1	chr22:39052658-39069853:+	0.3	5.01	9.94E-7	Resting heart rate	
CESC	cis	1	rs5750669	chr22:39080638	CBY1	chr22:39052658-39069853:+	0.31	5.04	8.5E-7	Resting heart rate	
CESC	cis	1	rs5750671	chr22:39094619	CBY1	chr22:39052658-39069853:+	0.22	3.96	9.72E-5	Resting heart rate	
CESC	cis	1	rs5750672	chr22:39104168	CBY1	chr22:39052658-39069853:+	-0.29	-4.77	3.04E-6	Resting heart rate	
CESC	cis	1	rs5750673	chr22:39110124	CBY1	chr22:39052658-39069853:+	0.29	4.81	2.45E-6	Resting heart rate	
CESC	cis	1	rs5750677	chr22:39147715	CBY1	chr22:39052658-39069853:+	0.26	4.35	1.94E-5	Resting heart rate	
CESC	cis	1	rs5751255	chr22:42648408	CYP2D6	chr22:42522502-42526883:-	-0.42	-7.38	1.85E-12	Cognitive function	
CESC	cis	1	rs57542652	chr2:228088	SH3YL1	chr2:218138-264810:-	-0.7	-11.26	1.87E-24	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs5757162	chr22:38993370	CBY1	chr22:39052658-39069853:+	0.26	4.13	4.79E-5	Resting heart rate	
CESC	cis	1	rs5757187	chr22:39021522	CBY1	chr22:39052658-39069853:+	-0.26	-4.25	2.98E-5	Resting heart rate	
CESC	cis	1	rs5757196	chr22:39039855	CBY1	chr22:39052658-39069853:+	0.25	4.11	5.23E-5	Resting heart rate	
CESC	cis	1	rs5757200	chr22:39043491	CBY1	chr22:39052658-39069853:+	0.25	4.11	5.23E-5	Resting heart rate	
CESC	cis	1	rs5757203	chr22:39044152	CBY1	chr22:39052658-39069853:+	0.25	4.11	5.23E-5	Resting heart rate	
CESC	cis	1	rs5757204	chr22:39046700	CBY1	chr22:39052658-39069853:+	0.25	4.11	5.23E-5	Resting heart rate	
CESC	cis	1	rs5757211	chr22:39051705	CBY1	chr22:39052658-39069853:+	0.25	4.11	5.23E-5	Resting heart rate	
CESC	cis	1	rs5757226	chr22:39070550	CBY1	chr22:39052658-39069853:+	0.28	4.76	3.11E-6	Resting heart rate	
CESC	cis	1	rs5757231	chr22:39071658	CBY1	chr22:39052658-39069853:+	-0.27	-4.43	1.36E-5	Resting heart rate	
CESC	cis	1	rs5757232	chr22:39071677	CBY1	chr22:39052658-39069853:+	0.28	4.76	3.11E-6	Resting heart rate	
CESC	cis	1	rs5757234	chr22:39072686	CBY1	chr22:39052658-39069853:+	0.22	3.96	9.67E-5	Resting heart rate	
CESC	cis	1	rs5757253	chr22:39104320	CBY1	chr22:39052658-39069853:+	0.23	4.01	7.81E-5	Resting heart rate	
CESC	cis	1	rs5758659	chr22:42622003	CYP2D6	chr22:42522502-42526883:-	-0.42	-7.41	1.57E-12	Cognitive function	
CESC	cis	1	rs5758660	chr22:42623718	CYP2D6	chr22:42522502-42526883:-	-0.42	-7.39	1.75E-12	Cognitive function	
CESC	cis	1	rs5758677	chr22:42643039	CYP2D6	chr22:42522502-42526883:-	-0.42	-7.4	1.71E-12	Cognitive function	
CESC	cis	1	rs5770922	chr22:51023408	CPT1B	chr22:51007291-51017096:-	-0.49	-3.98	8.91E-5	Narcolepsy	
CESC	cis	1	rs577227	chr10:131404528	MGMT	chr10:131265454-131565783:+	0.34	6.13	3.02E-9	Response to temozolomide	
CESC	cis	1	rs58062456	chr7:65394852	CCT6P1	chr7:65216092-65228661:+	0.45	4.32	2.14E-5	Diabetic kidney disease	
CESC	cis	1	rs580745	chr10:131414401	MGMT	chr10:131265454-131565783:+	0.34	6.07	4.16E-9	Response to temozolomide	
CESC	cis	1	rs58122682	chr17:65876915	LOC651250	chr17:66097696-66157623:+	-0.31	-4.05	6.54E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs584438	chr17:38599172	CASC3	chr17:38296507-38328431:+	0.28	4.67	4.62E-6	Height	
CESC	cis	1	rs58461606	chr2:267367	SH3YL1	chr2:218138-264810:-	-0.7	-11.72	5.27E-26	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs58551145	chr17:65837235	LOC651250	chr17:66097696-66157623:+	-0.31	-3.99	8.5E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs58603761	chr2:73726605	ALMS1P	chr2:73872046-73912692:+	0.38	5.45	1.12E-7	Metabolite levels	
CESC	cis	1	rs58669269	chr7:65951953	CCT6P1	chr7:65216092-65228661:+	0.57	5.28	2.57E-7	Diabetic kidney disease	
CESC	cis	1	rs58669269	chr7:65951953	LOC493754	chr7:65993446-66057363:-	0.51	3.98	8.67E-5	Diabetic kidney disease	
CESC	cis	1	rs58717741	chr5:150284936	IRGM	chr5:150226085-150280295:+	0.46	4.52	9.03E-6	Crohn's disease	
CESC	cis	1	rs58717741	chr5:150284936	LOC134466	chr5:150310000-150326146:-	0.67	6.73	1.01E-10	Crohn's disease	
CESC	cis	1	rs58749629	chr20:44571317	WFDC3	chr20:44402847-44420547:-	-0.43	-4.23	3.23E-5	Abdominal aortic aneurysm	
CESC	cis	1	rs58837313	chr19:18748431	PGPEP1	chr19:18451408-18480763:+	0.3	4.06	6.52E-5	Orofacial clefts	
CESC	cis	1	rs59226697	chr22:25870037	CRYBB2	chr22:25615612-25627836:+	0.64	4.79	2.72E-6	Bipolar disorder with mood-incongruent psychosis	
CESC	cis	1	rs59321715	chr5:150313480	LOC134466	chr5:150310000-150326146:-	0.68	5.82	1.67E-8	Crohn's disease	
CESC	cis	1	rs59531858	chr5:150247063	LOC134466	chr5:150310000-150326146:-	0.52	5.39	1.51E-7	Crohn's disease	
CESC	cis	1	rs595918	chr1:209966843	C1orf133	chr1:210404804-210407466:-	-0.28	-4.17	4.16E-5	Orofacial clefts	
CESC	cis	1	rs59715748	chr5:150189287	LOC134466	chr5:150310000-150326146:-	0.7	6.34	9.29E-10	Crohn's disease	
CESC	cis	1	rs59794892	chr7:65415873	CCT6P1	chr7:65216092-65228661:+	0.46	4.45	1.27E-5	Diabetic kidney disease	
CESC	cis	1	rs59925331	chr17:38169273	GSDMA	chr17:38119226-38134019:+	-0.31	-4.85	2.09E-6	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
CESC	cis	1	rs59937473	chr2:271797	SH3YL1	chr2:218138-264810:-	-0.68	-11.35	9.39E-25	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs59950564	chr17:65860859	LOC651250	chr17:66097696-66157623:+	-0.32	-4.1	5.36E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs5995610	chr22:39064681	CBY1	chr22:39052658-39069853:+	0.25	4.12	5.0E-5	Resting heart rate	
CESC	cis	1	rs5996946	chr22:25875988	CRYBB2	chr22:25615612-25627836:+	0.85	9.39	2.43E-18	Bipolar disorder with mood-incongruent psychosis	
CESC	cis	1	rs59980321	chr5:150241813	LOC134466	chr5:150310000-150326146:-	0.46	5.49	9.03E-8	Crohn's disease	
CESC	cis	1	rs6001182	chr22:39047443	CBY1	chr22:39052658-39069853:+	0.25	4.11	5.23E-5	Resting heart rate	
CESC	cis	1	rs6001188	chr22:39062194	CBY1	chr22:39052658-39069853:+	0.25	4.08	5.86E-5	Resting heart rate	
CESC	cis	1	rs6001191	chr22:39074452	CBY1	chr22:39052658-39069853:+	0.28	4.76	3.11E-6	Resting heart rate	
CESC	cis	1	rs6001204	chr22:39100239	CBY1	chr22:39052658-39069853:+	0.22	3.95	0.000101	Resting heart rate	
CESC	cis	1	rs6001214	chr22:39149155	CBY1	chr22:39052658-39069853:+	0.25	4.27	2.65E-5	Resting heart rate	
CESC	cis	1	rs6004667	chr22:25874464	CRYBB2	chr22:25615612-25627836:+	-0.85	-8.78	1.79E-16	Bipolar disorder with mood-incongruent psychosis	
CESC	cis	1	rs6004668	chr22:25874502	CRYBB2	chr22:25615612-25627836:+	-0.83	-8.75	2.15E-16	Bipolar disorder with mood-incongruent psychosis	
CESC	cis	1	rs6004669	chr22:25875803	CRYBB2	chr22:25615612-25627836:+	0.83	9.02	3.29E-17	Bipolar disorder with mood-incongruent psychosis	
CESC	cis	1	rs6004672	chr22:25881013	CRYBB2	chr22:25615612-25627836:+	0.85	9.18	1.05E-17	Bipolar disorder with mood-incongruent psychosis	
CESC	cis	1	rs6004673	chr22:25885353	CRYBB2	chr22:25615612-25627836:+	0.88	9.3	4.52E-18	Bipolar disorder with mood-incongruent psychosis	
CESC	cis	1	rs6011674	chr20:61854452	FLJ16779	chr20:61885330-61892963:+	0.38	4.05	6.73E-5	Response to cytadine analogues (cytosine arabinoside)	
CESC	cis	1	rs60134818	chr5:150261043	LOC134466	chr5:150310000-150326146:-	0.4	4.69	4.36E-6	Crohn's disease	
CESC	cis	1	rs60149603	chr2:285421	SH3YL1	chr2:218138-264810:-	-0.73	-12.32	4.61E-28	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs60228607	chr8:130735460	GSDMC	chr8:130760443-130799134:-	0.3	5.42	1.28E-7	Infant length;Height	
CESC	cis	1	rs60326618	chr7:66166358	CCT6P1	chr7:65216092-65228661:+	0.56	5.28	2.57E-7	Gout	
CESC	cis	1	rs60326618	chr7:66166358	LOC493754	chr7:65993446-66057363:-	0.57	4.57	7.5E-6	Gout	
CESC	cis	1	rs60484953	chr2:221560	SH3YL1	chr2:218138-264810:-	-0.71	-11.48	3.42E-25	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs6050565	chr20:25347563	PYGB	chr20:25228706-25278647:+	0.26	3.97	9.05E-5	Liver enzyme levels (alkaline phosphatase)	
CESC	cis	1	rs6050573	chr20:25366065	PYGB	chr20:25228706-25278647:+	-0.29	-4.27	2.64E-5	Liver enzyme levels (alkaline phosphatase)	
CESC	cis	1	rs60512868	chr3:48483445	TREX1	chr3:48501186-48509043:+	-0.19	-4.17	4.07E-5	Longevity	
CESC	cis	1	rs6053815	chr20:5970438	MCM8	chr20:5931298-5975829:+	-0.3	-4.8	2.62E-6	HIV-1 viral setpoint	
CESC	cis	1	rs6053816	chr20:5970750	MCM8	chr20:5931298-5975829:+	-0.26	-4.14	4.67E-5	HIV-1 viral setpoint	
CESC	cis	1	rs6065	chr17:4836381	SPAG7	chr17:4862523-4871132:-	0.44	4.34	2.0E-5	Platelet count	
CESC	cis	1	rs60683927	chr7:65394768	CCT6P1	chr7:65216092-65228661:+	0.45	4.32	2.14E-5	Diabetic kidney disease	
CESC	cis	1	rs60693825	chr14:35514456	PPP2R3C	chr14:35554679-35591679:-	0.47	5.27	2.72E-7	Atopic dermatitis	
CESC	cis	1	rs60844734	chr2:73623205	ALMS1P	chr2:73872046-73912692:+	0.4	5.61	4.9E-8	Metabolite levels	
CESC	cis	1	rs6092354	chr20:55294474	BMP7	chr20:55743809-55841707:-	0.44	3.95	0.0001	Cognitive decline rate in late mild cognitive impairment	
CESC	cis	1	rs60929805	chr1:95646386	RWDD3	chr1:95583479-95712773:+	0.66	5.44	1.15E-7	Stearic acid (18:0) plasma levels	
CESC	cis	1	rs60982898	chr6:49385806	CENPQ	chr6:49431096-49460820:+	-0.25	-4.5	1.02E-5	Folate pathway vitamin levels	
CESC	cis	1	rs60982898	chr6:49385806	MUT	chr6:49398994-49431031:-	0.38	6.68	1.3E-10	Folate pathway vitamin levels	
CESC	cis	1	rs61037750	chr11:43681372	HSD17B12	chr11:43702143-43878160:+	-0.36	-5.41	1.4E-7	Forced vital capacity	
CESC	cis	1	rs61102033	chr1:46382441	CCDC163P	chr1:45960581-45965646:-	-0.32	-5.23	3.36E-7	Body mass index	
CESC	cis	1	rs61172708	chr3:52996052	RFT1	chr3:53122503-53164470:-	0.53	4.53	8.93E-6	Immune reponse to smallpox (secreted IL-2)	
CESC	cis	1	rs6120974	chr20:34126827	CPNE1	chr20:34213968-34262539:-	-0.57	-6.11	3.4E-9	Triglycerides	
CESC	cis	1	rs61248595	chr19:18748435	PGPEP1	chr19:18451408-18480763:+	0.3	4.06	6.52E-5	Orofacial clefts	
CESC	cis	1	rs61270113	chr5:150226263	LOC134466	chr5:150310000-150326146:-	0.44	5.04	8.53E-7	Crohn's disease	
CESC	cis	1	rs61366424	chr10:60004851	IPMK	chr10:59955618-60027694:-	0.23	5.13	5.55E-7	Inflammatory bowel disease	
CESC	cis	1	rs6151429	chr22:51063477	ARSA	chr22:51063450-51066607:-	-0.83	-6.73	1.0E-10	Blood metabolite levels	
CESC	cis	1	rs61524473	chr15:45646283	SPATA5L1	chr15:45694519-45713614:+	0.41	5.69	3.26E-8	Metabolite levels (small molecules and protein measures)	
CESC	cis	1	rs61530785	chr5:150261364	IRGM	chr5:150226085-150280295:+	0.44	4.25	2.98E-5	Crohn's disease	
CESC	cis	1	rs61530785	chr5:150261364	LOC134466	chr5:150310000-150326146:-	0.56	5.29	2.46E-7	Crohn's disease	
CESC	cis	1	rs61577980	chr12:51345370	TFCP2	chr12:51488608-51566917:-	-0.35	-4.04	7.05E-5	Type 2 diabetes	
CESC	cis	1	rs61640457	chr6:154953253	CNKSR3	chr6:154726434-154831753:-	0.32	3.96	9.74E-5	Diabetic kidney disease	
CESC	cis	1	rs61783200	chr1:46297403	CCDC163P	chr1:45960581-45965646:-	-0.35	-5.77	2.08E-8	Body mass index	
CESC	cis	1	rs61783220	chr1:46335312	CCDC163P	chr1:45960581-45965646:-	-0.33	-5.46	1.05E-7	Body mass index	
CESC	cis	1	rs61876326	chr11:467368	RNH1	chr11:494512-507273:-	-0.37	-4.04	6.84E-5	Body mass index	
CESC	cis	1	rs61995742	chr12:48954030	HDAC7	chr12:48176509-48213763:-	0.48	4.24	3.02E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs62084210	chr17:65828710	LOC651250	chr17:66097696-66157623:+	-0.32	-4.04	6.83E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs62084213	chr17:65842016	LOC651250	chr17:66097696-66157623:+	-0.31	-3.99	8.36E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs62084214	chr17:65843325	LOC651250	chr17:66097696-66157623:+	-0.31	-3.99	8.36E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs62084238	chr17:65856573	LOC651250	chr17:66097696-66157623:+	-0.31	-4.02	7.46E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs62084240	chr17:65859233	LOC651250	chr17:66097696-66157623:+	-0.32	-4.1	5.42E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs62084246	chr17:65867911	LOC651250	chr17:66097696-66157623:+	-0.32	-4.13	4.82E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs62084248	chr17:65874541	LOC651250	chr17:66097696-66157623:+	-0.31	-4.05	6.54E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs62084249	chr17:65874998	LOC651250	chr17:66097696-66157623:+	-0.31	-4.05	6.54E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs62084251	chr17:65878736	LOC651250	chr17:66097696-66157623:+	-0.31	-4.05	6.54E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs62085992	chr17:65923083	LOC651250	chr17:66097696-66157623:+	-0.33	-4.25	2.98E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs62085993	chr17:65923152	LOC651250	chr17:66097696-66157623:+	-0.31	-4.15	4.5E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs62097350	chr18:13298943	CEP192	chr18:12991361-13125049:+	0.34	3.95	0.000101	3-hydroxy-1-methylpropylmercapturic acid levels in smokers	
CESC	cis	1	rs62103177	chr18:77624479	HSBP1L1	chr18:77724582-77730820:+	0.44	4.62	5.88E-6	Opioid sensitivity	
CESC	cis	1	rs62103177	chr18:77624479	TXNL4A	chr18:77732869-77793915:-	0.37	4.36	1.83E-5	Opioid sensitivity	
CESC	cis	1	rs62111717	chr19:35978567	USF2	chr19:35759896-35770718:+	-0.36	-4.24	2.99E-5	Bipolar disorder	
CESC	cis	1	rs62114497	chr2:214837	SH3YL1	chr2:218138-264810:-	-0.68	-10.99	1.6E-23	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs62114501	chr2:231741	SH3YL1	chr2:218138-264810:-	-0.71	-11.56	1.91E-25	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs62114505	chr2:242426	SH3YL1	chr2:218138-264810:-	-0.72	-11.87	1.63E-26	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs62114544	chr2:269679	SH3YL1	chr2:218138-264810:-	-0.72	-11.93	9.89E-27	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs62114548	chr2:274672	SH3YL1	chr2:218138-264810:-	-0.71	-11.82	2.34E-26	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs62120832	chr19:23064264	ZNF492	chr19:22817126-22850472:+	-0.36	-4.05	6.78E-5	Bronchopulmonary dysplasia	
CESC	cis	1	rs62136864	chr2:46829124	ATP6V1E2	chr2:46738988-46769696:-	-0.35	-5.1	6.27E-7	Height	
CESC	cis	1	rs62151652	chr2:73700131	ALMS1P	chr2:73872046-73912692:+	0.42	5.86	1.31E-8	Metabolite levels	
CESC	cis	1	rs62271515	chr3:134300507	ANAPC13	chr3:134196547-134204865:-	0.3	4.08	5.9E-5	Height	
CESC	cis	1	rs622832	chr1:209974232	C1orf133	chr1:210404804-210407466:-	-0.26	-3.95	0.0001	Orofacial clefts	
CESC	cis	1	rs62377945	chr5:151208004	ATOX1	chr5:151122384-151138210:-	-0.23	-4.2	3.57E-5	Preschool internalizing problems	
CESC	cis	1	rs62377945	chr5:151208004	SLC36A1	chr5:150816553-150871939:+	-0.3	-3.97	9.09E-5	Preschool internalizing problems	
CESC	cis	1	rs62394155	chr5:151248069	SLC36A1	chr5:150816553-150871939:+	-0.3	-3.98	8.96E-5	Preschool internalizing problems	
CESC	cis	1	rs62625008	chr1:95702582	RWDD3	chr1:95583479-95712773:+	0.58	4.71	4.01E-6	Stearic acid (18:0) plasma levels	
CESC	cis	1	rs632746	chr1:209982515	C1orf133	chr1:210404804-210407466:-	-0.28	-4.07	6.19E-5	Orofacial clefts	
CESC	cis	1	rs641018	chr11:65655393	CTSW	chr11:65647284-65651212:+	-0.51	-10.54	4.92E-22	Crohn's disease	
CESC	cis	1	rs641862	chr13:110790232	ARHGEF7	chr13:111767624-111958080:+	0.57	4.04	6.94E-5	Obesity-related traits	
CESC	cis	1	rs641862	chr13:110790232	CARKD	chr13:111267881-111292340:+	0.71	4.62	5.8E-6	Obesity-related traits	
CESC	cis	1	rs641862	chr13:110790232	ING1	chr13:111365083-111373420:+	0.61	4.14	4.62E-5	Obesity-related traits	
CESC	cis	1	rs6427049	chr1:166956593	MAEL	chr1:166958519-166991447:+	-0.34	-4.43	1.38E-5	Refractive astigmatism	
CESC	cis	1	rs6429567	chr1:45956700	CCDC163P	chr1:45960581-45965646:-	-0.8	-14.39	2.28E-35	Homocysteine levels	
CESC	cis	1	rs6429569	chr1:46001330	CCDC163P	chr1:45960581-45965646:-	-0.64	-11.25	2.08E-24	Homocysteine levels	
CESC	cis	1	rs6429582	chr1:46321843	CCDC163P	chr1:45960581-45965646:-	0.3	4.87	1.92E-6	Body mass index	
CESC	cis	1	rs642961	chr1:209989270	C1orf133	chr1:210404804-210407466:-	-0.29	-4.41	1.51E-5	Orofacial clefts	
CESC	cis	1	rs6430585	chr2:136506927	LCT	chr2:136545415-136594750:-	0.34	4.55	8.17E-6	Corneal structure	
CESC	cis	1	rs6435079	chr2:202200331	ALS2CR12	chr2:202153148-202222101:-	-0.33	-4.55	7.89E-6	Basal cell carcinoma	
CESC	cis	1	rs6435081	chr2:202220623	ALS2CR12	chr2:202153148-202222101:-	-0.31	-4.13	4.86E-5	Basal cell carcinoma	
CESC	cis	1	rs6439484	chr3:134249899	ANAPC13	chr3:134196547-134204865:-	0.3	4.05	6.69E-5	Height	
CESC	cis	1	rs6441104	chr3:156681441	LEKR1	chr3:156544076-156763918:+	-0.36	-3.99	8.43E-5	Bone mineral density	
CESC	cis	1	rs6442117	chr3:48419897	TREX1	chr3:48501186-48509043:+	0.2	4.46	1.18E-5	Longevity	
CESC	cis	1	rs6442118	chr3:48440047	TREX1	chr3:48501186-48509043:+	-0.2	-4.44	1.28E-5	Longevity	
CESC	cis	1	rs6442119	chr3:48440178	TREX1	chr3:48501186-48509043:+	-0.21	-4.78	2.86E-6	Longevity	
CESC	cis	1	rs6442120	chr3:48464503	TREX1	chr3:48501186-48509043:+	-0.2	-4.5	1.03E-5	Longevity	
CESC	cis	1	rs6442123	chr3:48500286	TREX1	chr3:48501186-48509043:+	-0.18	-3.99	8.44E-5	Longevity	
CESC	cis	1	rs6450408	chr5:56098146	C5orf35	chr5:56205103-56213010:+	0.83	12.23	9.15E-28	Type 2 diabetes	
CESC	cis	1	rs6450409	chr5:56101399	C5orf35	chr5:56205103-56213010:+	0.81	12.76	1.33E-29	Type 2 diabetes	
CESC	cis	1	rs6454513	chr6:86720049	SNHG5	chr6:86386726-86388451:-	0.62	11.7	6.29E-26	Response to antipsychotic treatment	
CESC	cis	1	rs6458685	chr6:49379536	CENPQ	chr6:49431096-49460820:+	-0.41	-7.51	8.28E-13	Homocysteine levels	
CESC	cis	1	rs6458685	chr6:49379536	MUT	chr6:49398994-49431031:-	0.27	4.51	9.74E-6	Homocysteine levels	
CESC	cis	1	rs6458688	chr6:49406056	CENPQ	chr6:49431096-49460820:+	-0.42	-7.7	2.44E-13	Homocysteine levels	
CESC	cis	1	rs6458688	chr6:49406056	MUT	chr6:49398994-49431031:-	0.26	4.3	2.37E-5	Homocysteine levels	
CESC	cis	1	rs6458690	chr6:49411619	CENPQ	chr6:49431096-49460820:+	-0.24	-4.32	2.2E-5	Folate pathway vitamin levels	
CESC	cis	1	rs6458690	chr6:49411619	MUT	chr6:49398994-49431031:-	0.39	6.99	2.11E-11	Folate pathway vitamin levels	
CESC	cis	1	rs6458694	chr6:49445306	CENPQ	chr6:49431096-49460820:+	-0.26	-4.57	7.4E-6	Folate pathway vitamin levels	
CESC	cis	1	rs6458694	chr6:49445306	MUT	chr6:49398994-49431031:-	0.38	6.64	1.69E-10	Folate pathway vitamin levels	
CESC	cis	1	rs6460260	chr7:65215455	CCT6P1	chr7:65216092-65228661:+	-0.62	-5.84	1.47E-8	Diabetic kidney disease	
CESC	cis	1	rs6460261	chr7:65215580	CCT6P1	chr7:65216092-65228661:+	-0.62	-5.84	1.47E-8	Diabetic kidney disease	
CESC	cis	1	rs6460274	chr7:65628484	CCT6P1	chr7:65216092-65228661:+	-0.51	-4.78	2.88E-6	Diabetic kidney disease	
CESC	cis	1	rs6460292	chr7:65810075	NCRNA00174	chr7:65841032-65865395:-	0.26	3.97	9.16E-5	Aortic root size	
CESC	cis	1	rs6464573	chr7:143748098	ARHGEF35	chr7:143883677-143892736:-	0.48	6.03	5.19E-9	Obesity-related traits	
CESC	cis	1	rs6464574	chr7:143748257	ARHGEF35	chr7:143883677-143892736:-	-0.5	-6.01	5.98E-9	Obesity-related traits	
CESC	cis	1	rs646867	chr1:25709258	RHCE	chr1:25688741-25756683:-	0.33	4.71	4.0E-6	Erythrocyte sedimentation rate	
CESC	cis	1	rs646867	chr1:25709258	RHD	chr1:25598981-25656935:+	-0.34	-4.72	3.72E-6	Erythrocyte sedimentation rate	
CESC	cis	1	rs6470763	chr8:130720646	GSDMC	chr8:130760443-130799134:-	-0.22	-4.01	7.87E-5	Infant length;Height	
CESC	cis	1	rs6470764	chr8:130725665	GSDMC	chr8:130760443-130799134:-	0.28	4.97	1.15E-6	Infant length;Height	
CESC	cis	1	rs6470765	chr8:130736697	GSDMC	chr8:130760443-130799134:-	0.3	5.47	1.01E-7	Infant length;Height	
CESC	cis	1	rs6485438	chr11:43686618	HSD17B12	chr11:43702143-43878160:+	-0.38	-5.78	2.06E-8	Forced vital capacity	
CESC	cis	1	rs6485443	chr11:43696316	HSD17B12	chr11:43702143-43878160:+	0.37	5.67	3.53E-8	Forced vital capacity	
CESC	cis	1	rs6490604	chr13:21284828	IFT88	chr13:21141208-21265574:+	0.32	4.31	2.3E-5	Dental caries	
CESC	cis	1	rs6490606	chr13:21285096	IFT88	chr13:21141208-21265574:+	-0.29	-4.15	4.46E-5	Dental caries	
CESC	cis	1	rs6496609	chr15:90379632	AP3S2	chr15:90373832-90456222:-	-0.46	-5.56	6.26E-8	Type 2 diabetes	
CESC	cis	1	rs6503530	chr17:38161823	GSDMA	chr17:38119226-38134019:+	-0.32	-4.85	2.03E-6	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
CESC	cis	1	rs6503877	chr17:56841948	RAD51C	chr17:56769963-56811690:+	0.34	5.85	1.43E-8	Cognitive test performance	
CESC	cis	1	rs6503882	chr17:56915761	RAD51C	chr17:56769963-56811690:+	0.36	6.25	1.56E-9	Cognitive test performance	
CESC	cis	1	rs6519119	chr22:38989007	CBY1	chr22:39052658-39069853:+	0.27	4.28	2.62E-5	Resting heart rate	
CESC	cis	1	rs6519120	chr22:38991393	CBY1	chr22:39052658-39069853:+	-0.28	-4.6	6.46E-6	Resting heart rate	
CESC	cis	1	rs6532078	chr4:76920809	NAAA	chr4:76831809-76862166:-	-0.32	-4.3	2.37E-5	Longevity	
CESC	cis	1	rs6546835	chr2:73664715	ALMS1P	chr2:73872046-73912692:+	0.37	5.29	2.44E-7	Metabolite levels	
CESC	cis	1	rs6546836	chr2:73677833	ALMS1P	chr2:73872046-73912692:+	0.4	5.84	1.51E-8	Metabolite levels	
CESC	cis	1	rs6546837	chr2:73677898	ALMS1P	chr2:73872046-73912692:+	0.39	5.6	5.09E-8	Metabolite levels	
CESC	cis	1	rs6546838	chr2:73679280	ALMS1P	chr2:73872046-73912692:+	0.39	5.6	5.09E-8	Metabolite levels	
CESC	cis	1	rs6546839	chr2:73680508	ALMS1P	chr2:73872046-73912692:+	0.39	5.6	5.09E-8	Metabolite levels	
CESC	cis	1	rs656980	chr11:65656282	CTSW	chr11:65647284-65651212:+	-0.51	-10.54	4.92E-22	Crohn's disease	
CESC	cis	1	rs6579245	chr20:34125271	CPNE1	chr20:34213968-34262539:-	-0.55	-5.81	1.7E-8	Cholesterol, total	
CESC	cis	1	rs6579803	chr5:150255559	LOC134466	chr5:150310000-150326146:-	0.4	4.92	1.48E-6	Crohn's disease	
CESC	cis	1	rs6579804	chr5:150255931	LOC134466	chr5:150310000-150326146:-	0.4	4.92	1.48E-6	Crohn's disease	
CESC	cis	1	rs6579806	chr5:150271084	LOC134466	chr5:150310000-150326146:-	0.38	4.49	1.07E-5	Crohn's disease	
CESC	cis	1	rs6581155	chr12:58178162	FAM119B	chr12:58166383-58176323:+	0.39	5.23	3.43E-7	Multiple sclerosis	
CESC	cis	1	rs6581155	chr12:58178162	TSFM	chr12:58176536-58191367:+	-0.32	-5.5	8.83E-8	Multiple sclerosis	
CESC	cis	1	rs6599175	chr3:41786009	ULK4	chr3:41288091-42003660:-	-0.52	-7.78	1.43E-13	Diastolic blood pressure	
CESC	cis	1	rs6599176	chr3:41788492	ULK4	chr3:41288091-42003660:-	-0.47	-7.17	6.9E-12	Diastolic blood pressure	
CESC	cis	1	rs6599179	chr3:41855284	ULK4	chr3:41288091-42003660:-	0.48	7.73	2.04E-13	Diastolic blood pressure	
CESC	cis	1	rs66480668	chr2:166192960	GRB14	chr2:165349333-165478360:-	0.27	4.27	2.67E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures (MMR vaccine-related);Febrile seizures	
CESC	cis	1	rs6651255	chr8:130723792	GSDMC	chr8:130760443-130799134:-	-0.24	-4.58	7.07E-6	Infant length;Height	
CESC	cis	1	rs6656992	chr1:46333068	CCDC163P	chr1:45960581-45965646:-	-0.34	-5.6	5.29E-8	Body mass index	
CESC	cis	1	rs6656999	chr1:166956807	MAEL	chr1:166958519-166991447:+	-0.35	-4.7	4.12E-6	Refractive astigmatism	
CESC	cis	1	rs6661910	chr1:46290632	CCDC163P	chr1:45960581-45965646:-	-0.34	-5.56	6.35E-8	Body mass index	
CESC	cis	1	rs6662641	chr1:46571509	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.82	1.63E-8	Body mass index	
CESC	cis	1	rs6665341	chr1:166947018	MAEL	chr1:166958519-166991447:+	-0.34	-4.55	8.12E-6	Refractive astigmatism	
CESC	cis	1	rs6667191	chr1:45982844	CCDC163P	chr1:45960581-45965646:-	-0.8	-14.11	2.23E-34	Homocysteine levels	
CESC	cis	1	rs6668284	chr1:46354510	CCDC163P	chr1:45960581-45965646:-	-0.34	-5.59	5.52E-8	Body mass index	
CESC	cis	1	rs6669522	chr1:46397941	CCDC163P	chr1:45960581-45965646:-	-0.35	-5.6	5.26E-8	Body mass index	
CESC	cis	1	rs6671200	chr1:95697529	RWDD3	chr1:95583479-95712773:+	-0.53	-4.65	5.16E-6	Stearic acid (18:0) plasma levels	
CESC	cis	1	rs6672898	chr1:46290588	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.91	9.9E-9	Body mass index	
CESC	cis	1	rs66744607	chr12:51336491	TFCP2	chr12:51488608-51566917:-	-0.34	-4.14	4.7E-5	Type 2 diabetes	
CESC	cis	1	rs6674970	chr1:151116279	SEMA6C	chr1:151104165-151119104:-	-0.29	-4.89	1.7E-6	Body mass index	
CESC	cis	1	rs6675726	chr1:46560643	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.89	1.14E-8	Body mass index	
CESC	cis	1	rs6675946	chr1:46371774	CCDC163P	chr1:45960581-45965646:-	-0.34	-5.55	6.67E-8	Body mass index	
CESC	cis	1	rs6677007	chr1:46400590	CCDC163P	chr1:45960581-45965646:-	-0.35	-5.6	5.26E-8	Body mass index	
CESC	cis	1	rs6678964	chr1:95694268	RWDD3	chr1:95583479-95712773:+	0.53	4.65	5.16E-6	Stearic acid (18:0) plasma levels	
CESC	cis	1	rs6680380	chr1:46300189	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.91	9.9E-9	Body mass index	
CESC	cis	1	rs6682062	chr1:166949979	MAEL	chr1:166958519-166991447:+	0.35	4.72	3.75E-6	Refractive astigmatism	
CESC	cis	1	rs6688613	chr1:166951869	MAEL	chr1:166958519-166991447:+	0.34	4.43	1.38E-5	Refractive astigmatism	
CESC	cis	1	rs6692187	chr1:93035020	EVI5	chr1:92974255-93257961:-	-0.33	-3.95	0.0001	Cholesterol, total	
CESC	cis	1	rs6695162	chr1:166953455	MAEL	chr1:166958519-166991447:+	-0.34	-4.47	1.14E-5	Refractive astigmatism	
CESC	cis	1	rs6695809	chr1:46285461	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.9	1.09E-8	Body mass index	
CESC	cis	1	rs6699159	chr1:166946072	MAEL	chr1:166958519-166991447:+	-0.34	-4.55	8.12E-6	Refractive astigmatism	
CESC	cis	1	rs6699520	chr1:166955405	MAEL	chr1:166958519-166991447:+	-0.34	-4.43	1.38E-5	Refractive astigmatism	
CESC	cis	1	rs6700597	chr1:46284246	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.88	1.17E-8	Body mass index	
CESC	cis	1	rs6700718	chr1:21299363	UBXN10	chr1:20512578-20519941:+	-0.19	-3.98	8.85E-5	Superior frontal gyrus grey matter volume	
CESC	cis	1	rs6701614	chr1:46309420	CCDC163P	chr1:45960581-45965646:-	-0.35	-5.77	2.08E-8	Body mass index	
CESC	cis	1	rs6705489	chr2:73648811	ALMS1P	chr2:73872046-73912692:+	0.41	5.64	4.28E-8	Metabolite levels	
CESC	cis	1	rs6707722	chr2:73654363	ALMS1P	chr2:73872046-73912692:+	0.38	5.47	1.03E-7	Metabolite levels	
CESC	cis	1	rs6709534	chr2:217334	SH3YL1	chr2:218138-264810:-	-0.7	-11.34	1.06E-24	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs6710438	chr2:73820108	ALMS1P	chr2:73872046-73912692:+	-0.39	-5.35	1.87E-7	Metabolite levels	
CESC	cis	1	rs6711033	chr2:73746643	ALMS1P	chr2:73872046-73912692:+	0.39	5.53	7.27E-8	Metabolite levels	
CESC	cis	1	rs6711941	chr2:202178130	PPIL3	chr2:201735680-201753999:-	-0.48	-4.53	8.73E-6	Rheumatoid arthritis	
CESC	cis	1	rs6714736	chr2:202214148	ALS2CR12	chr2:202153148-202222101:-	0.33	4.37	1.75E-5	Basal cell carcinoma	
CESC	cis	1	rs6715284	chr2:202154397	PPIL3	chr2:201735680-201753999:-	-0.54	-5.55	6.85E-8	Rheumatoid arthritis	
CESC	cis	1	rs6715380	chr2:202214505	PPIL3	chr2:201735680-201753999:-	-0.52	-4.07	6.03E-5	Rheumatoid arthritis	
CESC	cis	1	rs6720809	chr2:88528943	THNSL2	chr2:88469835-88486145:+	-0.43	-4.2	3.55E-5	Plasma clusterin levels	
CESC	cis	1	rs6722069	chr2:88533151	THNSL2	chr2:88469835-88486145:+	-0.43	-4.21	3.48E-5	Plasma clusterin levels	
CESC	cis	1	rs67239267	chr7:143745116	ARHGEF35	chr7:143883677-143892736:-	-0.5	-6.32	1.06E-9	Obesity-related traits	
CESC	cis	1	rs6724782	chr2:73679990	ALMS1P	chr2:73872046-73912692:+	0.39	5.6	5.09E-8	Metabolite levels	
CESC	cis	1	rs67257959	chr19:17158145	HAUS8	chr19:17160573-17186343:-	-0.24	-4.02	7.45E-5	Selective IgA deficiency	
CESC	cis	1	rs6732236	chr2:136501509	LCT	chr2:136545415-136594750:-	-0.35	-4.35	1.91E-5	Corneal structure	
CESC	cis	1	rs6736866	chr2:73661986	ALMS1P	chr2:73872046-73912692:+	0.43	5.6	5.11E-8	Metabolite levels	
CESC	cis	1	rs6737085	chr2:202221441	ALS2CR12	chr2:202153148-202222101:-	-0.3	-4.08	5.96E-5	Basal cell carcinoma	
CESC	cis	1	rs6740223	chr2:73653332	ALMS1P	chr2:73872046-73912692:+	0.38	5.47	1.03E-7	Metabolite levels	
CESC	cis	1	rs6742276	chr2:61768745	AHSA2	chr2:61404553-61414058:+	-0.22	-4.12	4.97E-5	Tuberculosis	
CESC	cis	1	rs6742276	chr2:61768745	C2orf74	chr2:61372243-61391964:+	0.37	4.92	1.51E-6	Tuberculosis	
CESC	cis	1	rs674433	chr1:209964875	C1orf133	chr1:210404804-210407466:-	0.27	4.16	4.19E-5	Orofacial clefts	
CESC	cis	1	rs6745368	chr2:73809974	ALMS1P	chr2:73872046-73912692:+	0.4	5.57	6.16E-8	Metabolite levels	
CESC	cis	1	rs6753344	chr2:73653138	ALMS1P	chr2:73872046-73912692:+	-0.38	-5.18	4.2E-7	Metabolite levels	
CESC	cis	1	rs67536397	chr7:65947917	CCT6P1	chr7:65216092-65228661:+	0.57	5.28	2.57E-7	Diabetic kidney disease	
CESC	cis	1	rs67536397	chr7:65947917	LOC493754	chr7:65993446-66057363:-	0.51	3.98	8.67E-5	Diabetic kidney disease	
CESC	cis	1	rs6755217	chr2:73641285	ALMS1P	chr2:73872046-73912692:+	0.37	4.98	1.14E-6	Metabolite levels	
CESC	cis	1	rs6755241	chr2:73641364	ALMS1P	chr2:73872046-73912692:+	0.39	5.36	1.79E-7	Metabolite levels	
CESC	cis	1	rs6756987	chr2:73687077	ALMS1P	chr2:73872046-73912692:+	0.38	5.46	1.05E-7	Metabolite levels	
CESC	cis	1	rs6759004	chr2:202004676	PPIL3	chr2:201735680-201753999:-	-0.66	-7.19	5.99E-12	Triptolide cytotoxicity	
CESC	cis	1	rs6761514	chr2:202227549	ALS2CR12	chr2:202153148-202222101:-	-0.32	-4.41	1.5E-5	Basal cell carcinoma	
CESC	cis	1	rs6763088	chr3:134254989	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.35	1.95E-5	Height	
CESC	cis	1	rs6763093	chr3:134254995	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.35	1.95E-5	Height	
CESC	cis	1	rs6763829	chr3:41897046	ULK4	chr3:41288091-42003660:-	0.51	8.24	6.95E-15	Diastolic blood pressure	
CESC	cis	1	rs6768128	chr3:41865080	ULK4	chr3:41288091-42003660:-	0.45	6.7	1.16E-10	Diastolic blood pressure	
CESC	cis	1	rs6768542	chr3:41865474	ULK4	chr3:41288091-42003660:-	0.45	6.68	1.35E-10	Diastolic blood pressure	
CESC	cis	1	rs6768563	chr3:41865541	ULK4	chr3:41288091-42003660:-	0.45	6.68	1.35E-10	Diastolic blood pressure	
CESC	cis	1	rs6769885	chr3:134286913	ANAPC13	chr3:134196547-134204865:-	0.32	4.25	2.89E-5	Height	
CESC	cis	1	rs6770470	chr3:48435123	TREX1	chr3:48501186-48509043:+	-0.19	-4.25	2.9E-5	Longevity	
CESC	cis	1	rs67728539	chr7:65378124	CCT6P1	chr7:65216092-65228661:+	0.45	4.32	2.14E-5	Diabetic kidney disease	
CESC	cis	1	rs6772896	chr3:134203347	ANAPC13	chr3:134196547-134204865:-	0.34	4.48	1.1E-5	Height	
CESC	cis	1	rs6776700	chr3:48496758	TREX1	chr3:48501186-48509043:+	-0.2	-4.3	2.39E-5	Longevity	
CESC	cis	1	rs6781326	chr3:41777028	ULK4	chr3:41288091-42003660:-	0.52	8.06	2.43E-14	Diastolic blood pressure	
CESC	cis	1	rs6782563	chr3:134295959	ANAPC13	chr3:134196547-134204865:-	-0.3	-4.04	6.84E-5	Height	
CESC	cis	1	rs6783001	chr3:41862232	ULK4	chr3:41288091-42003660:-	0.5	7.95	4.94E-14	Diastolic blood pressure	
CESC	cis	1	rs6783003	chr3:49524778	WDR6	chr3:49044637-49053386:+	0.28	4.49	1.03E-5	Menarche (age at onset)	
CESC	cis	1	rs6784322	chr3:48422235	TREX1	chr3:48501186-48509043:+	-0.2	-4.45	1.25E-5	Longevity	
CESC	cis	1	rs6789260	chr3:41776350	ULK4	chr3:41288091-42003660:-	0.39	5.03	8.74E-7	Diastolic blood pressure	
CESC	cis	1	rs6790466	chr3:134197740	ANAPC13	chr3:134196547-134204865:-	0.33	4.36	1.87E-5	Height	
CESC	cis	1	rs6790732	chr3:41864872	ULK4	chr3:41288091-42003660:-	0.5	8.05	2.45E-14	Diastolic blood pressure	
CESC	cis	1	rs6791806	chr3:41889995	ULK4	chr3:41288091-42003660:-	0.51	8.19	1.02E-14	Diastolic blood pressure	
CESC	cis	1	rs6793487	chr3:134299426	ANAPC13	chr3:134196547-134204865:-	-0.3	-4.04	6.84E-5	Height	
CESC	cis	1	rs6794875	chr3:48455626	TREX1	chr3:48501186-48509043:+	-0.19	-4.3	2.39E-5	Longevity	
CESC	cis	1	rs6796491	chr3:48430465	TREX1	chr3:48501186-48509043:+	-0.2	-4.44	1.28E-5	Longevity	
CESC	cis	1	rs6802340	chr3:41894034	ULK4	chr3:41288091-42003660:-	0.51	8.19	1.02E-14	Diastolic blood pressure	
CESC	cis	1	rs6803560	chr3:41824480	ULK4	chr3:41288091-42003660:-	0.51	8.11	1.65E-14	Diastolic blood pressure	
CESC	cis	1	rs6803652	chr3:41824556	ULK4	chr3:41288091-42003660:-	0.51	8.11	1.65E-14	Diastolic blood pressure	
CESC	cis	1	rs6804770	chr3:134230234	ANAPC13	chr3:134196547-134204865:-	0.3	4.03	7.12E-5	Height	
CESC	cis	1	rs6804774	chr3:48430617	TREX1	chr3:48501186-48509043:+	-0.19	-4.39	1.63E-5	Longevity	
CESC	cis	1	rs6805880	chr3:41865397	ULK4	chr3:41288091-42003660:-	0.45	6.68	1.35E-10	Diastolic blood pressure	
CESC	cis	1	rs680923	chr1:209986672	C1orf133	chr1:210404804-210407466:-	-0.28	-4.07	6.19E-5	Orofacial clefts	
CESC	cis	1	rs6810060	chr3:48434748	TREX1	chr3:48501186-48509043:+	-0.19	-4.25	2.9E-5	Longevity	
CESC	cis	1	rs68171315	chr6:86707400	SNHG5	chr6:86386726-86388451:-	-0.6	-9.55	7.48E-19	Response to antipsychotic treatment	
CESC	cis	1	rs68189316	chr7:65409169	CCT6P1	chr7:65216092-65228661:+	0.51	5	1.04E-6	Diabetic kidney disease	
CESC	cis	1	rs6827617	chr4:76916146	NAAA	chr4:76831809-76862166:-	-0.32	-4.26	2.77E-5	Longevity	
CESC	cis	1	rs6862814	chr5:150245259	LOC134466	chr5:150310000-150326146:-	0.4	4.92	1.46E-6	Crohn's disease	
CESC	cis	1	rs6874560	chr5:150182713	LOC134466	chr5:150310000-150326146:-	0.7	6.39	7.04E-10	Crohn's disease	
CESC	cis	1	rs6875011	chr5:150182710	LOC134466	chr5:150310000-150326146:-	0.52	5.23	3.3E-7	Crohn's disease	
CESC	cis	1	rs687672	chr11:65649984	CTSW	chr11:65647284-65651212:+	0.5	9.88	6.52E-20	Crohn's disease	
CESC	cis	1	rs6885541	chr5:56110857	C5orf35	chr5:56205103-56213010:+	0.81	11.67	7.96E-26	Type 2 diabetes	
CESC	cis	1	rs6902429	chr6:49393500	CENPQ	chr6:49431096-49460820:+	-0.41	-7.65	3.29E-13	Homocysteine levels	
CESC	cis	1	rs6902429	chr6:49393500	MUT	chr6:49398994-49431031:-	0.27	4.49	1.06E-5	Homocysteine levels	
CESC	cis	1	rs6910233	chr6:33534726	BAK1	chr6:33540324-33548070:-	0.24	4.23	3.25E-5	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
CESC	cis	1	rs6914463	chr6:86653415	SNHG5	chr6:86386726-86388451:-	-0.61	-11.38	7.34E-25	Response to antipsychotic treatment	
CESC	cis	1	rs6915187	chr6:49423547	CENPQ	chr6:49431096-49460820:+	-0.41	-7.71	2.25E-13	Homocysteine levels	
CESC	cis	1	rs6915187	chr6:49423547	MUT	chr6:49398994-49431031:-	0.27	4.58	7.06E-6	Homocysteine levels	
CESC	cis	1	rs6916888	chr6:49383804	CENPQ	chr6:49431096-49460820:+	-0.41	-7.65	3.29E-13	Homocysteine levels	
CESC	cis	1	rs6916888	chr6:49383804	MUT	chr6:49398994-49431031:-	0.27	4.49	1.06E-5	Homocysteine levels	
CESC	cis	1	rs6918347	chr6:49406348	CENPQ	chr6:49431096-49460820:+	-0.41	-7.8	1.26E-13	Homocysteine levels	
CESC	cis	1	rs6918347	chr6:49406348	MUT	chr6:49398994-49431031:-	0.26	4.41	1.47E-5	Homocysteine levels	
CESC	cis	1	rs6923124	chr6:49419864	CENPQ	chr6:49431096-49460820:+	-0.24	-4.18	3.88E-5	Folate pathway vitamin levels	
CESC	cis	1	rs6923124	chr6:49419864	MUT	chr6:49398994-49431031:-	0.41	7.37	1.97E-12	Folate pathway vitamin levels	
CESC	cis	1	rs6923148	chr6:86767786	SNHG5	chr6:86386726-86388451:-	0.59	10.99	1.53E-23	Response to antipsychotic treatment	
CESC	cis	1	rs6927188	chr6:42912589	GNMT	chr6:42928500-42931617:+	0.38	5.07	7.34E-7	Diabetic kidney disease	
CESC	cis	1	rs6927188	chr6:42912589	PEX6	chr6:42931613-42946981:-	-0.61	-7.17	6.91E-12	Diabetic kidney disease	
CESC	cis	1	rs6930076	chr6:88088654	C6orf162	chr6:88032306-88052043:+	-0.26	-4.15	4.39E-5	Depressive episodes in bipolar disorder	
CESC	cis	1	rs6933377	chr6:86705255	SNHG5	chr6:86386726-86388451:-	0.43	7.26	4.03E-12	Response to antipsychotic treatment	
CESC	cis	1	rs6936048	chr6:86702608	SNHG5	chr6:86386726-86388451:-	-0.56	-8.77	1.9E-16	Response to antipsychotic treatment	
CESC	cis	1	rs693824	chr11:65654783	CTSW	chr11:65647284-65651212:+	-0.51	-10.54	4.92E-22	Crohn's disease	
CESC	cis	1	rs6940458	chr6:86644992	SNHG5	chr6:86386726-86388451:-	-0.57	-9.02	3.37E-17	Response to antipsychotic treatment	
CESC	cis	1	rs6945843	chr7:65734783	NCRNA00174	chr7:65841032-65865395:-	0.26	4.02	7.56E-5	Aortic root size	
CESC	cis	1	rs6949812	chr7:65387101	CCT6P1	chr7:65216092-65228661:+	0.52	5.01	9.6E-7	Diabetic kidney disease	
CESC	cis	1	rs694994	chr11:65653309	CTSW	chr11:65647284-65651212:+	-0.52	-10.67	1.8E-22	Crohn's disease	
CESC	cis	1	rs6958289	chr7:65657111	CCT6P1	chr7:65216092-65228661:+	-0.51	-4.76	3.19E-6	Diabetic kidney disease	
CESC	cis	1	rs6958420	chr7:65751171	CCT6P1	chr7:65216092-65228661:+	-0.54	-5.06	7.72E-7	Diabetic kidney disease	
CESC	cis	1	rs6958420	chr7:65751171	LOC493754	chr7:65993446-66057363:-	-0.53	-4.17	4.17E-5	Diabetic kidney disease	
CESC	cis	1	rs6958484	chr7:65599446	NCRNA00174	chr7:65841032-65865395:-	0.26	3.99	8.33E-5	Aortic root size	
CESC	cis	1	rs6959002	chr7:65650496	CCT6P1	chr7:65216092-65228661:+	-0.51	-4.76	3.19E-6	Diabetic kidney disease	
CESC	cis	1	rs6961717	chr7:65587537	NCRNA00174	chr7:65841032-65865395:-	0.26	3.98	8.68E-5	Aortic root size	
CESC	cis	1	rs6963646	chr7:65685767	NCRNA00174	chr7:65841032-65865395:-	0.26	4.09	5.61E-5	Aortic root size	
CESC	cis	1	rs6964245	chr7:65718717	CCT6P1	chr7:65216092-65228661:+	-0.54	-5.06	7.72E-7	Diabetic kidney disease	
CESC	cis	1	rs6964245	chr7:65718717	LOC493754	chr7:65993446-66057363:-	-0.53	-4.17	4.17E-5	Diabetic kidney disease	
CESC	cis	1	rs6964530	chr7:65718851	CCT6P1	chr7:65216092-65228661:+	-0.54	-5.07	7.34E-7	Diabetic kidney disease	
CESC	cis	1	rs6964530	chr7:65718851	LOC493754	chr7:65993446-66057363:-	-0.54	-4.3	2.37E-5	Diabetic kidney disease	
CESC	cis	1	rs6966322	chr7:65646754	CCT6P1	chr7:65216092-65228661:+	-0.51	-4.76	3.19E-6	Diabetic kidney disease	
CESC	cis	1	rs6970243	chr7:65388490	CCT6P1	chr7:65216092-65228661:+	0.51	5	1.04E-6	Diabetic kidney disease	
CESC	cis	1	rs6970597	chr7:21583519	DNAH11	chr7:21582833-21941455:+	-0.52	-7.58	5.24E-13	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
CESC	cis	1	rs6970985	chr7:21583597	DNAH11	chr7:21582833-21941455:+	-0.53	-7.68	2.77E-13	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
CESC	cis	1	rs6974373	chr7:99590893	TRIM4	chr7:99488037-99517154:-	-0.33	-4.87	1.89E-6	Interstitial lung disease	
CESC	cis	1	rs6974723	chr7:65637939	CCT6P1	chr7:65216092-65228661:+	-0.51	-4.78	2.88E-6	Diabetic kidney disease	
CESC	cis	1	rs6986256	chr8:130728361	GSDMC	chr8:130760443-130799134:-	0.29	5.31	2.3E-7	Infant length;Height	
CESC	cis	1	rs7007450	chr8:71640269	XKR9	chr8:71581600-71648176:+	0.94	16.81	4.01E-44	Bone mineral density	
CESC	cis	1	rs7017914	chr8:71591203	XKR9	chr8:71581600-71648176:+	0.94	16.47	6.79E-43	Bone mineral density	
CESC	cis	1	rs7022397	chr9:116007677	CDC26	chr9:116029290-116037869:-	-0.36	-5.36	1.77E-7	Hematology traits	
CESC	cis	1	rs703842	chr12:58162739	FAM119B	chr12:58166383-58176323:+	-0.39	-5.29	2.53E-7	Multiple sclerosis	
CESC	cis	1	rs703842	chr12:58162739	TSFM	chr12:58176536-58191367:+	0.31	5.44	1.16E-7	Multiple sclerosis	
CESC	cis	1	rs7038769	chr9:116007583	CDC26	chr9:116029290-116037869:-	-0.36	-5.36	1.77E-7	Hematology traits	
CESC	cis	1	rs7045881	chr9:26935996	IFT74	chr9:26947037-27062923:+	0.51	4.4	1.56E-5	Schizophrenia	
CESC	cis	1	rs705696	chr12:56480648	RPS26	chr12:56435686-56438005:+	0.52	8.38	2.79E-15	Cognitive function	
CESC	cis	1	rs7072216	chr10:100156853	PYROXD2	chr10:100143323-100174978:-	0.39	6.47	4.38E-10	Metabolite levels	
CESC	cis	1	rs708152	chr11:2384348	C11orf21	chr11:2317507-2323143:-	-0.25	-4.29	2.45E-5	Bacteremia	
CESC	cis	1	rs709592	chr17:38175553	GSDMA	chr17:38119226-38134019:+	-0.32	-4.9	1.6E-6	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
CESC	cis	1	rs7111	chr15:90373873	AP3S2	chr15:90373832-90456222:-	-0.44	-5.31	2.25E-7	Type 2 diabetes	
CESC	cis	1	rs7115737	chr11:43681249	HSD17B12	chr11:43702143-43878160:+	-0.36	-5.41	1.4E-7	Forced vital capacity	
CESC	cis	1	rs71327718	chr3:125592857	ALG1L	chr3:125648118-125655882:-	-0.35	-4.35	1.95E-5	Metabolite levels (HVA/5-HIAA ratio)	
CESC	cis	1	rs7144423	chr14:35572547	PPP2R3C	chr14:35554679-35591679:-	0.48	5.29	2.5E-7	Atopic dermatitis	
CESC	cis	1	rs7153160	chr14:74509377	LIN52	chr14:74551656-74667117:+	0.41	7.94	5.15E-14	Common traits (Other)	
CESC	cis	1	rs7153587	chr14:74509660	LIN52	chr14:74551656-74667117:+	0.42	8.29	5.04E-15	Common traits (Other)	
CESC	cis	1	rs7154306	chr14:35540499	PPP2R3C	chr14:35554679-35591679:-	0.49	5.36	1.72E-7	Atopic dermatitis	
CESC	cis	1	rs7156322	chr14:35544330	PPP2R3C	chr14:35554679-35591679:-	0.48	5.32	2.14E-7	Atopic dermatitis	
CESC	cis	1	rs7157566	chr14:74649129	LIN52	chr14:74551656-74667117:+	-0.4	-7.84	1.02E-13	Common traits (Other)	
CESC	cis	1	rs7157940	chr14:94563193	IFI27L1	chr14:94547639-94569059:+	0.41	6.7	1.18E-10	Anthropometric traits	
CESC	cis	1	rs71654417	chr1:95661200	RWDD3	chr1:95583479-95712773:+	0.62	5.06	7.61E-7	Stearic acid (18:0) plasma levels	
CESC	cis	1	rs71654418	chr1:95662658	RWDD3	chr1:95583479-95712773:+	0.62	5.06	7.61E-7	Stearic acid (18:0) plasma levels	
CESC	cis	1	rs71654419	chr1:95664497	RWDD3	chr1:95583479-95712773:+	0.62	5.06	7.61E-7	Stearic acid (18:0) plasma levels	
CESC	cis	1	rs7196911	chr16:68587243	NIP7	chr16:69373546-69377007:+	0.3	4.09	5.62E-5	Response to antipsychotic treatment in schizophrenia (reasoning);HIV-1 viral setpoint	
CESC	cis	1	rs720475	chr7:144074929	OR2A7	chr7:143955790-143974852:-	-0.36	-4.46	1.2E-5	Breast cancer	
CESC	cis	1	rs7205409	chr16:642610	WFIKKN1	chr16:679239-684116:+	0.33	5.08	7.08E-7	Height	
CESC	cis	1	rs7209180	chr17:79581519	TSPAN10	chr17:79609349-79615778:+	0.4	6.31	1.1E-9	Eye color traits	
CESC	cis	1	rs7209675	chr17:65831258	LOC651250	chr17:66097696-66157623:+	-0.28	-4.07	6.07E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs7213129	chr17:79581573	TSPAN10	chr17:79609349-79615778:+	0.4	6.31	1.1E-9	Eye color traits	
CESC	cis	1	rs7214085	chr17:38169095	GSDMA	chr17:38119226-38134019:+	-0.31	-4.85	2.09E-6	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
CESC	cis	1	rs7214758	chr17:65880538	LOC651250	chr17:66097696-66157623:+	-0.31	-4.08	5.89E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs7216064	chr17:65898809	LOC651250	chr17:66097696-66157623:+	-0.32	-4.22	3.28E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs7218362	chr17:56888299	RAD51C	chr17:56769963-56811690:+	0.34	6	6.18E-9	Cognitive test performance	
CESC	cis	1	rs7219014	chr17:37624790	PGAP3	chr17:37827376-37844310:-	-0.23	-4.06	6.44E-5	Urinary metabolites	
CESC	cis	1	rs7222241	chr17:79574714	TSPAN10	chr17:79609349-79615778:+	0.41	6.39	7.18E-10	Eye color traits	
CESC	cis	1	rs7223613	chr17:79574803	TSPAN10	chr17:79609349-79615778:+	-0.4	-6.31	1.1E-9	Eye color traits	
CESC	cis	1	rs7223813	chr17:65945840	LOC651250	chr17:66097696-66157623:+	-0.32	-4.2	3.55E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs7224923	chr17:65842265	LOC651250	chr17:66097696-66157623:+	-0.31	-3.99	8.36E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs725309	chr3:48418708	TREX1	chr3:48501186-48509043:+	0.19	4.4	1.53E-5	Longevity	
CESC	cis	1	rs725310	chr3:48418571	TREX1	chr3:48501186-48509043:+	0.21	4.92	1.49E-6	Longevity	
CESC	cis	1	rs7255679	chr19:42063981	CEACAM21	chr19:42055886-42093196:+	0.51	7.63	3.8E-13	Schizophrenia	
CESC	cis	1	rs72627120	chr14:74363480	PTGR2	chr14:74318534-74352166:+	0.36	3.98	8.68E-5	Morning vs. evening chronotype	
CESC	cis	1	rs72627122	chr14:74368236	PTGR2	chr14:74318534-74352166:+	0.37	4.01	7.96E-5	Morning vs. evening chronotype	
CESC	cis	1	rs72627123	chr14:74368331	PTGR2	chr14:74318534-74352166:+	0.37	4.01	7.96E-5	Morning vs. evening chronotype	
CESC	cis	1	rs72627124	chr14:74369128	PTGR2	chr14:74318534-74352166:+	0.37	4.01	7.96E-5	Morning vs. evening chronotype	
CESC	cis	1	rs72627125	chr14:74369623	PTGR2	chr14:74318534-74352166:+	0.37	4.01	7.96E-5	Morning vs. evening chronotype	
CESC	cis	1	rs72627126	chr14:74370024	PTGR2	chr14:74318534-74352166:+	0.37	4.01	7.96E-5	Morning vs. evening chronotype	
CESC	cis	1	rs72627127	chr14:74370098	PTGR2	chr14:74318534-74352166:+	0.37	4.01	7.96E-5	Morning vs. evening chronotype	
CESC	cis	1	rs72644211	chr10:81781695	LOC219347	chr10:81805991-81838949:-	0.47	4.17	4.05E-5	Chronic obstructive pulmonary disease-related biomarkers	
CESC	cis	1	rs72644212	chr10:81782514	LOC219347	chr10:81805991-81838949:-	0.43	4.02	7.57E-5	Chronic obstructive pulmonary disease-related biomarkers	
CESC	cis	1	rs72802204	chr5:151183183	ATOX1	chr5:151122384-151138210:-	-0.22	-3.96	9.45E-5	Preschool internalizing problems	
CESC	cis	1	rs72802204	chr5:151183183	SLC36A1	chr5:150816553-150871939:+	-0.29	-4.01	7.96E-5	Preschool internalizing problems	
CESC	cis	1	rs72819593	chr17:2199489	SRR	chr17:2207248-2228553:+	-0.38	-4.9	1.62E-6	Esophageal cancer (squamous cell)	
CESC	cis	1	rs72843784	chr6:26498758	BTN3A2	chr6:26365398-26378546:+	-0.69	-5.2	3.86E-7	Schizophrenia	
CESC	cis	1	rs7285549	chr22:25874580	CRYBB2	chr22:25615612-25627836:+	0.85	9.22	8.25E-18	Bipolar disorder with mood-incongruent psychosis	
CESC	cis	1	rs728615	chr10:81848089	PLAC9	chr10:81892258-81904784:+	-0.45	-5.6	5.16E-8	Chronic obstructive pulmonary disease-related biomarkers	
CESC	cis	1	rs728616	chr10:81847914	PLAC9	chr10:81892258-81904784:+	-0.44	-5.52	7.94E-8	Chronic obstructive pulmonary disease-related biomarkers	
CESC	cis	1	rs7289577	chr22:39042214	CBY1	chr22:39052658-39069853:+	0.25	4.11	5.23E-5	Resting heart rate	
CESC	cis	1	rs7289855	chr22:39042221	CBY1	chr22:39052658-39069853:+	0.25	3.99	8.38E-5	Resting heart rate	
CESC	cis	1	rs72934999	chr2:202223524	PPIL3	chr2:201735680-201753999:-	-0.51	-3.96	9.74E-5	Rheumatoid arthritis	
CESC	cis	1	rs72937106	chr2:202225520	PPIL3	chr2:201735680-201753999:-	-0.51	-3.96	9.74E-5	Rheumatoid arthritis	
CESC	cis	1	rs72937118	chr2:202229527	PPIL3	chr2:201735680-201753999:-	-0.51	-3.96	9.74E-5	Rheumatoid arthritis	
CESC	cis	1	rs7300362	chr12:16412845	MGST1	chr12:16500076-16523342:+	-0.29	-4.02	7.56E-5	Visceral fat	
CESC	cis	1	rs73069392	chr3:41787009	ULK4	chr3:41288091-42003660:-	0.44	5.54	7.21E-8	Diastolic blood pressure	
CESC	cis	1	rs73069394	chr3:41787233	ULK4	chr3:41288091-42003660:-	0.53	8.02	3.09E-14	Diastolic blood pressure	
CESC	cis	1	rs73069396	chr3:41787236	ULK4	chr3:41288091-42003660:-	0.53	8.02	3.09E-14	Diastolic blood pressure	
CESC	cis	1	rs73071329	chr3:41810539	ULK4	chr3:41288091-42003660:-	0.49	7.31	2.96E-12	Diastolic blood pressure	
CESC	cis	1	rs73074358	chr3:48427247	TREX1	chr3:48501186-48509043:+	-0.2	-4.44	1.28E-5	Longevity	
CESC	cis	1	rs73077367	chr3:41851959	ULK4	chr3:41288091-42003660:-	0.46	6.93	3.02E-11	Diastolic blood pressure	
CESC	cis	1	rs73079316	chr3:41863859	ULK4	chr3:41288091-42003660:-	0.39	5.13	5.41E-7	Diastolic blood pressure	
CESC	cis	1	rs73079321	chr3:41863910	ULK4	chr3:41288091-42003660:-	0.46	7.07	1.26E-11	Diastolic blood pressure	
CESC	cis	1	rs73081353	chr3:41906448	ULK4	chr3:41288091-42003660:-	0.4	5.25	2.98E-7	Diastolic blood pressure	
CESC	cis	1	rs73081364	chr3:41913616	ULK4	chr3:41288091-42003660:-	0.4	5.25	2.98E-7	Diastolic blood pressure	
CESC	cis	1	rs73090629	chr12:51335777	TFCP2	chr12:51488608-51566917:-	-0.35	-3.99	8.32E-5	Type 2 diabetes	
CESC	cis	1	rs73090649	chr12:51349641	TFCP2	chr12:51488608-51566917:-	-0.36	-4.07	6.22E-5	Type 2 diabetes	
CESC	cis	1	rs73092531	chr12:51357987	TFCP2	chr12:51488608-51566917:-	-0.36	-4.09	5.72E-5	Type 2 diabetes	
CESC	cis	1	rs73092537	chr12:51358517	TFCP2	chr12:51488608-51566917:-	-0.35	-4.05	6.64E-5	Type 2 diabetes	
CESC	cis	1	rs73142121	chr7:65311206	CCT6P1	chr7:65216092-65228661:+	0.5	4.96	1.23E-6	Diabetic kidney disease	
CESC	cis	1	rs73142122	chr7:65311298	CCT6P1	chr7:65216092-65228661:+	0.55	5.34	1.91E-7	Diabetic kidney disease	
CESC	cis	1	rs73142162	chr7:65374296	CCT6P1	chr7:65216092-65228661:+	0.6	5.73	2.7E-8	Diabetic kidney disease	
CESC	cis	1	rs73142166	chr7:65375832	CCT6P1	chr7:65216092-65228661:+	0.6	5.64	4.13E-8	Diabetic kidney disease	
CESC	cis	1	rs73150014	chr7:65450919	CCT6P1	chr7:65216092-65228661:+	0.56	5.46	1.05E-7	Diabetic kidney disease	
CESC	cis	1	rs73221372	chr12:120899189	GCN1L1	chr12:120565016-120632513:-	-0.54	-4.51	9.52E-6	Insulin resistance/response	
CESC	cis	1	rs73221372	chr12:120899189	RAB35	chr12:120532904-120554599:-	-0.56	-4.38	1.67E-5	Insulin resistance/response	
CESC	cis	1	rs73221372	chr12:120899189	RNF10	chr12:120972132-121015396:+	-0.68	-3.99	8.59E-5	Insulin resistance/response	
CESC	cis	1	rs73221372	chr12:120899189	RNF34	chr12:121837902-121868389:+	-0.65	-4.11	5.18E-5	Insulin resistance/response	
CESC	cis	1	rs73221373	chr12:120901045	GCN1L1	chr12:120565016-120632513:-	-0.54	-4.51	9.52E-6	Insulin resistance/response	
CESC	cis	1	rs73221373	chr12:120901045	RAB35	chr12:120532904-120554599:-	-0.56	-4.38	1.67E-5	Insulin resistance/response	
CESC	cis	1	rs73221373	chr12:120901045	RNF10	chr12:120972132-121015396:+	-0.68	-3.99	8.59E-5	Insulin resistance/response	
CESC	cis	1	rs73221373	chr12:120901045	RNF34	chr12:121837902-121868389:+	-0.65	-4.11	5.18E-5	Insulin resistance/response	
CESC	cis	1	rs73221378	chr12:120910521	GCN1L1	chr12:120565016-120632513:-	-0.54	-4.51	9.52E-6	Insulin resistance/response	
CESC	cis	1	rs73221378	chr12:120910521	RAB35	chr12:120532904-120554599:-	-0.56	-4.38	1.67E-5	Insulin resistance/response	
CESC	cis	1	rs73221378	chr12:120910521	RNF10	chr12:120972132-121015396:+	-0.68	-3.99	8.59E-5	Insulin resistance/response	
CESC	cis	1	rs73221378	chr12:120910521	RNF34	chr12:121837902-121868389:+	-0.65	-4.11	5.18E-5	Insulin resistance/response	
CESC	cis	1	rs73221381	chr12:120913895	GCN1L1	chr12:120565016-120632513:-	-0.52	-4.22	3.34E-5	Insulin resistance/response	
CESC	cis	1	rs73221382	chr12:120917765	GCN1L1	chr12:120565016-120632513:-	-0.52	-4.22	3.34E-5	Insulin resistance/response	
CESC	cis	1	rs73225208	chr12:120932576	GCN1L1	chr12:120565016-120632513:-	-0.52	-4.22	3.34E-5	Insulin resistance/response	
CESC	cis	1	rs73225218	chr12:120952310	GCN1L1	chr12:120565016-120632513:-	-0.52	-4.22	3.34E-5	Insulin resistance/response	
CESC	cis	1	rs73225225	chr12:120960474	GCN1L1	chr12:120565016-120632513:-	-0.52	-4.22	3.34E-5	Insulin resistance/response	
CESC	cis	1	rs73225238	chr12:120967488	GCN1L1	chr12:120565016-120632513:-	-0.52	-4.22	3.34E-5	Insulin resistance/response	
CESC	cis	1	rs73225245	chr12:120970633	GCN1L1	chr12:120565016-120632513:-	-0.52	-4.22	3.34E-5	Insulin resistance/response	
CESC	cis	1	rs73225248	chr12:120971517	GCN1L1	chr12:120565016-120632513:-	-0.52	-4.22	3.34E-5	Insulin resistance/response	
CESC	cis	1	rs73230306	chr12:120985336	GCN1L1	chr12:120565016-120632513:-	-0.52	-4.22	3.34E-5	Insulin resistance/response	
CESC	cis	1	rs73230308	chr12:120986986	GCN1L1	chr12:120565016-120632513:-	-0.52	-4.22	3.34E-5	Insulin resistance/response	
CESC	cis	1	rs73230318	chr12:120997937	GCN1L1	chr12:120565016-120632513:-	-0.52	-4.22	3.34E-5	Insulin resistance/response	
CESC	cis	1	rs73230322	chr12:121010885	GCN1L1	chr12:120565016-120632513:-	-0.52	-4.2	3.65E-5	Insulin resistance/response	
CESC	cis	1	rs73230328	chr12:121019639	GCN1L1	chr12:120565016-120632513:-	-0.53	-4.31	2.27E-5	Insulin resistance/response	
CESC	cis	1	rs73282209	chr5:150174959	LOC134466	chr5:150310000-150326146:-	0.53	5.63	4.35E-8	Crohn's disease	
CESC	cis	1	rs73282234	chr5:150195924	IRGM	chr5:150226085-150280295:+	0.42	4.1	5.35E-5	Crohn's disease	
CESC	cis	1	rs73282234	chr5:150195924	LOC134466	chr5:150310000-150326146:-	0.54	5.19	4.1E-7	Crohn's disease	
CESC	cis	1	rs73282255	chr5:150223647	LOC134466	chr5:150310000-150326146:-	0.42	4.82	2.35E-6	Crohn's disease	
CESC	cis	1	rs73284126	chr5:150261307	LOC134466	chr5:150310000-150326146:-	0.4	4.73	3.64E-6	Crohn's disease	
CESC	cis	1	rs73284141	chr5:150266086	LOC134466	chr5:150310000-150326146:-	0.4	4.73	3.64E-6	Crohn's disease	
CESC	cis	1	rs7371896	chr3:134249769	ANAPC13	chr3:134196547-134204865:-	0.3	3.97	9.21E-5	Height	
CESC	cis	1	rs7374158	chr3:134270156	ANAPC13	chr3:134196547-134204865:-	0.3	4.05	6.69E-5	Height	
CESC	cis	1	rs7374325	chr3:134275601	ANAPC13	chr3:134196547-134204865:-	0.3	3.96	9.6E-5	Height	
CESC	cis	1	rs73958618	chr2:136500475	LCT	chr2:136545415-136594750:-	-0.36	-4.36	1.86E-5	Corneal structure	
CESC	cis	1	rs7397068	chr12:51401904	TFCP2	chr12:51488608-51566917:-	-0.35	-4.05	6.79E-5	Type 2 diabetes	
CESC	cis	1	rs7406003	chr17:79597597	TSPAN10	chr17:79609349-79615778:+	0.38	5.82	1.68E-8	Eye color traits	
CESC	cis	1	rs7425670	chr2:88522028	THNSL2	chr2:88469835-88486145:+	-0.47	-4.61	6.24E-6	Plasma clusterin levels	
CESC	cis	1	rs7426847	chr3:134267519	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.35	1.95E-5	Height	
CESC	cis	1	rs7427492	chr3:134261654	ANAPC13	chr3:134196547-134204865:-	0.3	3.96	9.6E-5	Height	
CESC	cis	1	rs7429866	chr3:134236306	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.36	1.84E-5	Height	
CESC	cis	1	rs7432268	chr3:134242051	ANAPC13	chr3:134196547-134204865:-	0.3	3.96	9.6E-5	Height	
CESC	cis	1	rs7433663	chr3:134235790	ANAPC13	chr3:134196547-134204865:-	0.3	4.09	5.62E-5	Height	
CESC	cis	1	rs7433991	chr3:134312292	ANAPC13	chr3:134196547-134204865:-	0.3	4.08	5.9E-5	Height	
CESC	cis	1	rs74372131	chr10:81787214	LOC219347	chr10:81805991-81838949:-	0.4	4	8.04E-5	Chronic obstructive pulmonary disease-related biomarkers	
CESC	cis	1	rs7444	chr22:21976934	CCDC116	chr22:21987086-21991615:+	-0.35	-4.65	5.13E-6	Systemic lupus erythematosus	
CESC	cis	1	rs74471041	chr3:49542543	KLHDC8B	chr3:49209068-49213918:+	0.29	4.46	1.22E-5	Menarche (age at onset)	
CESC	cis	1	rs74471041	chr3:49542543	WDR6	chr3:49044637-49053386:+	0.29	4.84	2.21E-6	Menarche (age at onset)	
CESC	cis	1	rs74544416	chr8:82657745	CHMP4C	chr8:82644688-82671746:+	-1.03	-6.65	1.55E-10	Epithelial ovarian cancer;Ovarian cancer	
CESC	cis	1	rs7456042	chr7:65299778	CCT6P1	chr7:65216092-65228661:+	0.51	5.07	7.32E-7	Diabetic kidney disease	
CESC	cis	1	rs7475154	chr10:131440584	MGMT	chr10:131265454-131565783:+	-0.32	-5.61	5.02E-8	Response to temozolomide	
CESC	cis	1	rs74758321	chr8:82667320	CHMP4C	chr8:82644688-82671746:+	-1.04	-6.61	1.96E-10	Epithelial ovarian cancer;Ovarian cancer	
CESC	cis	1	rs74955473	chr5:150174558	LOC134466	chr5:150310000-150326146:-	0.69	6.83	5.49E-11	Crohn's disease	
CESC	cis	1	rs75012476	chr6:50294126	MUT	chr6:49398994-49431031:-	0.47	3.97	9.23E-5	Body mass index	
CESC	cis	1	rs7503018	chr17:37931220	ZPBP2	chr17:38024455-38034144:+	-0.54	-3.97	9.08E-5	Systemic lupus erythematosus	
CESC	cis	1	rs7503679	chr17:79583843	TSPAN10	chr17:79609349-79615778:+	0.4	6.31	1.1E-9	Eye color traits	
CESC	cis	1	rs75071288	chr5:150224379	LOC134466	chr5:150310000-150326146:-	0.43	4.95	1.27E-6	Crohn's disease	
CESC	cis	1	rs7515491	chr1:46355079	CCDC163P	chr1:45960581-45965646:-	-0.32	-5.25	3.04E-7	Body mass index	
CESC	cis	1	rs7515577	chr1:93009438	EVI5	chr1:92974255-93257961:-	-0.38	-4.58	7.13E-6	Cholesterol, total	
CESC	cis	1	rs7518155	chr1:166954896	MAEL	chr1:166958519-166991447:+	0.34	4.53	8.89E-6	Refractive astigmatism	
CESC	cis	1	rs75181745	chr2:88520408	THNSL2	chr2:88469835-88486145:+	-0.52	-5.04	8.59E-7	Plasma clusterin levels	
CESC	cis	1	rs7522601	chr1:46419021	CCDC163P	chr1:45960581-45965646:-	-0.35	-5.59	5.36E-8	Body mass index	
CESC	cis	1	rs7522705	chr1:45992300	CCDC163P	chr1:45960581-45965646:-	0.61	10.86	4.25E-23	Homocysteine levels	
CESC	cis	1	rs7524495	chr1:46266932	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.88	1.17E-8	Body mass index	
CESC	cis	1	rs7528684	chr1:157670816	FCRL3	chr1:157646278-157670775:-	0.34	8.28	5.36E-15	Type 1 diabetes autoantibodies	
CESC	cis	1	rs7528849	chr1:166954870	MAEL	chr1:166958519-166991447:+	-0.31	-4	8.02E-5	Refractive astigmatism	
CESC	cis	1	rs75294883	chr5:150196503	LOC134466	chr5:150310000-150326146:-	0.71	6.02	5.55E-9	Crohn's disease	
CESC	cis	1	rs75309929	chr2:88524377	THNSL2	chr2:88469835-88486145:+	-0.53	-5.06	7.55E-7	Plasma clusterin levels	
CESC	cis	1	rs7533688	chr1:166944123	MAEL	chr1:166958519-166991447:+	-0.34	-4.52	9.4E-6	Refractive astigmatism	
CESC	cis	1	rs7534016	chr1:59853319	OMA1	chr1:58939504-59012446:-	-0.35	-4.08	6.0E-5	Obesity-related traits	
CESC	cis	1	rs7534467	chr1:45988691	CCDC163P	chr1:45960581-45965646:-	-0.79	-13.94	8.65E-34	Homocysteine levels	
CESC	cis	1	rs7536557	chr1:45992114	CCDC163P	chr1:45960581-45965646:-	-0.67	-11.7	6.4E-26	Homocysteine levels	
CESC	cis	1	rs7539932	chr1:46292354	CCDC163P	chr1:45960581-45965646:-	-0.35	-5.77	2.08E-8	Body mass index	
CESC	cis	1	rs7540325	chr1:46338217	CCDC163P	chr1:45960581-45965646:-	-0.34	-5.6	5.29E-8	Body mass index	
CESC	cis	1	rs7545911	chr1:166947681	MAEL	chr1:166958519-166991447:+	-0.34	-4.52	9.04E-6	Refractive astigmatism	
CESC	cis	1	rs7550698	chr1:166951081	MAEL	chr1:166958519-166991447:+	-0.34	-4.52	9.02E-6	Refractive astigmatism	
CESC	cis	1	rs7550746	chr1:46351719	CCDC163P	chr1:45960581-45965646:-	-0.34	-5.57	6.12E-8	Body mass index	
CESC	cis	1	rs7554962	chr1:166956297	MAEL	chr1:166958519-166991447:+	-0.34	-4.43	1.38E-5	Refractive astigmatism	
CESC	cis	1	rs7556436	chr1:46363880	CCDC163P	chr1:45960581-45965646:-	0.33	5.4	1.44E-7	Body mass index	
CESC	cis	1	rs7556615	chr1:46461369	CCDC163P	chr1:45960581-45965646:-	-0.35	-5.69	3.27E-8	Body mass index	
CESC	cis	1	rs7558944	chr2:73810909	ALMS1P	chr2:73872046-73912692:+	0.39	5.34	1.96E-7	Metabolite levels	
CESC	cis	1	rs7560357	chr2:99247820	UNC50	chr2:99225042-99234975:+	0.39	4.19	3.76E-5	Bipolar disorder	
CESC	cis	1	rs75610822	chr12:48948898	HDAC7	chr12:48176509-48213763:-	0.48	4.25	2.92E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs7564890	chr2:73641853	ALMS1P	chr2:73872046-73912692:+	0.41	5.66	3.83E-8	Metabolite levels	
CESC	cis	1	rs7566279	chr2:281178	SH3YL1	chr2:218138-264810:-	-0.69	-11.48	3.4E-25	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs7572722	chr2:73724675	ALMS1P	chr2:73872046-73912692:+	0.42	5.86	1.31E-8	Metabolite levels	
CESC	cis	1	rs7576245	chr2:73829678	ALMS1P	chr2:73872046-73912692:+	0.38	5.46	1.08E-7	Metabolite levels	
CESC	cis	1	rs75774363	chr5:150223722	LOC134466	chr5:150310000-150326146:-	0.48	5.33	2.04E-7	Crohn's disease	
CESC	cis	1	rs7578199	chr2:242192848	SEPT2	chr2:242254723-242293439:+	0.32	4.1	5.48E-5	Chronic lymphocytic leukemia	
CESC	cis	1	rs7579277	chr2:28996295	TRMT61B	chr2:29072690-29093175:-	-0.28	-4.03	7.2E-5	Body mass index	
CESC	cis	1	rs7580825	chr2:73635148	ALMS1P	chr2:73872046-73912692:+	0.41	5.64	4.26E-8	Metabolite levels	
CESC	cis	1	rs7581224	chr2:84709215	DNAH6	chr2:84743579-85046711:+	0.38	6.67	1.36E-10	Coronary artery calcification	
CESC	cis	1	rs75824542	chr14:74523047	LIN52	chr14:74551656-74667117:+	0.41	8.35	3.49E-15	Common traits (Other)	
CESC	cis	1	rs7582606	chr2:73813945	ALMS1P	chr2:73872046-73912692:+	0.38	5.24	3.22E-7	Metabolite levels	
CESC	cis	1	rs7583255	chr2:73797996	ALMS1P	chr2:73872046-73912692:+	0.41	5.66	3.88E-8	Metabolite levels	
CESC	cis	1	rs7584575	chr2:73666402	ALMS1P	chr2:73872046-73912692:+	0.39	5.48	9.62E-8	Metabolite levels	
CESC	cis	1	rs7585004	chr2:73666645	ALMS1P	chr2:73872046-73912692:+	0.35	4.92	1.51E-6	Metabolite levels	
CESC	cis	1	rs7586463	chr2:73798476	ALMS1P	chr2:73872046-73912692:+	0.41	5.7	3.03E-8	Metabolite levels	
CESC	cis	1	rs75889859	chr14:35539054	PPP2R3C	chr14:35554679-35591679:-	0.49	5.36	1.72E-7	Atopic dermatitis	
CESC	cis	1	rs7589728	chr2:88518440	THNSL2	chr2:88469835-88486145:+	-0.53	-5.05	7.89E-7	Plasma clusterin levels	
CESC	cis	1	rs75913297	chr10:81789845	LOC219347	chr10:81805991-81838949:-	0.44	4.21	3.49E-5	Chronic obstructive pulmonary disease-related biomarkers	
CESC	cis	1	rs7591472	chr2:201889751	PPIL3	chr2:201735680-201753999:-	-0.55	-6.15	2.72E-9	Triptolide cytotoxicity	
CESC	cis	1	rs7592764	chr2:240448167	MYEOV2	chr2:241065980-241075764:-	-0.41	-4.99	1.08E-6	Blood pressure (smoking interaction)	
CESC	cis	1	rs7592764	chr2:240448167	NDUFA10	chr2:240900158-240964798:-	-0.62	-6.23	1.76E-9	Blood pressure (smoking interaction)	
CESC	cis	1	rs7594511	chr2:73681639	ALMS1P	chr2:73872046-73912692:+	0.44	6.06	4.35E-9	Metabolite levels	
CESC	cis	1	rs7595075	chr2:264019	SH3YL1	chr2:218138-264810:-	-0.71	-11.75	4.05E-26	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs7598396	chr2:73652628	ALMS1P	chr2:73872046-73912692:+	0.43	5.99	6.58E-9	Metabolite levels	
CESC	cis	1	rs7598419	chr2:73798223	ALMS1P	chr2:73872046-73912692:+	0.43	5.66	3.73E-8	Metabolite levels	
CESC	cis	1	rs7604682	chr2:73788026	ALMS1P	chr2:73872046-73912692:+	0.38	5.54	7.12E-8	Metabolite levels	
CESC	cis	1	rs7605824	chr2:280819	SH3YL1	chr2:218138-264810:-	0.71	11.77	3.7E-26	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs76064624	chr1:95661033	RWDD3	chr1:95583479-95712773:+	0.62	5.06	7.61E-7	Stearic acid (18:0) plasma levels	
CESC	cis	1	rs7607014	chr2:73730174	ALMS1P	chr2:73872046-73912692:+	-0.39	-5.73	2.64E-8	Metabolite levels	
CESC	cis	1	rs7609851	chr3:156638503	LEKR1	chr3:156544076-156763918:+	-0.36	-4.1	5.37E-5	Bone mineral density	
CESC	cis	1	rs7611611	chr3:134307877	ANAPC13	chr3:134196547-134204865:-	0.3	4.07	6.03E-5	Height	
CESC	cis	1	rs7613491	chr3:49508976	WDR6	chr3:49044637-49053386:+	0.28	4.49	1.03E-5	Menarche (age at onset)	
CESC	cis	1	rs7615952	chr3:125649403	ALG1L	chr3:125648118-125655882:-	0.28	4.63	5.65E-6	Blood pressure (smoking interaction)	
CESC	cis	1	rs7616044	chr3:125649354	ALG1L	chr3:125648118-125655882:-	-0.29	-4.59	6.75E-6	Blood pressure (smoking interaction)	
CESC	cis	1	rs7616844	chr3:41874343	ULK4	chr3:41288091-42003660:-	0.51	8.24	6.92E-15	Diastolic blood pressure	
CESC	cis	1	rs76181214	chr12:121013785	GCN1L1	chr12:120565016-120632513:-	-0.53	-4.31	2.27E-5	Insulin resistance/response	
CESC	cis	1	rs7622259	chr3:41881351	ULK4	chr3:41288091-42003660:-	0.51	8.19	1.01E-14	Diastolic blood pressure	
CESC	cis	1	rs76230314	chr12:120930908	GCN1L1	chr12:120565016-120632513:-	-0.52	-4.22	3.34E-5	Insulin resistance/response	
CESC	cis	1	rs7624372	chr3:41881107	ULK4	chr3:41288091-42003660:-	0.51	8.19	1.01E-14	Diastolic blood pressure	
CESC	cis	1	rs762676	chr22:51017794	CPT1B	chr22:51007291-51017096:-	-0.51	-4.74	3.45E-6	Narcolepsy	
CESC	cis	1	rs762677	chr22:51017713	CPT1B	chr22:51007291-51017096:-	-0.51	-4.74	3.45E-6	Narcolepsy	
CESC	cis	1	rs763014	chr16:675680	WFIKKN1	chr16:679239-684116:+	0.34	5.3	2.43E-7	Height	
CESC	cis	1	rs7630741	chr3:48419723	TREX1	chr3:48501186-48509043:+	-0.21	-4.66	4.92E-6	Longevity	
CESC	cis	1	rs7630874	chr3:134293291	ANAPC13	chr3:134196547-134204865:-	-0.33	-4.42	1.43E-5	Height	
CESC	cis	1	rs7631057	chr3:41817951	ULK4	chr3:41288091-42003660:-	0.51	7.87	8.46E-14	Diastolic blood pressure	
CESC	cis	1	rs7632387	chr3:41853161	ULK4	chr3:41288091-42003660:-	0.42	5.74	2.5E-8	Diastolic blood pressure	
CESC	cis	1	rs7633265	chr3:195048814	C3orf21	chr3:194789015-194991895:-	0.25	4.1	5.48E-5	Body mass index	
CESC	cis	1	rs7634377	chr3:48421258	TREX1	chr3:48501186-48509043:+	-0.19	-4.41	1.5E-5	Longevity	
CESC	cis	1	rs7636044	chr3:48484560	TREX1	chr3:48501186-48509043:+	-0.19	-4.17	4.07E-5	Longevity	
CESC	cis	1	rs7637227	chr3:134244155	ANAPC13	chr3:134196547-134204865:-	0.3	4.05	6.69E-5	Height	
CESC	cis	1	rs7639514	chr3:156576067	LEKR1	chr3:156544076-156763918:+	-0.37	-4.13	4.79E-5	Bone mineral density	
CESC	cis	1	rs76433514	chr5:150306532	IRGM	chr5:150226085-150280295:+	0.44	4.04	7.07E-5	Crohn's disease	
CESC	cis	1	rs76433514	chr5:150306532	LOC134466	chr5:150310000-150326146:-	0.71	6.66	1.47E-10	Crohn's disease	
CESC	cis	1	rs7643617	chr3:114753078	ZBTB20	chr3:114057525-114866127:-	0.38	3.96	9.45E-5	Type 2 diabetes	
CESC	cis	1	rs7644148	chr3:49545241	KLHDC8B	chr3:49209068-49213918:+	0.29	4.46	1.22E-5	Menarche (age at onset)	
CESC	cis	1	rs7644148	chr3:49545241	WDR6	chr3:49044637-49053386:+	0.29	4.84	2.21E-6	Menarche (age at onset)	
CESC	cis	1	rs7645295	chr3:134307734	ANAPC13	chr3:134196547-134204865:-	0.3	4.1	5.54E-5	Height	
CESC	cis	1	rs7645611	chr3:53125297	RFT1	chr3:53122503-53164470:-	0.44	4.22	3.26E-5	Immune reponse to smallpox (secreted IL-2)	
CESC	cis	1	rs7646144	chr3:41853125	ULK4	chr3:41288091-42003660:-	0.42	5.74	2.5E-8	Diastolic blood pressure	
CESC	cis	1	rs76467433	chr7:142824852	KEL	chr7:142638203-142659503:-	0.43	4.06	6.48E-5	Dermatomyositis	
CESC	cis	1	rs76471037	chr3:41799414	ULK4	chr3:41288091-42003660:-	0.52	8.19	1.0E-14	Diastolic blood pressure	
CESC	cis	1	rs7647973	chr3:49510931	WDR6	chr3:49044637-49053386:+	0.28	4.49	1.03E-5	Menarche (age at onset)	
CESC	cis	1	rs7648357	chr3:41849670	ULK4	chr3:41288091-42003660:-	0.49	7.29	3.21E-12	Diastolic blood pressure	
CESC	cis	1	rs7648578	chr3:41858731	ULK4	chr3:41288091-42003660:-	0.47	7.64	3.53E-13	Diastolic blood pressure	
CESC	cis	1	rs7650227	chr3:41794937	ULK4	chr3:41288091-42003660:-	0.52	8.25	6.68E-15	Diastolic blood pressure	
CESC	cis	1	rs7651407	chr3:48443816	TREX1	chr3:48501186-48509043:+	-0.21	-4.67	4.73E-6	Longevity	
CESC	cis	1	rs7653691	chr3:48419689	TREX1	chr3:48501186-48509043:+	0.19	4.44	1.28E-5	Longevity	
CESC	cis	1	rs76542740	chr15:43891512	CATSPER2	chr15:43922774-43959900:-	-0.4	-4.98	1.12E-6	Tumor biomarkers	
CESC	cis	1	rs76542740	chr15:43891512	CKMT1A	chr15:43985084-43991419:+	-0.41	-4.61	6.26E-6	Tumor biomarkers	
CESC	cis	1	rs76542740	chr15:43891512	CKMT1B	chr15:43885252-43891603:+	-0.32	-4	8.07E-5	Tumor biomarkers	
CESC	cis	1	rs76548544	chr5:150223515	LOC134466	chr5:150310000-150326146:-	0.42	4.82	2.35E-6	Crohn's disease	
CESC	cis	1	rs7655841	chr4:129890790	C4orf33	chr4:130014829-130033842:+	0.38	5.76	2.26E-8	Chronic obstructive pulmonary disease (moderate to severe)	
CESC	cis	1	rs76568228	chr12:48949457	HDAC7	chr12:48176509-48213763:-	0.48	4.25	2.92E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs76604840	chr12:51376494	TFCP2	chr12:51488608-51566917:-	-0.38	-4.39	1.62E-5	Type 2 diabetes	
CESC	cis	1	rs76872831	chr5:150171559	LOC134466	chr5:150310000-150326146:-	0.69	6.83	5.44E-11	Crohn's disease	
CESC	cis	1	rs7687557	chr4:39769260	RPL9	chr4:39455747-39460568:-	-0.34	-4.47	1.16E-5	Plasma amyloid beta peptide concentrations (ABx-40)	
CESC	cis	1	rs76882722	chr12:48950252	HDAC7	chr12:48176509-48213763:-	0.48	4.25	2.92E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs76949596	chr1:75862560	SLC44A5	chr1:75667816-76143610:-	-0.53	-4.36	1.85E-5	Whole-brain volume (Alzheimer's disease interaction)	
CESC	cis	1	rs7705093	chr5:96290647	ERAP2	chr5:96211644-96255398:+	0.95	23.74	1.58E-68	Birdshot chorioretinopathy	
CESC	cis	1	rs7705542	chr5:150228318	LOC134466	chr5:150310000-150326146:-	0.44	5.04	8.53E-7	Crohn's disease	
CESC	cis	1	rs7709388	chr5:150246539	LOC134466	chr5:150310000-150326146:-	0.4	4.98	1.1E-6	Crohn's disease	
CESC	cis	1	rs7709464	chr5:150269441	LOC134466	chr5:150310000-150326146:-	0.4	4.73	3.64E-6	Crohn's disease	
CESC	cis	1	rs7709650	chr5:150246685	LOC134466	chr5:150310000-150326146:-	0.45	5.24	3.19E-7	Crohn's disease	
CESC	cis	1	rs7714415	chr5:150270292	LOC134466	chr5:150310000-150326146:-	0.39	4.67	4.81E-6	Crohn's disease	
CESC	cis	1	rs7714584	chr5:150270420	LOC134466	chr5:150310000-150326146:-	0.4	4.73	3.64E-6	Crohn's disease	
CESC	cis	1	rs7715981	chr5:150258107	LOC134466	chr5:150310000-150326146:-	0.43	5.2	3.81E-7	Crohn's disease	
CESC	cis	1	rs7716903	chr5:150258574	LOC134466	chr5:150310000-150326146:-	0.43	5.2	3.81E-7	Crohn's disease	
CESC	cis	1	rs7724036	chr5:150284808	LOC134466	chr5:150310000-150326146:-	-0.44	-5.32	2.12E-7	Crohn's disease	
CESC	cis	1	rs7724558	chr5:150328866	LOC134466	chr5:150310000-150326146:-	0.55	4.49	1.04E-5	Crohn's disease	
CESC	cis	1	rs7732643	chr5:150261436	LOC134466	chr5:150310000-150326146:-	0.4	4.71	4.0E-6	Crohn's disease	
CESC	cis	1	rs7732945	chr5:150261601	LOC134466	chr5:150310000-150326146:-	0.4	4.73	3.64E-6	Crohn's disease	
CESC	cis	1	rs7734778	chr5:150256556	LOC134466	chr5:150310000-150326146:-	0.4	4.82	2.41E-6	Crohn's disease	
CESC	cis	1	rs7734928	chr5:150256613	LOC134466	chr5:150310000-150326146:-	0.4	4.92	1.48E-6	Crohn's disease	
CESC	cis	1	rs7736554	chr5:150258308	LOC134466	chr5:150310000-150326146:-	0.43	5.2	3.81E-7	Crohn's disease	
CESC	cis	1	rs7736873	chr5:150258482	LOC134466	chr5:150310000-150326146:-	0.43	5.2	3.81E-7	Crohn's disease	
CESC	cis	1	rs77477310	chr14:35615793	PPP2R3C	chr14:35554679-35591679:-	0.46	5.3	2.37E-7	Atopic dermatitis	
CESC	cis	1	rs7747824	chr6:86647106	SNHG5	chr6:86386726-86388451:-	-0.62	-11.71	5.84E-26	Response to antipsychotic treatment	
CESC	cis	1	rs7750918	chr6:49430082	MUT	chr6:49398994-49431031:-	0.4	6.91	3.39E-11	Folate pathway vitamin levels	
CESC	cis	1	rs7756203	chr6:86627707	SNHG5	chr6:86386726-86388451:-	-0.57	-9.02	3.37E-17	Response to antipsychotic treatment	
CESC	cis	1	rs7759071	chr6:49433198	CENPQ	chr6:49431096-49460820:+	-0.44	-8.13	1.46E-14	Homocysteine levels	
CESC	cis	1	rs7759071	chr6:49433198	MUT	chr6:49398994-49431031:-	0.25	3.99	8.47E-5	Homocysteine levels	
CESC	cis	1	rs7760207	chr6:86721700	SNHG5	chr6:86386726-86388451:-	-0.61	-9.67	3.23E-19	Response to antipsychotic treatment	
CESC	cis	1	rs7761921	chr6:150416929	PLEKHG1	chr6:150920999-151164799:+	0.36	4.06	6.29E-5	Post bronchodilator FEV1	
CESC	cis	1	rs7766645	chr6:86622238	SNHG5	chr6:86386726-86388451:-	-0.61	-11.52	2.47E-25	Response to antipsychotic treatment	
CESC	cis	1	rs776746	chr7:99270539	CYP3A5	chr7:99245818-99332821:-	-0.28	-4.01	7.92E-5	Blood metabolite levels	
CESC	cis	1	rs77698001	chr5:150250367	LOC134466	chr5:150310000-150326146:-	0.45	5.35	1.83E-7	Crohn's disease	
CESC	cis	1	rs7771342	chr6:86631936	SNHG5	chr6:86386726-86388451:-	-0.57	-9.02	3.37E-17	Response to antipsychotic treatment	
CESC	cis	1	rs7773817	chr6:150416596	PLEKHG1	chr6:150920999-151164799:+	0.36	4.07	6.06E-5	Post bronchodilator FEV1	
CESC	cis	1	rs7774688	chr6:49387292	CENPQ	chr6:49431096-49460820:+	-0.41	-7.65	3.29E-13	Homocysteine levels	
CESC	cis	1	rs7774688	chr6:49387292	MUT	chr6:49398994-49431031:-	0.27	4.49	1.06E-5	Homocysteine levels	
CESC	cis	1	rs7777389	chr7:143744802	ARHGEF35	chr7:143883677-143892736:-	-0.5	-6.32	1.06E-9	Obesity-related traits	
CESC	cis	1	rs7778911	chr7:65694506	CCT6P1	chr7:65216092-65228661:+	-0.54	-5.06	7.72E-7	Diabetic kidney disease	
CESC	cis	1	rs7778911	chr7:65694506	LOC493754	chr7:65993446-66057363:-	-0.53	-4.17	4.17E-5	Diabetic kidney disease	
CESC	cis	1	rs7781669	chr7:21584820	DNAH11	chr7:21582833-21941455:+	-0.53	-7.62	4.16E-13	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
CESC	cis	1	rs778679	chr7:65840911	CCT6P1	chr7:65216092-65228661:+	0.56	5.23	3.42E-7	Diabetic kidney disease	
CESC	cis	1	rs778679	chr7:65840911	LOC493754	chr7:65993446-66057363:-	0.53	4.19	3.8E-5	Diabetic kidney disease	
CESC	cis	1	rs778691	chr7:65873092	CCT6P1	chr7:65216092-65228661:+	0.56	5.23	3.42E-7	Diabetic kidney disease	
CESC	cis	1	rs778691	chr7:65873092	LOC493754	chr7:65993446-66057363:-	0.53	4.19	3.8E-5	Diabetic kidney disease	
CESC	cis	1	rs778704	chr7:65863467	CCT6P1	chr7:65216092-65228661:+	0.56	5.23	3.42E-7	Diabetic kidney disease	
CESC	cis	1	rs778704	chr7:65863467	LOC493754	chr7:65993446-66057363:-	0.53	4.19	3.8E-5	Diabetic kidney disease	
CESC	cis	1	rs7787230	chr7:65629099	CCT6P1	chr7:65216092-65228661:+	-0.51	-4.78	2.88E-6	Diabetic kidney disease	
CESC	cis	1	rs778729	chr7:65824419	CCT6P1	chr7:65216092-65228661:+	0.56	5.23	3.42E-7	Diabetic kidney disease	
CESC	cis	1	rs778729	chr7:65824419	LOC493754	chr7:65993446-66057363:-	0.53	4.19	3.8E-5	Diabetic kidney disease	
CESC	cis	1	rs778758	chr2:61782161	AHSA2	chr2:61404553-61414058:+	-0.23	-4.38	1.66E-5	Tuberculosis	
CESC	cis	1	rs778758	chr2:61782161	C2orf74	chr2:61372243-61391964:+	0.39	5.25	3.08E-7	Tuberculosis	
CESC	cis	1	rs778762	chr2:61782921	AHSA2	chr2:61404553-61414058:+	-0.25	-4.61	6.22E-6	Tuberculosis	
CESC	cis	1	rs778762	chr2:61782921	C2orf74	chr2:61372243-61391964:+	0.39	5.11	6.01E-7	Tuberculosis	
CESC	cis	1	rs778763	chr2:61785639	AHSA2	chr2:61404553-61414058:+	-0.24	-4.51	9.47E-6	Tuberculosis	
CESC	cis	1	rs778763	chr2:61785639	C2orf74	chr2:61372243-61391964:+	0.4	5.37	1.66E-7	Tuberculosis	
CESC	cis	1	rs7792391	chr7:65773429	CCT6P1	chr7:65216092-65228661:+	-0.54	-5.06	7.72E-7	Diabetic kidney disease	
CESC	cis	1	rs7792391	chr7:65773429	LOC493754	chr7:65993446-66057363:-	-0.53	-4.17	4.17E-5	Diabetic kidney disease	
CESC	cis	1	rs7794661	chr7:65389730	CCT6P1	chr7:65216092-65228661:+	0.53	5.17	4.47E-7	Diabetic kidney disease	
CESC	cis	1	rs7795242	chr7:65390094	CCT6P1	chr7:65216092-65228661:+	0.45	4.32	2.14E-5	Diabetic kidney disease	
CESC	cis	1	rs7801282	chr7:65613687	NCRNA00174	chr7:65841032-65865395:-	0.26	4.07	6.19E-5	Aortic root size	
CESC	cis	1	rs78022318	chr12:48949120	HDAC7	chr12:48176509-48213763:-	0.48	4.25	2.92E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs7804223	chr7:65664559	CCT6P1	chr7:65216092-65228661:+	-0.51	-4.78	2.88E-6	Diabetic kidney disease	
CESC	cis	1	rs7808329	chr7:100512232	C7orf59	chr7:99746530-99751833:+	0.37	4.24	3.02E-5	Type 2 diabetes	
CESC	cis	1	rs781142	chr7:65438778	CCT6P1	chr7:65216092-65228661:+	0.5	5.03	8.88E-7	Diabetic kidney disease	
CESC	cis	1	rs781149	chr7:65481284	CCT6P1	chr7:65216092-65228661:+	0.46	4.45	1.27E-5	Diabetic kidney disease	
CESC	cis	1	rs781150	chr7:65480973	CCT6P1	chr7:65216092-65228661:+	0.59	5.72	2.71E-8	Diabetic kidney disease	
CESC	cis	1	rs781156	chr7:65479141	CCT6P1	chr7:65216092-65228661:+	0.53	5.13	5.56E-7	Diabetic kidney disease	
CESC	cis	1	rs781157	chr7:65478311	CCT6P1	chr7:65216092-65228661:+	0.45	4.4	1.53E-5	Diabetic kidney disease	
CESC	cis	1	rs7814941	chr8:130718859	GSDMC	chr8:130760443-130799134:-	0.24	4.3	2.41E-5	Infant length;Height	
CESC	cis	1	rs7815298	chr8:130732739	GSDMC	chr8:130760443-130799134:-	0.31	5.54	6.9E-8	Infant length;Height	
CESC	cis	1	rs7816131	chr8:130719718	GSDMC	chr8:130760443-130799134:-	0.24	4.3	2.41E-5	Infant length;Height	
CESC	cis	1	rs78188367	chr6:50293663	MUT	chr6:49398994-49431031:-	0.47	3.97	9.23E-5	Body mass index	
CESC	cis	1	rs78207779	chr14:35506387	PPP2R3C	chr14:35554679-35591679:-	0.44	4.95	1.27E-6	Atopic dermatitis	
CESC	cis	1	rs7825175	chr8:32416274	C8orf41	chr8:33330904-33370703:-	-0.4	-4.13	4.81E-5	Thyroid hormone levels	
CESC	cis	1	rs7826493	chr8:130738972	GSDMC	chr8:130760443-130799134:-	0.31	5.55	6.64E-8	Infant length;Height	
CESC	cis	1	rs78285894	chr12:48948835	HDAC7	chr12:48176509-48213763:-	0.48	4.25	2.92E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs78350765	chr12:48949043	HDAC7	chr12:48176509-48213763:-	0.48	4.25	2.92E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs7841981	chr8:130735330	GSDMC	chr8:130760443-130799134:-	0.3	5.46	1.06E-7	Infant length;Height	
CESC	cis	1	rs7853287	chr9:117549327	TNFSF8	chr9:117665124-117692770:-	-0.25	-4.34	2.04E-5	Serum IgA levels	
CESC	cis	1	rs785464	chr1:46523089	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.96	7.75E-9	Body mass index	
CESC	cis	1	rs785471	chr1:46518677	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.88	1.16E-8	Body mass index	
CESC	cis	1	rs785479	chr1:46492144	CCDC163P	chr1:45960581-45965646:-	-0.34	-5.43	1.24E-7	Body mass index	
CESC	cis	1	rs785481	chr1:46554518	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.91	1.03E-8	Body mass index	
CESC	cis	1	rs785485	chr1:46574424	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.89	1.13E-8	Body mass index	
CESC	cis	1	rs785488	chr1:46576095	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.89	1.13E-8	Body mass index	
CESC	cis	1	rs785489	chr1:46576390	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.89	1.13E-8	Body mass index	
CESC	cis	1	rs785491	chr1:46583418	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.89	1.13E-8	Body mass index	
CESC	cis	1	rs785492	chr1:46583607	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.82	1.61E-8	Body mass index	
CESC	cis	1	rs785494	chr1:46586626	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.91	1.01E-8	Body mass index	
CESC	cis	1	rs785495	chr1:46587887	CCDC163P	chr1:45960581-45965646:-	-0.33	-5.5	8.71E-8	Body mass index	
CESC	cis	1	rs785503	chr1:46595868	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.89	1.1E-8	Body mass index	
CESC	cis	1	rs785520	chr1:46568836	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.89	1.14E-8	Body mass index	
CESC	cis	1	rs7871089	chr9:117541147	TNFSF8	chr9:117665124-117692770:-	-0.24	-4.22	3.29E-5	Serum IgA levels	
CESC	cis	1	rs78723311	chr6:50270015	MUT	chr6:49398994-49431031:-	0.47	3.97	9.23E-5	Body mass index	
CESC	cis	1	rs78724141	chr8:82659661	CHMP4C	chr8:82644688-82671746:+	-1.03	-6.65	1.55E-10	Epithelial ovarian cancer;Ovarian cancer	
CESC	cis	1	rs78740005	chr8:82659306	CHMP4C	chr8:82644688-82671746:+	-1.03	-6.64	1.64E-10	Epithelial ovarian cancer;Ovarian cancer	
CESC	cis	1	rs78803505	chr7:65382572	CCT6P1	chr7:65216092-65228661:+	0.45	4.32	2.14E-5	Diabetic kidney disease	
CESC	cis	1	rs789227	chr3:128600585	SNORA7B	chr3:129115060-129116797:-	-0.3	-3.97	9.35E-5	IgG glycosylation	
CESC	cis	1	rs791856	chr6:86681841	SNHG5	chr6:86386726-86388451:-	0.61	11.42	5.72E-25	Response to antipsychotic treatment	
CESC	cis	1	rs79199019	chr14:35581125	PPP2R3C	chr14:35554679-35591679:-	0.47	5.22	3.49E-7	Atopic dermatitis	
CESC	cis	1	rs79436302	chr14:35578797	PPP2R3C	chr14:35554679-35591679:-	0.47	5.22	3.49E-7	Atopic dermatitis	
CESC	cis	1	rs79442859	chr5:150171210	LOC134466	chr5:150310000-150326146:-	0.69	6.84	5.16E-11	Crohn's disease	
CESC	cis	1	rs79548696	chr3:41803385	ULK4	chr3:41288091-42003660:-	0.51	7.65	3.46E-13	Diastolic blood pressure	
CESC	cis	1	rs7968870	chr12:54159249	HNRNPA1	chr12:54674488-54680872:+	-0.24	-4.17	4.06E-5	Tanning	
CESC	cis	1	rs79702597	chr14:35558856	PPP2R3C	chr14:35554679-35591679:-	0.48	5.26	2.91E-7	Atopic dermatitis	
CESC	cis	1	rs79716074	chr2:277003	SH3YL1	chr2:218138-264810:-	-0.71	-11.79	3.13E-26	Spherical equivalent (joint main effects and education interaction)	
CESC	cis	1	rs7976	chr19:35978299	USF2	chr19:35759896-35770718:+	-0.37	-4.35	1.94E-5	Bipolar disorder	
CESC	cis	1	rs79780973	chr5:150174810	LOC134466	chr5:150310000-150326146:-	0.7	6.86	4.59E-11	Crohn's disease	
CESC	cis	1	rs79792083	chr12:48949185	HDAC7	chr12:48176509-48213763:-	0.48	4.25	2.92E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs7980687	chr12:123822711	CDK2AP1	chr12:123745542-123756687:-	-0.38	-4.24	3.09E-5	Educational attainment;Height;Head circumference (infant)	
CESC	cis	1	rs79808876	chr11:465763	RNH1	chr11:494512-507273:-	-0.37	-4.04	6.84E-5	Body mass index	
CESC	cis	1	rs79888893	chr14:35510676	PPP2R3C	chr14:35554679-35591679:-	0.44	4.99	1.09E-6	Atopic dermatitis	
CESC	cis	1	rs79890728	chr12:48952720	HDAC7	chr12:48176509-48213763:-	0.45	4.01	7.76E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs800142	chr11:2385071	C11orf21	chr11:2317507-2323143:-	-0.24	-4.2	3.66E-5	Bacteremia	
CESC	cis	1	rs800153	chr11:2373515	C11orf21	chr11:2317507-2323143:-	-0.27	-4.47	1.12E-5	Bacteremia	
CESC	cis	1	rs800156	chr11:2376436	C11orf21	chr11:2317507-2323143:-	-0.27	-4.47	1.12E-5	Bacteremia	
CESC	cis	1	rs800157	chr11:2376602	C11orf21	chr11:2317507-2323143:-	-0.27	-4.48	1.1E-5	Bacteremia	
CESC	cis	1	rs800160	chr11:2380134	C11orf21	chr11:2317507-2323143:-	0.26	4.57	7.33E-6	Bacteremia	
CESC	cis	1	rs8003506	chr14:75586288	EIF2B2	chr14:75469612-75476292:+	-0.25	-4.05	6.72E-5	Height	
CESC	cis	1	rs80075680	chr5:150223737	LOC134466	chr5:150310000-150326146:-	0.43	4.95	1.27E-6	Crohn's disease	
CESC	cis	1	rs8010715	chr14:24609147	FAM158A	chr14:24608175-24610797:-	-0.38	-6.6	2.07E-10	IgG glycosylation	
CESC	cis	1	rs8013540	chr14:35513760	PPP2R3C	chr14:35554679-35591679:-	0.45	5.05	8.22E-7	Atopic dermatitis	
CESC	cis	1	rs8014374	chr14:75322914	RPS6KL1	chr14:75372347-75389958:-	-0.28	-4.21	3.42E-5	Caffeine consumption	
CESC	cis	1	rs80211218	chr12:48952049	HDAC7	chr12:48176509-48213763:-	0.48	4.25	2.92E-5	Prostate cancer (gene x gene interaction)	
CESC	cis	1	rs8028182	chr15:75718669	MAN2C1	chr15:75648135-75660941:-	0.33	4.76	3.07E-6	Sudden cardiac arrest	
CESC	cis	1	rs8031576	chr15:90380214	AP3S2	chr15:90373832-90456222:-	-0.46	-5.54	6.96E-8	Type 2 diabetes	
CESC	cis	1	rs80337562	chr1:75878243	SLC44A5	chr1:75667816-76143610:-	-0.52	-3.97	9.22E-5	Whole-brain volume (Alzheimer's disease interaction)	
CESC	cis	1	rs8049439	chr16:28837515	EIF3CL	chr16:28699879-28747052:+;chr16	0.3	4.46	1.17E-5	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
CESC	cis	1	rs8070454	chr17:38160754	GSDMA	chr17:38119226-38134019:+	-0.32	-4.85	2.03E-6	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
CESC	cis	1	rs8072225	chr17:65912960	LOC651250	chr17:66097696-66157623:+	-0.28	-4.12	5.06E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs8078723	chr17:38166879	GSDMA	chr17:38119226-38134019:+	-0.31	-4.86	2.01E-6	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
CESC	cis	1	rs8079754	chr17:65887896	LOC651250	chr17:66097696-66157623:+	-0.34	-4.66	5.04E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs8082512	chr17:65837059	LOC651250	chr17:66097696-66157623:+	-0.31	-3.99	8.36E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
CESC	cis	1	rs809775	chr1:46538040	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.95	8.02E-9	Body mass index	
CESC	cis	1	rs8113312	chr19:23061182	ZNF492	chr19:22817126-22850472:+	-0.37	-4.22	3.26E-5	Bronchopulmonary dysplasia	
CESC	cis	1	rs8137478	chr22:51017296	CPT1B	chr22:51007291-51017096:-	-0.51	-4.74	3.45E-6	Narcolepsy	
CESC	cis	1	rs8138996	chr22:39047435	CBY1	chr22:39052658-39069853:+	0.25	4.11	5.23E-5	Resting heart rate	
CESC	cis	1	rs8181644	chr12:58173466	FAM119B	chr12:58166383-58176323:+	0.4	5.31	2.27E-7	Multiple sclerosis	
CESC	cis	1	rs8181644	chr12:58173466	TSFM	chr12:58176536-58191367:+	-0.34	-5.9	1.09E-8	Multiple sclerosis	
CESC	cis	1	rs830407	chr9:33217266	SPINK4	chr9:33240196-33248564:+	-0.3	-4.11	5.21E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs830414	chr9:33219138	SPINK4	chr9:33240196-33248564:+	0.31	4.24	3.01E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs830416	chr9:33219441	SPINK4	chr9:33240196-33248564:+	0.31	4.24	3.01E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs830418	chr9:33219502	SPINK4	chr9:33240196-33248564:+	0.31	4.24	3.01E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs830419	chr9:33219547	SPINK4	chr9:33240196-33248564:+	0.31	4.24	3.01E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs830420	chr9:33219575	SPINK4	chr9:33240196-33248564:+	0.31	4.24	3.01E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs830421	chr9:33219690	SPINK4	chr9:33240196-33248564:+	0.31	4.22	3.33E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs830422	chr9:33219724	SPINK4	chr9:33240196-33248564:+	0.31	4.22	3.33E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs832551	chr5:56180112	C5orf35	chr5:56205103-56213010:+	0.83	11.96	7.94E-27	Type 2 diabetes	
CESC	cis	1	rs832553	chr5:56114786	C5orf35	chr5:56205103-56213010:+	0.83	12.57	6.3E-29	Type 2 diabetes	
CESC	cis	1	rs832554	chr5:56115036	C5orf35	chr5:56205103-56213010:+	0.82	12.08	3.12E-27	Type 2 diabetes	
CESC	cis	1	rs832565	chr5:56150803	C5orf35	chr5:56205103-56213010:+	0.84	12.12	2.21E-27	Type 2 diabetes	
CESC	cis	1	rs832568	chr5:56153776	C5orf35	chr5:56205103-56213010:+	0.83	12.1	2.72E-27	Type 2 diabetes	
CESC	cis	1	rs832569	chr5:56154584	C5orf35	chr5:56205103-56213010:+	0.83	12.1	2.72E-27	Type 2 diabetes	
CESC	cis	1	rs832578	chr5:56164223	C5orf35	chr5:56205103-56213010:+	0.85	12.72	1.83E-29	Type 2 diabetes	
CESC	cis	1	rs832582	chr5:56177743	C5orf35	chr5:56205103-56213010:+	0.83	12.07	3.39E-27	Type 2 diabetes	
CESC	cis	1	rs832583	chr5:56178217	C5orf35	chr5:56205103-56213010:+	0.83	11.97	7.32E-27	Type 2 diabetes	
CESC	cis	1	rs832584	chr5:56179212	C5orf35	chr5:56205103-56213010:+	-0.81	-11.89	1.34E-26	Type 2 diabetes	
CESC	cis	1	rs853676	chr6:28299687	ZSCAN23	chr6:28393287-28411279:-	0.33	4	8.27E-5	Depression	
CESC	cis	1	rs853819	chr9:33219410	SPINK4	chr9:33240196-33248564:+	0.31	4.24	3.01E-5	Bipolar disorder and schizophrenia	
CESC	cis	1	rs8589	chr6:49403282	CENPQ	chr6:49431096-49460820:+	-0.41	-7.8	1.26E-13	Homocysteine levels	
CESC	cis	1	rs8589	chr6:49403282	MUT	chr6:49398994-49431031:-	0.26	4.41	1.47E-5	Homocysteine levels	
CESC	cis	1	rs860580	chr5:56149429	C5orf35	chr5:56205103-56213010:+	-0.82	-12.63	3.84E-29	Type 2 diabetes	
CESC	cis	1	rs861020	chr1:209977111	C1orf133	chr1:210404804-210407466:-	-0.27	-3.95	0.000101	Orofacial clefts	
CESC	cis	1	rs861283	chr5:56184610	C5orf35	chr5:56205103-56213010:+	0.83	11.96	7.94E-27	Type 2 diabetes	
CESC	cis	1	rs863840	chr5:56128999	C5orf35	chr5:56205103-56213010:+	0.85	13.01	1.75E-30	Type 2 diabetes	
CESC	cis	1	rs866222	chr5:56184444	C5orf35	chr5:56205103-56213010:+	0.83	11.96	7.94E-27	Type 2 diabetes	
CESC	cis	1	rs873686	chr4:185638876	MLF1IP	chr4:185615220-185655286:-	0.51	8.45	1.75E-15	Kawasaki disease	
CESC	cis	1	rs876403	chr14:75602834	EIF2B2	chr14:75469612-75476292:+	0.24	3.96	9.47E-5	Height	
CESC	cis	1	rs876719	chr17:53366566	HLF	chr17:53342321-53402426:+	0.26	4.04	6.88E-5	QRS duration	
CESC	cis	1	rs882803	chr1:45976147	CCDC163P	chr1:45960581-45965646:-	-0.67	-11.88	1.54E-26	Homocysteine levels	
CESC	cis	1	rs884841	chr6:86680300	SNHG5	chr6:86386726-86388451:-	-0.56	-8.95	5.37E-17	Response to antipsychotic treatment	
CESC	cis	1	rs891368	chr3:53123273	RFT1	chr3:53122503-53164470:-	-0.36	-5.38	1.56E-7	Height	
CESC	cis	1	rs892006	chr5:151180890	SLC36A1	chr5:150816553-150871939:+	-0.29	-3.98	8.99E-5	Preschool internalizing problems	
CESC	cis	1	rs898225	chr3:48413179	TREX1	chr3:48501186-48509043:+	0.21	4.82	2.43E-6	Longevity	
CESC	cis	1	rs906134	chr7:65444288	CCT6P1	chr7:65216092-65228661:+	0.59	5.67	3.52E-8	Diabetic kidney disease	
CESC	cis	1	rs917911	chr12:9905851	CLECL1	chr12:9868457-9885860:-	0.26	5.69	3.32E-8	Type 1 diabetes	
CESC	cis	1	rs926299	chr22:39095698	CBY1	chr22:39052658-39069853:+	0.22	3.96	9.72E-5	Resting heart rate	
CESC	cis	1	rs9283717	chr5:56078659	C5orf35	chr5:56205103-56213010:+	0.81	11.81	2.71E-26	Type 2 diabetes	
CESC	cis	1	rs9289275	chr3:125648659	ALG1L	chr3:125648118-125655882:-	-0.26	-4.03	7.37E-5	Blood pressure (smoking interaction)	
CESC	cis	1	rs9289471	chr3:134230811	ANAPC13	chr3:134196547-134204865:-	0.3	3.95	9.83E-5	Height	
CESC	cis	1	rs9289475	chr3:134236459	ANAPC13	chr3:134196547-134204865:-	0.3	4.09	5.62E-5	Height	
CESC	cis	1	rs9294377	chr6:88084839	C6orf162	chr6:88032306-88052043:+	-0.26	-4.21	3.48E-5	Depressive episodes in bipolar disorder	
CESC	cis	1	rs9296504	chr6:46629505	SLC25A27	chr6:46620679-46645925:+	0.27	4.29	2.43E-5	QRS complex (Sokolow-Lyon)	
CESC	cis	1	rs9296505	chr6:46629841	SLC25A27	chr6:46620679-46645925:+	0.28	4.58	6.96E-6	QRS complex (Sokolow-Lyon)	
CESC	cis	1	rs9296616	chr6:49414235	CENPQ	chr6:49431096-49460820:+	-0.23	-4.1	5.54E-5	Folate pathway vitamin levels	
CESC	cis	1	rs9296616	chr6:49414235	MUT	chr6:49398994-49431031:-	0.4	6.93	3.02E-11	Folate pathway vitamin levels	
CESC	cis	1	rs9296617	chr6:49428360	CENPQ	chr6:49431096-49460820:+	-0.25	-4.34	1.98E-5	Folate pathway vitamin levels	
CESC	cis	1	rs9296617	chr6:49428360	MUT	chr6:49398994-49431031:-	0.4	6.97	2.29E-11	Folate pathway vitamin levels	
CESC	cis	1	rs929843	chr16:70045748	PDXDC2	chr16:70010210-70099851:-	-0.38	-5.23	3.44E-7	Menarche (age at onset)	
CESC	cis	1	rs9303401	chr17:56847945	RAD51C	chr17:56769963-56811690:+	0.34	5.85	1.43E-8	Cognitive test performance	
CESC	cis	1	rs9304742	chr19:53451291	ZNF468	chr19:53341786-53360902:-	0.27	3.95	0.0001	Psoriasis	
CESC	cis	1	rs9306329	chr22:39072454	CBY1	chr22:39052658-39069853:+	0.28	4.76	3.11E-6	Resting heart rate	
CESC	cis	1	rs9309473	chr2:73743982	ALMS1P	chr2:73872046-73912692:+	0.41	5.58	5.81E-8	Metabolite levels	
CESC	cis	1	rs931058	chr5:150333698	LOC134466	chr5:150310000-150326146:-	0.5	4.32	2.21E-5	Crohn's disease	
CESC	cis	1	rs9311288	chr3:41804581	ULK4	chr3:41288091-42003660:-	0.52	8.15	1.28E-14	Diastolic blood pressure	
CESC	cis	1	rs9311423	chr3:48420308	TREX1	chr3:48501186-48509043:+	-0.19	-4.41	1.5E-5	Longevity	
CESC	cis	1	rs9320287	chr6:109744690	SMPD2	chr6:109761931-109765121:+	0.25	3.95	9.93E-5	Height	
CESC	cis	1	rs9324660	chr5:150257054	LOC134466	chr5:150310000-150326146:-	0.41	5.1	6.23E-7	Crohn's disease	
CESC	cis	1	rs933107	chr1:95672229	RWDD3	chr1:95583479-95712773:+	-0.46	-4.47	1.14E-5	Stearic acid (18:0) plasma levels	
CESC	cis	1	rs934093	chr3:134195885	ANAPC13	chr3:134196547-134204865:-	0.3	3.98	8.76E-5	Height	
CESC	cis	1	rs936525	chr19:23056189	ZNF492	chr19:22817126-22850472:+	-0.32	-3.97	9.08E-5	Bronchopulmonary dysplasia	
CESC	cis	1	rs9369898	chr6:49382193	CENPQ	chr6:49431096-49460820:+	-0.41	-7.65	3.29E-13	Homocysteine levels	
CESC	cis	1	rs9369898	chr6:49382193	MUT	chr6:49398994-49431031:-	0.27	4.49	1.06E-5	Homocysteine levels	
CESC	cis	1	rs937108	chr7:65428452	CCT6P1	chr7:65216092-65228661:+	0.5	5.04	8.37E-7	Diabetic kidney disease	
CESC	cis	1	rs9378930	chr6:5070042	RPP40	chr6:4995281-5004271:-	0.23	4.05	6.71E-5	Venous thromboembolism (SNP x SNP interaction)	
CESC	cis	1	rs9378931	chr6:5070238	RPP40	chr6:4995281-5004271:-	0.26	4.29	2.47E-5	Venous thromboembolism (SNP x SNP interaction)	
CESC	cis	1	rs9381469	chr6:46630068	SLC25A27	chr6:46620679-46645925:+	-0.27	-4.29	2.46E-5	QRS complex (Sokolow-Lyon)	
CESC	cis	1	rs9381784	chr6:49398115	CENPQ	chr6:49431096-49460820:+	0.43	7.81	1.25E-13	Homocysteine levels	
CESC	cis	1	rs9392650	chr6:5070660	RPP40	chr6:4995281-5004271:-	0.25	4.29	2.51E-5	Venous thromboembolism (SNP x SNP interaction)	
CESC	cis	1	rs9392652	chr6:5071102	RPP40	chr6:4995281-5004271:-	0.24	4.03	7.31E-5	Venous thromboembolism (SNP x SNP interaction)	
CESC	cis	1	rs9394931	chr6:42873245	GNMT	chr6:42928500-42931617:+	0.27	4.1	5.34E-5	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)	
CESC	cis	1	rs9394931	chr6:42873245	PEX6	chr6:42931613-42946981:-	-0.55	-7.75	1.78E-13	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)	
CESC	cis	1	rs9395493	chr6:49427409	CENPQ	chr6:49431096-49460820:+	-0.41	-7.69	2.69E-13	Homocysteine levels	
CESC	cis	1	rs9395493	chr6:49427409	MUT	chr6:49398994-49431031:-	0.26	4.36	1.84E-5	Homocysteine levels	
CESC	cis	1	rs941653	chr14:35592538	PPP2R3C	chr14:35554679-35591679:-	0.44	4.98	1.14E-6	Atopic dermatitis	
CESC	cis	1	rs9416684	chr10:59994722	IPMK	chr10:59955618-60027694:-	0.23	5.09	6.79E-7	Inflammatory bowel disease	
CESC	cis	1	rs9419788	chr10:96013705	RBP4	chr10:95351594-95360993:-	-0.3	-4.26	2.8E-5	Personality traits in bipolar disorder	
CESC	cis	1	rs9429183	chr1:46524582	CCDC163P	chr1:45960581-45965646:-	-0.36	-5.96	7.69E-9	Body mass index	
CESC	cis	1	rs9450662	chr6:88088593	C6orf162	chr6:88032306-88052043:+	-0.25	-4.08	5.96E-5	Depressive episodes in bipolar disorder	
CESC	cis	1	rs945635	chr1:157670290	FCRL3	chr1:157646278-157670775:-	0.35	8.35	3.34E-15	Type 1 diabetes autoantibodies	
CESC	cis	1	rs9463473	chr6:49380121	CENPQ	chr6:49431096-49460820:+	-0.26	-4.53	8.98E-6	Folate pathway vitamin levels	
CESC	cis	1	rs9463473	chr6:49380121	MUT	chr6:49398994-49431031:-	0.38	6.66	1.52E-10	Folate pathway vitamin levels	
CESC	cis	1	rs9463474	chr6:49380199	CENPQ	chr6:49431096-49460820:+	-0.26	-4.53	8.98E-6	Folate pathway vitamin levels	
CESC	cis	1	rs9463474	chr6:49380199	MUT	chr6:49398994-49431031:-	0.38	6.66	1.52E-10	Folate pathway vitamin levels	
CESC	cis	1	rs9463475	chr6:49380899	CENPQ	chr6:49431096-49460820:+	0.26	4.71	4.02E-6	Folate pathway vitamin levels	
CESC	cis	1	rs9463475	chr6:49380899	MUT	chr6:49398994-49431031:-	-0.37	-6.43	5.61E-10	Folate pathway vitamin levels	
CESC	cis	1	rs9463477	chr6:49386446	CENPQ	chr6:49431096-49460820:+	-0.25	-4.5	1.02E-5	Folate pathway vitamin levels	
CESC	cis	1	rs9463477	chr6:49386446	MUT	chr6:49398994-49431031:-	0.38	6.68	1.3E-10	Folate pathway vitamin levels	
CESC	cis	1	rs9463478	chr6:49386564	CENPQ	chr6:49431096-49460820:+	-0.41	-7.64	3.71E-13	Homocysteine levels	
CESC	cis	1	rs9463478	chr6:49386564	MUT	chr6:49398994-49431031:-	0.26	4.29	2.5E-5	Homocysteine levels	
CESC	cis	1	rs9463479	chr6:49393275	CENPQ	chr6:49431096-49460820:+	-0.25	-4.5	1.02E-5	Folate pathway vitamin levels	
CESC	cis	1	rs9463479	chr6:49393275	MUT	chr6:49398994-49431031:-	0.38	6.68	1.3E-10	Folate pathway vitamin levels	
CESC	cis	1	rs9463480	chr6:49400795	CENPQ	chr6:49431096-49460820:+	-0.25	-4.43	1.37E-5	Folate pathway vitamin levels	
CESC	cis	1	rs9463480	chr6:49400795	MUT	chr6:49398994-49431031:-	0.39	6.84	5.2E-11	Folate pathway vitamin levels	
CESC	cis	1	rs946529	chr1:46485548	CCDC163P	chr1:45960581-45965646:-	-0.34	-5.49	9.13E-8	Body mass index	
CESC	cis	1	rs9473549	chr6:49380020	CENPQ	chr6:49431096-49460820:+	-0.24	-4.16	4.22E-5	Folate pathway vitamin levels	
CESC	cis	1	rs9473549	chr6:49380020	MUT	chr6:49398994-49431031:-	0.4	6.92	3.17E-11	Folate pathway vitamin levels	
CESC	cis	1	rs9473550	chr6:49385182	CENPQ	chr6:49431096-49460820:+	-0.42	-7.81	1.23E-13	Homocysteine levels	
CESC	cis	1	rs9473550	chr6:49385182	MUT	chr6:49398994-49431031:-	0.26	4.28	2.59E-5	Homocysteine levels	
CESC	cis	1	rs9473552	chr6:49387154	CENPQ	chr6:49431096-49460820:+	-0.25	-4.5	1.02E-5	Folate pathway vitamin levels	
CESC	cis	1	rs9473552	chr6:49387154	MUT	chr6:49398994-49431031:-	0.38	6.68	1.3E-10	Folate pathway vitamin levels	
CESC	cis	1	rs9473553	chr6:49395977	CENPQ	chr6:49431096-49460820:+	-0.24	-4.27	2.73E-5	Folate pathway vitamin levels	
CESC	cis	1	rs9473553	chr6:49395977	MUT	chr6:49398994-49431031:-	0.39	6.78	7.18E-11	Folate pathway vitamin levels	
CESC	cis	1	rs9473555	chr6:49409487	CENPQ	chr6:49431096-49460820:+	-0.25	-4.43	1.37E-5	Folate pathway vitamin levels	
CESC	cis	1	rs9473555	chr6:49409487	MUT	chr6:49398994-49431031:-	0.39	6.84	5.2E-11	Folate pathway vitamin levels	
CESC	cis	1	rs9473560	chr6:49427918	CENPQ	chr6:49431096-49460820:+	-0.25	-4.34	1.98E-5	Folate pathway vitamin levels	
CESC	cis	1	rs9473560	chr6:49427918	MUT	chr6:49398994-49431031:-	0.4	6.97	2.29E-11	Folate pathway vitamin levels	
CESC	cis	1	rs9473561	chr6:49428755	CENPQ	chr6:49431096-49460820:+	-0.24	-4.32	2.14E-5	Folate pathway vitamin levels	
CESC	cis	1	rs9473561	chr6:49428755	MUT	chr6:49398994-49431031:-	0.39	6.87	4.19E-11	Folate pathway vitamin levels	
CESC	cis	1	rs9473563	chr6:49453651	CENPQ	chr6:49431096-49460820:+	-0.23	-4.06	6.35E-5	Folate pathway vitamin levels	
CESC	cis	1	rs9473563	chr6:49453651	MUT	chr6:49398994-49431031:-	0.4	6.84	5.12E-11	Folate pathway vitamin levels	
CESC	cis	1	rs9480955	chr6:109744533	SMPD2	chr6:109761931-109765121:+	0.25	3.95	9.93E-5	Height	
CESC	cis	1	rs950027	chr15:45801035	SPATA5L1	chr15:45694519-45713614:+	-0.31	-4.44	1.33E-5	Response to fenofibrate (adiponectin levels)	
CESC	cis	1	rs9506537	chr13:21280410	IFT88	chr13:21141208-21265574:+	-0.3	-4.22	3.33E-5	Dental caries	
CESC	cis	1	rs9527	chr10:104623578	C10orf32	chr10:104613967-104624718:+	-0.46	-6.13	3.04E-9	Arsenic metabolism	
CESC	cis	1	rs955196	chr6:86729951	SNHG5	chr6:86386726-86388451:-	0.61	9.57	6.38E-19	Response to antipsychotic treatment	
CESC	cis	1	rs955197	chr6:86729675	SNHG5	chr6:86386726-86388451:-	-0.59	-9.01	3.61E-17	Response to antipsychotic treatment	
CESC	cis	1	rs955227	chr6:86651032	SNHG5	chr6:86386726-86388451:-	-0.57	-8.49	1.3E-15	Response to antipsychotic treatment	
CESC	cis	1	rs9579929	chr13:21282724	IFT88	chr13:21141208-21265574:+	-0.3	-4.21	3.48E-5	Dental caries	
CESC	cis	1	rs9607566	chr22:39075434	CBY1	chr22:39052658-39069853:+	0.3	4.94	1.39E-6	Resting heart rate	
CESC	cis	1	rs9610986	chr22:39025277	CBY1	chr22:39052658-39069853:+	0.25	4.05	6.68E-5	Resting heart rate	
CESC	cis	1	rs9610993	chr22:39042818	CBY1	chr22:39052658-39069853:+	0.25	4.11	5.23E-5	Resting heart rate	
CESC	cis	1	rs9622833	chr22:39000397	CBY1	chr22:39052658-39069853:+	0.25	4.04	6.98E-5	Resting heart rate	
CESC	cis	1	rs9647603	chr6:86639341	SNHG5	chr6:86386726-86388451:-	-0.61	-11.52	2.47E-25	Response to antipsychotic treatment	
CESC	cis	1	rs9650676	chr9:15457776	C9orf93	chr9:15552872-15971895:+	-0.39	-4.92	1.46E-6	Schizophrenia	
CESC	cis	1	rs9650682	chr9:15457777	C9orf93	chr9:15552872-15971895:+	-0.39	-4.92	1.46E-6	Schizophrenia	
CESC	cis	1	rs9653557	chr2:73795962	ALMS1P	chr2:73872046-73912692:+	0.41	5.59	5.34E-8	Metabolite levels	
CESC	cis	1	rs9674872	chr17:79581931	TSPAN10	chr17:79609349-79615778:+	0.4	6.31	1.1E-9	Eye color traits	
CESC	cis	1	rs9689	chr1:25688276	RHCE	chr1:25688741-25756683:-	0.3	4.38	1.66E-5	Erythrocyte sedimentation rate	
CESC	cis	1	rs9689	chr1:25688276	RHD	chr1:25598981-25656935:+	-0.33	-4.58	7.12E-6	Erythrocyte sedimentation rate	
CESC	cis	1	rs973529	chr5:151188158	ATOX1	chr5:151122384-151138210:-	-0.22	-3.96	9.45E-5	Preschool internalizing problems	
CESC	cis	1	rs973529	chr5:151188158	SLC36A1	chr5:150816553-150871939:+	-0.29	-4.01	7.96E-5	Preschool internalizing problems	
CESC	cis	1	rs9747349	chr17:79584297	TSPAN10	chr17:79609349-79615778:+	0.4	6.31	1.1E-9	Eye color traits	
CESC	cis	1	rs9748176	chr17:79584043	TSPAN10	chr17:79609349-79615778:+	0.4	6.32	1.04E-9	Eye color traits	
CESC	cis	1	rs9769882	chr7:65642925	CCT6P1	chr7:65216092-65228661:+	-0.51	-4.76	3.19E-6	Diabetic kidney disease	
CESC	cis	1	rs9783304	chr11:43660255	HSD17B12	chr11:43702143-43878160:+	0.35	5.28	2.69E-7	Forced vital capacity	
CESC	cis	1	rs979971	chr19:39144244	LGALS7B	chr19:39279850-39282393:+	0.23	3.96	9.63E-5	Heart rate	
CESC	cis	1	rs9809619	chr3:134280948	ANAPC13	chr3:134196547-134204865:-	0.3	4.05	6.67E-5	Height	
CESC	cis	1	rs9809843	chr3:48434398	TREX1	chr3:48501186-48509043:+	-0.2	-4.44	1.28E-5	Longevity	
CESC	cis	1	rs9812647	chr3:48448914	TREX1	chr3:48501186-48509043:+	0.22	4.9	1.63E-6	Longevity	
CESC	cis	1	rs9813774	chr3:134227100	ANAPC13	chr3:134196547-134204865:-	0.3	4.03	7.12E-5	Height	
CESC	cis	1	rs9814567	chr3:134218557	ANAPC13	chr3:134196547-134204865:-	-0.3	-4.17	4.11E-5	Height	
CESC	cis	1	rs9815103	chr3:48414215	TREX1	chr3:48501186-48509043:+	-0.22	-4.96	1.22E-6	Longevity	
CESC	cis	1	rs9815354	chr3:41912651	ULK4	chr3:41288091-42003660:-	0.4	5.25	2.98E-7	Diastolic blood pressure	
CESC	cis	1	rs9817615	chr3:48470756	TREX1	chr3:48501186-48509043:+	-0.19	-4.24	3.07E-5	Longevity	
CESC	cis	1	rs9818169	chr3:41860599	ULK4	chr3:41288091-42003660:-	0.45	6.8	6.42E-11	Diastolic blood pressure	
CESC	cis	1	rs9819532	chr3:134288644	ANAPC13	chr3:134196547-134204865:-	0.31	4.19	3.82E-5	Height	
CESC	cis	1	rs9820192	chr3:41889281	ULK4	chr3:41288091-42003660:-	0.51	8.19	1.02E-14	Diastolic blood pressure	
CESC	cis	1	rs9823254	chr3:41894768	ULK4	chr3:41288091-42003660:-	0.4	5.25	3.03E-7	Diastolic blood pressure	
CESC	cis	1	rs9824731	chr3:41889698	ULK4	chr3:41288091-42003660:-	0.4	5.25	3.03E-7	Diastolic blood pressure	
CESC	cis	1	rs9825741	chr3:41761828	ULK4	chr3:41288091-42003660:-	-0.49	-7.86	8.86E-14	Diastolic blood pressure	
CESC	cis	1	rs9826195	chr3:48433635	TREX1	chr3:48501186-48509043:+	-0.2	-4.44	1.28E-5	Longevity	
CESC	cis	1	rs9826496	chr3:134224437	ANAPC13	chr3:134196547-134204865:-	0.3	4.07	6.19E-5	Height	
CESC	cis	1	rs9827987	chr3:134272621	ANAPC13	chr3:134196547-134204865:-	0.3	3.96	9.6E-5	Height	
CESC	cis	1	rs9828398	chr3:41895893	ULK4	chr3:41288091-42003660:-	0.51	8.19	1.02E-14	Diastolic blood pressure	
CESC	cis	1	rs9829092	chr3:134229866	ANAPC13	chr3:134196547-134204865:-	0.32	4.25	2.96E-5	Height	
CESC	cis	1	rs9830064	chr3:41881801	ULK4	chr3:41288091-42003660:-	0.51	8.24	6.92E-15	Diastolic blood pressure	
CESC	cis	1	rs983331	chr1:75880565	SLC44A5	chr1:75667816-76143610:-	-0.55	-4.34	2.01E-5	Whole-brain volume (Alzheimer's disease interaction)	
CESC	cis	1	rs9834098	chr3:41833493	ULK4	chr3:41288091-42003660:-	0.48	7.25	4.27E-12	Diastolic blood pressure	
CESC	cis	1	rs9838618	chr3:48487353	TREX1	chr3:48501186-48509043:+	-0.22	-4.84	2.15E-6	Longevity	
CESC	cis	1	rs9840037	chr3:41827522	ULK4	chr3:41288091-42003660:-	0.5	7.39	1.79E-12	Diastolic blood pressure	
CESC	cis	1	rs9840532	chr3:41885697	ULK4	chr3:41288091-42003660:-	0.51	8.19	1.01E-14	Diastolic blood pressure	
CESC	cis	1	rs9842261	chr3:41822708	ULK4	chr3:41288091-42003660:-	-0.39	-5.29	2.46E-7	Diastolic blood pressure	
CESC	cis	1	rs9846634	chr3:41894049	ULK4	chr3:41288091-42003660:-	0.4	5.25	3.03E-7	Diastolic blood pressure	
CESC	cis	1	rs9847975	chr3:41786904	ULK4	chr3:41288091-42003660:-	0.43	5.42	1.3E-7	Diastolic blood pressure	
CESC	cis	1	rs9848754	chr3:41753647	ULK4	chr3:41288091-42003660:-	0.38	4.94	1.37E-6	Diastolic blood pressure	
CESC	cis	1	rs9849509	chr3:48483432	TREX1	chr3:48501186-48509043:+	-0.19	-4.17	4.07E-5	Longevity	
CESC	cis	1	rs9850015	chr3:134269541	ANAPC13	chr3:134196547-134204865:-	0.31	4.08	5.96E-5	Height	
CESC	cis	1	rs9854155	chr3:46294468	PRSS45	chr3:46783582-46790130:-	0.27	4.32	2.15E-5	Obesity-related traits;Monocyte chemoattractant protein-1	
CESC	cis	1	rs9854776	chr3:46294851	PRSS45	chr3:46783582-46790130:-	-0.27	-4.31	2.28E-5	Obesity-related traits;Monocyte chemoattractant protein-1	
CESC	cis	1	rs9854833	chr3:41775577	ULK4	chr3:41288091-42003660:-	0.4	5.11	6.15E-7	Diastolic blood pressure	
CESC	cis	1	rs9854838	chr3:41805670	ULK4	chr3:41288091-42003660:-	0.52	8.15	1.28E-14	Diastolic blood pressure	
CESC	cis	1	rs9855965	chr3:41860508	ULK4	chr3:41288091-42003660:-	0.45	6.8	6.42E-11	Diastolic blood pressure	
CESC	cis	1	rs9856088	chr3:41860482	ULK4	chr3:41288091-42003660:-	0.45	6.8	6.42E-11	Diastolic blood pressure	
CESC	cis	1	rs9856633	chr3:42013850	ULK4	chr3:41288091-42003660:-	0.48	7.78	1.47E-13	Diastolic blood pressure	
CESC	cis	1	rs9856693	chr3:134306913	ANAPC13	chr3:134196547-134204865:-	0.3	4.01	7.75E-5	Height	
CESC	cis	1	rs9857175	chr3:41822054	ULK4	chr3:41288091-42003660:-	0.49	7.44	1.32E-12	Diastolic blood pressure	
CESC	cis	1	rs9860055	chr3:49506900	KLHDC8B	chr3:49209068-49213918:+	0.29	4.46	1.22E-5	Menarche (age at onset)	
CESC	cis	1	rs9860055	chr3:49506900	TREX1	chr3:48501186-48509043:+	0.2	4.13	4.86E-5	Menarche (age at onset)	
CESC	cis	1	rs9860055	chr3:49506900	WDR6	chr3:49044637-49053386:+	0.29	4.84	2.21E-6	Menarche (age at onset)	
CESC	cis	1	rs9864217	chr3:41762206	ULK4	chr3:41288091-42003660:-	0.39	5.1	6.29E-7	Diastolic blood pressure	
CESC	cis	1	rs9864371	chr3:48426766	TREX1	chr3:48501186-48509043:+	-0.2	-4.62	5.8E-6	Longevity	
CESC	cis	1	rs9864439	chr3:134298671	ANAPC13	chr3:134196547-134204865:-	0.3	4.05	6.7E-5	Height	
CESC	cis	1	rs9864582	chr3:129970462	LOC729375	chr3:129816625-129830276:-	0.32	3.99	8.64E-5	Response to amphetamines	
CESC	cis	1	rs9864898	chr3:138111751	ARMC8	chr3:137906148-138016219:+	0.34	4.02	7.47E-5	Coronary artery disease;Coronary heart disease	
CESC	cis	1	rs9865127	chr3:41807448	ULK4	chr3:41288091-42003660:-	0.53	8.21	8.5E-15	Diastolic blood pressure	
CESC	cis	1	rs9865780	chr3:41895802	ULK4	chr3:41288091-42003660:-	0.51	8.19	1.02E-14	Diastolic blood pressure	
CESC	cis	1	rs9866092	chr3:41895967	ULK4	chr3:41288091-42003660:-	0.51	8.19	1.02E-14	Diastolic blood pressure	
CESC	cis	1	rs9867627	chr3:41795841	ULK4	chr3:41288091-42003660:-	-0.43	-5.7	3.16E-8	Diastolic blood pressure	
CESC	cis	1	rs9869207	chr3:41878661	ULK4	chr3:41288091-42003660:-	0.51	8.19	1.01E-14	Diastolic blood pressure	
CESC	cis	1	rs9869981	chr3:134248801	ANAPC13	chr3:134196547-134204865:-	0.3	4.05	6.69E-5	Height	
CESC	cis	1	rs9871024	chr3:49554241	KLHDC8B	chr3:49209068-49213918:+	0.28	4.45	1.26E-5	Menarche (age at onset)	
CESC	cis	1	rs9871024	chr3:49554241	WDR6	chr3:49044637-49053386:+	0.28	4.57	7.23E-6	Menarche (age at onset)	
CESC	cis	1	rs9871305	chr3:134213538	ANAPC13	chr3:134196547-134204865:-	0.3	4.04	6.96E-5	Height	
CESC	cis	1	rs9873207	chr3:41884750	ULK4	chr3:41288091-42003660:-	0.4	5.23	3.4E-7	Diastolic blood pressure	
CESC	cis	1	rs9874513	chr3:41909508	ULK4	chr3:41288091-42003660:-	0.4	5.25	2.98E-7	Diastolic blood pressure	
CESC	cis	1	rs9875083	chr3:41775786	ULK4	chr3:41288091-42003660:-	0.4	5.09	6.74E-7	Diastolic blood pressure	
CESC	cis	1	rs9875107	chr3:41822313	ULK4	chr3:41288091-42003660:-	0.49	7.37	2.07E-12	Diastolic blood pressure	
CESC	cis	1	rs9876781	chr3:48487338	TREX1	chr3:48501186-48509043:+	-0.19	-4.19	3.82E-5	Longevity	
CESC	cis	1	rs9881491	chr3:48487911	TREX1	chr3:48501186-48509043:+	-0.2	-4.5	1.02E-5	Longevity	
CESC	cis	1	rs9883759	chr3:48463618	TREX1	chr3:48501186-48509043:+	-0.2	-4.5	1.03E-5	Longevity	
CESC	cis	1	rs9883927	chr3:48463711	TREX1	chr3:48501186-48509043:+	-0.19	-4.24	3.07E-5	Longevity	
CESC	cis	1	rs9894429	chr17:79596811	TSPAN10	chr17:79609349-79615778:+	0.38	5.82	1.68E-8	Eye color traits	
CESC	cis	1	rs9904677	chr17:56873025	RAD51C	chr17:56769963-56811690:+	0.34	5.85	1.43E-8	Cognitive test performance	
CESC	cis	1	rs9929496	chr16:74668473	RFWD3	chr16:74655298-74700779:-	-0.24	-4.09	5.78E-5	Testicular germ cell tumor	
CESC	cis	1	rs9968172	chr3:134231251	ANAPC13	chr3:134196547-134204865:-	-0.31	-4.17	4.12E-5	Height	
CESC	cis	1	rs9973222	chr19:35984721	USF2	chr19:35759896-35770718:+	-0.32	-4.05	6.67E-5	Bipolar disorder	
CESC	cis	1	rs997872	chr22:25878614	CRYBB2	chr22:25615612-25627836:+	0.84	8.96	5.08E-17	Bipolar disorder with mood-incongruent psychosis	
CESC	cis	1	rs997873	chr22:25878282	CRYBB2	chr22:25615612-25627836:+	0.86	9.27	5.52E-18	Bipolar disorder with mood-incongruent psychosis	
CESC	cis	1	rs9984563	chr21:44423653	ZNF295	chr21:43406941-43430496:-	-0.34	-4.05	6.54E-5	Information processing speed	
CESC	trans	1	rs10037055	chr5:176691279	LOC388955	chr2:63849182-63850159:-	-0.45	-8.08	2.0E-14	Migraine without aura	
CESC	trans	1	rs10794671	chr1:121168242	NBPF14	chr1:148003643-148346791:-	0.34	7.11	9.89E-12	Hip geometry	
CESC	trans	1	rs10903159	chr1:121181997	NBPF14	chr1:148003643-148346791:-	0.34	7.1	1.04E-11	Hip geometry	
CESC	trans	1	rs10903161	chr1:121178741	NBPF14	chr1:148003643-148346791:-	0.32	6.47	4.58E-10	Hip geometry	
CESC	trans	1	rs11249350	chr1:121178446	NBPF14	chr1:148003643-148346791:-	0.34	7.1	1.04E-11	Hip geometry	
CESC	trans	1	rs11249351	chr1:121171942	NBPF14	chr1:148003643-148346791:-	0.31	6.36	8.26E-10	Hip geometry	
CESC	trans	1	rs1167827	chr7:75163169	TRIM74	chr7:75021265-75040277:+	-0.39	-6.63	1.81E-10	Body mass index	
CESC	trans	1	rs12047116	chr1:121185770	NBPF14	chr1:148003643-148346791:-	0.34	7.05	1.48E-11	Hip geometry	
CESC	trans	1	rs1591882	chr1:121183313	NBPF14	chr1:148003643-148346791:-	0.35	7.18	6.34E-12	Hip geometry	
CESC	trans	1	rs1832558	chr1:121177380	NBPF14	chr1:148003643-148346791:-	0.32	6.56	2.68E-10	Hip geometry	
CESC	trans	1	rs1856572	chr1:121169579	NBPF14	chr1:148003643-148346791:-	0.34	7.11	9.89E-12	Hip geometry	
CESC	trans	1	rs1986111	chr1:121204788	NBPF14	chr1:148003643-148346791:-	0.33	6.71	1.14E-10	Hip geometry	
CESC	trans	1	rs2185281	chr1:121179991	NBPF14	chr1:148003643-148346791:-	0.35	7.22	4.95E-12	Hip geometry	
CESC	trans	1	rs2319969	chr1:121207335	NBPF14	chr1:148003643-148346791:-	0.32	6.31	1.09E-9	Hip geometry	
CESC	trans	1	rs4844380	chr1:121193620	NBPF14	chr1:148003643-148346791:-	0.35	7.29	3.39E-12	Hip geometry	
CESC	trans	1	rs4844381	chr1:121184898	NBPF14	chr1:148003643-148346791:-	0.34	7.16	7.17E-12	Hip geometry	
CESC	trans	1	rs4844607	chr1:121184059	NBPF14	chr1:148003643-148346791:-	-0.33	-6.67	1.41E-10	Hip geometry	
CESC	trans	1	rs4844616	chr1:121171208	NBPF14	chr1:148003643-148346791:-	0.34	6.99	2.06E-11	Hip geometry	
CESC	trans	1	rs6600669	chr1:121213639	NBPF14	chr1:148003643-148346791:-	0.33	6.76	8.19E-11	Hip geometry	
CESC	trans	1	rs6600671	chr1:121200490	NBPF14	chr1:148003643-148346791:-	-0.33	-6.41	6.44E-10	Hip geometry	
CESC	trans	1	rs6886255	chr5:176718361	LOC388955	chr2:63849182-63850159:-	0.43	7.67	2.96E-13	Migraine without aura	
CESC	trans	1	rs9295695	chr6:26528250	ZNF322B	chr9:99957633-99961910:-	-0.41	-6.6	2.11E-10	Educational attainment	
CESC	trans	1	rs9467779	chr6:26536687	ZNF322B	chr9:99957633-99961910:-	-0.4	-6.64	1.65E-10	Educational attainment	
CESC	trans	1	rs9467783	chr6:26542894	ZNF322B	chr9:99957633-99961910:-	0.4	6.39	7.03E-10	Educational attainment	
CESC	trans	1	rs9467791	chr6:26562486	ZNF322B	chr9:99957633-99961910:-	-0.47	-7.88	7.89E-14	Educational attainment	
